<SEC-DOCUMENT>0001144204-15-022219.txt : 20150410
<SEC-HEADER>0001144204-15-022219.hdr.sgml : 20150410
<ACCEPTANCE-DATETIME>20150410140328
ACCESSION NUMBER:		0001144204-15-022219
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20150410
DATE AS OF CHANGE:		20150410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-203323
		FILM NUMBER:		15763521

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>v406652_s3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 70%; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>As filed with the Securities and Exchange Commission on April&nbsp;10, 2015</b></font></td>
    <TD STYLE="width: 30%; padding-right: 0.8pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Registration No.&nbsp; 333-</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp; <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington,&nbsp;D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 39pt; width: 178.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Exact Name of Registrant as Specified
in Its Charter)</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 49%; padding-right: 0.8pt; font-size: 10pt; text-align: center">&nbsp;</td>
    <TD STYLE="width: 2%; padding-right: 0.8pt; font-size: 10pt; text-align: center">&nbsp;</td>
    <TD STYLE="width: 49%; padding-right: 0.8pt; font-size: 10pt; text-align: center">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Nevada</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>(State or Other Jurisdiction
        of</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>Incorporation or Organization)</i></P></td>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: center; font-size: 10pt">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>13-3808303</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp; <i>(I.R.S.
        Employer</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>Identification Number)</i></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>155 Gibbs Street, Suite 412<BR>
Rockville, Maryland 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(734)&nbsp;332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Address, Including
Zip Code, and Telephone Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 100%; padding-right: 0.8pt; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>617 Detroit Street, Suite 100</b></font></td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ann Arbor, Michigan 48104</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Mailing Address and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Jeffrey Riley</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Chief Executive Officer and President</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>155 Gibbs Street, Suite 412<BR>
Rockville, Maryland 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(734)&nbsp;332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Name, Address, Including Zip Code, and
Telephone Number, Including Area Code of Agent for Service)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>With copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Leslie Marlow, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Gracin &amp; Marlow, LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The Chrysler Building</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>405 Lexington Avenue, 26th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, New York 10174</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) 907-6457</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximate date of commencement of proposed sale to the public:
&nbsp;&nbsp;From time to time after the effective date of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box.&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans,
check the following box.&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering.&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is a post-effective amendment filed pursuant to
Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following box.&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction&nbsp;I.D. filed to register
additional securities or additional classes of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the following
box.&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large accelerated
filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act. (Check
one):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 20%; padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="width: 20%; padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="width: 34%; padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="width: 20%; padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer&nbsp; </font><font style="font: 10pt Wingdings">&uml;</font></td>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Accelerated filer&nbsp; </font><font style="font: 10pt Wingdings">&thorn;</font></td>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif">Non-accelerated
        filer&nbsp; </font><font style="font-family: Wingdings">&uml;</font></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 0; text-align: center">(Do not check if a smaller reporting
        company)</P></td>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Smaller reporting</font><br>
<font style="font: 10pt Times New Roman, Times, Serif">company&nbsp;</font><font style="font: 10pt Wingdings">&uml;</font><font style="font: 10pt Times New Roman, Times, Serif"> </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Title of Each Class of<BR> Securities to be Registered</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount to be<BR> Registered (1)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Proposed Maximum<BR> Offering<BR> Price per Security(2)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Proposed Maximum<BR> Aggregate<BR> Offering Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount of<BR> Registration<BR> Fee(3)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif">Common stock, par value $0.001 per share</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10pt">655,321 shares</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.05</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,343,408</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">156.11</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
is also being registered hereunder an indeterminate number of additional shares of common stock as shall be issuable pursuant
to Rule 416 to prevent dilution resulting from stock splits, stock dividends or similar transactions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the
registration fee in accordance with Rule 457(c) of the Securities Act based upon a $2.05 per share average of high and low prices
of the registrant&rsquo;s common stock on the NYSE MKT on April 7, 2015.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
fee of $156.11 is being paid with the filing of this registration statement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registrant hereby amends this
registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file
a further amendment which specifically states that this registration statement shall thereafter become effective in
accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such
date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Red"><B>The
    information contained in this prospectus is not complete and may be changed. The Selling Stockholder may not sell these securities
    until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an
    offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale
    is not permitted.</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="color: Black"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Red"><B>SUBJECT
TO COMPLETION, DATED APRIL 10, 2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 39pt; width: 178.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">655,321 Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the resale by
the stockholder listed in the section titled &ldquo;Selling Stockholder&rdquo;, and we refer to the stockholder as the Selling
Stockholder (the &ldquo;Selling Stockholder&rdquo;) of up to 655,321 shares of our common stock, par value $0.001 per share (the
&ldquo;Shares&rdquo;). The Shares were acquired by the Selling Stockholder in connection with an asset purchase agreement that
we executed on November 8, 2012 (the &ldquo;Asset Purchase Agreement&rdquo;) with Prev ABR, LLC (&ldquo;PREV&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the Shares described
above were previously issued upon the attainment of certain milestones in connection with the Asset Purchase Agreement. &nbsp;We
will not receive any proceeds from the disposition of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is traded on NYSE MKT
under the symbol &ldquo;SYN&rdquo;. On April 7, 2015, the last reported sale price for the common stock was $2.04 per share. We
urge prospective purchasers of our common stock to obtain current information about the market prices of our common stock. The
prices at which the Selling Stockholder may sell the Shares in this offering will be determined by the prevailing market price
for the shares of common stock or in negotiated transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive offices are located at 155
Gibbs Street, Suite 412, Rockville, Maryland 20850 and our administrative offices are located at 617 Detroit Street, Suite 100,
Ann Arbor, Michigan 48104. Our telephone number is (734) 332-7800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our common stock involves
risks. Risks associated with an investment in our common stock are described in &ldquo;Risk Factors&rdquo; on page&nbsp;3.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy
of the prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Page</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 91%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 2%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="width: 5%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="width: 1%; padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt"><A HREF="#a_001"><font style="font: 10pt Times New Roman, Times, Serif">About this Prospectus</font></A></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">1</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-right: 0.8pt"><A HREF="#a_002"><font style="font: 10pt Times New Roman, Times, Serif">Prospectus Summary</font></A></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">1</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_003">Risk Factors</A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">3</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><A HREF="#a_004">Special Note Regarding Forward-Looking Statements</A></P></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">4</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt"><A HREF="#a_005"><font style="font: 10pt Times New Roman, Times, Serif">Use of Proceeds</font></A></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">4</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_0014">Dividend Policy</A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">4</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt"><A HREF="#a_006"><font style="font: 10pt Times New Roman, Times, Serif">Selling Stockholder</font></A></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">4</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_007">Plan of Distribution</A></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">5</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><A HREF="#a_008">Description of Securities</A></P></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">6</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-right: 0.8pt"><A HREF="#a_009"><font style="font: 10pt Times New Roman, Times, Serif">Legal Matters</font></A></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">7</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt"><A HREF="#a_010"><font style="font: 10pt Times New Roman, Times, Serif">Experts</font></A></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">7</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-right: 0.8pt"><A HREF="#a_011"><font style="font: 10pt Times New Roman, Times, Serif">Where You Can Find More Information</font></A></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">7</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt"><A HREF="#a_012"><font style="font: 10pt Times New Roman, Times, Serif">Incorporation of Certain Documents by Reference</font></A></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">7</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="padding-right: 0.8pt"><A HREF="#a_013"><font style="font: 10pt Times New Roman, Times, Serif">Disclosure of the Securities and Exchange Commission Position on Indemnification for Securities Act Liabilities</font></A></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: center">8</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registration statement containing
this prospectus, including the exhibits to the registration statement, provides additional information about us and the common
stock offered under this prospectus. The registration statement, including the exhibits and the documents incorporated herein by
reference, can be read on the Securities and Exchange Commission website or at the Securities and Exchange Commission offices mentioned
under the heading &ldquo;Where You Can Find More Information.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is not an offer or solicitation
in respect to these securities in any jurisdiction in which such offer or solicitation would be unlawful.&nbsp;&nbsp;This prospectus
is part of a registration statement that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).&nbsp;&nbsp;The
registration statement that contains this prospectus (including the exhibits to the registration statement) contains additional
information about our company and the securities offered under this prospectus.&nbsp;&nbsp;That registration statement can be read
at the SEC website or at the SEC&rsquo;s offices listed under the heading &ldquo;Where You Can Find More Information.&rdquo;&nbsp;&nbsp;We
have not authorized anyone else to provide you with different information or additional information.&nbsp;&nbsp;You should not
assume that the information in this prospectus, or any supplement or amendment to this prospectus, is accurate at any date other
than the date indicated on the cover page of such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_002"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0"><B>Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify">We are a clinical-stage biotechnology
company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome.
We are developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics
for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable
bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition, we
are developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction
in MS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 272.25pt; width: 8in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify"><I>Summary of Pathogen-Specific
Therapy Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>C.
difficile</I></B> <B>infections (CDI):</B> &nbsp; We are in clinical development of a novel second-generation oral enzyme candidate,
SYN-004, for co-administration with commonly used IV beta-lactam antibiotics, intended to protect the microbiome and prevent the
development of and severe effects from CDI. CDIs are a leading type of hospital acquired infection (HAI) and are frequently associated
with IV antibiotic treatment. Designed to be given orally and co-administered with certain IV beta-lactam antibiotics (e.g., penicillins
and cephalosporins), SYN-004 is intended to protect the gut while the IV antibiotics fight the primary infection. SYN-004 is believed
to not only have a similar profile to its first-generation predecessor, which demonstrated protection of the microbiome (gut flora)
during treatment with certain penicillins, but also has the potential to act against a broader spectrum of IV beta-lactam antibiotics.
Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin
classes of antibiotics. SYN-004&rsquo;s target market is significant and represented by annual U.S. hospitals purchases of approximately
118 million doses of IV beta-lactam antibiotics which are administered to approximately 14 million patients.* Currently there
are no approved treatments designed to protect the gut microbiome from the damaging effects of IV antibiotics. This worldwide
market could represent a multi-billion dollar opportunity for us. In December 2014, the U.S. Patent and Trademark Office (USPTO)
issued Patent No. 8,894,994 that has claims to compositions of matter and pharmaceutical compositions of beta-lactamases, including
SYN-004, and carries a patent term to at least 2031. We also have an extensive patent estate on other aspects of this program
which includes patent applications that could carry a term to at least 2035. In the fourth quarter of 2014, we initiated our randomized,
double-blind placebo-controlled Phase 1a clinical trial, reported positive topline safety and tolerability results from the Phase
1a clinical trial, and initiated the Phase 1b clinical trial evaluating multiple ascending doses of SYN-004. In February 2015,
we reported positive topline results from the Phase 1b clinical trial of escalating doses of oral SYN-004, with no safety or tolerability
issues reported at dose levels and dose regimens both meeting and exceeding those expected to be studied in upcoming clinical
trials. In March 2015, we reported positive pharmacokinetics data from both Phase 1 clinical trials, with supportive evidence
that SYN-004 should have no effect on the IV antibiotic in the bloodstream, allowing the antibiotic to fight the primary infection.
We also initiated a Phase 2a clinical trial to evaluate the GI antibiotic-degrading effects and the safety of SYN-004. The initiation
of a Phase 2b proof-of-concept clinical trial is expected in the second half of 2015, with Phase 2b topline data anticipated during
the second half of 2015.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">This information is an estimate derived from the use
of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year
2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><B>IBS-C:</B> &nbsp;&nbsp;In December 2013, through
our majority-owned subsidiary, Synthetic Biomics, Inc., we entered into a worldwide exclusive license agreement with Cedars-Sinai
Medical Center (CSMC) for the right to develop products for therapeutic and prophylactic treatments of acute and chronic diseases,
including the development of SYN-010 to target IBS-C. An investigational team led by Mark Pimentel, M.D., at CSMC discovered that
SYN-010 may reduce the production of methane gas by certain gastrointestinal (GI) microorganisms. Methane produced by these organisms
is perceived as an underlying cause of pain, bloating, and constipation associated with IBS-C, and may contribute to the pathology
of other diseases. SYN-010 is a modified release formulation of a statin being designed to reduce the impact of methane producing
organisms on IBS-C. A 505(b)(2) regulatory pathway is anticipated for the development of SYN-010. We licensed an extensive intellectual
property portfolio from CSMS including granted use patents and pending patent applications for SYN-010. Additional worldwide patent
filings having composition of matter claims, which were recently filed by CSMC and licensed to us, could extend patent protection
of SYN-010 to 2035. Based on guidance from the members on our IBS clinical advisory board, we plan to file an Investigational
New Drug (IND) application with the U.S. FDA to support the initiation of Phase 2 clinical trials in the second quarter of 2015,
with Phase 2 topline data anticipated during the second half of 2015.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><B>Pertussis:</B> &nbsp;&nbsp;In December 2012, in collaboration with Intrexon Corporation
                                                                                      (NYSE: XON) (Intrexon), we initiated development of a monoclonal antibody (mAb) therapy for the treatment of Pertussis
                                                                                      infections, more commonly known as whooping cough. Combining two mAbs, SYN-005 is designed to target and neutralize
                                                                                      pertussis                                                                                       toxin as a prophylaxis for
                                                                                      high-risk newborns and in order to reduce the mortality rate in infected infants. To further the
                                                                                      development of this potential therapy for Pertussis, we entered into an agreement with The University of Texas at Austin
                                                                                      (UT)                                                                                       to license the rights to certain
                                                                                      research and pending patents related to pertussis antibodies. We have patents pending on
                                                                                      compositions and uses of SYN-005 and we have an issued U.S. patent on other pertussis mAbs from UT. According to the World
                                                                                      Health Organization, each year, <I>B. pertussis</I> infection is estimated to cause up to 300,000 deaths worldwide,
                                                                                      primarily among unvaccinated infants. Positive preclinical research findings for SYN-005 were reported in April 2014, and
                                                                                      again in September 2014, for our proprietary mAb combination therapy for treating Pertussis, in non-human primate studies.
                                                                                      In                                                                                       September 2014 we received a U.S.
                                                                                      Orphan Drug designation for SYN-005 for the treatment of Pertussis. We intend to seek
                                                                                      non-dilutive funding to support preclinical and clinical development of SYN-005 for prophylaxis and treatment of Pertussis,
                                                                                      including                                                                                       the anticipated filing of an
                                                                                      IND application in 2015 and the anticipated initiation of a Phase 1 clinical trial during the
                                                                                      second half of 2015, with topline Phase 1 data expected during 2015.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><B><I>Acinetobacter infections: </I></B>&nbsp;&nbsp;In
September 2012, in collaboration with Intrexon, we initiated efforts to develop a mAb therapy for the treatment of <I>Acinetobacter
</I>infections. Many strains of <I>Acinetobacter</I> are multidrug-resistant and pose an increasing global threat to hospitalized
patients, wounded military personnel and those affected by natural disasters. A treatment for <I>Acinetobacter </I>infections
represents a billion dollar market opportunity. This program is in the discovery stage and the generation of a panel of antibodies
to treat this infection is ongoing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify"><I>Summary of Multiple Sclerosis
Program:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Relapsing-Remitting
MS:</B> &nbsp;&nbsp;Patient follow-up is complete in the UCLA-led Phase 2, investigator-initiated, randomized (n = 158), double-blinded,
placebo-controlled trial which evaluated our drug candidate, Trimesta, in women with relapsing-remitting MS at 16 sites across
the U.S. In April 2014, the principal investigator presented positive Phase 2 topline efficacy and safety results. In September
2014, the lead principal investigator presented additional Phase 2 clinical outcome data, including more detailed results on improvements
in cognitive and disability measures, at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple
Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston. The data as reported by the lead principal investigator for the UCLA-led Phase
2 study provided supportive data for the potential of Trimesta to have a novel dual mechanism of action for both the anti-inflammatory
effects that improve relapse rate, and a neuroprotective effect that improves standard measures of disability and cognition. Further
analyses of the magnetic resonance imaging (MRI) data are ongoing, with topline data expected from the principal investigator
during the first half of 2015. This investigator-initiated Phase 2 clinical trial was supported by grants exceeding $8 million,
awarded primarily by the National Multiple Sclerosis Society (NMSS) in partnership with the NMSS&rsquo;s Southern California chapter,
and the National Institutes of Health. Annual worldwide sales of MS therapies are forecasted to be approximately $17.8 billion
in 2019. We have licensed issued method of treatment patents in the U.S. for MS therapy with estriol and estriol combination therapies
(including estriol with Copaxone&reg;) from UCLA, and numerous new provisional patent applications have been filed based on the
Phase 2 clinical results. We are engaging with the neurology community and potential strategic partners, as we determine next
steps for Trimesta.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cognitive
Dysfunction in MS:</B> &nbsp;&nbsp;Trimesta is also being developed for the treatment of cognitive dysfunction in female MS patients.
This 12-month, UCLA-led, randomized, double-blind, placebo-controlled investigator-initiated Phase 2 clinical trial is being conducted
at four sites in the United States. The primary endpoint is the effect on cognitive function as assessed by Paced Auditory Serial
Addition Test (PASAT). Patient enrollment is ongoing. The majority of the costs of this trial are being funded by grants from
foundations and charitable organizations through direct funding to the principal investigator and we have pledged approximately
$500,000 to UCLA to partially fund this trial, payable over three years. An estimated 50&nbsp;&ndash;&nbsp;65% of MS patients
are expected to develop disabilities due to cognitive dysfunction and there is currently no approved treatment for this indication.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify">Since our inception in January
2001, our efforts and resources have been focused primarily on acquiring and developing our product candidates, our clinical trials,
raising capital, manufacturing and recruiting personnel. To date, we have financed our operations primarily through public and
private sales of our common stock, and we expect to continue to seek to obtain the required capital in a similar manner. We have
incurred an accumulated deficit of $101.0 million through December 31, 2014. We cannot provide any assurance that we will be able
to achieve profitability on a sustained basis, if at all, obtain the required funding, obtain the required regulatory approvals,
or complete additional corporate partnering or acquisition transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0"><B>Company History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0; text-align: justify">Our predecessor, Sheffield Pharmaceuticals,
Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics, Inc., a Delaware corporation formed
in 2001. After the merger, we changed our name to Pipex Pharmaceuticals, Inc., and in October 2008 we changed our name to Adeona
Pharmaceuticals, Inc. On October 15, 2009, we engaged in a merger with a wholly owned subsidiary for the purpose of reincorporating
in the State of Nevada. After reprioritizing our focus on the emerging area of synthetic biologics and entering into our first
collaboration with Intrexon, we amended our Articles of Incorporation to change our name to Synthetic Biologics, Inc. on February
15, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our executive offices are located at 155 Gibbs Street, Suite
412, Rockville, Maryland 20850. We also maintain an administrative and finance office in Ann Arbor, Michigan. Our telephone number
is (732) 332-7800, and our website address is <FONT STYLE="color: Black"><U>www.syntheticbiologics.com</U>. The</FONT> information
contained on our website is not part of, and should not be construed as being incorporated by reference into this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As used in this prospectus supplement, unless the context otherwise
requires, references to &ldquo;Synthetic,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and similar references
refer to Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_003"></A><B>RISK
FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>An
investment in our common stock involves a high degree of risk.</I></FONT><I> <FONT STYLE="font-family: Times New Roman, Times, Serif">You
should consider carefully the risks discussed under the section captioned &ldquo;Risk Factors&rdquo; contained in our most recent
annual report on Form 10-K and in our subsequent quarterly reports on Form 10-Q, as updated by our subsequent filings under the
Securities Exchange Act of 1934, as amended, or the Exchange Act, each of which is incorporated by reference in this prospectus
in its entirety, together with other information in this prospectus, and the information and documents incorporated by reference
in this prospectus, and any free writing prospectus that we have authorized for use in connection with this offering before you
make a decision to invest in our common stock. If any of these events actually occur, our business, operating results, prospects
or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline
and you may lose all or part of your investment. </FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_004"></A><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements contained or incorporated
by reference in this prospectus may include forward-looking statements that reflect our current views with respect to our ongoing
and planned clinical trials, business strategy, business plan, financial performance and other future events. These statements
include forward-looking statements both with respect to us, specifically, and the biotechnology sector, in general. We make these
statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that include
the words &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;will&rdquo; and similar statements of a future or forward-looking
nature identify forward-looking statements for purposes of the federal securities laws or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All forward-looking statements involve
inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially
from those indicated in these statements. We believe that these factors include, but are not limited to, those factors set forth
under the caption &ldquo;Risk Factors&rdquo; in this prospectus and under the captions &ldquo;Risk Factors,&rdquo; &ldquo;Business,&rdquo;
and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; in our most recent
Annual Report on Form&nbsp;10-K and our subsequent Quarterly Reports on Form10-Q, all of which you should review carefully. Please
consider our forward-looking statements in light of those risks as you read this prospectus supplement and the accompanying prospectus.
We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information,
future developments or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If one or more of these or other risks
or uncertainties materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially from
what we anticipate. All subsequent written and oral forward-looking statements attributable to us or individuals acting on our
behalf are expressly qualified in their entirety by this Note. Before purchasing any shares of common stock, you should consider
carefully all of the factors set forth or referred to in this prospectus that could cause actual results to differ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not receive any proceeds from the
disposition by the Selling Stockholder of any of the Shares covered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_0014"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid cash dividends on our
common stock. Moreover, we do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. We
intend to use all available cash and liquid assets in the operation and growth of our business. Any future determination about
the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital
requirements, operating and financial conditions and on such other factors as our board of directors deems relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus covers the disposition
by the Selling Stockholder identified below, or its transferee(s), of a total of 655,321 shares of our common stock.&nbsp;All of
the Shares included in this offering were issued as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder has indicated to
us that neither it nor any of its affiliates has held any position or office or had any other material relationship with us in
the past three years except as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the
number of shares of the common stock owned by the Selling Stockholder as of April 1, 2015 and after giving effect to this
offering assuming all of the shares covered hereby are sold by the Selling Stockholder. The percentage of beneficial
ownership is based on 72,725,987 shares of our common stock outstanding as of April 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Selling Stockholder</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Beneficial<BR> Ownership Before<BR> the Sale of all Shares Covered by this Prospectus</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Percentage of<BR> Beneficial<BR> Ownership<BR> Before<BR> the Sale of all Shares Covered by this Prospectus</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total Shares<BR> Offered<BR> By Selling<BR> Stockholder in the Offering Covered by this Prospectus</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Beneficial<BR> Ownership After<BR> the Sale of all Shares Covered by this Prospectus(1)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Percentage of</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif"><b>Beneficial</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif"><b>Ownership</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif"><b>After</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif"><b>the Sale of all Shares Covered by this Prospectus</b></font></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">PREV ABR, LLC(2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">655,321</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">655,321</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">*</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*less than 1%</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">These numbers assume the Selling Stockholder sells all
of the Shares being registered in this prospectus, which are being registered in this prospectus.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Mike Floyd is the manager of PREV and has voting and
disposition power over PREV.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2012, a closing was held
for the transaction contemplated by the Asset Purchase Agreement we entered into with PREV pursuant to which we acquired the&nbsp;<I>C.
diff</I>&nbsp;program assets of PREV, including pre-Investigational New Drug (IND) package, Phase 1 and Phase 2 clinical data,
manufacturing process data and all issued and pending U.S. and international patents.&nbsp; Pursuant to the Asset Purchase Agreement,
we paid PREV an initial cash payment of $100,000 upon execution of the Asset Purchase Agreement and at closing paid an additional
cash payment of $135,000 and issued 625,000 unregistered shares of our common stock to PREV.&nbsp; In addition, upon the achievement
of the milestones set forth below, PREV may be entitled to receive additional consideration payable 50% in cash and 50% in our
stock, subject to PREV&rsquo;s option to receive the entire payment in shares of our stock: (i) upon commencement of an IND; (ii)
upon commencement of a Phase 1 clinical trial; (iii) upon commencement of a Phase 2 clinical trial; (iv) upon commencement of a
Phase 3 clinical trial; (v) upon Biologic License Application (BLA) filing in the U.S. and for territories outside of the U.S.
(as defined in the Asset Purchase Agreement); and (vi) upon BLA approval in the U.S. and upon approval in territories outside the
U.S.&nbsp; The future stock issuances are subject to prior approval of the NYSE MKT, LLC. No royalties are payable to PREV under
the Asset Purchase Agreement. In lieu of receiving any cash payment for achieving the first three milestones, PREV has exercised
its option to receive the full milestone payment in 655,321 shares of our common stock. The number of shares of common stock issued
upon achievement of each milestone was based upon the average of the opening and closing prices of our stock on the date each milestone
was achieved as specified in the Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering the Shares previously
issued to the Selling Stockholder to permit the resale of these shares of common stock by the holder of the common stock from time
to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholder of
the shares of common stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder, or its pledges,
donees, transferees, or any of its successors in interest selling shares received from the Selling Stockholder as a gift, partnership
distribution or other non-sale related transfer after the date of this prospectus, may sell all or a portion of the Shares beneficially
owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the
shares of common stock are sold through underwriters or broker-dealers, the Selling Stockholder will be responsible for underwriting
discounts or commissions or agent's commissions. The Shares may be sold in one or more transactions at fixed prices, at prevailing
market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. The Selling Stockholder
will act independently of us in making decisions with respect to the timing, manner and size of each sale. These sales may be affected
in transactions, which may involve crosses or block transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 5%; padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="width: 89%; padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">in the over-the-counter market;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">in transactions otherwise than on these exchanges or systems or in the over-the-counter market;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">through the writing of options, whether such options are listed on an options exchange or otherwise;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">an exchange distribution in accordance with the rules of the applicable exchange;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">privately negotiated transactions;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">short sales;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">through the distribution of the common stock by any Selling Stockholder to its partners, members or stockholders;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">through one or more underwritten offerings on a firm commitment or best efforts basis;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">sales pursuant to Rule 144;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">broker-dealers may agree with the Selling Stockholder to sell a specified number of such shares at a stipulated price per share;</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">a combination of any such methods of sale; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">any other method permitted pursuant to applicable law.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder may also transfer
the Shares by gift. The Selling Stockholder may engage brokers and dealers, and any brokers or dealers may arrange for other brokers
or dealers to participate in effecting sales of the Shares. These brokers, dealers or underwriters may act as principals, or as
an agent of a Selling Stockholder. Broker-dealers may agree with the Selling Stockholder to sell a specified number of the Shares
at a stipulated price per security. If the broker-dealer is unable to sell the Shares acting as agent for the Selling Stockholder,
it may purchase as principal any unsold Shares at the stipulated price. Broker-dealers who acquire Shares as principals may thereafter
resell the Shares from time to time in transactions in any stock exchange or automated interdealer quotation system on which the
Shares are then listed, at prices and on terms then prevailing at the time of sale, at prices related to the then-current market
price or in negotiated transactions. Broker-dealers may use block transactions and sales to and through broker-dealers, including
transactions of the nature described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder may also sell the
Shares in accordance with Rule 144 under the Securities Act, rather than pursuant to this prospectus, regardless of whether the
Shares are covered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Selling Stockholder effects such
transactions by selling Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents
may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholder or commissions from purchasers
of the shares of common stock for whom they may act as agent or to whom they may sell as principal (which discounts, concessions
or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions
involved). In connection with sales of the Shares or otherwise, the Selling Stockholder may enter into hedging transactions with
broker-dealers, which may in turn engage in short sales of the Shares in the course of hedging in positions they assume. The Selling
Stockholder may also sell Shares short and deliver Shares covered by this prospectus to close out short positions and to return
borrowed shares in connection with such short sales. The Selling Stockholder may also loan or pledge Shares to broker-dealers that
in turn may sell such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 100%; padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Selling Stockholder may pledge or grant a security interest in some or all of the Shares &nbsp;owned by it and, if it defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the Shares &nbsp;from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholder under this prospectus. The Selling Stockholder also may transfer and donate the Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</font></td></tr>
<tr>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Selling Stockholder may,
from time to time, sell the Shares short, and, in those instances, this prospectus may be delivered in connection with the short
sales and the Shares offered under this prospectus may be used to cover short sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder and any broker-dealer
participating in the distribution of the Shares may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities
Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting
commissions or discounts under the Securities Act. At the time a particular offering of the Shares is made, a prospectus supplement,
if required, will be distributed which will set forth the aggregate amount of Shares being offered and the terms of the offering,
including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation
from the Selling Stockholder and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers. The
Selling Stockholder may indemnify any broker-dealer that participates in transactions involving the sale of the Shares against
certain liabilities, including liabilities arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the securities laws of some states,
the Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the Shares
may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or
qualification is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that the Selling
Stockholder will sell any or all of the Shares registered pursuant to the registration statement, of which this prospectus forms
a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder and any other person
participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder,
including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the
shares of common stock by the Selling Stockholders and any other participating person. Regulation M may also restrict the ability
of any person engaged in the distribution of the Shares to engage in market-making activities with respect to the shares of common
stock. All of the foregoing may affect the marketability of the Shares and the ability of any person or entity to engage in market-making
activities with respect to the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shares offered hereby were
originally issued to the Selling Stockholder pursuant to an exemption from the registration requirements of the Securities
Act. We agreed to register the Shares under the Securities Act, We will pay all expenses of the registration of the Shares
estimated to be $30,000 in total, including, without limitation, SEC filing fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once sold under the registration statement,
of which this prospectus forms a part, the Shares will be freely tradable in the hands of persons other than our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_008"></A><B>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital consists of 100
million shares of common stock, par value $0.001 per share, and 10 million shares of preferred stock, par value $0.001 per share.
As of April 1, 2015, 72,725,987 shares of common stock and no shares of preferred stock were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of shares of common stock have
the right to cast one vote for each share of common stock in their name on the books of our company, whether represented in person
or by proxy, on all matters submitted to a vote of holders of common stock, including election of directors. There is no right
to cumulative voting in election of directors. Except where a greater requirement is provided by statute, by our articles of incorporation,
or by our bylaws, the presence, in person or by proxy duly authorized, of the one or more holders of a majority of the outstanding
shares of our common stock constitutes a quorum for the transaction of business. The vote by the holders of a majority of outstanding
shares is required to effect certain fundamental corporate changes such as liquidation, merger, or amendment of our articles of
incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no restrictions in our articles
of incorporation or bylaws that prevent us from declaring dividends. We have not declared any dividends, and we do not plan to
declare any dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of shares of our common stock are
not entitled to preemptive or subscription or conversion rights, and no redemption or sinking fund provisions are applicable to
our common stock. All outstanding shares of common stock are, and the shares of common stock sold in the offering will when issued
be fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23pt; text-align: justify; text-indent: -23pt"><B><I>Outstanding
Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23pt; text-align: justify; text-indent: -23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of April 1, 2015, we had issued and
outstanding a total of 7,974,794 warrants to purchase our common stock outstanding at a weighted-average price of $1.80.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Outstanding Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of April 1, 2015, we had issued and
outstanding a total of 6,531,106 options to purchase our common stock outstanding at a weighted-average price of $1.97.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Parsons Behle &amp; Latimer, Reno, Nevada will pass upon certain
legal matters relating to the issuance and sale of the common stock offered hereby on behalf of Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements of Synthetic Biologics, Inc. as of
December 31, 2014 and 2013 and for each of the three years ended in the period ended December 31, 2014 and management&rsquo;s assessment
of the effectiveness of internal control over financial reporting as of December 31, 2014 incorporated by reference in this Prospectus
have been so incorporated in reliance on the reports of BDO USA, LLP, an independent registered accounting firm, incorporated herein
by reference, given on authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and special reports,
proxy statements and other information with the SEC. You may read and copy any document we file at the SEC&rsquo;s public reference
room located at 100&nbsp;F&nbsp;Street N.E., Washington,&nbsp;D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information
on the operation of the public reference room. Our public filings are also available to the public at the SEC&rsquo;s web site
at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration
statement on Form&nbsp;S-3 that we have filed with the SEC under the Securities Act. This prospectus does not contain all of the
information in the registration statement. We have omitted certain parts of the registration statement, as permitted by the rules
and regulations of the SEC. You may inspect and copy the registration statement, including exhibits, at the SEC&rsquo;s public
reference room or Internet site.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with it which means that we can disclose important information to you by referring
you to those documents instead of having to repeat the information in this prospectus. The information incorporated by reference
is considered to be part of this prospectus, and later information that we file with the SEC will automatically update and supersede
this information. We incorporate by reference the documents listed below and any future filings made with the SEC (other than any
portions of any such documents that are not deemed &ldquo;filed&rdquo; under the Exchange Act in accordance with the Exchange Act
and applicable SEC rules) under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus
and the termination of the offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="width: 6%; padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="width: 88%; padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our annual report on Form&nbsp;10-K for the fiscal year ended December 31, 2014 filed with the SEC on March 16, 2015 (File No. 001-12584);</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="width: 6%; padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="width: 88%; padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our
    current reports on Form 8-K filed with the SEC on January 12, 2015 (with respect to Item 5.02 of Form 8-K) and March 19,
    2015     (File     No.     001-12584)<font style="color: #1F497D">;</font></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="width: 6%; padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="width: 88%; padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Our preliminary proxy statement on Schedule 14A filed with the SEC on March 23, 2015 (File No. 001-12584); and</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; text-align: justify">&nbsp;</td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="padding-right: 0.8pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The description of our common stock set forth in our registration statement on Form&nbsp;8-A12B, filed with the SEC on June 20, 2007 (File No.&nbsp;000-12584).</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may obtain, free of charge, a copy
of any of these documents (other than exhibits to these documents unless the exhibits are specifically incorporated by reference
into these documents or referred to in this prospectus) by writing or calling us at the following address and telephone number:
Synthetic Biologics, Inc., <FONT STYLE="font-family: Times New Roman, Times, Serif">617 Detroit Street, Suite 100 Ann Arbor,
Michigan 48104. (734) 332-7800.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>DISCLOSURE OF SECURITIES AND EXCHANGE
COMMISSION POSITION ON INDEMNIFICATION<BR>
FOR SECURITIES ACT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated bylaws contain
provisions that permit us to indemnify our directors and officers to the full extent permitted by Nevada law, and our Articles
of Incorporation, as amended, contains provisions that eliminate the personal liability of our directors in each case for monetary
damages to us or our stockholders for breach of their fiduciary duties, except to the extent that Nevada law prohibits indemnification
or elimination of liability. These provisions do not limit or eliminate our rights or the rights of any stockholder to seek an
injunction or any other non-monetary relief in the event of a breach of a director&rsquo;s or officer&rsquo;s fiduciary duty. In
addition, these provisions apply only to claims against a director or officer arising out of his or her role as a director or officer
and do not relieve a director or officer from liability if he or she engaged in willful misconduct or a knowing violation of the
criminal law or any federal or state securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rights of indemnification provided
in our amended and restated bylaws are not exclusive of any other rights that may be available under any insurance or other agreement,
by vote of stockholders or disinterested directors or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions,
we have been informed that in the opinion of the SEC this type of indemnification is against public policy as expressed in the
Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;<BR CLEAR="ALL">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -4.5pt">&nbsp; <IMG SRC="image_001.jpg" ALT="" STYLE="height: 39pt; width: 178.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>655,321 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained or incorporated by reference in this prospectus. We have not authorized anyone to provide you with different information.
You should not assume that the information contained or incorporated by reference in this prospectus is accurate as of any date
other than the date of this prospectus. We are not making an offer of these securities in any state where the offer is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS</B></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 0.8pt">&nbsp;</td>
    <td style="width: 91%; padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item&nbsp;14. <i>&nbsp;&nbsp;</i></b></font></td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Other Expenses of Issuance and Distribution.</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the estimated
fees and expenses in connection with the shelf registration of the common stock registered under this registration statement, other
than any underwriting discounts and commissions. The actual amounts of such fees and expenses will be determined from time to time.
All amounts shown are estimates except for the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font: 10pt Times New Roman, Times, Serif; text-align: left">SEC registration fee</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">156</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Legal fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounting fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Transfer agent and registrar fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Printing and engraving expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Miscellaneous</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,344</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Item&nbsp;15. <i>&nbsp;&nbsp;</i></b></font></td>
    <td style="width: 91%; padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Indemnification of Directors and Officers.</i></b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 78.138 of the Nevada Revised Statute
provides that a director or officer is not individually liable to the corporation or its stockholders or creditors for any damages
as a result of any act or failure to act in his capacity as a director or officer unless it is proven that (1) his act or failure
to act constituted a breach of his fiduciary duties as a director or officer and (2) his breach of those duties involved intentional
misconduct, fraud or a knowing violation of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This provision is intended to afford directors
and officers protection against and to limit their potential liability for monetary damages resulting from suits alleging a breach
of the duty of care by a director or officer. As a consequence of this provision, stockholders of our company will be unable to
recover monetary damages against directors or officers for action taken by them that may constitute negligence or gross negligence
in performance of their duties unless such conduct falls within one of the foregoing exceptions. The provision, however, does not
alter the applicable standards governing a director&rsquo;s or officer&rsquo;s fiduciary duty and does not eliminate or limit the
right of our company or any stockholder to obtain an injunction or any other type of non-monetary relief in the event of a breach
of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant&rsquo;s Articles of Incorporation,
as amended, and amended and restated bylaws provide for indemnification of directors, officers, employees or agents of the Registrant
to the fullest extent permitted by Nevada law (as amended from time to time).&nbsp;&nbsp;Section 78.7502 of the Nevada Revised
Statute provides that such indemnification may only be provided if the person acted in good faith and in a manner he reasonably
believed to be in, or not opposed to, the best interest of the Registrant and, with respect to any criminal action or proceeding,
had no reasonable cause to behave his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item&nbsp;16. <I></I></B></FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><B><I>Exhibits</I></B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Incorporation, as
                                                                                                                                             amended (Incorporated by reference to (i) Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed October 16,
                                                                                                                                             2008(File No. 001-12584), (ii) Exhibit 3.1 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly period
                                                                                                                                             ended June
                                                                                                                                             30,
                                                                                                                                             2001
                                                                                                                                             filed August 14, 2001(File No. 001-12584) and (iii) Exhibits 3.1, 4.1 and 4.2 of the Registrant&rsquo;s Quarterly Report on
                                                                                                                                             Form 10-Q for the
                                                                                                                                             quarterly period ended June 30, 1998 filed August 14, 1998(File No. 001-12584) .)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Articles
of Merger (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009(File No. 001-12584).)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate
of Merger filed with the Secretary of State of Delaware (Incorporated by reference to Exhibit 3.2 of the Registrant&rsquo;s Current
Report on Form 8-K filed October 19, 2009(File No. 001-12584).)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Articles
of Incorporation filed with the Nevada Secretary of State (Incorporated by reference to Exhibit 3.3 of the Registrant&rsquo;s
Current Report on Form 8-K filed October 19, 2009(File No. 001-12584).)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By-Laws
(Incorporated by reference to (i) Exhibit 3.4 of the Registrant&rsquo;s Current Report on Form 8-K filed October 19, 2009 and
(ii) Exhibit 3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed June 3, 2010(File No. 001-12584).)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended
and Restated Bylaws Adopted and Effective October 31, 2011 (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s
Current Report on Form 8-K filed November 2, 2011(File No. 001-12584).)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate
of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on
Form 8-K filed February 16, 2012(File No. 001-12584).)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal
opinion of Parsons Behle &amp; Latimer*</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Asset
Purchase Agreement dated November 8, 2012 between Synthetic Biologics, Inc. and Prev ABR LLC (Incorporated by reference to Exhibit
10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed November 13, 2012(File No. 001-12584).)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">List
of Subsidiaries (Incorporated by reference to Exhibit 21 to the Registrant&rsquo;s Annual Report on Form 10-K filed on March 16,
2015(File No. 001-12584).)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent
of Independent Registered Public Accounting Firm (BDO USA, LLP) *</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent
of Parson Behle &amp; Latimer (included in Exhibit 5.1)*</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Powers
of Attorney for our directors (included on signature page)*</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*Filed</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp;herewith</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></FONT></FONT></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item&nbsp;17. <I></I></B></FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt"><B><I>Undertakings.</I></B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;The undersigned registrant
hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(1) To file, during
any period in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i) To
include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii) To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b)
if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering
price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii) To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>provided, however</I> , that the undertakings
set forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section
13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement or
is contained in a form of prospectus filed pursuant to Rule 424(b) that is a part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(2) That, for the
purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(3) To remove from
registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(4) That, for the
purpose of determining liability under the Securities Act of 1933 to any purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i) Each prospectus
filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the
filed prospectus was deemed part of and included in the registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii) Each prospectus
required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B
relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required
by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the
earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities
in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that
is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to
the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of
contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or
prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-weight: normal">(iii)</FONT>
Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included
in the registration statement as of the date it is first used after effectiveness<I>; provided, however,</I> that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or
deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will,
as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(5) That, for the
purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i) Any preliminary
prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii) Any free writing
prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned
registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii) The portion
of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iv) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;The undersigned registrant hereby
undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&rsquo;s
annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of
an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated
by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers,
and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or
controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of
1933 and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(6)&nbsp;If this registration statement
is permitted by Rule 430A, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)&nbsp;For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus
filed by the registrant pursuant to Rule 424(b) (1)&nbsp;or (4)&nbsp;or 497(h) under the Securities Act of 1933 shall be
deemed to be part of this registration statement as of the time it was declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii)&nbsp;For the purpose of determining
any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14pt"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on Form&nbsp;S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Rockville, State of Maryland, April 10, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 1.8pt"><font style="font: 10pt Times New Roman, Times, Serif">SYNTHETIC BIOLOGICS, INC.</font></td>
    <td colspan="2" style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">By: &nbsp;&nbsp;&nbsp;</font></td>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;/s/ Jeffrey Riley</font></td>
    <td colspan="2" style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt 0pt 0">Chief Executive Officer,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt 0pt 0">President and Director</P></td></tr>
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="3" style="padding-right: 1.8pt"><font style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</font></td></tr>
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2" style="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">By:</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">/s/ C. Evan Ballantyne</font></td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td></tr>
<tr style="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td>
    <td colspan="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">(Principal Financial and Accounting Officer)<br>
        <br>
        </P></td>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <TD STYLE="width: 40%">&nbsp;</td>
    <TD STYLE="width: 10%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 43%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We, the undersigned hereby severally constitute
and appoint each of Jeffrey Riley and C. Evan Ballantyne our true and lawful attorney and agent, with full power to each to sign
for us, and in our names in the capacities indicated below, any and all amendments to this registration statement, any subsequent
registration statements pursuant to Rule 462 of the Securities Act of 1933, as amended, and to file the same, with all exhibits
thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to
be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents, or any of them or their substitute or substitutes, may lawfully do or cause
to be done by virtue hereof. This power of attorney may be executed in counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act 1933, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt 0pt 0"><u>/s/ Jeffrey Riley</u> &nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt 0pt 0">Jeffrey Riley</P></td>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="width: 30%; padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer,</font><br>
<font style="font: 10pt Times New Roman, Times, Serif">President and Director</font></td>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="width: 16%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">April 10, 2015</P></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.4pt 0pt 0; text-align: center">(Principal Executive Officer)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.4pt 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P></td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<TR STYLE="vertical-align: top">
    <TD><U>/s/ C. Evan Ballantyne</U></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Chief Financial Officer</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April&nbsp;10, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> C. Evan Ballantyne</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Principal Financial and Accounting Officer) </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt 0pt 0"><u>/s/&nbsp;&nbsp;Jeffrey J. Kraws</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Jeffrey J. Kraws</P></td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: -0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Chairman</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">April&nbsp;10, 2015</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: -0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: -2.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 0"><u>/s/ Scott L. Tarriff</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt 0pt 0">Scott L. Tarriff</P></td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Director</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">April 10, 2015</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: -2.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: -2.8pt">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt 0pt 0"><u>/s/ Jeffrey Wolf</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt 0pt 0">Jeffrey Wolf</P></td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Director</font></td>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">April 10, 2015</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>v406652_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pbl_logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">April 10, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">155 Gibbs Street, Suite 412</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Re:</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Synthetic Biologics, Inc.
    Form S-3 dated as of April 10, 2015</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as special
Nevada counsel to Synthetic Biologics, Inc., a Nevada corporation (the &ldquo; <B><I>Company</I></B> &rdquo;), in connection with
its filing on the date hereof with the Securities and Exchange Commission (the &ldquo; <B><I>Commission</I></B> &rdquo;) of a registration
statement on Form S-3 (as amended, the &ldquo; <B><I>Registration Statement</I></B> &rdquo;), under the Securities Act of 1933,
as amended (the &ldquo;<B><I>Act</I></B> &rdquo;), relating to the registration for issue and sale by the Company of 655,321 shares
of common stock (the &ldquo;<B><I>Securities</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is being
furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein
as to any matter pertaining to the contents of the Registration Statement or related applicable Prospectus or the Sales Agreement
Prospectus, other than as expressly stated herein with respect to the issuance of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As such counsel, we
have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your
consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without
having independently verified such factual matters. We are opining herein as to the Nevada Revised Statutes (the &ldquo;<B><I>NRS</I></B>&rdquo;),
and we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction
or, in the case of Nevada, any other laws, or as to any matters of municipal law or the laws of any local agencies within any state
or of federal law, including, without limitation, federal securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Materials Reviewed</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In arriving at the
opinions expressed below we have reviewed and relied upon the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Articles of Incorporation of Adeona Pharmaceuticals, Inc. (20080829837-57) filed with the Nevada Secretary of State on December 23, 2008.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Articles of Merger (20090740844-88) filed with the Nevada Secretary of State on October 15, 2009, along with the Agreement and Plan of Merger attached thereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated By-Laws of Adeona Pharmaceuticals, Inc., adopted and effective as of October 31, 2011 (unsigned).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Certificate of Good
    Standing of the Company issued by the Nevada Secretary of State, on April 6, 2015</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Secretary&rsquo;s
    Certificate from the Secretary of the Company dated April 10, 2015</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt">Minutes<FONT STYLE="font: 10pt Times New Roman, Times, Serif">   of the Board of Directors of the Company, dated as of     April 7, 2015</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(the &ldquo;Reliance Documents&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
this opinion, we have examined and relied upon the representations and warranties as to factual matters contained in and made pursuant
to the Reliance Documents, Registration Statement and upon such other documents as in our judgment are necessary or appropriate
to enable us to render the opinions expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 10, 2015</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our knowledge of the
Company and its legal and other affairs is limited by the scope of our engagement, which scope includes the delivery of this opinion
letter. We do not represent the Company with respect to all legal matters or issues. The Company may employ other independent counsel
and, to our knowledge, handles certain matters and issues without the assistance of independent counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our examination
of the foregoing, we have assumed, without independent investigation or verification: (i) the genuineness of all signatures on
all agreements, instruments and other documents submitted to us; (ii) the legal capacity and authority of all persons or entities
executing all agreements, instruments and other documents submitted to us; (iii) the authenticity and completeness of all agreements,
instruments, corporate records, certificates and other documents submitted to us as originals; (iv) that all agreements, instruments,
corporate records, certificate and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic
or other copies conform to authentic originals thereof, and that such originals are authentic and complete; (v) the due authorization,
execution and delivery of all instruments, agreements, and other documents by the parties thereto; (vi) that the statements contained
in the certificates and comparable documents of public officials, officers and representatives of the Company and other persons
on which we have relied for the purposes of this letter are true and correct; and (vii) that the officers and directors of the
Company have properly exercised their fiduciary duties. We have assumed that the issuance and sale of the Securities by the Company
will not, in each case, violate or constitute a default or breach under (i) any agreement or instrument to which the Company is
subject, (ii) any law, rule or regulation to which the Company is subject, (iii) any judicial or regulatory order or decree of
any governmental authority, or (iv) any consent, approval, license, authorization or validation of, or filing, recording or registration
with any governmental authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have further assumed
that: (i) the Registration Statement and any amendments thereto will have become effective under the Act and comply with all applicable
laws at the time the Securities are offered or issued as contemplated by the Registration Statement; (ii) an appropriate prospectus
supplement, free writing prospectus or term sheet relating to the Securities offered thereby will be prepared and filed with the
Commission in compliance with the Act and will comply with all applicable laws at the time the Securities are offered or issued
as contemplated by the Registration Statement; (iii) all Securities will be issued and sold in compliance with the applicable provisions
of the Act and the Securities or Blue Sky Laws of various states and in the manner stated in the Registration Statement and the
applicable prospectus supplement; (iv) any purchase, underwriting, warrant, deposit, unit or similar agreement (collectively the
&ldquo;Securities Agreements&rdquo;) relating to the Securities being offered will be duly authorized, executed and delivered by
the Company and other parties thereto; and (v) the number of shares of Common Stock offered pursuant to the Registration Statement
does not exceed, at the time of issuance, the authorized but unissued shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the foregoing and the other matters
set forth herein, it is our opinion that, as of the date hereof that the Securities have been duly authorized and are validly issued
and are fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is for
your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it
pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement
and to the reference to our firm contained in each of the Prospectus under the heading &ldquo;Legal Matters.&rdquo; We further
consent to the incorporation by reference of this letter and consent into any registration statement or post-effective amendment
to the Registration Statement filed pursuant to Rule 462(b) under the Act with respect to the Securities. In giving such consent,
we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules
and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 50%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PARSONS BEHLE &amp; LATIMER</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>v406652_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT&nbsp;23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consent of Independent Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rockville, Maryland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation
by reference in the Prospectus constituting a part of this Registration Statement of our reports dated March 16, 2015, relating
to the consolidated financial statements and the effectiveness of Synthetic Biologics, Inc.&rsquo;s internal control over financial
reporting, appearing in the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to us
under the caption &ldquo;Experts&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>/s/ BDO USA, LLP</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BDO USA, LLP&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Troy, Michigan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 10, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"``T`.X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#U^ZO8+-<S
M/@GHHY)JI'JSSD^192.`,@DXS[5G6ZG4=49Y3D;N!Z"NA5%10J@`#L*&",D:
MS?)_K]&N%`ZF-@U6(-;L9L!I#`[':%F&PD_C6A4%U9VUY$8[F%)5/9A6-.%2
M,O>G=>ALYTY?9MZ/_,FI:P9+._T3,NG.US:CEK60Y*C_`&3_`$K3T[4;?4[8
M3V[9&<,IX9#Z$5T./5$.-E=;%NH+R[M["TEN[J58H85+.[=`*GKGO'.EW>K^
M%+JULE+S?*X0=7P<D5)!S=S\7(3.RZ?HL]S&I^^S[21ZX`./QK5\/_$73]?D
M:U2VDM[[:3%!(XQ*0/NAO7ZBN+\(^.4\)VTFF7VE.<R%F=?ED&>Q!ZXK>TN'
MP5XE\3)J=E=W%KJ'F+*MN<1AF7T&.<XYP:`-;0?B)9ZSK7]E36,UC.<A?-8'
M+CJOL>OY5N^(-=M?#NDR:A=98*0J1J>9&/0"N`^)GAV33[Z/Q+IP,>YQYY3^
M"0?=?\?Y_6L34=8U/XAZQIVG1Q^7M4*5'*AL?/(?:@#MD^)2-H4NL'1;A;:.
M985)E7YV.2<?3'ZUL^%?%MGXJM99+>-H)86P\+L"P!Z'CL:YSXA:;;Z/\/K;
M3[5=L4$\:CU/!R3[D\UQ6C3W_A"?2_$"`O:7BL'`Z,`Q#(??C(H`]/\`%GC:
M#PI/;1364MR;A68%'`Q@CU^M9.I_%6STS49K)]+GD:(@%A*H!R`?ZU@_%6[@
MOY-'N[:020S6[NC#N"17I=I864ME!)):0.[1*2S1@D\"@#B?^%Q60_Y@]Q_W
M]6K4'Q3M)]+N[\:7.%M7C4IYBY;?G^6*Y;X?00S>/9XY8DD39-\K*".OI76_
M$ZUM[;P<_D01Q;KB/.Q`N>OI0!T7AK7H_$FD+J,5N\"L[+L=@3P?:LWQ9XX@
M\*75O!-8RW)GC+@HX&,''>N*\(_$/3_#>@IIUQ9W$LBR,Q9"N.3[FLCQQXJM
M?%5Y;7%K!+"L$11A(1SDY[4`>@:[\2+;0[R*VDTV:8R0),&611@,,XK,_P"%
MQV/_`$"+C_OZM<QXY=8_$=A(XRJ65NQ'J`*ZG_A97A#_`*!$G_@/'_C0!+_P
MMFR_L[[;_94^WSO*V^:N<[<YJ$?&*R/31[C_`+^K75>'[[1_$FE"]L["-(/,
M*[9(5!R.^!7G7Q6@AM_$=HD,,<2FU!(10H/SMZ4`='IOQ7L]1U.UL5TN=&N9
M5B#&52%R<9K1T7Q];ZSXC?14T^6)U,@\UG!'R>U=#:Z?9+##(MG`KA5(81*"
M#CZ5Y'X/F^S?$*\G(SY0NGQ],F@#T'Q-X\TKPU)]FD#W5WC)AB(^4?[1/2N=
M@^,,)F`NM%ECB8_>28,0/H0,_G6)\/M.C\2^++J_U11<>4#.ROR&=CQGV'/Z
M5ZEK&@V&M:9)8W,$>UE(1P@S&>Q'TH`FTK5;+6K".^L)A+"_?H0>X([&KE<Y
MX1\(_P#"*)<QIJ,EU'.5;:\84*1W'/?^E='0!A+`]EJ4QRJQC#AF.!R>GZUM
MHZR*&4@@^AS574[$ZA9FW67RB2#N`STYKG8[NZT2\$=W&`W0,?N2#V/K7)6Q
M$J4U>/N]R7*SU.NHJC::M:78`$@1_P"X_!_^O5ZNF$XS5XNXTTPKC?$-Y;^$
M=6AU3RYA!.&#K&>'8=B/QS^%=@S*@RS!1G')K@_B"YU=4L;"0W,EN=\L$:Y/
M/&0?;N/<4Y.:@W$Z\%[*6(C3JNREIO8[J":.X@CGB8-'(H96'<'D5A>-M6U7
M1-!.H:5'&[12#S?,0L`ASSP?7%3^$4N(?#%E!=1212Q1[&5Q@\'C\,8K6G>%
M(6-PR+$1AO,("X/KFA.ZN8U8*%244[V9PNC>+O#7B/25'B06"7JY$BS1@`C/
M!4GV]ZXC68=+?QE;1>$BS(TD>S9D@29_ASSCI^M>DS_#WPGJ;?:8K4*&.<VT
MQ"G\!Q^5:>C>$]$T%S)I]BJ2D8\UB6?'U/3\*9F3>(HTE\-:DDBAU^RR$@C(
MX4FO/O@]&C7NI2E`76.,*V.0"3G^0_*O3IXH;N&6UEPZ2(5D3/.TC'^-4-&\
M-:3H#2MIEJ(#,`'^=CG'3J?>@#G_`(K_`/(HK_U])_(U%X;T.W\0_"VUT^?`
M+K(8WQRCAVP:ZC7-/TG4[$6VL",V^\,!))L&X=.<BK&FZ?::58165C&([>/.
MQ02<9.>I]S0!\^:FM_:.-)OMP-B[JJ'^#)R<>QZ_C7T+8?\`(/MO^N2_R%9N
MJ^$-"UN\^UZA8++/M"EPS*2!TS@UK0B-8E2(C8@V``YQCC%`'D/PZ_Y*#/\`
M[DW_`*%77_%3_D3C_P!?$?\`6MK3O">B:3J#7]E9"*Y8,"^]CUZ\$U:UK3=-
MU33VM]51&M0P<[WV@$=#G(H`Y7X;:9I]UX0BEN;&VFD,T@WR1*QZ^I%<U\6+
M.UL]4L%M;:&!6@8D1(%!.[VKU#1].T[2].2WTM%6UR67:^X'/4YS5?6/"^CZ
M_+'+J=H)WB4JAWL,`_0T`>3^.&1/$FGM)]P6=N6R,\8YKMO^$M^'W_/.T_\`
M`'_[&M;5?"OAB]N8I-2MXO-V+%'OF*DJ.``,\U%_PKGPK_T"Q_W]?_&@"]X=
MUK0]6AF30RGEP$;UCA,8!/M@>E>=?%S_`)&6S_Z]!_Z&U>EZ-X=TK0!,-,M1
M`)B"_P`Q.<9QU/O4.J^%]$\03QW=_:K<.J;$<2,/ESGL?>@#5M_^/:+_`'!_
M*O'?!<2S_$:YA?[LGVE3]#D5[*JA%"J,`#`K"L/#GAW3=;-U:0Q1Z@VYC^^)
M;YNIVDT`>:Z!?R?#[QC<6VI1.(&!B=@.J9RKCU'_`->NVUSXCZ%;:1,^G7RW
M-VZ$0I&IX8]"<CC%=#J^@Z7KL(CU*SCG"_=8\,OT(Y%8D/PW\*VDAG>T9U3D
MB:8E!]?_`*]`%/X:W>NZG9W.H:M>33P.0EN)`!G'WF&!]!^==Q4-JUL;=!:&
M(PJ-J>41M`'88XJ:@`J*XMH;N$PW$2R1MU5AFI:0T-7W`YJ\\),,MIUV4'_/
M*8;E_`]16:]IXGL>(X)74=X)P1^1KM'1R/E;'OBH!;76_/VP[?[OEBN5X2FW
M=:>ADZ47MH<F$UO4[$V5U:WL<C2AO,F4%,`<#@Y'/-5]/\!SW6H&35WV0Q'B
M.(\2CZ]AZ]Z[Q58#ELTZN^C6J4:?LXO_`#.:6`I2JJK*[:$1%C1410JJ,``<
M`5E>)K>:YTE4AC>1EN(G(1`Y`#@D[3P>.U:]%9'<8GAJVGMTO6EB=$EGWQF2
M,1LPVJ#\@X'(_'K6W110!GV\$J:[>SLA$<D,*JW8D%\_S%:%%%`&)J<7E:U'
M>7%A)>VWV8Q*L<?F&-]V3\ON,#/M[U:T*VFM-&@AG0QNNXB,G/EJ6)5<^P('
MX5HT4`%8NC2R6T]S:2V=RA>[FD60Q_NRI8D'=]*VJ*`"LG7('>6QN#;-=6]O
M,6FA1=Q.5(#;>^">GX]JUJ*`,K0H'C%Y-]F:U@GGWPPL,%1M`)QVR03CWK5H
MHH`Y?6;6<7FH,;!KIKJ-!;N(!*H`!!C.2-O/.??VKH;+S/L%OYR;)?*7>O\`
M=.!D5/10`G:J&A02VVB6D,R&.1(P&4]0:T**`"N:M+8PS+;3:.\UV+UI3=%<
M+@L2'W^NT@;?PZ5TM%`!6=KMO]JT>:'R99@VTE(B`^`P.1G@XQG!Z].]:-%`
M&+X<CGC2[,L'EH\H*2-#Y+R?*`2R#@=,9XSZ5M444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
$4`?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0$`E@"6``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`*8!7T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V&YE\BUEE
M`R8T+8]<#->8K\7[H?>TJ$_24C^E>G77-I-_N-_*OFRNK#TXSOS(PK3E&UCT
M?_A<$_\`T"(_^_Y_^)H_X7!/_P!`B/\`[_G_`.)KSBBNCV%/L8>VGW/1_P#A
M<$__`$"(_P#O^?\`XFC_`(7!/_T"(_\`O^?_`(FO.**/84^P>VGW/1_^%P3_
M`/0(C_[_`)_^)H_X7!/_`-`B/_O^?_B:\XHH]A3[![:?<]'_`.%P3_\`0(C_
M`._Y_P#B:/\`A<$__0(C_P"_Y_\`B:\XHH]A3[![:?<]'_X7!/\`]`B/_O\`
MG_XFC_A<$_\`T"(_^_Y_^)KSBBCV%/L'MI]ST?\`X7!/_P!`B/\`[_G_`.)H
M_P"%P3_]`B/_`+_G_P")KSBBCV%/L'MI]ST?_A<$_P#T"(_^_P"?_B:/^%P3
M_P#0(C_[_G_XFO.**/84^P>VGW/1_P#A<$__`$"(_P#O^?\`XFC_`(7!/_T"
M(_\`O^?_`(FO.**/84^P>VGW/1_^%P3_`/0(C_[_`)_^)H_X7!/_`-`B/_O^
M?_B:\XHH]A3[![:?<]'_`.%P3_\`0(C_`._Y_P#B:/\`A<$__0(C_P"_Y_\`
MB:\XHH]A3[![:?<]'_X7!/\`]`B/_O\`G_XFC_A<$_\`T"(_^_Y_^)KSBBCV
M%/L'MI]ST?\`X7!/_P!`B/\`[_G_`.)H_P"%P3_]`B/_`+_G_P")KSBBCV%/
ML'MI]ST?_A<$_P#T"(_^_P"?_B:/^%P3_P#0(C_[_G_XFO.**/84^P>VGW/1
M_P#A<$__`$"(_P#O^?\`XFC_`(7!/_T"(_\`O^?_`(FO.**/84^P>VGW/1_^
M%P3_`/0(C_[_`)_^)H_X7!/_`-`B/_O^?_B:\XHH]A3[![:?<]'_`.%P3_\`
M0(C_`._Y_P#B:1?C!<8^;28B?:8C^E><T4>PI]@]K/N>C_\`"X)_^@1'_P!_
MS_\`$T?\+@G_`.@1'_W_`#_\37G%%'L*?8/;3[GH_P#PN"?_`*!$?_?\_P#Q
M-'_"X)_^@1'_`-_S_P#$UYQ11["GV#VT^YZ/_P`+@G_Z!$?_`'_/_P`31_PN
M"?\`Z!$?_?\`/_Q-><44>PI]@]M/N>C_`/"X)_\`H$1_]_S_`/$T?\+@G_Z!
M$?\`W_/_`,37G%%'L*?8/;3[GH__``N"?_H$1_\`?\__`!-'_"X)_P#H$1_]
M_P`__$UYQ11["GV#VT^YZ/\`\+@G_P"@1'_W_/\`\31_PN"?_H$1_P#?\_\`
MQ-><44>PI]@]M/N>C_\`"X)_^@1'_P!_S_\`$T?\+@G_`.@1'_W_`#_\37G%
M%'L*?8/;3[GH_P#PN"?_`*!$?_?\_P#Q-'_"X)_^@1'_`-_S_P#$UYQ11["G
MV#VT^YZ/_P`+@G_Z!$?_`'_/_P`31_PN"?\`Z!$?_?\`/_Q-><44>PI]@]M/
MN>C_`/"X)_\`H$1_]_S_`/$TG_"X+C=_R"8L>GG'_"O.:*/84^P>UGW/1_\`
MA<$__0(C_P"_Y_\`B:/^%P3_`/0(C_[_`)_^)KSBBCV%/L'MI]ST?_A<$_\`
MT"(_^_Y_^)H_X7!/_P!`B/\`[_G_`.)KSBBCV%/L'MI]ST?_`(7!/_T"(_\`
MO^?_`(FC_A<$_P#T"(_^_P"?_B:\XHH]A3[![:?<]'_X7!/_`-`B/_O^?_B:
M/^%P3_\`0(C_`._Y_P#B:\XHH]A3[![:?<]'_P"%P3_]`B/_`+_G_P")H_X7
M!/\`]`B/_O\`G_XFO.**/84^P>VGW/1_^%P3_P#0(C_[_G_XFC_A<$__`$"(
M_P#O^?\`XFO.**/84^P>VGW/1_\`A<$__0(C_P"_Y_\`B:/^%P3_`/0(C_[_
M`)_^)KSBBCV%/L'MI]ST?_A<$_\`T"(_^_Y_^)H_X7!/_P!`B/\`[_G_`.)K
MSBBCV%/L'MI]ST?_`(7!/_T"(_\`O^?_`(FC_A<$_P#T"(_^_P"?_B:\XHH]
MA3[![:?<]'_X7!/_`-`B/_O^?_B:/^%P3_\`0(C_`._Y_P#B:\XHH]A3[![:
M?<]'_P"%P3_]`B/_`+_G_P")H_X7!/\`]`B/_O\`G_XFO.**/84^P>VGW/1_
M^%P3_P#0(C_[_G_XFC_A<$__`$"(_P#O^?\`XFO.**/84^P>VGW/1_\`A<$_
M_0(C_P"_Y_\`B:/^%P3_`/0(C_[_`)_^)KSBK%KI]Y?>8;.TGN/+&7\J,OM'
MOCI1["GV#VL^YW__``N"?_H$1_\`?\__`!-'_"X)_P#H$1_]_P`__$UYQ11[
M"GV#VT^YZ/\`\+@G_P"@1'_W_/\`\32+\8+C'S:3$3[3$?TKSFBCV%/L'M9]
MST?_`(7!/_T"(_\`O^?_`(FC_A<$_P#T"(_^_P"?_B:\XHH]A3[![:?<]'_X
M7!/_`-`B/_O^?_B:/^%P3_\`0(C_`._Y_P#B:\XHH]A3[![:?<]'_P"%P3_]
M`B/_`+_G_P")H_X7!/\`]`B/_O\`G_XFO.**/84^P>VGW/1_^%P3_P#0(C_[
M_G_XFC_A<$__`$"(_P#O^?\`XFO.**/84^P>VGW/1_\`A<$__0(C_P"_Y_\`
MB:/^%P3_`/0(C_[_`)_^)KSBBCV%/L'MI]ST?_A<$_\`T"(_^_Y_^)H_X7!/
M_P!`B/\`[_G_`.)KSBBCV%/L'MI]ST?_`(7!/_T"(_\`O^?_`(FC_A<$_P#T
M"(_^_P"?_B:\XHH]A3[![:?<]'_X7!/_`-`B/_O^?_B:/^%P3_\`0(C_`._Y
M_P#B:\XHH]A3[![:?<]'_P"%P3_]`B/_`+_G_P")I&^,%QCY=)B!]YB?Z5YS
M11["GV#VL^YZ/_PN"?\`Z!,?_?\`/_Q-'_"X)_\`H$1_]_S_`/$UYQ11["GV
M#VT^YZ/_`,+@G_Z!$?\`W_/_`,31_P`+@G_Z!$?_`'_/_P`37G%%'L*?8/;3
M[GH__"X)_P#H$1_]_P`__$T?\+@G_P"@1'_W_/\`\37G%%'L*?8/;3[GH_\`
MPN"?_H$1_P#?\_\`Q-'_``N"?_H$1_\`?\__`!-><44>PI]@]M/N>C_\+@G_
M`.@1'_W_`#_\31_PN"?_`*!$?_?\_P#Q-><44>PI]@]M/N>C_P#"X)_^@1'_
M`-_S_P#$T?\`"X)_^@1'_P!_S_\`$UYQ11["GV#VT^YZ/_PN"?\`Z!$?_?\`
M/_Q-'_"X)_\`H$1_]_S_`/$UYQ11["GV#VT^YZ/_`,+@G_Z!$?\`W_/_`,31
M_P`+@G_Z!$?_`'_/_P`37G%%'L*?8/;3[GH__"X)_P#H$1_]_P`__$T?\+@G
M_P"@1'_W_/\`\37G%%'L*?8/;3[GH_\`PN"?_H$1_P#?\_\`Q-'_``N"?_H$
M1_\`?\__`!-><44>PI]@]M/N>C#XP7'\6DQ'Z3'_``I?^%P3_P#0(C_[_G_X
MFO.**/84^P>UGW/1_P#A<$__`$"(_P#O^?\`XFC_`(7!/_T"(_\`O^?_`(FO
M.**/84^P>VGW/1_^%P3_`/0(C_[_`)_^)H_X7!/_`-`B/_O^?_B:\XHH]A3[
M![:?<]'_`.%P3_\`0(C_`._Y_P#B:/\`A<$__0(C_P"_Y_\`B:\XHH]A3[![
M:?<]'_X7!/\`]`B/_O\`G_XFC_A<$_\`T"(_^_Y_^)KSBBCV%/L'MI]ST?\`
MX7!/_P!`B/\`[_G_`.)H_P"%P3_]`B/_`+_G_P")KSBBCV%/L'MI]ST?_A<$
M_P#T"(_^_P"?_B:/^%P3_P#0(C_[_G_XFO.**/84^P>VGW/1_P#A<$__`$"(
M_P#O^?\`XFC_`(7!/_T"(_\`O^?_`(FO.**/84^P>VGW/1_^%P3_`/0(C_[_
M`)_^)H_X7!/_`-`B/_O^?_B:\XHH]A3[![:?<]'_`.%P3_\`0(C_`._Y_P#B
M:/\`A<$__0(C_P"_Y_\`B:\XHH]A3[![:?<]'_X7!/\`]`B/_O\`G_XFC_A<
M$_\`T"(_^_Y_^)KSBBCV%/L'MI]ST?\`X7!/_P!`B/\`[_G_`.)H_P"%P3_]
M`B/_`+_G_P")KSBBCV%/L'MI]ST?_A<$_P#T"(_^_P"?_B:/^%P3_P#0(C_[
M_G_XFO.**/84^P>VGW/1_P#A<$__`$"(_P#O^?\`XFC_`(7!/_T"(_\`O^?_
M`(FO.**/84^P>VGW/1_^%P3_`/0(C_[_`)_^)H_X7!/_`-`B/_O^?_B:\XHH
M]A3[![:?<]'_`.%P3_\`0(C_`._Y_P#B:/\`A<$__0(C_P"_Y_\`B:\XHH]A
M3[![:?<]'_X7!/\`]`B/_O\`G_XFC_A<$_\`T"(_^_Y_^)KSBBCV%/L'MI]S
MT?\`X7!/_P!`B/\`[_G_`.)H_P"%P3_]`B/_`+_G_P")KSBBCV%/L'MI]ST?
M_A<$_P#T"(_^_P"?_B:/^%P3_P#0(C_[_G_XFO.**/84^P>VGW/1_P#A<$__
M`$"(_P#O^?\`XFC_`(7!/_T"(_\`O^?_`(FO.**/84^P>VGW/1_^%P3_`/0(
MC_[_`)_^)H_X7!/_`-`B/_O^?_B:\XHH]A3[![:?<]'_`.%P3_\`0(C_`._Y
M_P#B:/\`A<$__0(C_P"_Y_\`B:\XHH]A3[![:?<]'_X7!/\`]`B/_O\`G_XF
MC_A<$_\`T"(_^_Y_^)KSBBCV%/L'MI]ST?\`X7!/_P!`B/\`[_G_`.)H_P"%
MP3_]`B/_`+_G_P")KSBBCV%/L'MI]ST?_A<$_P#T"(_^_P"?_B:/^%P3_P#0
M(C_[_G_XFO.**/84^P>VGW/1_P#A<$__`$"(_P#O^?\`XFFM\7[HXVZ5"/K*
M3_2O.J*/84^P>UGW/I"PN3>:?;7)7:9HED*@YQD`X_6K%5=,&-*M`.GDI_Z"
M*M5YSW.U;$5U_P`>LW^XW\J^;*^D[K_CUF_W&_E7S977A.ISXCH%%%%=AS!1
M110`45I:AX?U+2K*VN[VV\J"Y`,3%U.[(ST!R./6LVDFGL#36X4444P"BBB@
M`HHHH`****`"BBB@`HHI\<;S2I'&I9W(50.Y/2@!E%:.KZ#J.@RQQZG;&!Y5
MW(-ZMD?4$UG4DT]4#5MPHHHI@%%%%`!1110`4444`%%%%`!1110`4444`%=U
M\//#NE:S9ZE/JML9_LY7:!(RX&"3T(]*X6O3?A0$.E:P)"0A*[B.PVMFLJ[:
M@VC2DDY:C++P[X5\8Z;=_P!@6]S8W=OR/-<G.0<9!9AM)';!X_/B[7POJ]]9
M"[M;)Y8#+Y09&4G=G&,9S^.,5V5MXD\,>#]+ND\.S7-]=W/\4JD!2!QDE5X&
M2>`2:L>&]0N-.^$][>6S[9T=RKGG!)`S]>:R4IQVVOI<OEC+_@'`WOA_5-/U
M--/N+.07DBADB3$C,.>FW/H:T+CP#XDMH'FDTN0HHR0DB.WX*I)/X"NG^&,\
M]_>ZI?W<TMU>0P*D;3.7;!W'&3SU`JCX(\2ZU?>-88[F\N)X[@N)8G<E%&"<
MA>BX('2K=2>MK:$J$=+]3B[.RN-0NX[6SA>:>0X5$&2?\^M>@^!/"^L:%XJC
MEU*R>&-X)%#AE=<\<$J3C\:VO#=I;P>.O$\L"+OCV;0/]H;F_45B?#OQ%J^H
M^*KB"\NYIX98WD=)"2$(/&W^Z.<8''Z5$ZDI1=MK%1@HM7.=U/0K_7/&6L0:
M7;^=)'<2.R[U7`W=>2/6L?3M'O=5U#[#8P>;<\_)O5>G7DD"O2/!O_)2/$7U
M?_T8*P?A[$Z_$&4%3E!-NX^[VY_&J51I/R1/(FUYLY0:3?-JK::EL[WBN8S$
MGS'<.O3CCUZ5IWG@?Q!81I)<:<RH[K&")$;YF.!G!.!GN>*[OPE"H\6>++I5
M#3Q2E4XR>2Q/ZJ*\\E\5ZY,DZ2ZG<NLQ#,K/D`@[AMS]W!_NXJE.4G9>0G&,
M5=G5:C\,+B+P_:36$5Q+JC;?M$+S1[$^4[L'COCN:\_92K%6X(.#7J'BC5+^
MW^&NBW4-[<QW$IBWRI*P=LHQ.2#DUY>2222<D]S11<FGS!423T$HHHK8S"BB
MB@`HHHH`T-!MHKW7]/MKA-\,UPB.N2,@L`1D<UZ'?:7X(T[Q%#HUQI-P+B4J
M%=99"@+=,G?G]*X'PO\`\C5I7_7W%_Z$*](\2^+]/T+Q8D5QH<-Q.JHWVL%?
M,4'TRN>![BN>KS.5EV-J=N6[.6O=%;PG\0K&#38C?9*2PPR.`QSD;2W0<@\_
M2L_QO/?:CXJ?[9IWV2Z9$06Z.)2>..5ZDY_E77Z]I"V7Q,T6^2:1_MLNYDD;
M.PKCI[<CCM_*W#;Q3_&*Y>4`M#:!X\]CM49_(FI52UI;Z%.&Z\S@QX`\2FW$
MW]EOL*[\&1-V,9^[G.?;&:O?#6)X?'"1S(R21QR!E<8*D#!!'8U83Q/KC?$0
M1F[N-GV[R?LVX^7LW;<;>G3O^-=.T,47QBC:(`-)9EI,?WL$?R`ISG*S4NJ%
M&,;IKN>?>)[::[\;:E!;1233/<N%2-2S'Z`5)<>`?$EM`\TFER%%&2$D1V_!
M5))_`5W/A:%/^$V\4W00-<1.5C^A))_]!%<_X(\2ZU?>-88[F\N)X[@N)8G<
ME%&"<A>BX('2G[25O=Z(7)&^O4XVPTZ[U2[2UL8'GG?HB#]3Z#W/%;I^'7B<
M#_D&?^1XO_BJ[GP_!''XY\406:>5(ZJ4G5-RQL1D_CN.<=\'TJ&[?4?"?@G4
M(M;UGSK^X)^RE)V9QP!P3AN.I[#\:3K2O:/D-4E:[.=TV_U.'X;7UK'HZ261
M9@]V9E&TDC/R=21Z_3TKG=(\,ZOKJ.^FV3S1H<,^Y57/IEB`3[5V>E?\D:U#
M_?;_`-"6IO$5W<Z%\-M$32YI+83"/S)(B5;E2QY'3)H4VFU%:M@XII-]CS[5
M-(OM%N_LVHV[038#`$@@CU!'!_"JL4;32I'&"SNP50.Y-6=1U:]U9HFU"X>X
M>%/+1GY;;G/)ZGKU/-;WPZTG^U/%<+N,Q6@\]N.X^Z/S(/X5LY.,;R,DKRLC
MK[GX?Z+_`&-/9009UF"T60R"5^7(.#C.,$J1TKRA$:1U1%+.QP%`R2?2O;;+
M0M8@\=76L33VILIT,7EJ[;PHQMXVXSD>O<UQRZ4NB_%V"+[.SP2S>;$JKG`8
M'G'HIS],5A2J6O=WTN;5(;:6,6/X>^)I8ED72V"L`P#31J?Q!;(^AK*N=$U"
MTU4Z;+:2?;1C]RGSL<C/&W.>*]A2SU+2?$M_K&J:R@T8H=D3R$!,XP-I^4>F
M1R?QKG?AO*NI>(-<U*61WEP`CN=SJA)]?95'X4U6E9R$Z2ND<??>"/$&G6KW
M-SIL@B3EBCHY`]2%)./>J6GZ#J.JVES<V-L9HK89E(=05X)Z$Y/3M7I>F^)_
M#6FWDL[>*-3N_,!#170=T'.<@>6,?A5;X>3Q1V_B2>RQY2REX>,#;ABO'Y4>
MUFHMM"]G%M),XFX\%Z_:Z>;V;3)5@5=['<I91ZE0=P]^..];/@KP&GB&TFN]
M1^T16Q'^CO#(@WD$AL@@GC`]*VOAIK>HZOJ&IQZC=RW*-&)-LAR`2><#L.>@
MXIOPJN)C+JUL9I#!"%\N,N2J9+9P.U$ZDTI+JK#C"-T^YP.KZ)?Z%<K!J4'D
MR.N]5WJV1G&?E)]*[;3"/#'PMN;W&VZU-MB'H<'('Y`,?QKBXS?>(M8MK>XN
M9[B:618E>5RY4$^_89S75?$^\CAGT[1+8XALH06`]2,`'Z`?^/5<[R<8LF-D
MG)'!T445L9!1110`4444`%%%:.D:#J.O321:9;&=XUW.-ZK@?5B*3:6K!*^Q
MG44^6-X97CD4JZ,593V(ZTRF`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%:E]X;U73HK22[M#&MY@0?.K%\X[`Y'4=:3:069E
MT5HZOH.HZ#+''J=L8'E7<@WJV1]036=0FGJ@:MN%%3V5E/J-Y%:VD9DGE;:B
M`@9/U/%2ZII-YHMX;34(##.%#;=P;@].02*+J]@L]RG1113`**<B-+(J(,LQ
M``]35[5]"U#09XX=3M_(DD7>HWJV1G'\)-*ZO8+,SZ***8!1110`4444`%%%
M:6H>']2TJRMKN]MO*@N0#$Q=3NR,]`<CCUI72"S,VBBBF`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%:4GA_4HM%35I+;;8R'"R[UYYQTSGJ/2LVDF
MGL#304444P"BBB@`HHHH`****`"BBB@`HHHH`****`"BBM+3/#^I:S!<3:?;
M>;';C,K;U7;P3W(ST/2DVEN"3>QFT444P"BBB@`HHHH`****`"BBB@`HHHH`
M^CM,_P"07:?]<4_]!%6JJZ9_R"[3_KBG_H(JU7D/<]%;$5U_QZS?[C?RKYLK
MZ3NO^/6;_<;^5?-E=>$ZG/B.@4445V',>D^!_'.HWFIZ=HLD%H+8)Y>Y48/A
M4..=V,\>E-\;^.=1MM2U/1$@M#:E?*WLC%\,HSSNQGGTKG?A[_R.^G_5_P#T
M!J;X_P#^1VU'_>7_`-`6N?V<?:[=#;GE[/?J=[XAT`:[X6T02WL%C;01(\T\
MQP%!0`8Y`R3ZD5POBKP7-X:@M[J.[CO+.?A947;SC(XR1@CH<UT?Q#)_X0S0
M!DX*KD?]LQ3-?.?A'HQ;)_>)_)ZBFY12UT;*FDV_0RM,^'YFTN*_UG5K72HI
MP#")L$L#SSEE`XP<<_A5#7_!UUH-]:QO/'/:W;!8;F,<'IU'8\YZ_C7I7B*\
M1-.TZYM_#4>NP.GRD*',0(!&!M8X/K[5RGB?6;V^M-%M[GP^=)MQ=`PAG&<+
MP0$V@J.?2G"I.3OT^7_#A*$4K$=[\,8].:1[[7K6WM]O[J25`AD?DE<%OZGZ
M5#9_#RU>&W%_XCL;2ZN%5TM\!F(;[O5E))^GYU:^+A+:WIZ%B$\@G!/`RQR?
MT%=#<:38^'/[/L]-\*KJQFY>Y=0VP\<EBIQGKV'I2]I/E3OJ_0.2/,U;8X"]
M\'7&G>*[;1;F=0+EU$<ZKD%2<`[<]>.F?QK;/PO$%\8+[7;6V61@ML64;YSQ
MG"EAW('!-;/B[_DI7AW_`(#_`.AFJ'C[PYK&H^,+>>RM9I8I41$E096,@\[C
M_#USDTU4D[:VT$X)7TOJ<GKGA._T778],*B>2<C[.R#`D!.!UZ'U';Z<UT*?
M#*)#';7GB&R@U&09%K@$D]L98$_]\_G73>([NVC^(/AN*9U\Q!)N)[%AA<_4
MBD\0:A)I^NN4\$#46&UTO(XPQ;WR(R001CDYXI>UFTK=A^SBKW.`L?!EU-XM
M.@WLPMI0"WFJN]2`,@CD9!JLOAW=XP_L+[3_`,O!@\_R_P!=N?ZUV=CJ=Q??
M%BU?4+(6$ZVYC\DRB3^`L.1QT-1Q>&]3/Q5>Z%I*+5;DSF=E(0KC/!Z$\XQ5
M^T:W?0GD73N5M`\&V5GXZEL;Z_MYA:!66&:)?])W*20%+'IU[TWQMX<L+#61
M=Z=J-I#</<1(MC"BJT/`^;`/J`>@ZU<O&"_&R`L0!E1S_P!<JR_&VGW<?CU[
MQ[69;62>$),4.QCM7C=TSP?RJ8MN:;?0;246DNH>.M)U=M?T^RNM1;5+F>/$
M6(%BVY8C&`<?C5AOAA%$4MI_$-G'J+IN6U*C+'G`&6!(XZ[?PKI->EBA^*.@
MM,0%,#*"?[QW`?J17)^,_#&M7WC.[:VT^XG2X93'(JDIC:!RW08QW(I0FVDK
MVT'**5W:YQ;J4=E/53CBNT^&6GQMJMSJUSQ!I\1;)Z;B#_(!OTKBV4HY5AAE
M."*]4T>UTO1/AQ''K5U)9IJGS/)&I+G=R`,`_P`(';O6M9VC;N9TE[U^Q1^(
M*1Z]X7TOQ%;)VV2X[`^OT8$?C7.^&/!<OBC3[R>WNUBEMV"K&R9#DCNV>/R-
M=[H=OH&J>%[_`$#1-1ENT*,W[]2"A;IC*KQN&:Q_AZLEMX8\1*VZ.6(,#V*L
M$:LE-Q@TNC-'%2DF^IS>H^#/)U:STW2M2M]2N;C<)!%@"$KUW8)XZ^G3I6M_
MPK*)V:UA\163ZFJY-K@9#8R1][=CWV_A57X62Q1^+BLI`>2W=8\]VR#_`"!K
MJKG5;G3]?E6V\!"2=92$NXE`WY_BWB/`R#SSQDYISG-/E3_(48Q:NS@='\)W
M&HZO=V5W<PV`L@6N9)CP@!QD=C^8'O6MJ'P\2/1KC4-(UJVU-;?+2+&H&`!D
MX(9N?;BMCP_IEKXD\6ZYJ&L:>//M67%EO#@-@@YZ!ON_3FMW2YS<>&=7D_X1
MU=$7R7`0*%,OR'DC:IX]_6E.K)/3R'&G%H\5HHHKK.<****`"BBB@`KIO"WC
M#_A&K*^M_L7VC[5CYO-V;>".F#GK7,T4I14E9C3:=T%=):>+OLO@RXT#[%N\
MYB?/\W&,D'[N/;UKFZ*'%2W!-K8U?#OB*\\-:C]KL]K;EVR1O]UU_P`]ZZB3
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MP\1F5A@#ME2I!(SUXXKC6.YB<`9.<#H*2BG&"C>PG)O<****H04444`%%%%`
M%O2[W^S=5M+WR_,^SRK+LSC=@YQGM7;3?$W3[B[6ZF\+6LERN"LKRJ7&.F&,
M>>*\^HJ)4XR=V5&;CL=)<^-;V^\36FKWD:/]D8&.!#M4#TSSR?6DO_&5U/XM
M&O64(MI@%7RV;>"`,$'@9!KG**/9Q[!SR[G?M\3X!*UW'X<LUU$KC[47!.<8
MR?E!Q[;NG>L'2_&%S9>*GUR\B^US.&#)OV#D8`!P<`5SU%)4H+H-U)/J=%:^
M,KRP\476LV<:I]I=C)`YW*5)SC/'3UK;D^)L4/GS:9X>L[2]F^]<;@Q.3DYP
MJD_B>M<%10Z4'N@522ZGIGPU\ZZM=<OI)#>7$O#VC%1YQP2"Q/J21Z=<Y[;'
M]BV5_I5\=<\+V6C0Q1[EFBEC+=\D%`,8XZ]<UY#;7=Q93B:TGE@E'`>)RK#\
M14UWJ^HZA&L=[?W5RBG<%FF9P#ZX)K.5%N5TRU425FC8M/%WV7P;<Z!]CWB9
MB1/YN-N2#]W'/3UJWH?CY].T?^R]2TV#4[1/]6DI`VC.<'(((]..*Y"BM73B
M^AFIR1L>)-?&OWL4D=E#9001B**&+HHSGK@#J3T`JYX:\7?\(UI]_##9>9<W
M8P)_-V^7@$#Y<'."2>HKFZ*?)%KEZ!S.]R2&9[>>.:-BLD;!U;T(.17I&D>)
M8_&7C32Y3#_9T]HDAWK*',PQ]S!48[^O&?K7F=*"5(*D@CD$=J4X*01FXGMW
M]G_;=;EBO/!UB+5W?=?/)$S,.<-M`W9/U[UYU-JX\&>-+UM`9'M4;RS&Y+*P
MP,KG.>#G!SV^M8LOB#5YXGBFU6_DC<;61[AR&'H1FL^LX4K;ERJ7V.\D^(]D
MLKW-IX7L8;XDLMPQ5B&/4G"`GJ>XK)\-^,3X?LM1@-EYYO?XA+LV<$=,'/6N
M9HJ_91M:Q/M)7N=#X1\5?\(K=W$WV3[3YT83'F[,<YST--\+^+)_#.J374<"
MS13C$D1;;GG((/8CZ>M8%%-PB[WZB4FK>1Z9X1N+3Q%XMDUB+3(-.MM/MSE8
M\8+MGYB0!VW=NU<%K>HMJVM7=\V?WTI89[+V'Y8JA12C347<;G=6"BM+5?#^
MI:+%;R:A;>2EP"8CO5MV,>A..HZUFU::>J(::W"BBBF`5ZCX%OY=+^'&IWL"
MHTL$TCJ'!*DA%ZXKRZO2O",,MQ\+-9B@C>65Y)`J(I+,=B\`"L:_PJ_<UI?$
M3>'O%T'C6Z.C^(M.M7,H8PM&I`!`Y'))!QGD$51\,^'M2L/%^KZ;IFK&Q-NH
MS(8%EWH2"N0>,X/6H_A]X3U*/Q#'J-]:36EO:ACF="A9BN``#SWSGIQ6]X2U
M&+5?B%K]U;D-$R*JL.C!<+G\<5C*T>91VL:1O*W-N<5H?A"?Q`][=W5_%:6=
MO(PENIN<MU/&0/J2>_>H?$?A5-%2TFL=2@U.WN6*+)"!]\8R."1W'>MGPQJ6
ML:;;7_DZ(VK:5/<LDD2KN(?OP`>,8SD8Z<BM'7=`T?2[K0=;MK>73XYKR/SK
M:;C:"=V2I)VD8Y'3ITK3GDIZO0CD3B9\7PS2&WM_[7UVTL+J?[L#*"?H"6&3
MSV'YUDZ1X'U#5M<N]/22)$LY-D]P<E1SC@=2>#QQ]16_\2M`U74/$L,]G97%
MS"\"HK1(7"D$Y!QTZ]ZM^#;"X_X0_P`0Z.BB/4T=T:/<,Y*8`STZ@BI]I+DY
MK_\``'R+FY;&5+\-5N+2:31==M-2FA^]$@`]>,AFP3C@''UK+L_!S7WA&ZUJ
M&\S+;%A):F+D;3S\V?3GI70_#/1-3TW6;J\OK6>TME@*L9T*;CD'H?3!YIW@
M+5(+SQ%K>FL=UKJ#221@]^3G\U/Z4W.2O9WL"C%VTM<YKP[X1.N:1?ZC->?9
M+>S!.3%OWD#)[C';\ZFT'P-)JFF?VGJ&H6^F6!X26;!+'..A(`'7OVZ5TGB>
M`>$?AW#I"M^_NY2'([C.XG\MHK5BN8Q\/=)GM]#CUM(XT5H"`Q0@8+`%6R0>
M.!WI.K*UUU8*G&]GV.!\2>"YM!LXK^WO(;_3Y2%6>+C!]QDC'N"?PK7/PR$=
MO;W5SK=O;V<D0=YIHPNQCC"\M@]>N14WB;7+V?P?):GPL=)LFF50S,$`;.[A
M-JGG!YZ5/\2F8>&=`4,=I7)&>"0BX_F::G-V5PY8*[,#5O!2V'AH:S9ZDE["
M)-CA(\`#<5R&W'/('YU#:^$3-X.GU^>\\A(R1'%Y6?,Y`'.1C)XZ'I70?#N9
M-8T'5O#L[?ZQ#)$3VR,'\CM-+\0YDT;P_I/AR!N4022X[XX'YG<?PI\\N;DZ
MW_`7+'EYOZN>=4445T&(4444`=]\(U!UZ])`R+;@^GS"NAT'Q-)XJUW4M#U:
MPM9;6,.5VH>BOCY@2>>1R,8(KG_A'_R';W_KV_\`9A3]2^(HTZ>^M]'T6TLK
MDRLCW`P2^"1N("C)[\D_C7)4BY3:2.B$E&"NRA8_#\ZQ=:REC>!#8W#0Q(Z9
M#\G&6SQT]#5/4?!GDZM9Z;I6I6^I7-QN$@BP!"5Z[L$\=?3ITKI/AY-(WA?Q
M%,7;S2&<OGG.QCG/K6/\+)8H_%Q64@/);NL>>[9!_D#5\TUS:[$\L7;3<M?\
M*RB=FM8?$5D^IJN3:X&0V,D?>W8]]OX5SVD^$M1U;7I=*5!#+`3Y[/TC`.,\
M=?;'7Z<UZ#<ZK<Z?K\JVW@(23K*0EW$H&_/\6\1X&0>>>,G--\(7SZAXE\3>
M=`MI?R[!Y/F!BFT%3\PZ\XY'K4*I-1;?Z%<D&TCE-;\"VVFZ7=75GKUK?26A
M'G0HH#("<<X8X.>QQWK=\?AVTCPP(GV2$J%;^Z=J8-</<>&-9M8;F:YTZXBB
MMN9))%VKUQP3][GTS7=^.O\`D'>%?]]?Y)5/XHZWW_(2V>EC+\7:)J-SXKTK
M3M3U@WCW*A4E^SK&(P6(^Z#@T\_"T0WQ@O-=MK<2,%MMR#?.<#.%+#H3C@G\
M*V/%W_)2O#O_``'_`-#-8/C]F_X6);\GY1#CGIS2A*322=M!RC%7;74SX_#>
MH:%XZL]-2[6&X:16AN43<-ISAMI^AR*F\1:%JVI>.3ICWGV^\=$_?M&(E"[<
M\@9``]OYUU/BC_DJ6@?[B_\`H35:M98H_B_>K(0'DLE6//<X4G]`:7M'\7D'
M(MO,Y6_^',%I;70B\06DU];1&5[78`V`,G^(D<>WI572?`]M=Z5;WNIZ_9:<
M+D%H4DP2R@X).67OZ9JKK7A;6VUS4G.GW#(LDDQF*_(5R6R&/!X[9S^-=C9Z
M18:%X4TZ[M?#@URYO%1I2R!RN5SG[K8`SC@?4U3FTE[UV_0E13>QR6M>$KCP
MMK>GAYTN+>>13%,HVYP1D$<XZ^IK7^+O_(<L?^O;_P!F-:WQ%!$7AP-"(")N
M8E((C^[\HQQQTK)^+O\`R'+'_KV_]F-*$G*46_,<HJ*DEY'`4445U&`4444`
M%>MV6LS^'?A397UG'"TJX&V125.7(/0BO)*]<L]2M]*^%5E=7=A%?Q*`#!+C
M:<N>>0>GTK"OJEZFM+KZ%/Q%]G\3_#E-?NK6*"_C`^=!UP^TC/7:>H!Z5H>(
M=`&N^%M$$M[!8VT$2/-/,<!04`&.0,D^I%<-XE\;W.OVD=C#:Q6.GQXVP1\Y
MP.`3@#`[``?C71?$,G_A#-`&3@JN1_VS%9\DDXK;5_(OF3NSG/%7@N;PU!;W
M4=W'>6<_"RHNWG&1QDC!'0YK1L_AY:R06_V_Q'8VEU<*KI;X#,0WW>K*23]/
MSJ_KWS?"31@3UD09/_`ZW+C2;'PY_9]GIOA5=6,W+W+J&V'CDL5.,]>P]*;J
M2M:^NH*$;[:'GVH^"]0L?$\.BJ8Y9;CF&0<*R\_,?3&#D<].]:][\.K>WM[A
M8?$-G/?V\9D>T"@-\HRP^\3T]ORK;\;MJ,?CS1WT>(2WJ0%HT.,-@MD')'&,
M]ZL)IEGXVMKN35O#]SI&H1ID7+*4#'UR0-W3D$'`[T>UE9-L/9QNU8X?PUX.
MN/$$$MY+<Q6.GPDB2XEZ9QG@9'3C))'6K.N>!'T[23J>FZE;ZI9QG$KP@`KS
M[$@CUY_"NN\)S1GX9_N--CU5X7?S+1L?.=^>A!R<$$#'TJC?Z_>KX8U."'P8
M=,M7CQ+(2(E!;Y0=I1=QZ=*/:3<]._D+DBHZGF=>O?#[4M,NA>VFD:?]F@MX
MH]TLF#+,QSDL?J#@9_+I7D->H?"S3+ZPDU-KRRN;=9(X]AEB9`WWNF1S5XA+
MD)HWYCS!OO'ZTE6;W3[S3Y`M[:3VS/RHFC*$CVR*K5NC(****`"BBB@#U3P1
M?/I7PUO[ZW2,S0R22`.."0!UQBGI=Q^.O`5_>ZI:01W5H)/+EC7&TJH;C))'
M8$9IG@FZBL?AI?7,]LES%$\C-"^-KC`X.0?Y5S.N>/YM1THZ9INGP:99,,/'
M$<D\Y(&```>_'XUQ\CE-V77<Z>9**OV.JM](?6_A7I]JL\5NH(DDFE.%1%9B
M2?P_R*Y3Q%X#;1M'35++4H=0L\@,\:XQDX!&"01GCK6YJ9(^#%D`2,LH/O\`
M.:CTXD_!B^YZ2G_T-:<7*.J?44DGIY&1I/@>VN]*M[W4]?LM.%R"T*28)90<
M$G++W],U4\2>"[S0-1M;=)5NX[P[;>1!M+'@8(SQR1W-=E9Z18:%X4TZ[M?#
M@URYO%1I2R!RN5SG[K8`SC@?4TOQ$6Z\KPXME`(;OSOW4*D81\+A0>G!X]*:
MJRY]]-1.FN4Q?^%9Q1E+:X\1646I.N1:D#);L`2P./?;^%8/AWPE>>(KV:*)
MXX8+<_OYW^ZG/8=SP?3IU%=_:PKXQG>T\3>&)[2[C0@7J*RJ2..&_'@98&H_
M`D,5IH^OZ?#%'?RV]S(ODL0!,H&%!SD8.TTO:R47=ZC]G%M=CF;_`.'@73)K
MS1=9M=5%N"TJ1``@8SQAFR?;BN,KU6V\0WMK!=_8_`9L5\EFE?B%=H'<F,9Q
MGIUKRJMJ4I._,9U%%6L>@>'_`(A7,=[I^F6&DV<5JS1Q.B*=[$X#-D8&3UY!
M^M,^*]A9VFKVDUM&D<]PC-,$&-V#PQ'J<GGOBM3POX9_X172?[<OK*>\U)E_
MT>VAC+LF1QT!P3W/8>]</XE;6;S47U#6K.YMVF.$\V%D4`=%7([5G!1=2\=O
MS+DVH6D8U%%%=)@%%%%`!7??"-0=>O20,BVX/I\PK@:[_P"$?_(=O?\`KV_]
MF%95OX;-*7QHZ#0?$TGBK7=2T/5K"UEM8PY7:AZ*^/F!)YY'(Q@BH/`VG+;'
MQ1I]L=RI,88R3[,!FLG4OB*-.GOK?1]%M+*Y,K(]P,$O@D;B`HR>_)/XU9^&
MLLDFB^()6=C(PW%L\D[6.:YY0:BW:RT-5).26YG-\,7DL)WLM9M+N]MQ^]MX
MAD*PZKNSG/!QD#\*Q?#?A9==BN+FYU*VT^TMR%>68\[CT&"0/UKH?A&3_:NH
MC/'D#_T*I/!6B:?)HVIZS<:?_:=U!*ZQVQ&X'`!QMYR3GN#TX%:.<H\R;[$J
M*=FD9&O>`SI>B_VKI^J0:E:*<2/&`-O.,C#$'GKSQ_)^E^`5N-(@U#5]9M=+
MCN!F%90"6'OEE'OCFNOU20R_#+49#HRZ/N&1;*`/XE^8@`8)]QVK+T6\O[C2
M]/TCQ#X9FO[%T7R;F*/=L1AA22.`??*D#]952;COU\AN$;G(77A.\C\4#1+2
M2.ZE?#1RKPI0C(8^@QSW]LUT'_"LHG9K6'Q%9/J:KDVN!D-C)'WMV/?;^%;.
MC:-8>&_B>UI;/B.>S+Q(S9*,3RN?HIZ]JGN=5N=/U^5;;P$))UE(2[B4#?G^
M+>(\#(///&3FB563LH]O(%"*W/*;RTFL+R:UN4*30L4=3V(KJO"GB35-,TQH
M-"T)+JX5R9KD0-(2I^ZIVX(Z'J36)XINYK[Q+?3W-L+68R;7A#A]A``(W#@]
M*T-!_P"$KTBQ%WH<%S]GO/XX8%FW;21R,$KU/7&:VE[T-3*.DM#K?'C17?@B
MTO-8M8K;6'V[$'WQS\P]<8.<'H2.]>65ZYKT3ZE\-3>>)+:.+4HX\HQ0*X;=
MQ]"PQD?I7D=3A_A:\RJVZ84445N9'T=IG_(+M/\`KBG_`*"*M55TS_D%VG_7
M%/\`T$5:KR'N>BMB*Z_X]9O]QOY5\V5])W7_`!ZS?[C?RKYLKKPG4Y\1T"BB
MBNPYBUIVHW.E7T=Y92^5<1YVOM#8R,="".AI-0U"YU2]DO+V3S;B4@N^T#/&
M.@X[56HI65[A=VL:6H^(=2U:SM[2^N?-@M@!$OEJNWC'4`$\>M)<:_J5UI$.
MES7.ZRA(,<6Q1@C/<#/<]ZSJ*.5=AW9LZ7XMUO1K?[/8:A)'#V1E5POT#`XZ
M]J@U+Q#JFKW45Q?WDDTD1!CR`%4^H4#';TK-HI<L;WL',[6N:&KZ[J&O3QS:
MG<>?)&NQ3L5<#.?X0*NP>-O$%M8"RAU.58`I0?*I8#V8C</;GCM6%11RQM:P
M<SWN=)IOB.[U/Q;I-WK-XKB"5%\QPJ!5SW(`_,UN>+_&E_8>)ICH6JJUL\29
M\LI*F<<XSD`^N*\_HJ73BW<KG=K$]W>7%_=R75U,\L\ARSL<DFMNW\?>)+:!
M8H]4D*KP#)&CM^+,"3^)KG:*IQB]T2I-;,LS:C>7%_\`;9KJ9[K<&$Q<[@1T
MP>V.U:USXY\0W:QK-J<A$;AP%1%R1TS@#(]CD5@44.*>Z#F:ZEV]UB^U#4_[
M1N;AC>94B50$((Z$;<8QBKFI>+M:U>&**^OC+'$XD0>6BX8=#P!FL:BCE78.
M9]S1U;7M1URXCGU&Y,TL2[48(J8&<_P@5H#QYXC%I]F_M27R]FS)1=^.GW\;
ML^^<USU%')':P<S[BDDDDG)/<UHZIX@U+6HH(M0N?-CMP1$HC50O3^Z!Z"LV
MBG9"NR]I.LW^AW37.FW!@F9"A;:K9'!Q@@CL*LP>*M7MA>B&[""^8M<`1)\Y
M.0>W'4],5D44.*>Z&I-#XI9()4EA=HY$(970X*D="#VKH!\0/$HA$7]J/M"[
M<F*/=C_>VYS[]:YRBAQ3W0*36Q?L-=U+3=0:^M+R5+E\[Y"=Q?/7=G(;\:T9
MO'7B*<2B74G99H_*=?+3:5Y[8P#R>1S^5<_12<(O=`I-=0HHHJA!1110`5O>
M#-!3Q#XBAM9\_9U!EEP<$J.WXD@5@UU_PRU&*P\6*DS!1=1&%2>FXD$#\<8J
M*C:@VBH).2N;FM_$%O#FIOI6AZ=9I:6K;&#(?F;O@*1CG/)SGK6`FG6?C37Y
MY[$6^CVD<*RW'F8VQGHQ4#`(S_NT_P`8^$=6A\27DMM87-S!<2-,CP1LXY.2
M#CH<GO6GX'\'1_VA>-KUBSSVL4<L5JY!W!LD$C//W<8/KS6*Y(0YHO4U]Z4N
M5E+4/AXD>C7&H:1K5MJ:V^6D6-0,`#)P0S<^W%5M`\!3^(M`;4+6\1)1+Y8A
M=,+@8R2V>.#GH>E=]I<YN/#.KR?\(ZNB+Y+@(%"F7Y#R1M4\>_K7/>'R5^$.
MJE20=TG3_@-2JD[;]4-PC?Y&5J?P\%MH<VIZ7K%OJ4<`)D$:@``=<$,02/3B
MJ7ACP3/XAM9[V:[CL;"'.9Y%SDCD\9'`'4D_UQO>`"?^$*\1C/'EM_Z+-6-,
MMYM4^#LMMIJ&2X5F#QI]YL2;B/<[<<=ZISDKJ_7<2A%V=NAIZ)H`T'P?K:PW
MT%];3Q2/%/">&&P@]"1U!Z$URNG6>J-\-+VYBU<Q6*LP:S$"G=R,_/G(SGI_
MC6_X1TJ^TOP#K(OX)(#,DKI'(,-C9C)7J.G>J.D_\D9U#_?;_P!"6H3LWUU1
M5M%Z,QM!\!/JFCG5-1U&'3+,_P"K>50=PSC)R0`,\#GG\L]7?Z0VB?"F]M#/
M%<*#OCFB/RNC2`J?R^OU-5M=LKK6/A?HXTJ%YQ&(S)'$N6.%*G@=<-_C3GT^
M[TSX.W%O?1M%-C?Y;'E09`0#Z?2B4G*S;Z[`HI7LNAS>D^![:[TJWO=3U^RT
MX7(+0I)@EE!P2<LO?TS3=4\"MH^NV5I>:E!'8W>=EZP`"X&3N!.!V[]_PKJ;
M/2+#0O"FG7=KX<&N7-XJ-*60.5RN<_=;`&<<#ZFJ_P`501H^C!H1`06S$I!$
M?RK\HQQQTJE4DYVOH[DN"4;V+/CCPIHQTZ":.[L-,>"*1E18D0W1`&`.1GI[
M_>KD]!\#2:IIG]IZAJ%OIE@>$EFP2QSCH2`!U[]NE=+\3K"ZOM/TB>TMI9XH
MHG:1XD+!!A3DXZ#@\UJ17,8^'NDSV^AQZVD<:*T!`8H0,%@"K9(/'`[U,9RC
M!6>Y3C%S=T<#XD\%S:#9Q7]O>0W^GRD*L\7&#[C)&/<$_A7-5Z%XFUR]G\'R
M6I\+'2;)IE4,S!`&SNX3:IYP>>E>>UT4G)KWC&:2>@4445H0%/C_`-:GU%,I
M\?\`K4^HH`]A\=>,;_PO/91V,-M()T9F\Y6.,$=,,/6L?5[;3O&O@RXUZVM$
MM=1MLM,5_B*C+`G^+C!!//;UI_Q2TN_U&[TYK&RN;D)&X8PQ,^WD=<"G6UD_
M@_X9:@FI;8[J^W!8B>064*!]<`FN**2A%K<ZI-N33V,/3_ARU_HMGJ9U6&"W
MF4O,98\"%>><[N?TJ&S\"PWW]L-;ZO'+%IPW+)'$&6;Y2W!#<=,=ZVM;9E^#
MNF!6(#,@(!ZC+'^E-^&$?VK1->M8R/-D0*!]58"KYY\KE?J1RQYE&QS/A'PK
M_P`)5=W$/VO[-Y,8?/E;\\XQU%.\-^#Y_$#W,K74=I8VI(EN)!P,`G@9`^N2
M,`UUWPOT+4=-N;^YOK26VC9!&HE4JS'.3@'M[TWP/:1WOA'6K?4`[6,MP5Q`
MK/*#@9(503_=(X/?/%.=5IRL^P1IK2Z[F7?_``YL[/1)M33Q%;RP(C-&PB&V
M1AG"AMYY)&.,UPM>@>+[FTT?PE!H6F6NH_9VEWM<W<#Q@G).T;E7)Z=!C%>?
MJ=K`^AS6E)R:NR*B2=D>I3&T^&WAJTF@LXIM7NUP99!G!P"W/7:.!@8S7+:[
MXQ3Q/I1BO]-A74ED7R;B!?X><J<DGOZD<]!76>.-.F\6^&M,U32$-SY:EC&G
M+$,!G`[D%<8ZUQ&F:%J.FWUIJ.HV$]O90747FO.FS&6'9N2/I65/E:YI;ESN
MGRK8VH?AL(+.*77-<M-,EF^Y%(`>PXR67GGD#/UK&\1^#[OPWJ$$$\B2P7#8
MBG0<'G'(['D''OUKIOB7H6JZAX@M[BSM+BZ@>`(IA0N%()SG'3J.3_2I_&V;
M+PUX<TZ[<&]1XRRYR1M7!_4BG&I+1WO<)06NFQ2G^%OV2[5;K7+:"U<!4ED0
M*SR'^$*6_K^%13?"^6SO)/M^L6EK8#`2ZDX+L<_+M)&#QZ^F,\XL?%UC_:6F
MC)P(6('XT[XL.QCT9=QVF-SC/&?EYI1E-\NNXY1@KZ;'.>)O!]QX:U&W@DG6
M:"Y.(YE7&>F05SP1GUK<NOA>+&Y!O-=M;:R*@+<3*$+.<_*%+8Z#KG\*O_$#
MG2?#+'DY'/\`P%*F^*&B:GJ=QI\UC:37,2*T;"(%BK$YY`[<=?:A5)/EUM>X
MG"*OH<;XJ\'7?A>YA5I!<V\_$4J*02>X(YP>?4YK8A^&P@LXI=<URTTR6;[D
M4@![#C)9>>>0,_6N@\5R)IFD^%;;477SX;B%I<G.`@`8_3)%9GQ+T+5=0\06
M]Q9VEQ=0/`$4PH7"D$YSCIU')_I1&I*5E>WF#A%7=CF?$?@^[\-ZA!!/(DL%
MPV(IT'!YQR.QY!Q[]:/%WA?_`(16^@M_M?VGS8_,W>7LQR1C&3Z5UGCAO[/\
M,>';"]D'VR)HV<9R0%7!_4_I3_B9H6HZMJNFRZ?:2W*O%Y>8UR%.[(R>@'/4
M\4XU6W&[[BE!:V\CE?$'@_\`L*VTN7[;YWV\=/*V[.%/J<_>]JVKGX7"RN1]
MKUVVM[1E`6>5`I:0Y^4*6]!G.?PJ_P#$>%K>V\.0OC?&=AQTR`@JI\7B?[2T
MT9.!"QQ^-*,YRY5?>XW&,;Z;6.;\4^$KKPQ?PP-(+F.X'[F1%(+'@$$=CR.Y
MZBMQ?ABT5G!]OUJTM+^X'[JUD`^9NR[MV2>1G`.,]ZU_&4T<7_"(2W!'EJZ,
MY;GCY,YJO\2=`U;5/$=G)8VDUQ"\(C5HQE4;<<[CT7J.3_2A5).RO;<'"*OI
M</BM&T.G:+&V-R!U./4!:\UKTOXL(T>GZ*DARZAPQSGG"UYI6E#^&B*WQL**
M**V,PK8TGQ9K.AVK6VFWGDPLY<KY2-R0!G)!/85CT4FD]&--K8V]2\8Z[JUN
M8+S496B.<HBK&&'H=H&1[&JFD:[J&@S22Z9<>0\B[6.Q6R.O1@:SZ*7+&UK!
MS.][FOI?BG6-%$PT^]:)9FWNNQ6!/K@@@?A5?5M<U'7)UEU*[DG91A0<!5^B
MC`'0=!5"BGRJ][!S.UC?L_'/B&PM$MK?4G$2#"AT1R!Z98$UG6>M:CI^H-?6
MMY,ETQ):3=DOW.[/WOQJC12Y8]@YGW-O4?&6O:M:FVO-1D>%OO(BK'N]CM`R
M/8UFZ?J%SI5['=V,IBN(\[7`!QD8Z'CO5:BFHI*R0-MNYHZQK^I:])')J=R9
MVB!5/D50`>O"@"GZ1XEU;0E==-O9(4?DI@,N?7:P(SP.:RZ*.56M;0.9WN:N
MK^)M7UU$34KV29$Y"`!5SZX4`$^],U/Q!J6L6UO;W]SYL5L,1+Y:KMX`[`9Z
M#K6;1244N@<S[G6?#B2"V\3BZNKZ"TAAB;)ED5!(3P%Y^N?PK.\8:N-:\3WE
MU&^Z$-Y<1'3:O`(^O7\:Q**7(N;F'S>[RA1115DA1110!H:1KFH:#.\VF7'D
M22+L8[%;(SG^(&J4TSW$\DTK;I)&+,<8R2<FF44K*]PN]C2T[Q!J6DV=Q:V-
MSY4%R,2KY:MNXQU()'![50BED@E26%VCD0AE=#@J1T(/:F446079T8^('B40
MB+^U'VA=N3%'NQ_O;<Y]^M8UOJ=[:Z@+Z&ZF6[#;O.WDL3WR>^>^>M5:*2C%
M;(;DWNS;U/QCKFL69M;Z_>2`D$HJ*@;Z[0,CVJO?>(]4U.&UBO+HR):8\D;%
M&SIW`YZ#K6910HQ6R#F;ZFM>>*-6O]2MM0N;O?=6V/*D\M!MP<]`,'GUJOJ&
MLWVJ:BM]>S^;<KMP^Q1TZ<`8JC1344N@<S9K7?B?5KW5+?4;B[WW=O@12>6@
MVX.>@&#U[BJ][K6H:AJ?]HW-RYO!C$J`(1CIC;C%4:*%%+H%V;]WXX\0WUF]
MK<:D[0R+M8+&BDCTR`#^O-1Z;XQUS2+,6MCJ#QP`Y",BOM^FX'`]A6)12Y(V
MM8?-+>YJ7_B35=4BMH[Z\>86IS$64;@>.2<9/0=<U'J^NZAKT\<VIW'GR1KL
M4[%7`SG^$"L^BFHI=!784444Q!1110`5IR>(M3ET5-)>YS8)C;%Y:\8.>N,]
M?>LRBDTGN";05I:CXAU+5K.WM+ZY\V"V`$2^6J[>,=0`3QZUFT463"[-&XU_
M4KK2(=+FN=UE"08XMBC!&>X&>Y[U<@\;>(+:P%E#J<JP!2@^52P'LQ&X>W/'
M:L*BER1[#YGW-:Y\4:Q>:C;7\]ZYNK8;8I`JJ5'IP.>O>I[_`,;:_J=H]M=:
ME(T+\,J(J;AZ$J`2/:L*BCDCV#F?<OZ5KFHZ',TNFW<D#-]X#!5OJIX/4]15
MO5/%^N:S;?9[_4))(<Y**JH&^NT#/XUBT4<L;WL',[6N%=*OQ#\3(H5=2P`,
M`>1%_P#$US5%-Q4MT"DUL:.L:_J6O212:G<^>T0*H=BK@'_=`K.HHH22T0FV
M]PHHHI@%%%%`&G;>(M3M-(FTN"YV64V=\7EJ<YZ\D9[>M9E%%))+8+MFE+XA
MU*;18])DN<V,9!6+RUXYSUQGOZTD>OZE#HLFDQW.+&0[FBV+R<@]<9Z@=ZSJ
M*.5=AW9MZ;XQUS2+,6MCJ#QP`Y",BOM^FX'`]A4%]XEU?4H[5;R^DE^R'="Q
MP'4\<[@,D\#DFLNBER1O>P<SVN=%/X^\27%NT,FJ2!&&"4C1&_[Z4`C\ZR-.
MU2]TFZ%SI]S)!,/XD/4=<$="/8U4HH48K1(')OJ;U]XW\0:C:O;7.I2&)^&"
M(B$CTRH!Q[5@T44U%+9`VWN=*GQ#\2QHJ+J6%48'[B+_`.)JAJ_BC5M>ACBU
M.[\^.-MRCRT7!Z?P@5DT4E"*=TAN4GU"BBBJ)"BBB@`K0TC7-0T&=YM,N/(D
MD78QV*V1G/\`$#6?12:3T8)VV'S3/<3R32MNDD8LQQC))R:OZ9XAU+1K>X@T
M^Y\F*X&)5\M6W<$=P<=3TK-HH:35F";1H:1KNHZ#+)+IEQY#R+M<[%;(_P"!
M`T[2O$.J:)-))IUX\+2_?&`RM[[2",^]9M%#BGT'=FW>>,M=O[6XMKK4'EAN
M<>8C(N#C'3CY>@Z8J2Q\<>(-.LX[6UU%EAB&U%:-'P/3+`FL"BER1M:P^:7<
ML2ZA=SWWVV6YF:ZW!O.+G?D=#GKQ6V/B!XE$(B_M1]H7;DQ1[L?[VW.??K7.
M44.,7NA*36S'RRR3RO+-(\DCG<SN<ECZDUJZ5XKUK1(#!I]_)%$3G855U'T#
M`XZ]JQZ*;2:LP3:V-+5O$.J:ZRG4KR2<)]U>%4>^T8&>>N*S:**$DM$)MO<*
M***8'T=IG_(+M/\`KBG_`*"*M55TS_D%VG_7%/\`T$5:KR'N>BMB*Z_X]9O]
MQOY5\V5])W7%I-_N-_*OFRNO"=3GQ'0****[#F"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"E
M!P<CK244`=%;^/?$EK`L,>J2%5Z&1$D;\68$G\35*+Q/K$.K/J::A,+QQAI#
M@@CTVGC'MC`K*HJ>2/8?-+N=!-XZ\13B42ZD[+-'Y3KY:;2O/;&`>3R.?RJC
M;^(=2M='ETN&YVV4Q)>+RU.<]>2,]AWK-HHY(KH',^YHZ?K^I:797-I97/E0
M7(Q*FQ3N&,=2,C@]J-(\0:GH4COIEV\!D&&&`RG\"",^]9U%/E78+LW'\9Z]
M(;HR:B[_`&M/+E#(I!7!&`,?+U/3'6JL/B#4H-&ETJ*YQ8RG+Q;%.>AZXSV'
M>LVBERQ[!S/N:VD>*-8T*)XM-O7AC<Y*%5=<^H#`X_"EG\5:S=65S:7%\\L%
MT^^57526/'?&0.!P..*R**.6-[V#F>US;TWQCKFD68M;'4'C@!R$9%?;]-P.
M!["JVI>(=3UBV@@U&[>XCM\^7O`R/JV,GIW)K-HHY8WO8.9VM<VH_&&N1Z4=
M-74'^R&,Q[&12=IXQN(SC'O4.D>)=6T)773;V2%'Y*8#+GUVL",\#FLNBCDC
MV#F?<U=7\3:OKJ(FI7LDR)R$`"KGUPH`)]ZRJ**:26B$VWN%%%%,`I02"".H
MI**`.F_X6+XG_P"@G_Y+Q?\`Q-8VIZO?ZQ<>=J-U+</SC>>%^@Z#\*I45*A%
M;(;DWNS2G\0:E<Z/%I4USNL8B"D7EJ,8SCG&>Y[U#I>K7NC78NM.N&@F`*[E
MP01Z$'@CZU3HI\JM:P79OGQSXA-Z+HZG(90AC&43:!W^7&W/OC-=5X'U;38_
M#5S:Q:I;Z5J\CEGN9T4Y&1C&[`/&1C/')Q7FU%1*E%JRT*C4:=SU?7?$-E9>
M$[VRO]=@UR\NE98O)B0!>`!G9D#!YR3GTZ5Y1113ITU!"G-R-32?$FK:$&&F
MWLD*-U3ADSQSM8$9X'.,T_5O%6LZY`L.HWSRQ*<[`JH"?<*!G\:R**?+&]["
MYG:US>L?&_B#3;1+:UU*00IPJNB/M'H"P)Q[5EW>I7E_>F[N[B2:XSG>YSCG
M.!Z#VZ55HH44G=(')OJ:.KZ]J.O2QR:G<>>\2[4.Q5P/^`@4:MK^HZYY']I7
M'G>0"L?R*NT''H!Z"LZBGRI=`NS7NO$>HZJ;*+4;KS(+5AY8\M5VC@=@,\#O
M7:>._&$]EJEG+X?U:-E,++)Y+I*N<\9'(S^M>:45#IQ;3[%*;29;U+5+W6+P
MW6H7#SS$8W-V'H`.`/85IV/C?Q!IMHEM:ZE((4X571'VCT!8$X]JP:*IQBU9
MHE2:UN6;[4+K4[IKF^N))YFZNYS^`]!["M.W\::_:Z<MC#J4J6ZKL4!5W*/0
M-C</;GBL.BFXIZ-`I-&E?>(-2U*&TBO+HRI:?ZG**"O3N!D]!US2:OKVHZ]+
M')J=QY[Q+M0[%7`_X"!6=11RI=`NS1U/7]2UB"WAO[GS8[8;8AL5=HP!V`ST
M'6KD'C7Q!;:>+*+4Y5@"[!PI8#V?&X>W/%85%+EC:U@YGO<T-1U[4=6MK:WO
MKDS16J[8@44;1@#J!D]!UK/HHII);";N%%%%,`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#Z.TS_D%VG_`%Q3_P!!%6JJ
MZ8<Z5:$=/)3_`-!%6J\A[GHK8ANP&LYP>08V!_*O(?AKHFGZWJ%['J5LLZ1Q
M*RAB1@Y]C7K]U_QZS?[C?RKR_P"$/_(4U'_KBO\`Z%6])M4Y6\C*HKSB=I_P
M@7AO_H%Q_P#?;_XT?\(%X;_Z!<?_`'V_^-=#167M)]S3DCV.>_X0+PW_`-`N
M/_OM_P#&C_A`O#?_`$"X_P#OM_\`&NAHH]I/N')'L<]_P@7AO_H%Q_\`?;_X
MT?\`"!>&_P#H%Q_]]O\`XUT-%'M)]PY(]CGO^$"\-_\`0+C_`.^W_P`:/^$"
M\-_]`N/_`+[?_&NAHH]I/N')'L<]_P`(%X;_`.@7'_WV_P#C1_P@7AO_`*!<
M?_?;_P"-=#11[2?<.2/8Y[_A`O#?_0+C_P"^W_QH_P"$"\-_]`N/_OM_\:Z&
MBCVD^X<D>QSW_"!>&_\`H%Q_]]O_`(T?\(%X;_Z!<?\`WV_^-=#11[2?<.2/
M8Y[_`(0+PW_T"X_^^W_QH_X0+PW_`-`N/_OM_P#&NAHH]I/N')'L<]_P@7AO
M_H%Q_P#?;_XT?\(%X;_Z!<?_`'V_^-=#11[2?<.2/8Y[_A`O#?\`T"X_^^W_
M`,:/^$"\-_\`0+C_`.^W_P`:Z&BCVD^X<D>QSW_"!>&_^@7'_P!]O_C1_P`(
M%X;_`.@7'_WV_P#C70T4>TGW#DCV.>_X0+PW_P!`N/\`[[?_`!H_X0+PW_T"
MX_\`OM_\:Z&BCVD^X<D>QSW_``@7AO\`Z!<?_?;_`.-'_"!>&_\`H%Q_]]O_
M`(UT-%'M)]PY(]CGO^$"\-_]`N/_`+[?_&C_`(0+PW_T"X_^^W_QKH:*/:3[
MAR1['/?\(%X;_P"@7'_WV_\`C1_P@7AO_H%Q_P#?;_XUT-%'M)]PY(]CGO\`
MA`O#?_0+C_[[?_&L'P7X1T34_"]M=7M@DL[O(&<LPSAV`Z'T%=_7,_#S_D3+
M3_?E_P#1C52G+E>O;]27&/,M"7_A`O#?_0+C_P"^W_QH_P"$"\-_]`N/_OM_
M\:Z&BI]I/N5R1['/?\(%X;_Z!<?_`'V_^-'_``@7AO\`Z!<?_?;_`.-=#11[
M2?<.2/8Y[_A`O#?_`$"X_P#OM_\`&C_A`O#?_0+C_P"^W_QKH:*/:3[AR1['
M/?\`"!>&_P#H%Q_]]O\`XT?\(%X;_P"@7'_WV_\`C70T4>TGW#DCV.>_X0+P
MW_T"X_\`OM_\:/\`A`O#?_0+C_[[?_&NAHH]I/N')'L<]_P@7AO_`*!<?_?;
M_P"-'_"!>&_^@7'_`-]O_C70T4>TGW#DCV.>_P"$"\-_]`N/_OM_\:/^$"\-
M_P#0+C_[[?\`QKH:*/:3[AR1['/?\(%X;_Z!<?\`WV_^-'_"!>&_^@7'_P!]
MO_C70T4>TGW#DCV.>_X0+PW_`-`N/_OM_P#&C_A`O#?_`$"X_P#OM_\`&NAH
MH]I/N')'L<]_P@7AO_H%Q_\`?;_XU@V_A'1'\<WEBU@AMH[-)%CW-@,6P3US
M7?US-I_R4G4/^P?'_P"A549RUU)E&.FA+_P@7AO_`*!<?_?;_P"-'_"!>&_^
M@7'_`-]O_C70T5/M)]RN2/8Y[_A`O#?_`$"X_P#OM_\`&C_A`O#?_0+C_P"^
MW_QKH:*/:3[AR1['/?\`"!>&_P#H%Q_]]O\`XT?\(%X;_P"@7'_WV_\`C70T
M4>TGW#DCV.>_X0+PW_T"X_\`OM_\:/\`A`O#?_0+C_[[?_&NAHH]I/N')'L<
M]_P@7AO_`*!<?_?;_P"-'_"!>&_^@7'_`-]O_C70T4>TGW#DCV.>_P"$"\-_
M]`N/_OM_\:/^$"\-_P#0+C_[[?\`QKH:*/:3[AR1['/?\(%X;_Z!<?\`WV_^
M-'_"!>&_^@7'_P!]O_C70T4>TGW#DCV.>_X0+PW_`-`N/_OM_P#&C_A`O#?_
M`$"X_P#OM_\`&NAHH]I/N')'L<]_P@7AO_H%Q_\`?;_XT?\`"!>&_P#H%Q_]
M]O\`XUT-%'M)]PY(]CGO^$"\-_\`0+C_`.^W_P`:/^$"\-_]`N/_`+[?_&NA
MHH]I/N')'L<]_P`(%X;_`.@7'_WV_P#C1_P@7AO_`*!<?_?;_P"-=#11[2?<
M.2/8Y[_A`O#?_0+C_P"^W_QH_P"$"\-_]`N/_OM_\:Z&BCVD^X<D>QSW_"!>
M&_\`H%Q_]]O_`(T?\(%X;_Z!<?\`WV_^-=#11[2?<.2/8Y[_`(0+PW_T"X_^
M^W_QH_X0+PW_`-`N/_OM_P#&NAHH]I/N')'L<]_P@7AO_H%Q_P#?;_XU@^"_
M".B:GX7MKJ]L$EG=Y`SEF&<.P'0^@KOZYGX>?\B9:?[\O_HQJI3ERO7M^I+C
M'F6A+_P@7AO_`*!<?_?;_P"-'_"!>&_^@7'_`-]O_C70T5/M)]RN2/8Y[_A`
MO#?_`$"X_P#OM_\`&C_A`O#?_0+C_P"^W_QKH:*/:3[AR1['/?\`"!>&_P#H
M%Q_]]O\`XT?\(%X;_P"@7'_WV_\`C70T4>TGW#DCV.>_X0+PW_T"X_\`OM_\
M:/\`A`O#?_0+C_[[?_&NAHH]I/N')'L<]_P@7AO_`*!<?_?;_P"-'_"!>&_^
M@7'_`-]O_C70T4>TGW#DCV.>_P"$"\-_]`N/_OM_\:/^$"\-_P#0+C_[[?\`
MQKH:*/:3[AR1['/?\(%X;_Z!<?\`WV_^-'_"!>&_^@7'_P!]O_C70T4>TGW#
MDCV.>_X0+PW_`-`N/_OM_P#&C_A`O#?_`$"X_P#OM_\`&NAHH]I/N')'L<]_
MP@7AO_H%Q_\`?;_XUA^,_"&AZ;X3OKNST](IXPFQPS'&74=SZ&N]KF_B#_R(
M^I?[J?\`HQ:J$Y<RU)G&/*]!8_`?APQJ3I<>2!_&_P#C3O\`A`O#?_0+C_[[
M?_&MZ+_5)_NBGU/M)]RN2/8Y[_A`O#?_`$"X_P#OM_\`&C_A`O#?_0+C_P"^
MW_QKH:*/:3[AR1['/?\`"!>&_P#H%Q_]]O\`XT?\(%X;_P"@7'_WV_\`C70T
M4>TGW#DCV.>_X0+PW_T"X_\`OM_\:/\`A`O#?_0+C_[[?_&NAHH]I/N')'L<
M]_P@7AO_`*!<?_?;_P"-'_"!>&_^@7'_`-]O_C70T4>TGW#DCV.>_P"$"\-_
M]`N/_OM_\:/^$"\-_P#0+C_[[?\`QKH:*/:3[AR1['/?\(%X;_Z!<?\`WV_^
M-'_"!>&_^@7'_P!]O_C70T4>TGW#DCV.>_X0+PW_`-`N/_OM_P#&C_A`O#?_
M`$"X_P#OM_\`&NAHH]I/N')'L<]_P@7AO_H%Q_\`?;_XT?\`"!>&_P#H%Q_]
M]O\`XUT-%'M)]PY(]CGO^$"\-_\`0+C_`.^W_P`:/^$"\-_]`N/_`+[?_&NA
MHH]I/N')'L<!X1\(Z)J.G74EW8)*Z7DL:DLPPH/`X-;W_"!>&_\`H%Q_]]O_
M`(U%X$_Y!-[_`-A"?_T*NFJJDY*3U)A&/*M#GO\`A`O#?_0+C_[[?_&C_A`O
M#?\`T"X_^^W_`,:Z&BI]I/N5R1['/?\`"!>&_P#H%Q_]]O\`XT?\(%X;_P"@
M7'_WV_\`C70T4>TGW#DCV.>_X0+PW_T"X_\`OM_\:/\`A`O#?_0+C_[[?_&N
MAHH]I/N')'L<]_P@7AO_`*!<?_?;_P"-'_"!>&_^@7'_`-]O_C70T4>TGW#D
MCV.>_P"$"\-_]`N/_OM_\:/^$"\-_P#0+C_[[?\`QKH:*/:3[AR1['/?\(%X
M;_Z!<?\`WV_^-'_"!>&_^@7'_P!]O_C70T4>TGW#DCV.>_X0+PW_`-`N/_OM
M_P#&C_A`O#?_`$"X_P#OM_\`&NAHH]I/N')'L<]_P@7AO_H%Q_\`?;_XU@Z7
MX1T2?QAKEG+8(UO;K`8DW-A=RDGOWKOZYG1O^1]\2?[EK_Z`:J,Y6>O]71,H
MQNM"7_A`O#?_`$"X_P#OM_\`&C_A`O#?_0+C_P"^W_QKH:*GVD^Y7)'L<]_P
M@7AO_H%Q_P#?;_XT?\(%X;_Z!<?_`'V_^-=#11[2?<.2/8Y[_A`O#?\`T"X_
M^^W_`,:/^$"\-_\`0+C_`.^W_P`:Z&BCVD^X<D>QSW_"!>&_^@7'_P!]O_C1
M_P`(%X;_`.@7'_WV_P#C70T4>TGW#DCV.>_X0+PW_P!`N/\`[[?_`!H_X0+P
MW_T"X_\`OM_\:Z&BCVD^X<D>QSW_``@7AO\`Z!<?_?;_`.-'_"!>&_\`H%Q_
M]]O_`(UT-%'M)]PY(]CGO^$"\-_]`N/_`+[?_&C_`(0+PW_T"X_^^W_QKH:*
M/:3[AR1['/?\(%X;_P"@7'_WV_\`C1_P@7AO_H%Q_P#?;_XUT-%'M)]PY(]C
MSZ]\):+%XXTRQ2P06TUM*[Q[FPQ'0]:Z#_A`O#?_`$"X_P#OM_\`&H-1_P"2
MD:/_`->DU=15SG*RUZ$QC'70Y[_A`O#?_0+C_P"^W_QH_P"$"\-_]`N/_OM_
M\:Z&BH]I/N5R1['/?\(%X;_Z!<?_`'V_^-'_``@7AO\`Z!<?_?;_`.-=#11[
M2?<.2/8Y[_A`O#?_`$"X_P#OM_\`&C_A`O#?_0+C_P"^W_QKH:*/:3[AR1['
M/?\`"!>&_P#H%Q_]]O\`XT?\(%X;_P"@7'_WV_\`C70T4>TGW#DCV.>_X0+P
MW_T"X_\`OM_\:/\`A`O#?_0+C_[[?_&NAHH]I/N')'L<]_P@7AO_`*!<?_?;
M_P"-'_"!>&_^@7'_`-]O_C70T4>TGW#DCV.>_P"$"\-_]`N/_OM_\:/^$"\-
M_P#0+C_[[?\`QKH:*/:3[AR1['/?\(%X;_Z!<?\`WV_^-<!\2]"T[1+C3UTV
MU6`2JY<*2<X(QU/O7L%>7?&#_CZTO_<D_FM:T)R<TFS.K%*#LCT;2E":19JH
MP!`@`_X"*MU5TS_D%VG_`%Q3_P!!%6JP>YJMB*Z_X]9O]QOY5Y?\(?\`D*:C
M_P!<5_\`0J]0NO\`CUF_W&_E7E_PA_Y"FH_]<5_]"K:G_#E\C.?QQ/5:***P
M-0HKD(M7\3ZGJ>IPZ6FCK!9W!A!N1*&/_?)Q6IX;UV;6([J&]MA;7]E)Y5Q&
MK97..JGT//%6X-*Y*DF;=%4Y=6T^"[%K-?VL=RQ`$+S*')/3Y<YYK+\5ZG=Z
M:^D"SE\L7%_'#+\H.Y#G(Y''X4E%MV&Y)*YT%%5KS4+/3U5KZ[M[96.%,T@0
M$^V34EO<P7<"SVTT<T+?=DC8,I^A'%*S'<EHJC)K6F0PQ2RZC9I%-GRW:=0K
MXZX.>?PJX\B1QM([JJ*-Q8G``]<T687'455L]3L=1W_8;VVN=F-WDRJ^W/3.
M#Q5#1;FX6#4)=3U.RN4BN'VO"R[88Q_"YP,$=\_G1RL5S9HJFVL:<LT,+7]H
M)9@K1(9EW2`]"HSSGMBK$TT5O"\L\B11(,L[L`JCU)-%F.Y)16?#K^D7$R10
M:K8R2N<*B7"$L?0`&M"AIK<+W"BJDVJV%N)3/?6T8A8+)OE4;">@.3P3[T^X
MO[2TMEN+FZ@A@;&)))`JG/3D\468KHL45%;W4%Y`L]K/%-"V<21N&4_B.*K2
M:WI<4,4TFI62139\MVG4*^.#@YYQ[46871>HJK=ZG8V'E_;+VVM_,^YYTJIN
M^F3SU%5/$DEW%HLKV%_:V$X9<3W)`11D9R2".>G2A*[!NQJT5A:OXIM-%O;"
MTGEMV>X<+*QG">2N,[R/3\J36_%UAI.GPW4,]K=>=(JHJW"C*DX+`\Y`[TU"
M3MIN+F1O45AZSJ1N]!FGT/6-/AD5U7[3)*K1+R,@GD9(/ZUJFZAA>&*:XB6:
M5244N`7P,D@=\4N5CN3T55L]2LM1W_8;RWN=F-WDRJ^W/3.#QTI+S5+#3F5;
MZ]MK8N,J)I53=],FBSV"Z+=%5K/4;+40QL;NWN0G#&&57V_7!JS2V&%<S\//
M^1,M/]^7_P!&-735S/P\_P"1,M/]^7_T8U6O@?R_4E_$OZ['34445!04444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7,VG_)2=0_[!\?_H5=-7,V
MG_)2=0_[!\?_`*%5PZ^A,NATU%%%04%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7,_#S_D3+3_?E_\`1C5T
MU<S\//\`D3+3_?E_]&-5KX'\OU)?Q+^NQTU%%%04%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!7-_$'_`)$?4O\`=3_T8M=)7-_$'_D1]2_W4_\`1BU=
M/XUZDS^%G0Q?ZI/]T4^F1?ZI/]T4^H*"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`.9\"?\@F]_P"PA/\`^A5TU<SX$_Y!-[_V$)__`$*N
MFJZGQ,F'PH****@H****`"BBB@`HHHH`****`"BBB@`HHHH`*YG1O^1]\2?[
MEK_Z`:Z:N9T;_D??$G^Y:_\`H!JX[2]/U1,MT=-1114%!1110`4444`%%%%`
M!1110`444R2:.'9YLBIO;:NXXW'K@>_!H`?1110`4444`<OJ/_)2-'_Z])JZ
MBN7U'_DI&C_]>DU=15SV7H3'=A1114%!1110`4444`%%%%`!1110`4444`%%
M%%`!7EWQ@_X^M+_W)/YK7J->7?&#_CZTO_<D_FM;8?\`B(RK?`ST?3/^07:?
M]<4_]!%6JJZ9_P`@NT_ZXI_Z"*M5D]S1;$5U_P`>LW^XW\J\O^$/_(4U'_KB
MO_H5>H77_'K-_N-_*O+_`(0_\A34?^N*_P#H5;4_X<OD9S^.)ZK1116!J>?Z
M:WB%-7\1-H:::\:WKEENM^]FQT7&!^=7O"\R0^%-3U6*62;4Y/-DNS(H4K,H
M/R[1T`_KVZ#>TC1O[*N]2F\_S?MMP9\;-NS(Z=3GZ\5'I_A\:=K&I7<4X-M?
MX9[79PK]VSGOSGBMG-.Z]#)1:.&TO3KN]\-*/^$.BO6ND+F^>]B$KLW\8)&Y
M?IFM/58KV#0O"<6IJ5NX[^%)`6#'C('()SQBM.'PCJ>FA[?1?$4UG8%BR6[V
MR3&//4!F.<?YZ\UH:CX;^WVVE0_;9?\`B7SI-YDP\QY=O8G(Y/K5.HK_`/#B
M4';_`(8R]?FL9/$1M[;PZFM:H(5,HE90D4>3CE\@'GTYSUJ#P.)(M5\10/8C
M3PLD;_9%D#K$2IS@CCG`Z5K:IX:NKC6#J>DZM)IUS)&(IOW*RK(!T^4]#[__
M`%\NT+PV="N-0N&OI;M[P(7:4?-N4')SWSGIC@#'-3S1Y+?Y_P###Y7S7,/P
M-X;TO4/"<5Q?6B74LX="TPWE%#,`$S]WN>.YJMIFFWNM_#N2PMI%D:VNV6)9
M6^69$;(0D=O\!TIGA'P]J%YX3ADT[79[".Y\P31>4)`3N(RI)!0X]*ZL^'/L
MN@V^G:/?36#6[!HYE`<D\YWCHP.3QZXJYRM)Z]?N)C&Z6G0S_#]SI@UK[/)H
M0T;5UA;]VJ`)(F>=K+P_0<X]<=ZR]*_Y%+QA_P!?-W_Z#70:7X;N;?5AJ6K:
MK)J5W'&8H285B2-3U^4=_>BT\+_9=)UBQ^U[O[2DEDW^7CR]XQC&><?A4\T>
M_8KE9@#PQI8^&KW!M4>Z:R^T&X<;I`X3(PW4`8`P.,4NM3M=Z!X7>YB>_+E)
M9;1`6>X`CR3COCK@]:ZG^Q?^*6_L;S_^73[-YVS_`&=N[;G],UR_B.S@LI/#
M.EW5X]I%"K+_`&BCF)EVH!@'.%W<<GI3C+F?WBE&R)-&TN'4/%T>I6OA]],L
MK>`J1<VRQ,\F<@JG;']X?2MIM6UX:B81X;S:^;L^T?;H_N9QOVXSTYQ6!;7"
MZ?XETRWT3Q%=ZL+AR+F&:X%PJQ@?>W`?*1^O\^]J:CL]?U*@M#B=,T:RU3QY
MX@EOX4N%@:()%*`R99.3M/!/%4]4%Q=>.;B"/08M6AL+9$AMWF2*.(,,EMK#
M!]/;%==IVB_8-9U2_P#/W_;VC.S9C9M&.N><Y]JK:QX;DOM2BU/3=0DT[4$3
MRFE5!(KIZ,AX/^?;#51<WR$X.WS,SPMIVI6>LZC-+HZZ587$080).DBB0<9`
M7ID>W:L_P-X;TS4?!YGO;5+B:?S$WRC<8U!(`3^[W/'<UU>D:5?61FDU+5YM
M0FE`4$QK&B`>B#C/)R>_'I2>'-#_`+`T./3OM'G["Q\S9MSDD],GU]:3J:.S
M[`H;?,Y?P?X<TW4?!?VF^MQ<SSQNGF3?,T:J2JA"?NX'I52ZF>?X,0-(Q9AM
M7)]!+@?H!7::#HG]B:!'IGG^=L#CS-FW.XD],GU]:SG\';O!2>'_`+;C:<^?
MY77Y]WW=WX=:KVBYKM]1<CM\BGXJT^SFUGPZTMI`[37(20M&"77;T/J/8T>.
MM*L(/#]MY-C:Q^7=1(FV%1M4MR!QP#W%;.O^'_[:M;58KM[2ZM)5E@G5`VUA
MZJ>HIE]X>EU;PT=,U+4'GN"=PNUB5"&!RIVCCC@>_M4QFERZ[#<=]#+\=V-K
MI_@>[CLK:"WC,D;%88P@)WKS@5'XJL(=4\2^&K2Z#&"03[U5BNX!5.,CL<<U
MHWGAJ^U/PW/IFI:P;B6216%Q]F5=J@@[=H//0\Y[U>O=$^V:SI5_Y^S^SQ(/
M+V9\S<H'7/&,>]"FEU[_`)`XM].QAWFGVNC^/=";3;>*U%U'-%,D*!%<*N1D
M#CJ?T%9KS6D?B/6Y;[0;G6U>8)'-!;>>(]JC,?/W<9'3^E=??Z+]NUS3-1\_
M9]A\S]WLSOW@#KGC&/0UQEE%IM[JNLRWFOW.B2?;77[+#>B#..-YW=2?;I50
M=U\OU%)6?]=CI?!&C2:/H*I<6T=O/*[.R*!N523M5F'WB!ZUT5<OX(OKB[@U
M!&O);ZR@N#':W4H^>1<<Y/\`%CU[UU%95+\SN:0MRJP5S/P\_P"1,M/]^7_T
M8U=-7,_#S_D3+3_?E_\`1C4+X'\OU!_$OZ['34445!11N=;TNSG:&ZU*R@E7
MJDLZJP_`FFPZ_I%Q,D4&JV,DKG"HEPA+'T`!JKX@T?3;C3;^ZGT^TDN!;N?-
M>%2^0IQR1GBL'1+2QT[X>P:O%IUBU]!:M,LKP*6+#."3U_6M%&+5R')IV.V=
M@B,S'"J,D^@JOINIVFKV27EA+YMNY(5]I&<'!X(!K$T35=<U>".^GM+*#39(
M2P1BWG,<?>QT"D]NN*S[;Q+-9_#4:Q;6=E#*C<0Q1%8A^]VG"@^G/7K1[-[=
M0YT=K17&7_B?7],M8M7N]-M%TEW4-`';[2BG@$_PYZ''N!ZFGWGB77]-2#4[
M[3;2+299%5HM[&XB5N`S'[O7G'OCWH]E(.='845AZ[K5U:WEKINDP13ZC=`L
MOG,1'$@ZLV.2/85#I>M:G'K0TG7H+5+B6,S036K-Y<@'5<-SD5/([7'S*]CH
MJ*Y"TU[Q%K!GO-(M-,:QAF:+R9I'$[[3SR/E4GMGI[U6\9_VP?$&B?918"/[
M0/LXEWY\S;SOQ_#].:I4W>S8G/2YW%%8TLWB"+2852VT^;4G8K(RR,L$0YPV
M#\Q[#`[FJ5CK6LVOB"WTO7H+$F[C9X);-GP"HR0P;GIW_GVGD;'S&C!K<D^H
M/9_V5?(\85I&9H=J*V<$XD)_A/0$TNG^(+34-)EU!!)%#"&,BR@!E`&<X!/4
M$$?6GP6LR:[?7#)B*6"%$;(Y*E\\?\"%8MGH5]$NG0&)5MI8HQ?`L#M:/E1C
MONX!QV%5:+%=HZ'3=035+".[BCDC63/R2@!E()!!`)[BK54-$MI;33$AG39(
M))"1D'@NQ'3V(J_4/?0I;!7,VG_)2=0_[!\?_H5=-7,VG_)2=0_[!\?_`*%5
M0Z^@I=#IJ***@H****`"BBB@`JK>:G8Z=L^W7EM;;\[?.E5-V.N,GGK4EW<"
MULYKAAD11LY'T&:Y3PCH5IJNEC6=8MX;Z^OR9&:=`X1<X55!R``!5QBK79+;
MO9'5VUW;WL`FM)XIXFSAXG#*?Q%35QES8P>&?&VERZ8@M[;4R\%Q`G"%@,JP
M7H#S_G)J:3Q#KEWXAU'2=*M+-GM64B>XW"-%*@X;!R22>,8Z4_9WV%S]SK:A
MN[J&QM);FY?9#"I=VP3@#KP.:Q;J;Q7),5L;728DC`!>YD=O-;`)*A>@SD<\
M\51FUJ36_`.L2W$`@N8(YK>=%;*[U'.#Z<__`*Z2@#D=3:W,5[:Q7-N^^&5`
MZ-@C(/(.#4M9?AC_`)%?2_\`KUC_`/015?7=:NK2\M=-TFWBGU&Z!9?.8B.)
M!U9L<D>PI<MY60^;2[-RBN=TO6M3CUH:3KT%JEQ+&9H)K5F\N0#JN&YR*I6F
MO>(M8,]YI%IIC6,,S1>3-(XG?:>>1\JD]L]/>G[-ASHZ^BN'\9_VP?$&B?91
M8"/[0/LXEWY\S;SOQ_#].:T-:U_5M`TO3I+NWM;B\GN?)ECM@VU@<X"9.<\#
MKFG[-V5NHN?>_0W=2U.TT>R:[OYO)@4@%]I/).!P`35I6#*&4Y!&0:Y#7=0U
MBQ\*7EUK5EI,S!X_*@"M(@!89#@]2/45HZWKUS93V6G:7;1W&I7@+(LAQ'$H
MZNV.<>P]_H3D[!S&_52WU.TN[ZZLX)=UQ:[?.3:1MW#(Y(P?PK#M==U?3];M
M=.\16]F!>Y%O<69;9N'56#<YZ<_SYQ'X>_Y'GQ/_`+T'_H)HY+)W#FVL=711
M16984444`%%%%`!7,_#S_D3+3_?E_P#1C5TU>;^#_%#V&B06*0(S*9&!9B,Y
M=C1.I&G3<I=U^I$FE)-_UL>D45RW_"5W7_/I'_WV:/\`A*[K_GTC_P"^S7+]
M=H]Q>UCW.IHKEO\`A*[K_GTC_P"^S1_PE=U_SZ1_]]FCZ[1[A[6/<ZFBN6_X
M2NZ_Y](_^^S1_P`)7=?\^D?_`'V:/KM'N'M8]SJ:*Y;_`(2NZ_Y](_\`OLT?
M\)7=?\^D?_?9H^NT>X>UCW.IHKEO^$KNO^?2/_OLT?\`"5W7_/I'_P!]FCZ[
M1[A[6/<ZFBN6_P"$KNO^?2/_`+[-'_"5W7_/I'_WV:/KM'N'M8]SJ:*Y;_A*
M[K_GTC_[[-'_``E=U_SZ1_\`?9H^NT>X>UCW.IHKEO\`A*[K_GTC_P"^S1_P
ME=U_SZ1_]]FCZ[1[A[6/<ZFN;^(/_(CZE_NI_P"C%J+_`(2NZ_Y](_\`OLUG
MZ[JMQKNC7&GR0)$LX`+J<D88'I^%5#&T%)-L4JD6FCMHO]4G^Z*?7*KXINE4
M+]DCX&/O&E_X2NZ_Y](_^^S4_7:/<?M8]SJ:*Y;_`(2NZ_Y](_\`OLT?\)7=
M?\^D?_?9H^NT>X>UCW.IHKEO^$KNO^?2/_OLT?\`"5W7_/I'_P!]FCZ[1[A[
M6/<ZFBN6_P"$KNO^?2/_`+[-'_"5W7_/I'_WV:/KM'N'M8]SJ:*Y;_A*[K_G
MTC_[[-'_``E=U_SZ1_\`?9H^NT>X>UCW.IHKEO\`A*[K_GTC_P"^S1_PE=U_
MSZ1_]]FCZ[1[A[6/<ZFBN6_X2NZ_Y](_^^S1_P`)7=?\^D?_`'V:/KM'N'M8
M]SJ:*Y;_`(2NZ_Y](_\`OLT?\)7=?\^D?_?9H^NT>X>UCW.IHKEO^$KNO^?2
M/_OLT?\`"5W7_/I'_P!]FCZ[1[A[6/<ZFBN6_P"$KNO^?2/_`+[-'_"5W7_/
MI'_WV:/KM'N'M8]Q_@3_`)!-[_V$)_\`T*NFKA=$U.XT6UFA2%)1+.\Q).,%
MCG%:/_"5W7_/I'_WV:J>.H.3:8HU(I6.IHKEO^$KNO\`GTC_`.^S1_PE=U_S
MZ1_]]FI^NT>X_:Q[G4T5RW_"5W7_`#Z1_P#?9H_X2NZ_Y](_^^S1]=H]P]K'
MN=317+?\)7=?\^D?_?9H_P"$KNO^?2/_`+[-'UVCW#VL>YU-%<M_PE=U_P`^
MD?\`WV:/^$KNO^?2/_OLT?7:/</:Q[G4T5RW_"5W7_/I'_WV:/\`A*[K_GTC
M_P"^S1]=H]P]K'N=317+?\)7=?\`/I'_`-]FC_A*[K_GTC_[[-'UVCW#VL>Y
MU-%<M_PE=U_SZ1_]]FC_`(2NZ_Y](_\`OLT?7:/</:Q[G4US.C?\C[XD_P!R
MU_\`0#3/^$KNO^?2/_OLUG6FISVFN:AJ0A1FO1&"A/"[!CK[U4<=02>HG4BV
MCNJ*Y;_A*[K_`)](_P#OLT?\)7=?\^D?_?9J?KM'N/VL>YU-%<M_PE=U_P`^
MD?\`WV:/^$KNO^?2/_OLT?7:/</:Q[G4T5RW_"5W7_/I'_WV:/\`A*[K_GTC
M_P"^S1]=H]P]K'N=317+?\)7=?\`/I'_`-]FC_A*[K_GTC_[[-'UVCW#VL>Y
MU-%<M_PE=U_SZ1_]]FC_`(2NZ_Y](_\`OLT?7:/</:Q[G4URGQ#.-!@_Z^5_
M]!:G?\)7=?\`/I'_`-]FLGQ'J-UKFG+;_9T0I()!ALYP",?K45,72E%I,3J1
M:*6E>)]2T^--LGVF#_GG*<D?1NH_6NQTKQ58:F1'O\F<_P#+.7@GZ'H:\XL#
MM)C<8SQ@]C5J6U##D5S0Q4Z;L]49JHT>K@@TM>:Z=XBU+22%#_:(!_RSE/(^
MC=1^M=?I7BJPU,B/?Y,Y_P"6<G!/T/0UWT\1"IMN;1FF4M1_Y*1H_P#UZ35U
M%<MJ!!^)&C_]>DU=375/9>@X[L****@H****`"BBB@`HHHH`****`"BBB@`H
MHHH`*\N^,'_'UI?^Y)_-:]1KR[XP?\?6E_[DG\UK;#_Q$95O@9Z/IG_(+M/^
MN*?^@BK55=,_Y!=I_P!<4_\`015JLGN:+8BNO^/6;_<;^5>7_"'_`)"FH_\`
M7%?_`$*O4+K_`(]9O]QOY5Y?\(?^0IJ/_7%?_0JVI_PY?(SG\<3U6BBBL#4*
M**Y'XAB1K+25@E,,K:E$$D`R4)#8./:JC'F=A2=E<ZZBO/O$7AN'P_<:7=:+
M<W-K>75TMK/<&4NTH<<LV>"<C/;D_3$^I:%;>%]:T2]TQ[A)KF[6VN6>5G-P
M'ZELGKD9^M7[-/9D<[['=4G6N8C_`.2HS?\`8+'_`*,HC_Y*C-_V"Q_Z,J>3
M\KE<Q+X8U82Z=J9:UM[>"PNI8DCMH]@VKSTSC)Y]*UM.U)-6TB*_M$<+,A:-
M9,`_C@FN.T;3K75/#_B2&\B\R-=1GD`W$?,!D'@U<\$:#IUIX;M]3@M]M[/;
M,))-['<,^A..P[5<XQU9$9/1'1Z+-J4^EQ2:Q;Q6]Z2=\<1RHY..Y[8[U?KS
M1&*_!8,IPP<$'T/GUH>(/"T&F:#+K5O<W)UFW`F-ZTK;I#W!&<`8.,`=`!0Z
M:OOUL"F[;=#H-3UFXL_$^D:=&D1AO1*9&8'<-JY&.<?I6K<VL%[`T-U!%/$W
M5)4#*?P-<GJ$YNO%_A*=EVM+#*Y'IF,&L:^N[76O$>I_VQI6L:G!:S&"WALX
MV:*+'4G:P^8_RH5.]O3]0Y[7/0;/3;+3M_V&SM[;?C=Y,2INQTS@<]:M5RO@
M5[M;:]MIK>_ALX91]D%]&5D$9'W>>H&/6MK7H;V?0KR+3'*7C1$1$-M.?8]C
MZ&HE'WK-EI^[<T**X/PK;^'H=4MDC@O=+UM%_>07#NIG^7GJ2&4G)&,'Y<XP
M*FM=(M_&&N:O/K7F7%O9W!M;:W\QD2/`&6^4CD_Y[8;II/42FV;?B/6;C1VT
MP6Z1-]KO$MW\P$X4]2,$<UMUQ'B/2X='M/#UG;/*T*:K&4$K[BH))V@^@Z"J
MOB2]BU'Q=/I^I6&J7]A9Q(1;6*%@SL,[GP0>,X%4H*25A<]F[GH-%<1X3,UO
M>ZE:VUAJEII!A\R".^B9?*?^)5)SP<YZU'X#\.6MUHEAJM\9+BYC+&WS(P6!
M0Q&``<<D$G/K2=-*]V-3;M9'=T5PNA:%:>,H+C6->$ET\LSI!$965($4X``4
MC\:=I7]J'1O$.B65U)+<6#F*TE=_GVD9"[O7`P#VSVQP.FMK[`I^1W%9UE-J
MCZM?QWEM#'8H5^RR*V6DX^;(R>_L/QKE/"MOX>AU2V2."]TO6T7]Y!<.ZF?Y
M>>I(92<D8P?ESC`J[HRRMXO\6+;L%F(A",>@;8<'\Z'"UQ<U['7U2N]'TV_E
M$MYI]I<2`;=\L*N<>F2*X30;/1[:^M(];AO].\0B4'[3-*^+E\G.U\E2",`^
MN<#/6O2*F4>1Z#B^9:C(XTAB6.)%2-`%55&`H'0`4^BBH+"N9^'G_(F6G^_+
M_P"C&KIJYGX>?\B9:?[\O_HQJM?`_E^I+^)?UV.FHHHJ"BEK7_(#O_\`KVD_
M]!-<Q9_\DA/_`%X/_6NTHJU*RL2XW9DZ+_R*-A_UY1_^@"N(/_)$6_WO_:]>
MFT4XU+/YW$X7.5\=?\B!<?[L/_H:T?$#_D2)O]Z+_P!#6NJHI*=K>3!QO<X7
MQMIEF->T_4]8M);G2A$8)VC+?N3G*N=ISCG_`#P#+X7A\(2:R)/#EI,\\4;%
MIU$VR//&#O.,GG''8UVM%/VCY>4.36YYIK.I:#++-=:$]_8^(V?`@@B=7D?=
MRKKC:>F3Z^_2MSQ=-+9IX?U*]0^7:7*M=,@+"/*X)X[9_I77T4_:+307)N<5
MXMU6'4M&TV[MY[@Z%-.1>2P*RL8^G/&=N<@_A[5DZ1%H0\<Z/)X;M94M2)@\
M["39(VP\+O.>._UKTNBA5+*R!PN[A11161H%%%%`!7,VG_)2=0_[!\?_`*%7
M35S-I_R4G4/^P?'_`.A5<.OH3+H=-1114%!1110`4444`1W$*W-M+"_W9$*'
MZ$8KBM!\1P>$]/71O$8ELY;5F6&8Q,R3IG(*E0>F?Y=\@=S151DDK,EJ[NCC
MH)V\7^)["^M895TC3@[I/(A47$AX^4'L,=?8U9\._P#(Y^)_]^#_`-`-=113
M<]+"4>IYOJCZ1)XHU)/&7VIRK#[!#B388R/X-G<D`'MG]'Z'&L7P[\2(D#P(
MLUQMBD^\@V+A3[@5Z+15^UTL+V>MS+\,?\BOI?\`UZQ_^@BN9\;Z99C7[#4]
M8M);G2A$8)VC+?N3G*N=ISCG_/`/=45$9VES%.-U8XKPO#X0DUD2>'+29YXH
MV+3J)MD>>,'><9/...QK)UG4M!EEFNM">_L?$;/@001.KR/NY5UQM/3)]??I
M7I=%4JFM]?O)Y-+'(>+II;-/#^I7J'R[2Y5KID!81Y7!/';/]*;XBU&VU:+P
MW>6,GFV\FJ1[7VE<X)!X(!ZBNQHI*=K:;#<=SE_B-_R)EU_OQ_\`H8JOKLK:
M)XGTW79XI'T\6QMKB1%W>3DY#$=<9/\`G@'L**(SLK`XW=SBYM2@\8>(=(&C
M^9-9V$IN+BY,;*@('"`L`2?;W_*SX>_Y'GQ/_O0?^@FNKHH<]+)!RZW"BBBL
MRPHHHH`****`"O%-&LI[N"$P@@)N)?T^=J]KKBO!EJLW@JU.Q=Q>7G'/^L:I
MJTW4I-+NOU,YJ[2,OR=0_P">H_[X%'DZA_SU'_?`K5FTJ<N<%@/:H_[*N/[S
M_F:X/J+\ON(]D9WDZA_SU'_?`H\G4/\`GJ/^^!6C_95Q_>?\S1_95Q_>?\S1
M]1?E]P>R,[R=0_YZC_O@4>3J'_/4?]\"M'^RKC^\_P"9H_LJX_O/^9H^HOR^
MX/9&=Y.H?\]1_P!\"CR=0_YZC_O@5H_V5<?WG_,T?V5<?WG_`#-'U%^7W![(
MSO)U#_GJ/^^!1Y.H?\]1_P!\"M'^RKC^\_YFC^RKC^\_YFCZB_+[@]D9WDZA
M_P`]1_WP*/)U#_GJ/^^!6C_95Q_>?\S1_95Q_>?\S1]1?E]P>R,[R=0_YZC_
M`+X%'DZA_P`]1_WP*T?[*N/[S_F:/[*N/[S_`)FCZB_+[@]D9WDZA_SU'_?`
MH\G4/^>H_P"^!6C_`&5<?WG_`#-']E7']Y_S-'U%^7W![(SO)U#_`)ZC_O@4
M>3J'_/4?]\"M'^RKC^\_YFLCQ7975IX:O)DEE1D"X96((^8#K36`;=M/N!TK
M*Y-Y.H?\]1_WP*/)U#_GJ/\`O@5?32K@HIW/T]33O[*N/[S_`)FE]1?E]P>R
M,[R=0_YZC_O@4>3J'_/4?]\"M'^RKC^\_P"9H_LJX_O/^9H^HOR^X/9&=Y.H
M?\]1_P!\"CR=0_YZC_O@5H_V5<?WG_,T?V5<?WG_`#-'U%^7W![(SO)U#_GJ
M/^^!1Y.H?\]1_P!\"M'^RKC^\_YFC^RKC^\_YFCZB_+[@]D9WDZA_P`]1_WP
M*/)U#_GJ/^^!6C_95Q_>?\S1_95Q_>?\S1]1?E]P>R,[R=0_YZC_`+X%'DZA
M_P`]1_WP*T?[*N/[S_F:/[*N/[S_`)FCZB_+[@]D9WDZA_SU'_?`H\G4/^>H
M_P"^!6C_`&5<?WG_`#-']E7']Y_S-'U%^7W![(SO)U#_`)ZC_O@4>3J'_/4?
M]\"M'^RKC^\_YFC^RKC^\_YFCZB_+[@]D9WDZA_SU'_?`H\G4/\`GJ/^^!6C
M_95Q_>?\S1_95Q_>?\S1]1?E]P>R,[R=0_YZC_O@4>3J'_/4?]\"M'^RKC^\
M_P"9H_LJX_O/^9H^HOR^X/9&=Y.H?\]1_P!\"CR=0_YZC_O@57\,6=U=6-R[
MRRN5NI5RS$\`]*V?[*N/[S_F:;P#3MI]P*E=7,[R=0_YZC_O@4>3J'_/4?\`
M?`K1_LJX_O/^9H_LJX_O/^9I?47Y?<'LC.\G4/\`GJ/^^!1Y.H?\]1_WP*T?
M[*N/[S_F:/[*N/[S_F:/J+\ON#V1G>3J'_/4?]\"CR=0_P">H_[X%:/]E7']
MY_S-']E7']Y_S-'U%^7W![(SO)U#_GJ/^^!1Y.H?\]1_WP*T?[*N/[S_`)FC
M^RKC^\_YFCZB_+[@]D9WDZA_SU'_`'P*/)U#_GJ/^^!6C_95Q_>?\S1_95Q_
M>?\`,T?47Y?<'LC.\G4/^>H_[X%'DZA_SU'_`'P*T?[*N/[S_F:/[*N/[S_F
M:/J+\ON#V1G>3J'_`#U'_?`H\G4/^>H_[X%:/]E7']Y_S-']E7']Y_S-'U%^
M7W![(SO)U#_GJ/\`O@4>3J'_`#U'_?`K1_LJX_O/^9K&T^SNI/%&L0&64K$L
M)"EC@94]!36`;[?<#I6+'DZA_P`]1_WP*/)U#_GJ/^^!6C_95Q_>?\S1_95Q
M_>?\S2^HOR^X/9&=Y.H?\]1_WP*/)U#_`)ZC_O@5H_V5<?WG_,T?V5<?WG_,
MT?47Y?<'LC.\G4/^>H_[X%'DZA_SU'_?`K1_LJX_O/\`F:/[*N/[S_F:/J+\
MON#V1G>3J'_/4?\`?`H\G4/^>H_[X%:/]E7']Y_S-']E7']Y_P`S1]1?E]P>
MR,[R=0_YZC_O@4>3J'_/4?\`?`K1_LJX_O/^9H_LJX_O/^9H^HOR^X/9&=Y.
MH?\`/4?]\"FR+>PQM)).JHHR25%:?]E7']Y_S-97B*REMM/1G9B#(!R?8U,L
M'RJ^GW`Z5D9$EYO9[B0C`'7`&:H-K=XQ.UE`]-HILB/<;8T!VCK[FKEKI!X,
MG`K*--/I<E(@COKZ8_>!_P"`"M"WLY[C'G,H!]JOVVGA<!$_'%;%GH[R$$@_
ME77#"=9&BI]RAI[FW\;:0AFEEVVTO,ASCV'M7HR-N7-<*VGB#X@:0OK:RFNZ
M1=HQ7>U9)+L5'J.HHHJ2PHHHH`****`"BBB@`HHHH`****`"BBB@`KR[XP?\
M?6E_[DG\UKU&O+OC!_Q]:7_N2?S6ML/_`!$95O@9Z/IG_(+M/^N*?^@BK55=
M,_Y!=I_UQ3_T$5:K)[FBV(KK_CUF_P!QOY5Y?\(?^0IJ/_7%?_0J]0NO^/6;
M_<;^5>7_``A_Y"FH_P#7%?\`T*MJ?\.7R,Y_'$]5HHHK`U"L3Q/HMQK4>GK;
M/$IMKV.X?S"1E5SD#`//-;=%--IW0FKJQC>(]'GU<:;]G>)?LM['</YA(RJY
MR!@'GFCQ!H\^K3:6T#Q*+2]2XDWDC*C.0,`\ULT4U)JP.*9SNM:'J3ZY;ZSH
M<]JEVD1@ECN@WER)U'*\Y!_SZQZ1H&J6WB>35]2O(+AIK3RG6,%0C;@=JC'W
M0!U)R37344^=VL+D5[F#H&@3:;:ZK!=O&RWMU+*OEDG",,<Y`YJ#PWI&MZ1:
MG3;R:PFT^*-D@>,.)3D\;L\`8)Z9KI:*'-NX<J.!UG2)]#^%$UA=/&TL;+EH
MB2O,P/&0/6KMSX?\1:K;1:9?ZC9MI6Y3)*B,+B5!R%8?=].1Z9]JZ?4=.M=5
MLGM+Z+S8),;DW%<X.1R"#U%60`H`'057M7;SN3R*YAW^A33^(]&OK<Q);6"R
M*R$D-AEP-HQC]:JW.AZSI^LW5]X=N;+9>X:>WO`VP./XE*\Y/?\`KQCIZ*E3
M97*C/TB+5([=VUBXMY;AWR$MT*QQC&,`GD],Y/K4VI17<UA*FGSI!=$9CD==
MR@YZ$>AZ?C5JBIOK<=M+'+1Z+KNIZO8W6O3::D-BYEC2R5\NQ&.2W0#VZTMQ
MH>M:=K-W?>'KBR\N](>>WO0^U7'\2E>>><_U[=115>T8N1'+WOAO4KRSTI9[
MZ.XN;:^6ZGDDRH(R<J@`/3.!4VK:'J2ZV-8T&YMX[IXQ#/#=`^5*HZ'*\@C_
M`#WST5%'.PY$9&F0:VR7#:U<619UV1PVJ,$7K\Q9N23GITX]Z/"VE3:)X=M;
M"Y:-Y8=VXQDE3EB>,@>M:]%)R;T&HV.2BT+7]"N+F/P]<Z<]C/(9A%>A\PL>
MH4KU'U_Q)NZ?X>O-*T:[2UOU;5KJ0SR74D8VL^>FWLN./Q)]JZ"BFYMB4$CE
MH]%UW4]7L;K7IM-2&Q<RQI9*^78C');H![=:M66AWEKK>NWJW$48OU00,HW-
M&54C)!&.O;-;]%#FPY$<A<:'XDUO[/:ZW<Z6ME%*LKM:J_FR%>@^;@9]1_\`
M6KKZ**4I-C4;!1114C"N9^'G_(F6G^_+_P"C&KIJYGX>?\B9:?[\O_HQJM?`
M_E^I+^)?UV.FHHHJ"@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"N9M/^2DZA_V#X__`$*NFKF;3_DI.H?]@^/_`-"JX=?0F70Z:BBBH*"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`KF/AZ`?!EIG^_+_Z,:NGKF?AY_R)EI_OR_\`HQJM?`_E^I+^)?UV.B,*
MGL*3R%]!4M%041>0OH*/(7T%2T4`1>0OH*/(7T%2T4`1>0OH*/(7T%2T4`1>
M0OH*/(7T%2T4`1>0OH*/(7T%2T4`1>0OH*/(7T%2T4`1>0OH*/(7T%2T4`1>
M0OH*YWX@0JO@C42`/NI_Z&M=/7-_$'_D1]2_W4_]&+5T_C7J3/X6;L4"^4G`
M^Z*=Y"^@IT7^J3_=%/J"B+R%]!1Y"^@J6B@"+R%]!1Y"^@J6B@"+R%]!1Y"^
M@J6B@"+R%]!1Y"^@J6B@"+R%]!1Y"^@J6B@"+R%]!1Y"^@J6B@"+R%]!1Y"^
M@J6B@"+R%]!1Y"^@J6B@"+R%]!1Y"^@J6B@#E?`L2G2KW@?\?\__`*%72^0O
MH*Y[P)_R";W_`+"$_P#Z%735=3XF3#X41>0OH*/(7T%2T5!1%Y"^@H\A?05+
M10!%Y"^@H\A?05+10!%Y"^@H\A?05+10!%Y"^@H\A?05+10!%Y"^@H\A?05+
M10!%Y"^@H\A?05+10!%Y"^@KFM'B4^//$8P.$MO_`$`UU5<SHW_(^^)/]RU_
M]`-7'9^GZHF6Z.A\A?04>0OH*EHJ"B+R%]!1Y"^@J6B@"+R%]!1Y"^@J6B@"
M+R%]!1Y"^@J6B@"+R%]!1Y"^@J6B@"+R%]!6+XHT635K"&"#:I68.Q8XPH5O
M\16_377<N*4HJ2LQ-7//'T-+(A(QN;NQ%7+31WD(+"NJ;3T>3<15F*W6,<"E
M&$8JR0));&59Z.D8!8"M6*W2,<`5*!BEJAG+:@,?$C1_^O2:NIKE]1_Y*1H_
M_7I-745<]EZ$QW84445!04444`%%%%`!1110`4444`%%%%`!1110`5Y=\8/^
M/K2_]R3^:UZC7EWQ@_X^M+_W)/YK6V'_`(B,JWP,]'TS_D%VG_7%/_015JJN
MF?\`(+M/^N*?^@BK59/<T6Q%=?\`'K-_N-_*O+_A#_R%-1_ZXK_Z%7I]V0+.
M8DX`C;^5>2_##5++2]1OGO[J&W5XE"F1@N3FMZ:O3E\C*?QQ/8**Q_\`A+=!
M_P"@O9?]_11_PEN@_P#07LO^_HK'DEV->9=S8HK'_P"$MT'_`*"]E_W]%'_"
M6Z#_`-!>R_[^BCDEV#F7<V**Q_\`A+=!_P"@O9?]_11_PEN@_P#07LO^_HHY
M)=@YEW-BBL?_`(2W0?\`H+V7_?T4?\);H/\`T%[+_OZ*.278.9=S8HK'_P"$
MMT'_`*"]E_W]%'_"6Z#_`-!>R_[^BCDEV#F7<V**Q_\`A+=!_P"@O9?]_11_
MPEN@_P#07LO^_HHY)=@YEW-BBL?_`(2W0?\`H+V7_?T4?\);H/\`T%[+_OZ*
M.278.9=S8HK'_P"$MT'_`*"]E_W]%'_"6Z#_`-!>R_[^BCDEV#F7<V**Q_\`
MA+=!_P"@O9?]_11_PEN@_P#07LO^_HHY)=@YEW-BBL?_`(2W0?\`H+V7_?T4
M?\);H/\`T%[+_OZ*.278.9=S8HK'_P"$MT'_`*"]E_W]%'_"6Z#_`-!>R_[^
MBCDEV#F7<V**Q_\`A+=!_P"@O9?]_11_PEN@_P#07LO^_HHY)=@YEW-BBL?_
M`(2W0?\`H+V7_?T4?\);H/\`T%[+_OZ*.278.9=S8HK'_P"$MT'_`*"]E_W]
M%'_"6Z#_`-!>R_[^BCDEV#F7<V**Q_\`A+=!_P"@O9?]_11_PEN@_P#07LO^
M_HHY)=@YEW-BN9^'G_(F6G^_+_Z,:KW_``EN@_\`07LO^_HKG_`WB+2+'PI;
M07>HVL,RO(2CR`$9=B./I5J,N1Z=OU(<ES+4[BBL?_A+=!_Z"]E_W]%'_"6Z
M#_T%[+_OZ*CDEV+YEW-BBL?_`(2W0?\`H+V7_?T4?\);H/\`T%[+_OZ*.278
M.9=S8HK'_P"$MT'_`*"]E_W]%'_"6Z#_`-!>R_[^BCDEV#F7<V**Q_\`A+=!
M_P"@O9?]_11_PEN@_P#07LO^_HHY)=@YEW-BBL?_`(2W0?\`H+V7_?T4?\);
MH/\`T%[+_OZ*.278.9=S8HK'_P"$MT'_`*"]E_W]%'_"6Z#_`-!>R_[^BCDE
MV#F7<V**Q_\`A+=!_P"@O9?]_11_PEN@_P#07LO^_HHY)=@YEW-BBL?_`(2W
M0?\`H+V7_?T4?\);H/\`T%[+_OZ*.278.9=S8HK'_P"$MT'_`*"]E_W]%'_"
M6Z#_`-!>R_[^BCDEV#F7<V*YFT_Y*3J'_8/C_P#0JO?\);H/_07LO^_HKG[;
MQ%I"^/KVZ;4;46[V4:+(9!M+!N1GUJX1EKH1*2TU.XHK'_X2W0?^@O9?]_11
M_P`);H/_`$%[+_OZ*CDEV+YEW-BBL?\`X2W0?^@O9?\`?T4?\);H/_07LO\`
MOZ*.278.9=S8HK'_`.$MT'_H+V7_`']%'_"6Z#_T%[+_`+^BCDEV#F7<V**Q
M_P#A+=!_Z"]E_P!_11_PEN@_]!>R_P"_HHY)=@YEW-BBL?\`X2W0?^@O9?\`
M?T4?\);H/_07LO\`OZ*.278.9=S8HK'_`.$MT'_H+V7_`']%'_"6Z#_T%[+_
M`+^BCDEV#F7<V**Q_P#A+=!_Z"]E_P!_11_PEN@_]!>R_P"_HHY)=@YEW-BB
ML?\`X2W0?^@O9?\`?T4?\);H/_07LO\`OZ*.278.9=S8HK'_`.$MT'_H+V7_
M`']%'_"6Z#_T%[+_`+^BCDEV#F7<V**Q_P#A+=!_Z"]E_P!_11_PEN@_]!>R
M_P"_HHY)=@YEW-BBL?\`X2W0?^@O9?\`?T4?\);H/_07LO\`OZ*.278.9=S8
MHK'_`.$MT'_H+V7_`']%'_"6Z#_T%[+_`+^BCDEV#F7<V**Q_P#A+=!_Z"]E
M_P!_11_PEN@_]!>R_P"_HHY)=@YEW-BBL?\`X2W0?^@O9?\`?T4?\);H/_07
MLO\`OZ*.278.9=S8KF?AY_R)EI_OR_\`HQJO?\);H/\`T%[+_OZ*Y_P-XBTB
MQ\*6T%WJ-K#,KR$H\@!&78CCZ5:C+D>G;]2')<RU.XHK'_X2W0?^@O9?]_11
M_P`);H/_`$%[+_OZ*CDEV+YEW-BBL?\`X2W0?^@O9?\`?T4?\);H/_07LO\`
MOZ*.278.9=S8HK'_`.$MT'_H+V7_`']%'_"6Z#_T%[+_`+^BCDEV#F7<V**Q
M_P#A+=!_Z"]E_P!_11_PEN@_]!>R_P"_HHY)=@YEW-BBL?\`X2W0?^@O9?\`
M?T4?\);H/_07LO\`OZ*.278.9=S8HK'_`.$MT'_H+V7_`']%'_"6Z#_T%[+_
M`+^BCDEV#F7<V**Q_P#A+=!_Z"]E_P!_11_PEN@_]!>R_P"_HHY)=@YEW-BB
ML?\`X2W0?^@O9?\`?T4?\);H/_07LO\`OZ*.278.9=S8KF_B#_R(^I?[J?\`
MHQ:N?\);H/\`T%[+_OZ*P?&_B/2+[PA?V]KJ5K-,X3:B2`D_.IZ55.,N9:$S
MDN5ZG9Q?ZI/]T4^L6/Q;H(C4'5[+(`_Y:BG?\);H/_07LO\`OZ*GDEV'S+N;
M%%8__"6Z#_T%[+_OZ*/^$MT'_H+V7_?T4<DNP^9=S8HK'_X2W0?^@O9?]_11
M_P`);H/_`$%[+_OZ*.278.9=S8HK'_X2W0?^@O9?]_11_P`);H/_`$%[+_OZ
M*.278.9=S8HK'_X2W0?^@O9?]_11_P`);H/_`$%[+_OZ*.278.9=S8HK'_X2
MW0?^@O9?]_11_P`);H/_`$%[+_OZ*.278.9=S8HK'_X2W0?^@O9?]_11_P`)
M;H/_`$%[+_OZ*.278.9=S8HK'_X2W0?^@O9?]_11_P`);H/_`$%[+_OZ*.27
M8.9=S8HK'_X2W0?^@O9?]_11_P`);H/_`$%[+_OZ*.278.9=S8HK'_X2W0?^
M@O9?]_11_P`);H/_`$%[+_OZ*.278.9=RCX$_P"03>_]A"?_`-"KIJX?P;XB
MTBSTV[2YU&UB9KV9U#R`$J3P?I70?\);H/\`T%[+_OZ*NI&7,]"827*M38HK
M'_X2W0?^@O9?]_11_P`);H/_`$%[+_OZ*CDEV*YEW-BBL?\`X2W0?^@O9?\`
M?T4?\);H/_07LO\`OZ*.278.9=S8HK'_`.$MT'_H+V7_`']%'_"6Z#_T%[+_
M`+^BCDEV#F7<V**Q_P#A+=!_Z"]E_P!_11_PEN@_]!>R_P"_HHY)=@YEW-BB
ML?\`X2W0?^@O9?\`?T4?\);H/_07LO\`OZ*.278.9=S8HK'_`.$MT'_H+V7_
M`']%'_"6Z#_T%[+_`+^BCDEV#F7<V**Q_P#A+=!_Z"]E_P!_11_PEN@_]!>R
M_P"_HHY)=@YEW-BN9T;_`)'WQ)_N6O\`Z`:O?\);H/\`T%[+_OZ*Y_2O$6D1
M>-->N9-1M5@F2W$<AD&'PA!P?:KC&5GI_5T3*2NM3N**Q_\`A+=!_P"@O9?]
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MD]`371?\);H/_07LO^_HJYQE9:="(R6NIL45C_\`"6Z#_P!!>R_[^BC_`(2W
M0?\`H+V7_?T5')+L7S+N;%%8_P#PEN@_]!>R_P"_HH_X2W0?^@O9?]_11R2[
M!S+N;%%8_P#PEN@_]!>R_P"_HH_X2W0?^@O9?]_11R2[!S+N;%%8_P#PEN@_
M]!>R_P"_HH_X2W0?^@O9?]_11R2[!S+N;%%8_P#PEN@_]!>R_P"_HH_X2W0?
M^@O9?]_11R2[!S+N;%%8_P#PEN@_]!>R_P"_HH_X2W0?^@O9?]_11R2[!S+N
M;%%8_P#PEN@_]!>R_P"_HH_X2W0?^@O9?]_11R2[!S+N;%>7?&#_`(^M+_W)
M/YK7<_\`"6Z#_P!!>R_[^BO._BCJMCJESIQL+N&X$:2!C$X;;DKC-;4(M5%=
M&59IP9ZEIG_(+M/^N*?^@BK55=+(;2;,J<@P(0?^`BK58/<U6Q%=#-I,#TV-
M_*O*/A59VUYJ5^MU;PSJL*D"1`V.?>O5[K_CUF_W&_E7E_PA_P"0IJ/_`%Q7
M_P!"K:G_``Y?(RG\<3T?^P]+_P"@;9?]^$_PH_L/2_\`H&V7_?A/\*O45CS/
MN:V11_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7
M_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!M
ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X61
M1_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/
M\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX
M3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/
M2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[
M#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"K
MU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`
MH&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_
M`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*YSP%I5A<^$;62>QM99"\N6
M>%6)_>-W(KL:YGX>?\B9:?[\O_HQJM-\C^7ZDM+F7]=C8_L/2_\`H&V7_?A/
M\*/[#TO_`*!ME_WX3_"KU%1S/N59%'^P]+_Z!ME_WX3_``H_L/2_^@;9?]^$
M_P`*O44<S[A9%'^P]+_Z!ME_WX3_``H_L/2_^@;9?]^$_P`*O44<S[A9%'^P
M]+_Z!ME_WX3_``H_L/2_^@;9?]^$_P`*O44<S[A9%'^P]+_Z!ME_WX3_``H_
ML/2_^@;9?]^$_P`*O44<S[A9%'^P]+_Z!ME_WX3_``H_L/2_^@;9?]^$_P`*
MO44<S[A9%'^P]+_Z!ME_WX3_``H_L/2_^@;9?]^$_P`*O44<S[A9%'^P]+_Z
M!ME_WX3_``H_L/2_^@;9?]^$_P`*O44<S[A9%'^P]+_Z!ME_WX3_``H_L/2_
M^@;9?]^$_P`*O44<S[A9%'^P]+_Z!ME_WX3_``KG+72K`_$*^A-C:F);&-@A
MA7:#NZXQUKL:YFT_Y*3J'_8/C_\`0JN#>OH3)+0V/[#TO_H&V7_?A/\`"C^P
M]+_Z!ME_WX3_``J]14<S[E611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"K
MU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`
MH&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_
M`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',
M^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7
M_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!M
ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X61
M1_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/
M\*/[#TO_`*!ME_WX3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX
M3_"KU%',^X611_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%',^X611_L/
M2_\`H&V7_?A/\*YSP%I5A<^$;62>QM99"\N6>%6)_>-W(KL:YGX>?\B9:?[\
MO_HQJM-\C^7ZDM+F7]=C8_L/2_\`H&V7_?A/\*/[#TO_`*!ME_WX3_"KU%1S
M/N59%'^P]+_Z!ME_WX3_``H_L/2_^@;9?]^$_P`*O44<S[A9%'^P]+_Z!ME_
MWX3_``H_L/2_^@;9?]^$_P`*O44<S[A9%'^P]+_Z!ME_WX3_``H_L/2_^@;9
M?]^$_P`*O44<S[A9%'^P]+_Z!ME_WX3_``H_L/2_^@;9?]^$_P`*O44<S[A9
M%'^P]+_Z!ME_WX3_``H_L/2_^@;9?]^$_P`*O44<S[A9%'^P]+_Z!ME_WX3_
M``H_L/2_^@;9?]^$_P`*O44<S[A9%'^P]+_Z!ME_WX3_``H_L/2_^@;9?]^$
M_P`*O44<S[A9%'^P]+_Z!ME_WX3_``KGO'>E:?;^#-0E@L;6*10F'2%01\Z]
MP*Z^N;^(/_(CZE_NI_Z,6KIM\Z)FERLTX]$TLQ)_Q+;+H/\`E@O^%/\`[#TO
M_H&V7_?A/\*MQ?ZI/]T4^HYGW*LBC_8>E_\`0-LO^_"?X4?V'I?_`$#;+_OP
MG^%7J*.9]PLBC_8>E_\`0-LO^_"?X4?V'I?_`$#;+_OPG^%7J*.9]PLBC_8>
ME_\`0-LO^_"?X4?V'I?_`$#;+_OPG^%7J*.9]PLBC_8>E_\`0-LO^_"?X4?V
M'I?_`$#;+_OPG^%7J*.9]PLBC_8>E_\`0-LO^_"?X4?V'I?_`$#;+_OPG^%7
MJ*.9]PLBC_8>E_\`0-LO^_"?X4?V'I?_`$#;+_OPG^%7J*.9]PLBC_8>E_\`
M0-LO^_"?X4?V'I?_`$#;+_OPG^%7J*.9]PLBC_8>E_\`0-LO^_"?X4?V'I?_
M`$#;+_OPG^%7J*.9]PLBC_8>E_\`0-LO^_"?X4?V'I?_`$#;+_OPG^%7J*.9
M]PLCCO!6E6%QI=XTUC:R,+Z907A4D`-P.1TKH_[#TO\`Z!ME_P!^$_PK'\"?
M\@F]_P"PA/\`^A5TU74;YF3!+E11_L/2_P#H&V7_`'X3_"C^P]+_`.@;9?\`
M?A/\*O45',^Y5D4?[#TO_H&V7_?A/\*/[#TO_H&V7_?A/\*O44<S[A9%'^P]
M+_Z!ME_WX3_"C^P]+_Z!ME_WX3_"KU%',^X611_L/2_^@;9?]^$_PH_L/2_^
M@;9?]^$_PJ]11S/N%D4?[#TO_H&V7_?A/\*/[#TO_H&V7_?A/\*O44<S[A9%
M'^P]+_Z!ME_WX3_"C^P]+_Z!ME_WX3_"KU%',^X611_L/2_^@;9?]^$_PH_L
M/2_^@;9?]^$_PJ]11S/N%D4?[#TO_H&V7_?A/\*YS2-*L'\;^(8GL;5HHTMM
MB&%2%RAS@8XKL:YG1O\`D??$G^Y:_P#H!JXMV?I^J)DE=&Q_8>E_]`VR_P"_
M"?X4?V'I?_0-LO\`OPG^%7J*CF?<JR*/]AZ7_P!`VR_[\)_A1_8>E_\`0-LO
M^_"?X5>HHYGW"R*/]AZ7_P!`VR_[\)_A1_8>E_\`0-LO^_"?X5>HHYGW"R*/
M]AZ7_P!`VR_[\)_A1_8>E_\`0-LO^_"?X5>HHYGW"R*/]AZ7_P!`VR_[\)_A
M1_8>E_\`0-LO^_"?X5>HHYGW"R*/]AZ7_P!`VR_[\)_A1_8>E_\`0-LO^_"?
MX5>HHYGW"R*/]AZ7_P!`VR_[\)_A1_8>E_\`0-LO^_"?X5>HHYGW"R*/]AZ7
M_P!`VR_[\)_A1_8>E_\`0-LO^_"?X5>HHYGW"R.,O]*L%^(.DPK8VPB>UE+(
M(EVDCH2,5TO]AZ7_`-`VR_[\)_A6+J/_`"4C1_\`KTFKJ*N;=EZ$Q2NRC_8>
ME_\`0-LO^_"?X4?V'I?_`$#;+_OPG^%7J*CF?<JR*/\`8>E_]`VR_P"_"?X4
M?V'I?_0-LO\`OPG^%7J*.9]PLBC_`&'I?_0-LO\`OPG^%']AZ7_T#;+_`+\)
M_A5ZBCF?<+(H_P!AZ7_T#;+_`+\)_A1_8>E_]`VR_P"_"?X5>HHYGW"R*/\`
M8>E_]`VR_P"_"?X4?V'I?_0-LO\`OPG^%7J*.9]PLBC_`&'I?_0-LO\`OPG^
M%']AZ7_T#;+_`+\)_A5ZBCF?<+(H_P!AZ7_T#;+_`+\)_A1_8>E_]`VR_P"_
M"?X5>HHYGW"R*/\`8>E_]`VR_P"_"?X5YM\5[*UL[G31:VT,`9)-PB0+GE>N
M*]7KR[XP?\?6E_[DG\UK;#M^T1G62Y&>CZ6`-*LP!@"!./\`@(JU573/^07:
M?]<4_P#015JL7N:+8BNO^/6;_<;^5>7_``A_Y"FH_P#7%?\`T*O4+K_CUF_W
M&_E7E_PA_P"0IJ/_`%Q7_P!"K:G_``Y?(SG\<3U6BL_7=7BT+1Y[^92PB'RH
M.KL>`/SK$M[+QA<6ZWLFKVD$[#>+`V@,0]%+YW#WZUDHW5[EN5G8ZNBLZ?6(
M=,TB*\UIX[(E1YBEMV'QRHQ]X]>F>E1Z1XFTC79'CTV]2:1!EDVLK8]<,`2/
MI2Y7:]A\RV-6BL?5?%FBZ)<"#4+Y(IB,[`K.0/?:#C\:6Q\4Z1J5E=7=G=^9
M!:+NF?RG&T8)Z$9/`/2GR2M>P<RO:YKT5@R>-O#\5Q#`^IQ"2959?E;`#=-Q
MQA?QQCO3O$C(&TLMJLNGYO$"^6K-YY_YYG'0'U/%'([ZBYET-RBN1U/Q]8Z9
MXG2PEN(UM41A<N8I"R2#H!CJ/P-7;F[M[S7M#GAU>:%)T=XK58WVW0*YR>PQ
MUY%/V;6X<ZZ'0T54T_4[35(Y7LY?,$4AB?Y2I5QU!!`IL.L6$YO/+N4Q9,4N
M&;*K&1R<D\5-F.Z+M%8FG>,="U6]%I9:A').<X0JR[OH2`#^%;=#36X)I[!1
M6=J_B#3-!CC?4[M8!(<(,%F/X`$X]ZP]/UV/4?&\DEI>O-IQTSS0JLQ4-OY.
MWLV..F::@VKB<DG8ZVBJVGZC:ZI91WEE*);>3.U\$9P<'@\]JI-XHTA-+;46
MO46T60Q^8RL-S#J%&,M^&>AI<K[#NC6HK&M_%VBW>G7-_!?*]M;8\YMC`IGI
M\N,_I7+^$]9MM:UN6ZN==OS>>=(\=DK,(/*`P,KMQTYZ@_C5JF[-OH2YJZ1Z
M#156QU*UU+3TOK.7S+9P2K[2,X)!X(SV-5_^$ATW^Q1J_P!I_P!`/27RV_O;
M>F,]>.E1ROL5=&E16*GB_0I-4&G)J,1NBVP*`=I;TW8VY_'KQUJ]J>K6.C6A
MN=1N$@BS@%LDD^@`Y)^E'*]K!S(N45SK^.=#?2KF]M;]'6'Y<&-\[B/ERN,X
M)[]*C\->,+/Q%8+$;E%U+R3)-''&X$?;()X[CN:KV<K7L+GC>USIJ*Q/#$\,
M?AB*9M6>_A7>S7DX*9`8YSN.0!TY]*;:>-O#]]?+:6^I1M.[;5!1E#'T#$`'
MVYYI<CN[=`YEI<W:*HWVLV&F3PPWURD#S*[)OR`0HRV3T&!ZU!I'B?2-=EDC
MTV]2:2,99"K(<>H#`9_"ERNU[#NKV-6N9^'G_(F6G^_+_P"C&KIJYGX>?\B9
M:?[\O_HQJI?`_E^HG\2_KL=-1114%!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%<S:?\E)U#_L'Q_^A5TU<S:?\E)U#_L'Q_\`H57#KZ$RZ'34
M445!04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%<S\//^1,M/]^7_P!&-735S/P\_P"1,M/]^7_T8U6O@?R_
M4E_$OZ['34445!04444`%%%%`!1110`4444`%%%%`!1110`4444`%<W\0?\`
MD1]2_P!U/_1BUTE<W\0?^1'U+_=3_P!&+5T_C7J3/X6=#%_JD_W13Z9%_JD_
MW13Z@H****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`YGP)_R
M";W_`+"$_P#Z%735S/@3_D$WO_80G_\`0JZ:KJ?$R8?"@HHHJ"@HHHH`****
M`"BBB@`HHHH`****`"BBB@`KF=&_Y'WQ)_N6O_H!KIJYG1O^1]\2?[EK_P"@
M&KCM+T_5$RW1TU%%%04%%%%`"*P894@C)'%+7ELNJWNG>)-1^QW#1DW,AV]5
M;YCU'2NFTSQS#(1'J<7V=_\`GHO*'^H_6N>.(@WRO1D*:O8ZRBHX9X[B-9(7
M5T;HRG(/XU)706%%%%`!1110`4444`%%%%`'+ZC_`,E(T?\`Z])JZBN7U'_D
MI&C_`/7I-745<]EZ$QW84445!04444`%%%%`!1110`4444`%%%%`!1110`5Y
M=\8/^/K2_P#<D_FM>HUY=\8/^/K2_P#<D_FM;8?^(C*M\#/1],_Y!=I_UQ3_
M`-!%6JJZ9_R"[3_KBG_H(JU63W-%L177_'K-_N-_*O+_`(0_\A34?^N*_P#H
M5>H77_'K-_N-_*O+_A#_`,A34?\`KBO_`*%6U/\`AR^1G/XXG5_$0,/#23;2
MT<%U%)*!_=!Y_F*Z>*6.>%)8G5XW4,K`\$'D&DFACN87AGC62*12K(PR&![$
M5S:^`=/C!BCOM52Q))-BMV1"0>JXZX/UK--.-F4TT[H@U$P7_P`1-'2=DEME
MM'FMQD,K29ZCUX&?PI_BB../Q7X;GA4"\:X:,E1RT>/FS[#/ZFM75/#.GZK9
MV]NZ/`;7'V:6W;8\.,?=/;H*9I7A:STN]-ZT]Y?7FW8L]Y-YCHOH.F!_B:M3
M6C$XLY^SN]2MM>UZ71](35(9;G8[M.D+(ZJ,J=W5>>.G>KL>D3Z+\.=1M;ID
M,QMYY&6/[B;@3M7V%<[(OAD:SJC^,8&@OGN6,:^7*J&+HK+LZYP<D]:WO">G
MM>Z)JMJPO(M'NG9+))B=ZQ,O)7.<+SQ5RT5_0B.KMZA'IUI'\*9(X[>-5?3S
M.P"_>?9NW'WR!^0JGJKM)X=\&LY+,;JVR3W^6NN_L>#^P?[(WR_9_L_V?=D;
M]NW;G.,9Q[56G\-6D]CIEJTDXCTV1)(2&&6*#`W<<_ABH4U?7N4X,S]0('Q(
MTGWLYJ9KW_(_>&_]V?\`]!K4UOPY:ZY);S23W5M<6Q/ESVLNQP".1G!X/^>]
M.;P_;O?:9=R3W+S:<C)&SN#OR,$N<9)_*DI+3T&XO7U.?:^3PKXKUGS>+:[M
MOMT8[&11A@/<]:R]3LKBQ^&]GG8)KZ[CGNS)PIWG=\_M]T&NO\0^%K#Q,+?[
M?YH-NQ93&0"0>H.0>.*T;W3[;4;&2SNX5EMY%VLAZ8_I351*S^_Y"<&[HY+4
M="\4ZK#:PW`T")+:5)(G@\U6CVG^'(('':NVKF[7P1:VTD/F:GJ]S!"RLEM-
M=$Q#;]WY0!T(&/I725,Y)Z(J*L<G9*DWQ.U)IP#+!9QB#=V4_>(_$_K3+*"V
MA^*=Z+9(U+Z>'E"?WRXR2/4C%:VL^&+36;F&Z::ZM+N$%5N+27RY-O\`=S@\
M<TFE>%=/T?4/MMJ9O/:$Q2-(^XRDMN+L2,EB??'M5<RM\K"Y7?YG,'4&\+67
MB/2D)WH_FV0'4B;@`?0FM:;PE/'H>CQ:;-#%>Z6PE03*3'(Y'S;L<C)R<C_Z
MXKZSI]MK/Q'TN/9E[*`W$[=B`W[M?SY^AKH-9T*'6A"SW-W:S0$F.:UE\MP#
MU&?0X'Y4W*UO,2CN4]"UB2[U2ZLM2TY+/588U,C(P99D[,&ZXR3P>F?7-4_!
M`SX;O0.OVNX_G6MHOAVUT1IY8I;FXN;C'FW%S)YDC@=`3Z"IM(TB#1;1[>V>
M1D>5I29""<L<GH!Q4.4=;>123TN8G@>1!\/K9BP"HDNXD\#YFZUS[<_!)?0X
M_P#1]=-_P@NF?:I7$U\MK+)YCV*SD6[-ZE>_(!Z_IQ5@^$[(^%QH/FW'V0?Q
M[EW_`']_7&.OM5\\;W\[D\LK6\K&7XVL+:S\`-';0I$EJT30A!C8=X&1[\GG
MWI]ZJ7'Q%TE;L!DCLGD@#=/-SR0/7`S^%;VKZ/!K6DR:?<O*L,FW+1D!N"".
MH([5#K/AZSUN&%;AIHI;<[H;B!]DD1XZ'WQ4QFK6?G^(W%WT\B;45MUMKUE6
M(7+6S;B`-Y4`XSWQDFLSP>0?`=AC_GW/\S5S2/#MKI'GLLMS=3W`"RSW<OF2
M.HZ#/H,U#I'A6VT267[)>7YMW5E6VDGW11@G/RKCK[G-*ZLU<=G>YQ:M_P`6
MJTN-V*V\MZ$G(_N>8V?Y"NJ\<V=FO@>[1XHTCMT4P`*!L8$!=OIZ<=C5^S\-
M:?:^'O[%='N++!!$Q!)R<]0!WZ8JA;>!;"*2#[1>ZE>P0$-%;75QOB0CH0N!
MTZ>E7SQ;OYW)Y&E;R,[5K9-1UWP?%J,0EWQ2-(D@R"P13R/J*NZVBQ>/_#LR
M#;)(D\;L/XE"Y`/YFMN[T>"]U6QU"1Y!-9;_`"U4C:=PP<\>WM1=Z/!>ZK8Z
MA(\HFLM_EJI&T[A@YX]O:IYUIZ/]1\N_R+]<S\//^1,M/]^7_P!&-735S/P\
M_P"1,M/]^7_T8U2O@?R_4I_$OZ['34445!1AZEXST/2+U[.^OO*N$P63R9&Q
MD9'(4BH[/QUX>O[N*UMM0WS2L$1?)D&2?<KBM/6O^0'?_P#7M)_Z":YW2+J:
MQ^%D=S;/LFALG=&P#@C..#Q6JC%Q_K_(S;DF=;(XCC9SG"@DXJEHNL0:]I<5
M_:I*D4A(`E`#<$CL3Z5CZ`^O7MI!JNH7\<<$D&X6:0*<_+\KE^N3UP!BLS_A
M)-3'PN.L&YS?AO\`6^6O_/7;TQCIQTI>SZ>8^?J=U17#ZOJ'B?1]-CUZ>\MF
MAWH9=-6$;41N`!)U)Y'MDGJ."_5+_P`3:+:PZU>7MLUN9$$^GI"-L:,<<2?>
M)Y'X^HH]F^X<_D=K17,>*/$$MGJ%II5G>VMA+<*9)+NYQMB0>@)P6)SP?_KB
MOH.OW*>(5TFZUBSUB.>(R17,`165AU1E0D=.1_G"]F[7#G5['7U%+=00/$DT
MT<;RMMC5W`+GT`[FN,TW4M<\075W)9ZY:6<]O,ZC3'MU8[5./G8G<`>Y'X>E
M'C.SU*7Q!HC0ZH(5EN`L*"W5O)?;RV3][/H:I4];-B<]+I'<45AW4&L6NB1Q
MC6+43J2;B_G@"[4Y.0@.W(X'/&,UCZ1KMY!XGM=-FUVSUN"\C<B2%$5H64$\
MA"1@CU_3O*A=73*<K;FY;ZGJ<NJRV<EA9H(51Y'6\9OE8MC`\L9/RGC(^M,T
MWQ+'>Z)/J$\!@:`;GB#[B00&7!P,Y!'X\5=ALI(]8O+LE?+GABC4`\@J7SG_
M`+Z%9-KX;N87TP--$(88D6[12?WC1\QXX[$G.?04_=8O>-?2+]]3TV*ZDA\A
MW+!H]^[:0Q!YP,]*NU2TFSDL-/6"4J7#NV5/'S.6'Z&KM0[7T*6VH5S-I_R4
MG4/^P?'_`.A5TU<S:?\`)2=0_P"P?'_Z%50Z^@I=#IJ***@H****`"BBB@`K
M'U7Q7HNB3B'4+^.*4_P*K.P^H4''7O6C?7!M+"XN`,F*)GQZX!-<_P"`K&./
MP]%J#@/>WQ::>8CYG)8\9]/:KBE:[);=[(V-*US3M<A,NFW<<ZK]X#(9?JIY
M'3N*OUR&MP1Z9XZT.^M4$<EZTEO<;1CS!@8)]P>_L/2F?;?$&J^*-6TRPOH[
M2VMF0_:&A61H\KD*%XSDY.3Z4^2^JV%SVT9V55M0O8]-T^XO)E=HX(S(P09)
M`&>*Y[5CJT$ZBX\5:?I4>T"+=`A:;`&YFWG@YSPO&,54BUFXUKX>:P]V\4DU
MNDUNTL/W)=J_>'US0J>S!SZ'6V%Y'J%A;W<(98YXUD4,.0",\U8K+\,?\BOI
M?_7K'_Z"*S/%&ORV>H6FE6E[:V$MPIDDN[G&V)!Z`G!8G/!_^N%RWE9#YK*[
M.GHKD-!U^Y3Q"NDW6L6>L1SQ&2*Y@"*RL.J,J$CIR/\`.*VFZEKGB"ZNY+/7
M+2SGMYG4:8]NK':IQ\[$[@#W(_#TI^S8N='9RW4$#Q)--'&\K;8U=P"Y]`.Y
MJ6N'\9V>I2^(-$:'5!"LMP%A06ZMY+[>6R?O9]#5OQ!?ZUH&F:5'#>+?7TUX
M(7=HEC$V<X4@=!TY'I1[.Z5GN'/:]UL;NMZS;Z#IDE]=)*\2%01$H+<G'<BK
MRL'0,,X(SS7(Z[/KOA_PI>7<^KI<71>/RV2V1!$"P!4==PYZGFKFN:OJ!U&Q
MT;2'CBO+J,RR7$B[A#&.X7H3GU_KD')=:!S=SI*S[/6;>^U6^T^))1-9%!(S
M`;3N&1CG_"L..^UGP_KUC9ZO?1ZE::@3&DP@6%XI!T&!P0>/\CE?#W_(\^)_
M]Z#_`-!-')9-_P!;AS:HZNBBBLRPHHHH`****`"O/O!?B:&P\/6]D8'>1&D;
MA@,@NU>@UXEI$$\T<!MP=R;CN';YVK.O.4*+<=[K]3*HVFK'I?\`PEJ?\^<O
M_?0H_P"$M3_GSE_[Z%<MNU#_`)YP?]\G_&EW:A_SS@_[Y/\`C7F?6:_=&?M)
MG4?\):G_`#YR_P#?0H_X2U/^?.7_`+Z%<ONU#_GG!_WR?\:-VH?\\X/^^3_C
M2^LU^Z#VDSJ/^$M3_GSE_P"^A1_PEJ?\^<O_`'T*Y?=J'_/.#_OD_P"-&[4/
M^><'_?)_QH^LU^Z#VDSJ/^$M3_GSE_[Z%'_"6I_SYR_]]"N7W:A_SS@_[Y/^
M-&Z__P"><'_?)_QH^LU^Z#VDSJ/^$M3_`)\Y?^^A1_PEJ?\`/G+_`-]"N7W7
M_P#SS@_[Y/\`C1NO_P#GG!_WR?\`&CZS7[H/:3.H_P"$M3_GSE_[Z%'_``EJ
M?\^<O_?0KE]U_P#\\X?^^3_C1NO_`/GG#_WR?\:/K-?N@]I,ZC_A+4_Y\Y?^
M^A1_PEJ?\^<O_?0KE]U__P`\X?\`OD_XTFZ__P"></\`WR?\:/K-?N@]I,ZG
M_A+4_P"?.7_OH4?\):G_`#YR_P#?0KEMVH?W(?\`OD_XT;M0_N0_]\G_`!H^
MLU^Z#VDSJ?\`A+4_Y\Y?^^A69XEU?^W-`NM/BMWB>8*`['(&&!_I63NO_P"Y
M#_WR?\:-VH?W(?\`OD_XTUBL0G=-"<YM6.H3Q8BHJ_8Y.!C[PI?^$M3_`)\Y
M?^^A7+;M0_N0_P#?)_QHW7_]R'_OD_XTOK-?NA^TF=3_`,):G_/G+_WT*/\`
MA+4_Y\Y?^^A7+9O_`.Y#_P!\G_&C-_\`W(O^^3_C1]9K]T'M)G4_\):G_/G+
M_P!]"C_A+4_Y\Y?^^A7+9U#^[%_WR?\`&C-__=B_[Y/^-'UFOW0>TF=3_P`)
M:G_/G+_WT*/^$M3_`)\Y?^^A7+9O_P"[%_WR?\:,W_\`=B_[Y/\`C1]9K]T'
MM)G4_P#"6I_SYR_]]"C_`(2U/^?.7_OH5RV;_P#NQ?\`?/\`]>C_`$_^[%_W
MS_\`7I_6:_=![29U/_"6I_SYR_\`?0H_X2U/^?.7_OH5RO\`I_\`=C_[Y_\`
MKT?Z?Z1_]\__`%Z/K-?N@]I,ZK_A+4_Y\Y?^^A1_PEJ?\^<O_?0KE?\`3_2/
M_OG_`.O1_I_I'_WS1]9K]T'M)G5?\):G_/G+_P!]"C_A+4_Y\Y?^^A7*XO\`
MTC_[YHQ?^B?]\T?6:_=![29U7_"6I_SYR_\`?0H_X2U/^?.7_OH5RN+_`/V/
M^^:,7_\`L?\`?-'UFOW0>TF=5_PEJ?\`/G+_`-]"C_A+4_Y\Y?\`OH5RFV__
M`-C_`+YHVW_^Q^5'UFOW0>TF:WA[5O[%LYX9+=I#+<R3`J<8#'.*U?\`A+4_
MY\Y?^^A7*;;_`/V?RHVW_P#L_E0\5B&[MH2G)*QU?_"6I_SYR_\`?0H_X2U/
M^?.7_OH5RFR_]5_*C9?^J_E1]9K]T/VDSJ_^$M3_`)\Y?^^A1_PEJ?\`/G+_
M`-]"N4V7WJ/RH\N^]1^5'UFOW0>TF=7_`,):G_/G+_WT*/\`A+4_Y\Y?^^A7
M)^7??WA^5'EWW]X?E1]9K]T'M)G6?\):G_/G+_WT*/\`A+4_Y\Y?^^A7)^5?
M?WA^5'E7W]X?E1]9K]T'M)G6?\):G_/G+_WT*/\`A+4_Y\Y?^^A7)^5??WA^
M5)Y-]_>_2CZS7[H/:3.M_P"$M3_GSE_[Z%'_``EJ?\^<O_?0KDO)O?[WZ4>1
M>_W_`-*/K-?N@]I,ZW_A+4_Y\Y?^^A1_PEJ?\^<O_?0KDO(O?[_Z4?9[W^_^
ME'UFOW#VDSK?^$M3_GSE_P"^A658ZM]D\1:IJ36[,EZL05`>5V*0<UC?9[W^
M_P#I1]FO/[_Z4UBJZZH3G)G7?\):G_/G+_WT*/\`A+4_Y\Y?^^A7(_9KS^_1
M]EO/[]+ZS7[C]I,Z[_A+4_Y\Y?\`OH4?\):G_/G+_P!]"N1^RWG]\TGV2\_O
MFCZS7[A[29GZGYG]LSW!0H)I6D7\3G^M61&LT8;'7K4=\KPJJ3N&9N0O?ZU3
MGU0V*JD05G/)#=!6+YIOS)U9I6ES>Z5*9+&=H\]5ZJWU'2NITOQS#(1'J<?V
M=_\`GHN2A_J/UKSS^W;I^D4/_?)_QJ:*XNKGCRHL'_9/^-;TZE6F7%RB>S0S
MQW$:R0NKHW1E.0?QJ2O-=`BO+6X#QW;6ZD_,J\AOP/%>@VUR)E!KTJ<W-7:L
M;Q=T6:***T&%%%%`!1110!R^H_\`)2-'_P"O2:NHKE]1_P"2D:/_`->DU=15
MSV7H3'=A1114%!1110`4444`%%%%`!1110`4444`%%%%`!7EWQ@_X^M+_P!R
M3^:UZC7EWQ@_X^M+_P!R3^:UMA_XB,JWP,]'TS_D%VG_`%Q3_P!!%6JJZ9_R
M"[3_`*XI_P"@BK59/<T6Q%=?\>LW^XW\J\O^$/\`R%-1_P"N*_\`H5>H77_'
MK-_N-_*O+_A#_P`A34?^N*_^A5M3_AR^1G/XXGJM4]6:9-)NFM;B*VF$3%)I
MB`D9QU.>,5<K(\5_\BGJO_7K)_*L8[HT>Q8L;L0Z78MJ%];233*B><K@),Y'
M\'3.>V*EM]3L;JY>WMKVVFGCSOCCE5F7!P<@'(YKB-9@6Z\%^%('9U66XMD)
M0X(!0C@U;\1:-8:'=>'[G2[6*UE2_C@W1+@LC`@AC_%TZGGDUKR)_B1SL[:J
MLNIV,'G^=>6T?V?;YV^51Y>[INYXSVS5JN'LM(L]4^(VO-?0B=(%A9(I/FC+
M%,9*G@D#.,^IJ(Q3O?H5)M6L==_:=C]A^V_;;;[)_P`]_-7R^N/O9QUXJ6"Z
M@NK=9[>>*6%LD21N&4XZ\CBN(T3PWILGC37+>6W62UM7CDAMFYA5I$RQV=,]
MAZ?E5SPS!'8:SXHL;9?+M8I$=(QT4LA)P.PXJG!*]F2I/J=7!=075N)[>:*6
M%LD21N&4XZ\CBL'Q;K<EIX2FU'1[N,MN0)-'MD4@N`<=0>XJ+P*<^`+3_<E_
M]#:N;E_Y(K#_`+P_]'&G&"4OG84I/E^1UVK>*K31[VPM9I("]RX64M.J&%<9
MW$>GY4_5;Z6XBTZ;2=6L(89+I5=WD4K.O=$.#EOI^=9'BK3[.;6?#K2VD#M-
M<A)"T8)==O0^H]C3O&%K!9IX?AM88X(EU2+:D:!5'7L*%&.E@;>IU,E[:PR.
MDMS"CQQ^:ZLX!5/[Q'8>]):7UKJ$1DLKF"XC!VEH9`X!],BN4U+3;;5?B7%#
M>*9($TY9#$3\CD2'&X=QSG!IR65OHWQ'M8]-B2WAO+-_.AC`5,J>&P.!^'O[
MTN16\[7*YG<T?"6IW>IIJAO)?,,%_)#'\H&U!C`X%:BZMI[WILTO[5KH$J81
M,I?(ZC;G-<+:WDUAX.\5W%LQ65;^90PZKDJ"?UJ"31+^XT".UL_!<4$P16BO
M5OHO-##D-G`)^F:ITTVWL0IM(]-J"ZO;:PA\V\N(;>+.-\KA%SZ9-%GYWV*#
M[4,3^6OF#T;'/ZUSGBK2+NXU:QU*'3X-5@MHW22RE8#K_$NX8)_P&/;**3=F
M:-M*Z.EMKJ"\@6:UFCGB;[KQN&4_B*KKK.FO>?9%U"T-SN*^2)EWY]-N<YKE
M+K5;"+P/K5QH%M)I\R-MF@,?E/"YPI^7HO'I_/-;.G^$=#BTVT0:=;NT:HXF
M*#S&88.2PYZ^^.W2J<4M6)2;V$T;4[N[\5:[9SR[K>U,7DIM`V[ER>0,G\:U
M)=6T^"[%K-?VL=RQ`$+S*')/3Y<YYKEK*X>T\1^,KB(9DBBC=?J(R16'I>G7
M=[X:4?\`"'17K72%S?/>Q"5V;^,$C<OTS5^S3U]/R)YVOQ/3)KF&W:,331QF
M5MB!V`WMZ#/4^U,MKZUO?,^R7,$_EG:_E2!MI]#CH:X;7+&\E\-^&+'5B\=R
MU['#,5<%@,,OW@3SBM#Q?96VD>'([33((K**]N8K:9X4"DH<YR1UXXY]34^S
M6BON/G>YTD&L:;=7/V>WU"TEGY_=1S*S<=>`<U-=7MM80^;>7$-O%G&^5PBY
M],FN4\6>&M)L/"<\]E:0VEQ9*LD,\2[9`RD8RPY.??ZTFLZ=?:B^CZRNG0:J
MD=MB:RE8+RR@[ER,9_P&/84(O6X.31T5]>"YT*YN-+O[5"8F,5T75HE([D\C
M`-.LKK[/HEO<:C>VSE8E,MRK@1,<?>!X&":YMKK2;GP5KQTFS>R(CD^T6SQ^
M6T;[<<KT'`'3^>:CN-(NM3\(^'9;2WBO!:)%*]G,P59QL`QD\9'OQR?H3D6S
M[AS/H=?:7UKJ$1DLKF"XC!VEH9`X!],BK%<WX7NM*EN[N.TTLZ5J"*@N;8Q[
M.!G!&.",D\\$_E725$E9V+B[H*YGX>?\B9:?[\O_`*,:NFKF?AY_R)EI_OR_
M^C&IKX'\OU$_B7]=CIJ***@HIZNC2:->I&I9VMY`JJ,DG:>`*YVULKE?A:;1
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M9`'3/'TZUL>*+6_B@T2^CMY;Z33[A7N$@7+L,8)4=^?YUU5%/VFV@<FYQOB?
M[1K>EZ5?+I=]+9Q7/F75@Z;9F4<`E,\X].^:J6-N;KQEI-[8^')M+L8Q*K.U
MN(F8E#]Y5Z#L">N>*[VBA5+*U@<+NX4445F6%%%%`!7,VG_)2=0_[!\?_H5=
M-7,VG_)2=0_[!\?_`*%5PZ^A,NATU%%%04%%%%`!1110`R6-9HGC<95U*GZ&
MN-TB]U+P?:G2;[2+^^MXF;[+<V,?F[D)SAAD;2,_YQD]K151E969+5]3D[.W
MO_$?B.UU:]LI;&PL5;[-#/Q+([<%F7^'&.A]O6K.@VL\/BSQ%-+!*D4SPF-V
M0A7PAS@]\>U='13<[Z`HG`W%M]@\3ZK-JWARZUAKIU:UF2`3(J8P%.>$QZ_Y
M+](TV]A\#>(;>73Y+>>66<QVZ)GJHP%P.1V&..*[NBJ]J[$^S,WP[%)!X<TV
M*9&CD2VC5D88*G:."*P_%>E.-;L=9_LM=5MXHS!<VVP.P4G(95/4@D_YY'74
M5*FU*Y3C=6.8T&2RN=2W67A2335C0EKF>T2!@3T50.3D9R>WXUB>()#KL;1I
MX5U.'6PX$5TL85$<'@^<",@#IGCZ=:]"HIJI9WL)PNK'*^*+6_B@T2^CMY;Z
M33[A7N$@7+L,8)4=^?YTW7'GUJ'P_=06%[&%U*-WCEA(>-02"6`S@>YKK**2
MG:P.)SGCVUGO/"5S#:P2SREX\)&A9C\X["J^NVU]IVNZ?KUG:2WD<4)M[F"+
MF383D,H[X/;V_$=710IV5AN-W<Y#?>>*]>TV;^S;RPT_3W,SM>)Y;R28^50N
M>GO]?QLZ%:7$/C+Q%/+!*D,QA\N1D(5\*<X/>NFHH<]+"Y>H4445!84444`%
M%%%`!7#>#K**3P;;2",>87ERW<_O&KN:Y?X?*&\&6F?[\O\`Z,:JY5*#375?
MJ0U>2_KL9\UI<ASM8@5']EN_[[5VIM4/:D^R)_=%9>RA_*BN5=CB_LMW_?:C
M[+=_WVKM/LB?W11]D3^Z*/90_E0<J['%_9;O^^U'V6[_`+[5VGV1/[HH^R)_
M=%'LH?RH.5=CB_LMW_?:C[+=_P!]J[3[(G]T4?9$_NBCV4/Y4'*NQQ?V6[_O
MM1]EN_[[5VGV1/[HH^R)_=%'LH?RH.5=CB_LMW_?:C[+=_WVKM/LB?W11]D3
M^Z*/90_E0<J['%_9;O\`OM1]EN_[[5VGV1/[HH^R)_=%'LH?RH.5=CB_LMW_
M`'VH^RW?]]J[3[(G]T4?9$_NBCV4/Y4'*NQQ?V6[_OM67XD-_8:!=7,,SHZ!
M<,.WS`?UKTC[(G]T5SOC^V1?!.HD`9`3_P!#6JA1IN27*ON)DDHO0S$MKPHI
MWMR*7[+=_P!]J[**T3RD^4?=%.^R)_=%3[*'\J*Y5V.+^RW?]]J/LMW_`'VK
MM/LB?W11]D3^Z*/90_E0<J['%_9;O^^U'V6[_OM7:?9$_NBC[(G]T4>RA_*@
MY5V.+^RW?]]J/LMW_?:NT^R)_=%'V1/[HH]E#^5!RKL<7]EN_P"^U'V6[_OM
M7:?9$_NBC[(G]T4>RA_*@Y5V.+^RW?\`?:C[+=_WVKM/LB?W11]D3^Z*/90_
ME0<J['%_9;O^^U'V6[_OM7:?9$_NBC[(G]T4>RA_*@Y5V.+^RW?]]J/LMW_?
M:NT^R)_=%'V1/[HH]E#^5!RKL<7]EN_[[4?9;O\`OM7:?9$_NBC[(G]T4>RA
M_*@Y5V.+^RW?]]J/LMW_`'VKM/LB?W11]D3^Z*/90_E0<J['FWAYM0OK.=Y9
MG<I<R(">P!Z5J_9;O^^U:'@:V1M*O20/^/\`G'_CU=)]D3^Z*J=&FI/W5]Q,
M4FMCB_LMW_?:C[+=_P!]J[3[(G]T4?9$_NBI]E#^5%<J['%_9;O^^U'V6[_O
MM7:?9$_NBC[(G]T4>RA_*@Y5V.+^RW?]]J/LMW_?:NT^R)_=%'V1/[HH]E#^
M5!RKL<7]EN_[[4?9;O\`OM7:?9$_NBC[(G]T4>RA_*@Y5V.+^RW?]]J/LMW_
M`'VKM/LB?W11]D3^Z*/90_E0<J['%_9;O^^U'V6[_OM7:?9$_NBC[(G]T4>R
MA_*@Y5V.+^RW?]]J/LMW_?:NT^R)_=%'V1/[HH]E#^5!RKL<7]EN_P"^U95B
MVH3>(M4M6F<QP+$57^[N7)KTG[(G]T5S>CVR'QWXC7`P$MO_`$`U4:-.S]U?
M<2TKK0S_`++=_P!]J/LMW_?:NT^R)_=%'V1/[HJ?90_E17*NQQ?V6[_OM1]E
MN_[[5VGV1/[HH^R)_=%'LH?RH.5=CQV_D=-0N#*2S*[#D^AQBJ4=G+=2%F!)
M)KL+SPO.^I7ES<`)$T[L@/)(W'!IL6G$-MC7BN*-"4F^B,E!MF-:Z2J8+\GT
MK7MK$G`1<"MFRT1F(+"MZUTI(@.*ZX48PUZFBBD8ECH[Y!-=':6WDJ!5A(E0
M<"GUJ4+1110`4444`%%%%`'+ZC_R4C1_^O2:NHKE]1_Y*1H__7I-745<]EZ$
MQW84445!04444`%%%%`!1110`4444`%%%%`!1110`5Y=\8/^/K2_]R3^:UZC
M7EWQ@_X^M+_W)/YK6V'_`(B,JWP,]'TS_D%VG_7%/_015JJNF?\`(+M/^N*?
M^@BK59/<T6Q%=?\`'K-_N-_*O+_A#_R%-1_ZXK_Z%7J%U_QZS?[C?RKR_P"$
M/_(4U'_KBO\`Z%6U/^'+Y&<_CB>JU3U:Q_M32;JR\SR_M$31[]N=N1C..]7*
M*P3L:[F#<>&//TK1[+[7M_LV:*7?Y>?,V#&,9XS^-6M<T7^V18_O_)^R7:7/
MW-V[;GY>HQUZUJ457.Q<J"LFQT/[%XAU+5/M&_[<(QY6S&S:,=<\Y^@K6HI)
MM`U<R['1?L6NZGJ7G[_MWE_N]F-FQ<=<\Y^@HT_1?L&LZI?^?YGV]HSY>S&S
M:I'7/.<^U:E%/F8<J.4A\%7%MYUI;:W<PZ/*Y8V:1+N`/51)U`SV`Z9]<U*W
M@[=X*3P_]MQM.?/\K_;W?=W?AUKIJ*?M)"Y(F-K_`(?_`+:M;58KM[2ZM)5E
M@G5`VUAZJ>HJ&[\.76HV>F1WVI^=<65TMPTWD!?-P3@;0<+P<9YZ5OT4E-H.
M5,XG5].DU'XCHEO>2V=Q'IHDBFC`.UO,(Y4\,.>0:V=%\-R:?J,^I:C?OJ.H
M2J(_.:,1A$'\*J.!SU__`%YV/LL'VK[3Y$7VC9L\W8-^W.<9ZXSVJ6J=1M60
ME!7N8>F^&8;.QU.TN9?M,.H3R2N-NS:'_AZG\^*HP>%-8MH5LX/%%RFGK\JQ
M"W3S53^Z)>H..`<<>E=512YY#Y$(J[5"Y)P,9/4UD:OI.I7ETEQIFMRZ>P38
MZ&%9D;G((5NA]_I6Q14IVU&U<P].\+06VFWUM?3O?2Z@2UU-(`I<D8X`^Z!V
M':J5IX1OH?(M;CQ!<SZ9`P,=J(E1B%.55I!R1[?RKJ:*KGD+D1D6&A"SUK5+
M]IQ*NH;,Q%,;-HQUSSGZ"LN'PCJ>FA[?1?$4UG8%BR6[VR3&//4!F.<?YZ\U
MU=%'/(.5&+?>'?MD&DQ?;)3_`&=<)-OF'F/+M[$Y')]:N:QI-MKFFRV-X&,4
MF.5.&4CH0?45>HI<S'RHY7_A$+^\2*VUKQ!/?V$94FW$"QF3;T#N"2P]<]>O
M6M'5M(U&ZN8YM*UJ73BJ>6T?DK*C#.00IZ'W^E;-%/G8N5'/6_A00Z)J5I)>
MR3W>I!C<7;H,EB,<*.@'89I\N@7J:5I]MIVL2V<UE&(_,6(.D@P!RA..W'/'
M-;U%+GD'*C%T3P_)IMY<7U]?R7]_<*$:9HQ&%0=%51T]ZVJ**3;;NQI6V"N9
M^'G_`")EI_OR_P#HQJZ:N9^'G_(F6G^_+_Z,:J7P/Y?J)_$OZ['34445!044
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7,VG_)2=0_[!\?_`*%7
M35S-I_R4G4/^P?'_`.A5<.OH3+H=-1114%!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5S/P\_Y$RT_WY?\`
MT8U=-7,_#S_D3+3_`'Y?_1C5:^!_+]27\2_KL=-1114%!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`5S?Q!_Y$?4O]U/_1BUTE<W\0?^1'U+_=3_`-&+
M5T_C7J3/X6=#%_JD_P!T4^F1?ZI/]T4^H*"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`.9\"?\@F]_["$__H5=-7,^!/\`D$WO_80G_P#0
MJZ:KJ?$R8?"@HHHJ"@HHHH`****`"BBB@`HHHH`****`"BBB@`KF=&_Y'WQ)
M_N6O_H!KIJYG1O\`D??$G^Y:_P#H!JX[2]/U1,MT=-1114%!1110!3N[7SQ@
MU!!I<<9S@?E6E2T`1I"J#@4^EHH`****`"BBB@`HHHH`****`.7U'_DI&C_]
M>DU=17+ZC_R4C1_^O2:NHJY[+T)CNPHHHJ"@HHHH`****`"BBB@`HHHH`***
M*`"BBB@`KR[XP?\`'UI?^Y)_-:]1KR[XP?\`'UI?^Y)_-:VP_P#$1E6^!GH^
MF?\`(+M/^N*?^@BK55=,_P"07:?]<4_]!%6JR>YHMB*Z_P"/6;_<;^5>7_"'
M_D*:C_UQ7_T*O3[M@MG.QZ"-C^E>/_#C7;+0[^]DOFD59(E5=D;/SGV%;TDW
M3DD95':<3V:BN9_X6#H7_/6Y_P#`:3_"C_A8.A?\];G_`,!I/\*R]G/L:<\>
MYTU%<S_PL'0O^>MS_P"`TG^%'_"P="_YZW/_`(#2?X4>SGV#GCW.FHKF?^%@
MZ%_SUN?_``&D_P`*/^%@Z%_SUN?_``&D_P`*/9S[!SQ[G345S/\`PL'0O^>M
MS_X#2?X4?\+!T+_GK<_^`TG^%'LY]@YX]SIJ*YG_`(6#H7_/6Y_\!I/\*/\`
MA8.A?\];G_P&D_PH]G/L'/'N=-17,_\`"P="_P">MS_X#2?X4?\`"P="_P">
MMS_X#2?X4>SGV#GCW.FHKF?^%@Z%_P`];G_P&D_PH_X6#H7_`#UN?_`:3_"C
MV<^P<\>YTU%<S_PL'0O^>MS_`.`TG^%'_"P="_YZW/\`X#2?X4>SGV#GCW.F
MHKF?^%@Z%_SUN?\`P&D_PH_X6#H7_/6Y_P#`:3_"CV<^P<\>YTU%<S_PL'0O
M^>MS_P"`TG^%'_"P="_YZW/_`(#2?X4>SGV#GCW.FHKF?^%@Z%_SUN?_``&D
M_P`*/^%@Z%_SUN?_``&D_P`*/9S[!SQ[G345S/\`PL'0O^>MS_X#2?X4?\+!
MT+_GK<_^`TG^%'LY]@YX]SIJ*YG_`(6#H7_/6Y_\!I/\*/\`A8.A?\];G_P&
MD_PH]G/L'/'N=-17,_\`"P="_P">MS_X#2?X4?\`"P="_P">MS_X#2?X4>SG
MV#GCW.FHKF?^%@Z%_P`];G_P&D_PH_X6#H7_`#UN?_`:3_"CV<^P<\>YTU<S
M\//^1,M/]^7_`-&-1_PL'0O^>MS_`.`TG^%8?@WQCI.E^&;>UNI)Q*C2$A8'
M8<N2.0/0U:IRY7IV_4ESCS+4]"HKF?\`A8.A?\];G_P&D_PH_P"%@Z%_SUN?
M_`:3_"H]G/L5SQ[G345S/_"P="_YZW/_`(#2?X4?\+!T+_GK<_\`@-)_A1[.
M?8.>/<Z:BN9_X6#H7_/6Y_\``:3_``H_X6#H7_/6Y_\``:3_``H]G/L'/'N=
M-17,_P#"P="_YZW/_@-)_A1_PL'0O^>MS_X#2?X4>SGV#GCW.FHKF?\`A8.A
M?\];G_P&D_PH_P"%@Z%_SUN?_`:3_"CV<^P<\>YTU%<S_P`+!T+_`)ZW/_@-
M)_A1_P`+!T+_`)ZW/_@-)_A1[.?8.>/<Z:BN9_X6#H7_`#UN?_`:3_"C_A8.
MA?\`/6Y_\!I/\*/9S[!SQ[G345S/_"P="_YZW/\`X#2?X4?\+!T+_GK<_P#@
M-)_A1[.?8.>/<Z:BN9_X6#H7_/6Y_P#`:3_"C_A8.A?\];G_`,!I/\*/9S[!
MSQ[G35S-I_R4G4/^P?'_`.A4?\+!T+_GK<_^`TG^%8=OXQTE/&]Y?M)/]GDL
MTC4^0^=P;)XQFKC3EKH3*<=-3T*BN9_X6#H7_/6Y_P#`:3_"C_A8.A?\];G_
M`,!I/\*CV<^Q7/'N=-17,_\`"P="_P">MS_X#2?X4?\`"P="_P">MS_X#2?X
M4>SGV#GCW.FHKF?^%@Z%_P`];G_P&D_PH_X6#H7_`#UN?_`:3_"CV<^P<\>Y
MTU%<S_PL'0O^>MS_`.`TG^%'_"P="_YZW/\`X#2?X4>SGV#GCW.FHKF?^%@Z
M%_SUN?\`P&D_PH_X6#H7_/6Y_P#`:3_"CV<^P<\>YTU%<S_PL'0O^>MS_P"`
MTG^%'_"P="_YZW/_`(#2?X4>SGV#GCW.FHKF?^%@Z%_SUN?_``&D_P`*/^%@
MZ%_SUN?_``&D_P`*/9S[!SQ[G345S/\`PL'0O^>MS_X#2?X4?\+!T+_GK<_^
M`TG^%'LY]@YX]SIJ*YG_`(6#H7_/6Y_\!I/\*/\`A8.A?\];G_P&D_PH]G/L
M'/'N=-17,_\`"P="_P">MS_X#2?X4?\`"P="_P">MS_X#2?X4>SGV#GCW.FH
MKF?^%@Z%_P`];G_P&D_PH_X6#H7_`#UN?_`:3_"CV<^P<\>YTU%<S_PL'0O^
M>MS_`.`TG^%'_"P="_YZW/\`X#2?X4>SGV#GCW.FHKF?^%@Z%_SUN?\`P&D_
MPH_X6#H7_/6Y_P#`:3_"CV<^P<\>YTU%<S_PL'0O^>MS_P"`TG^%'_"P="_Y
MZW/_`(#2?X4>SGV#GCW.FKF?AY_R)EI_OR_^C&H_X6#H7_/6Y_\``:3_``K#
M\&^,=)TOPS;VMU).)4:0D+`[#ER1R!Z&K5.7*].WZDN<>9:GH5%<S_PL'0O^
M>MS_`.`TG^%'_"P="_YZW/\`X#2?X5'LY]BN>/<Z:BN9_P"%@Z%_SUN?_`:3
M_"C_`(6#H7_/6Y_\!I/\*/9S[!SQ[G345S/_``L'0O\`GK<_^`TG^%'_``L'
M0O\`GK<_^`TG^%'LY]@YX]SIJ*YG_A8.A?\`/6Y_\!I/\*/^%@Z%_P`];G_P
M&D_PH]G/L'/'N=-17,_\+!T+_GK<_P#@-)_A1_PL'0O^>MS_`.`TG^%'LY]@
MYX]SIJ*YG_A8.A?\];G_`,!I/\*/^%@Z%_SUN?\`P&D_PH]G/L'/'N=-17,_
M\+!T+_GK<_\`@-)_A1_PL'0O^>MS_P"`TG^%'LY]@YX]SIJ*YG_A8.A?\];G
M_P`!I/\`"C_A8.A?\];G_P`!I/\`"CV<^P<\>YTU<W\0?^1'U+_=3_T8M-_X
M6#H7_/6Y_P#`:3_"L3QCXRTG5/"M[:6LDYFD"[0T#J.'4]2,=JJ%.2DM"9SC
MRO4[Z+_5)_NBGUR\?Q`T,1J#+<Y`'_+M)_A3O^%@Z%_SUN?_``&D_P`*GV<^
MQ7/'N=-17,_\+!T+_GK<_P#@-)_A1_PL'0O^>MS_`.`TG^%'LY]@YX]SIJ*Y
MG_A8.A?\];G_`,!I/\*/^%@Z%_SUN?\`P&D_PH]G/L'/'N=-17,_\+!T+_GK
M<_\`@-)_A1_PL'0O^>MS_P"`TG^%'LY]@YX]SIJ*YG_A8.A?\];G_P`!I/\`
M"C_A8.A?\];G_P`!I/\`"CV<^P<\>YTU%<S_`,+!T+_GK<_^`TG^%'_"P="_
MYZW/_@-)_A1[.?8.>/<Z:BN9_P"%@Z%_SUN?_`:3_"C_`(6#H7_/6Y_\!I/\
M*/9S[!SQ[G345S/_``L'0O\`GK<_^`TG^%'_``L'0O\`GK<_^`TG^%'LY]@Y
MX]SIJ*YG_A8.A?\`/6Y_\!I/\*/^%@Z%_P`];G_P&D_PH]G/L'/'N=-17,_\
M+!T+_GK<_P#@-)_A1_PL'0O^>MS_`.`TG^%'LY]@YX]P\"?\@F]_["$__H5=
M-7GOA/QCI.FZ?=1W,DX9[R61=L#M\I/'05N?\+!T+_GK<_\`@-)_A5U*<G)Z
M$PG'E6ITU%<S_P`+!T+_`)ZW/_@-)_A1_P`+!T+_`)ZW/_@-)_A4>SGV*YX]
MSIJ*YG_A8.A?\];G_P`!I/\`"C_A8.A?\];G_P`!I/\`"CV<^P<\>YTU%<S_
M`,+!T+_GK<_^`TG^%'_"P="_YZW/_@-)_A1[.?8.>/<Z:BN9_P"%@Z%_SUN?
M_`:3_"C_`(6#H7_/6Y_\!I/\*/9S[!SQ[G345S/_``L'0O\`GK<_^`TG^%'_
M``L'0O\`GK<_^`TG^%'LY]@YX]SIJ*YG_A8.A?\`/6Y_\!I/\*/^%@Z%_P`]
M;G_P&D_PH]G/L'/'N=-17,_\+!T+_GK<_P#@-)_A1_PL'0O^>MS_`.`TG^%'
MLY]@YX]SIJYG1O\`D??$G^Y:_P#H!H_X6#H7_/6Y_P#`:3_"L/3/&.DV_B[6
M[R22?R;E8!&1`Y)VJ0<C&15QIRL]/ZNB93C=:GH5%<S_`,+!T+_GK<_^`TG^
M%'_"P="_YZW/_@-)_A4>SGV*YX]SIJ*YG_A8.A?\];G_`,!I/\*/^%@Z%_SU
MN?\`P&D_PH]G/L'/'N=-17,_\+!T+_GK<_\`@-)_A1_PL'0O^>MS_P"`TG^%
M'LY]@YX]SIJ*YG_A8.A?\];G_P`!I/\`"C_A8.A?\];G_P`!I/\`"CV<^P<\
M>YTU%<S_`,+!T+_GK<_^`TG^%'_"P="_YZW/_@-)_A1[.?8.>/<Z:BN9_P"%
M@Z%_SUN?_`:3_"C_`(6#H7_/6Y_\!I/\*/9S[!SQ[G345S/_``L'0O\`GK<_
M^`TG^%'_``L'0O\`GK<_^`TG^%'LY]@YX]SIJ*YG_A8.A?\`/6Y_\!I/\*/^
M%@Z%_P`];G_P&D_PH]G/L'/'N-U'_DI&C_\`7I-745YW>^,-*E\;:;?))-]G
MAMY$<F!\Y/3C&36]_P`+!T+_`)ZW/_@-)_A5SIRLM.A,9QUU.FHKF?\`A8.A
M?\];G_P&D_PH_P"%@Z%_SUN?_`:3_"H]G/L5SQ[G345S/_"P="_YZW/_`(#2
M?X4?\+!T+_GK<_\`@-)_A1[.?8.>/<Z:BN9_X6#H7_/6Y_\``:3_``H_X6#H
M7_/6Y_\``:3_``H]G/L'/'N=-17,_P#"P="_YZW/_@-)_A1_PL'0O^>MS_X#
M2?X4>SGV#GCW.FHKF?\`A8.A?\];G_P&D_PH_P"%@Z%_SUN?_`:3_"CV<^P<
M\>YTU%<S_P`+!T+_`)ZW/_@-)_A1_P`+!T+_`)ZW/_@-)_A1[.?8.>/<Z:BN
M9_X6#H7_`#UN?_`:3_"C_A8.A?\`/6Y_\!I/\*/9S[!SQ[G35Y=\8/\`CZTO
M_<D_FM=7_P`+!T+_`)ZW/_@-)_A7!_$C7K'7;BP:Q:1A$KAM\;)U(QU'M6U"
M$E--HSJR3@[,]8TS_D%VG_7%/_015JJFE,'TBS8=#`A'_?(JW7.]S5;$5U_Q
MZS?[C?RKR_X0_P#(4U'_`*XK_P"A5ZA=?\>LW^XW\J\O^$/_`"%-1_ZXK_Z%
M6U/^'+Y&<_CB>JT445@:A1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%<S\//^1,M/\`?E_]&-735S/P
M\_Y$RT_WY?\`T8U6O@?R_4E_$OZ['34445!04444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!7,VG_`"4G4/\`L'Q_^A5TU<S:?\E)U#_L'Q_^A5<.
MOH3+H=-1114%!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`5S/P\_Y$RT_P!^7_T8U=-7,_#S_D3+3_?E_P#1
MC5:^!_+]27\2_KL=-1114%!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M5S?Q!_Y$?4O]U/\`T8M=)7-_$'_D1]2_W4_]&+5T_C7J3/X6=#%_JD_W13Z9
M%_JD_P!T4^H*"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M.9\"?\@F]_["$_\`Z%735S/@3_D$WO\`V$)__0JZ:KJ?$R8?"@HHHJ"@HHHH
M`****`"BBB@`HHHH`****`"BBB@`KF=&_P"1]\2?[EK_`.@&NFKF=&_Y'WQ)
M_N6O_H!JX[2]/U1,MT=-1114%!1110`4444`%%%%`!1110`4444`%%%%`!11
M10!R^H_\E(T?_KTFKJ*Y?4?^2D:/_P!>DU=15SV7H3'=A1114%!1110`4444
M`%%%%`!1110`4444`%%%%`!7EWQ@_P"/K2_]R3^:UZC7EWQ@_P"/K2_]R3^:
MUMA_XB,JWP,]'TS_`)!=I_UQ3_T$5:JKIG_(+M/^N*?^@BK59/<T6Q%=?\>L
MW^XW\J\O^$/_`"%-1_ZXK_Z%7J%U_P`>LW^XW\J\O^$/_(4U'_KBO_H5;4_X
M<OD9S^.)ZK1116!J%%%8GB?79-$LH5M(1/?W<@AMHCT+'N?84TFW9";LKFW1
M7+1^$M0EC$][XEU7[<1N)@E"0ANV(\8('X9]LUTMNDD=O&DTOFR*H#R%0N\X
MY.!P,TVDMF";?0DHI.E<T_CS3%ED*07TEG&^Q[Z.W+6ZG_>^O'2DHN6P.26Y
MTU%<%IDUK!\.;_4-2^T+#J,TLDH@QYGSOM`7/%)XKU(Z5H]CX>T^TU0+((HC
M*D>2T>/F12.KX'('')K3V5W8CVFESOJ*\QU6ZM-)TB+3-$T76;`ZE(GG9C;>
MR#.Y5RQ^<@=!V-:D6E>'XWT6TAT_4[%[NY-S'`QPVZ,=9`Q)`QZ4.E97#G.Z
MHK#U/Q99Z=?&RBM[V_NE&Z2&RA\UHQV+<C%4-=U+2]=\,VBW2WZ6^HW*0+'$
MH64.&/#`\8!7GK4J#TN4Y(ZNBN7U!1=>/M'M`,QV5M)<D>F?D6K%]XRLK2ZF
MM[>TU#4'@.)S90>8L1]&.0,_X&CD>E@YEU.@HJKINI6VK6$5[92>9!*,JV,>
MQX^M0>(-571-#NKX@%HD^13_`!.>%'YD5-G>P[JURY%=032RQ131O)"0)$5P
M2A/0$=JEKE89AX+\&F[O%:>]E/F2C/S2SOVS^GT%-MO#6J:I"MWK6NZE;W,@
MW>18R^3'$#SMQ@Y(SU_GUJ^1;WT)YGV.LHJMI]O/:V,4-U=-=S("&F9`I;GC
M('MQ5FLRPHKGKWQK86E[-;QVU_>"W.+B:U@\R.`]]QSVQSC-9OAZ_MYHO$WB
M!F<V\DS`.G4QQIP5SW.:OV;M=D<ZO8[.BN`O]5B\,^`[:VT6VU/_`$N+=!.Z
M`F,NV?F8<!L$X`]JH375IX;\.2RZ3HNLVFHW<?V<W-Q&P.[(RQ^8X)R<8'45
M:I-B=2QZ5/<0VL1EN)8XHP0"\C!0,G`Y/O4E>>G1=,@\!ZK=6VF7UG<-;E)3
M>!EDD*X;=M)(P3Z8KM]+F-SI-G,WWI($<_4J#42BDM"HRN6Z***@H*YGX>?\
MB9:?[\O_`*,:NFKF?AY_R)EI_OR_^C&JU\#^7ZDOXE_78Z:BBBH*"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*YFT_Y*3J'_8/C_\`0JZ:N9M/
M^2DZA_V#X_\`T*KAU]"9=#IJ***@H****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"N9^'G_(F6G^_+_P"C&KIJ
MYGX>?\B9:?[\O_HQJM?`_E^I+^)?UV.FHHHJ"@HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`*YOX@_P#(CZE_NI_Z,6NDKF_B#_R(^I?[J?\`HQ:NG\:]
M29_"SH8O]4G^Z*?3(O\`5)_NBGU!04444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110!S/@3_D$WO\`V$)__0JZ:N9\"?\`()O?^PA/_P"A5TU7
M4^)DP^%!1114%!1110`4444`%%%%`!1110`4444`%%%%`!7,Z-_R/OB3_<M?
M_0#735S.C?\`(^^)/]RU_P#0#5QVEZ?JB9;HZ:BBBH*"BBB@`HHHH`****`"
MBBB@`HHJIJ&IVNE11RWDGEQR2",-@D`D$\_E2;2U8%NBHX;B*XC62&1)$89#
M*<@U)3`****`.7U'_DI&C_\`7I-745R^H_\`)2-'_P"O2:NHJY[+T)CNPHHH
MJ"@HHHH`****`"BBB@`HHHH`****`"BBB@`KR[XP?\?6E_[DG\UKU&O+OC!_
MQ]:7_N2?S6ML/_$1E6^!GH^F?\@NT_ZXI_Z"*M55TS_D%VG_`%Q3_P!!%6JR
M>YHMB*Z_X]9O]QOY5Y?\(?\`D*:C_P!<5_\`0J]0NO\`CUF_W&_E7E_PA_Y"
MFH_]<5_]"K:G_#E\C.?QQ/5:***P-0KCO$LT=IX[\.W%XX2T"RJ'?A5<CCGM
MU%=C574=,L]6M&M;^W2>%OX6'0^H/4'W%5"5GJ3)71-+<0P-&LTL<;2ML0,P
M&]O0>IIL5U;SRRQPSQ220G;(J."4/H1VK,TOPAH>C7/VBQT^..;L[,SE?IN)
MQ^%7;+2K/3IKF6TA$<EU)YLS;B=[>O)X^@H?+T&K]3-\;W,MIX.U*2'(?R]N
M1U`8@']":R]=U&R\/_#Y+6W>,O/:"*W13DON7E@/3DG/^-==<6\5U;R07$:R
M12*5=&&016+!X(\/VUO+#%IJ!)L;\R.2<$$#).0,@<#KBJA**2OW)E%MZ&/K
M5F8="\,Z&,9FN(4D]U09;]:NZGB^^(FD6V219V\ERP[9;Y16QJMO:QF/5)K.
M:ZGL0S0K""S\C!VKG!./6L+29+LZAJWB6[TZ\C1XUBM[7R\SE%ZG;GJ3VJD[
MJ_\`5V2U9V_K0EU/%]\1-(MLDBSMY+EAVRWRBAB;SXDD\%-/L,X_VW/^%.\.
M0W=]KNHZ[=VDUHDZI!;PSKMD"+U+#MD]JW8--M;:^N;R&+;<76WS7+$[MHP.
MIP/PI-J.GD-*^OF<W\/YH7\.W.HS.BS3W,LMT['&TY[GL`.?QJ77&^W^,O#]
MHC`QQ^9=MCG.!A3^=6Y_!'AZXOVO)=,C:9GWM\S!2?=0=OZ<UIC3+0:F-0$/
M^E"+R0^X\)G.`,X'/M0YQYN9`HNUF<M'<2-K?BS5(<EK2W%O%@9Y5"Q_7%4O
M#>BZB?"UO/'XI%KITL9DF6.VC!3/W_WI.01S\QZ?A7;6>F6FGBX%K#L^T2M-
M+EBV]CU/)/Y=*R5\!^'%N_M(TN+S-^_!=]F>OW<[<>V,4U46PN1FII&EVNC:
M7!960/D1CY2QR6SR23ZDFL/QJOVF;0[%L^7<:@A<>JKDXKJ:Y_Q3:32W.BW5
MO#),;:_0N$4DA#D$X'IQ40?O794E[MBAX_80G0YYSBSBU!&F)Z`>I_6NIDO+
M>*W6>2XB2%L8D9P%.>G/3G-%U:P7MN]O=1)-"XPR.N0?PK'L?!'A_3KI;BVT
MV,2I]TN[2`'U`8D9]Z+Q<4GT"S3NC86ZMVNFMEGB-PB[FB#C>!ZD=<5#JT\E
MKH][/""9(H'=<>H4D41:59P:G/J$<(%W.H223<3D#H,9P.G:K;*&4JP!!&"#
MWJ=+E:G':#J-EX=^'-M>-(A:2-I,9R993GY?<YX_#VK.>.2P^$D$"X\^_*J/
M<R/G_P!!-=+!X)\/V[SO#IL:M.C(YWMT;J%Y^7@XXQ5Z[TFQ>QMXY;9I(;$K
M)!$K-P4'RX&>?H:UYXWNN]S/D=OD8/B6%&O/#.C*3M-R)"!W6):E\78N]6\/
MZ;D_OKSSV`[K&,_UJ*QDN]:\3G6I=.O+2SL;9HX8[B/;+(YY8A<^G'O_`"?I
MGVO7O%BZO+875E9V=N884NH]DCNQ^8[<\#''^>'M;R_,-_F3^/+AH_"TUO'S
M->.EM&O<EC_@#6]:P"UM(8%Z1(J#\!BL&:TN-9\8Q230RQZ?I0W(74J)IF[C
M/4*._K725G+2*1:U;84445!05S/P\_Y$RT_WY?\`T8U=-7,_#S_D3+3_`'Y?
M_1C5:^!_+]27\2_KL=-1114%!574M2M=(L9+R^E$4$?5B"?H`!UJU6-XJT63
M7M$>UMY5BG5UEB9_N[E.0#[4XV;5Q.]M"'3?%UOJ%[#;/IVJ6;3@^4]U;;$D
M(&<`Y/.,G\*O:1K=OK/VI84EBEM9C#+%*`&4CZ$\&LG2O%<_]H0Z5X@L'T^_
MD&(W!W0S'`^ZW8\].?KGBL_Q3)<>%M<_MRQB:2.^B-M-&H_Y:X_=M_3\#ZUK
MR7=K$<UE<Z%/$=I)-JB(D[+IJYFD"C82!DJISR1CFCP]XCLO$MD]S8^8H1]C
MI*`&4^X!/6L^'1_[$\!7ELYW7#6TLMP_=Y&4ECG]/PK!TD'P[_8.L)Q8ZA;1
M6UYCHKX^1S_+/^-')%IV#F::N=II^LV^I7U_:0I*LEC((Y"X`!)&>.?\*T*Y
M#P]<Q6>M^++FX?9##.KNV"<*%))P*EO/&6D:IH^IQ:5?>;<QV<L@'E.N`%ZY
M('J*ETW?1#4U;4?<>/-/CDG^SV>I7EO`2LMU;6^^%".N6R.GK6S_`&UIYT?^
MU?M4?V'9O\[G&/IUSGC'7/%4O!T,<7@_3$10%:W5B,=2>3^IKA%/_%+Q6'_+
MM_PD/V?9VV9SC\ZM0C)V70GF:5V=?#X]T]Y(?M%GJ5I;3L%CN[FWV0L3TPV>
M]=-GC/:L/QK#'+X-U-74$+"6`QT(Y'\JS;G4+G4-%T?1[.1A>ZC;1O/*O6&'
M:-[_`%/0?6IY5))K0KF:=F:FC>*[#7=1N;.R6<FW&XRLH".,XRISDC/M6W7)
M:-:Q67CZ_MK=`D,6GPHBCL`:ZVIFDGH.+;6H4445!05S-I_R4G4/^P?'_P"A
M5TU<S:?\E)U#_L'Q_P#H57#KZ$RZ'34445!04444`%%%8OC&XEM?".I2PDAQ
M"0".HSP3^1II7=A-V5RK-XWLOM$D5A9:GJ:Q':\MC;>8BMZ9R.?IQ6CHNOV.
MO0N]E(V^([989%VR1-Z,/\C@TOAVTALO#UA#;J%C$"'CN2,D_B3FL611:_%&
M$PC'VNP/G`=RK<$^_`%:6B[I$WDK-G645POA^RU+7[C47NM9OX;6UOY$B2WF
MVLQ!SAB<_*!@!>G6H->NM-M[VY2_\9ZG%?#<5CM698X^3M4JBD9'?)!/M1[/
M6UQ<^ESK?$>M?\(_HLM_Y'G^6RCR]^W.2!UP?6M)6W(K>HS7`:QJ4^K_``D2
M\NV#3R%`[`8W$2XS@?2N^B_U2?[HI2CRKSNQQE=CZ*X/Q/XB@/B9]+OM8N=*
MLK>)69K56\R9SR!N`.``1]?Y3^#==6ZU._TVWU.;4[.*(307$X/F+DX96)`)
MY/6CV3Y>8/:*]CM:*\]\.Z5JWB'PNEY<^(-0B<*XMU@E*\@GF0GE^>V1@#WK
M<T9YO%O@VSENKV[M9VR9)K23RW8J2.N.AZXHE3MU!3OT.FHKBO"-I<76JW]U
M#JNIW.DJIMX&N;DN97_B=>F`,8!'YU8\/ZU+8>'-335)7EN=(DD21Y&)9P.4
M))]>E#IVV!3[G6T5Y[?3:SI_@_0Y1?3?VA=W\;LTDC$?.&(1N?NCC(Z5-K=G
MK'ANXT^ZLM<N[F>\G%M*EVVZ+<XX94'W0"#P/8=.K]EYBY_([RBN*N[;4/#6
MLZ1<?VS>WJ7MR+:YBN&!0ENZ+T09'0=.E0>)_$4!\3/I=]K%SI5E;Q*S-:JW
MF3.>0-P!P`"/K_)*FV]!N=MSO**XSP7KJW6K7VF6^I3:G9Q1B6"XG!\P9.&5
MB0">3UKLZF47%V8XRYE<****DH****`"N9^'G_(F6G^_+_Z,:NFKRGPQXDN[
M#3+>RCF6./+E24!Y+M2J5%3IN3[K]3.4N629ZM17&?VWJO\`S\#_`+]K_A1_
M;>J_\_`_[]K_`(5Q_7Z7F+VT3LZ*XS^V]5_Y^!_W[7_"C^V]5_Y^!_W[7_"C
MZ_2\P]M$[.BN,_MO5?\`GX'_`'[7_"C^V]5_Y^!_W[7_``H^OTO,/;1.SHKC
M/[;U7_GX'_?M?\*/[;U7_GX'_?M?\*/K]+S#VT3LZ*XS^V]5_P"?@?\`?M?\
M*/[;U7_GX'_?M?\`"CZ_2\P]M$[.BN,_MO5?^?@?]^U_PH_MO5?^?@?]^U_P
MH^OTO,/;1.SHKC/[;U7_`)^!_P!^U_PH_MO5?^?@?]^U_P`*/K]+S#VT3LZ*
MXS^V]5_Y^!_W[7_"C^V]5_Y^!_W[7_"CZ_2\P]M$[.N;^(/_`"(^I?[J?^C%
MJA_;>J_\_`_[]K_A574KJ]U;3Y;*\EWP2XWJ%`S@@]1[BG#,:*DGJ*56+31W
M47^J3_=%/KBQK6JJ`!<#`_Z9K_A2_P!MZK_S\#_OVO\`A2^OTO,?MHG9T5QG
M]MZK_P`_`_[]K_A1_;>J_P#/P/\`OVO^%'U^EYA[:)V=%<9_;>J_\_`_[]K_
M`(4?VWJO_/P/^_:_X4?7Z7F'MHG9T5QG]MZK_P`_`_[]K_A1_;>J_P#/P/\`
MOVO^%'U^EYA[:)V=%<9_;>J_\_`_[]K_`(4?VWJO_/P/^_:_X4?7Z7F'MHG9
MT5QG]MZK_P`_`_[]K_A1_;>J_P#/P/\`OVO^%'U^EYA[:)V=%<9_;>J_\_`_
M[]K_`(4?VWJO_/P/^_:_X4?7Z7F'MHG9T5QG]MZK_P`_`_[]K_A1_;>J_P#/
MP/\`OVO^%'U^EYA[:)V=%<9_;>J_\_`_[]K_`(4?VWJO_/P/^_:_X4?7Z7F'
MMHG9T5QG]MZK_P`_`_[]K_A1_;>J_P#/P/\`OVO^%'U^EYA[:)=\"?\`()O?
M^PA/_P"A5TU<#I]S>:7#)%:2[$DD:5@5!^9N3UJW_;>J_P#/P/\`OVO^%5/,
M:+DWJ3&K%*QV=%<9_;>J_P#/P/\`OVO^%']MZK_S\#_OVO\`A4_7Z7F5[:)V
M=%<9_;>J_P#/P/\`OVO^%']MZK_S\#_OVO\`A1]?I>8>VB=G17&?VWJO_/P/
M^_:_X4?VWJO_`#\#_OVO^%'U^EYA[:)V=%<9_;>J_P#/P/\`OVO^%']MZK_S
M\#_OVO\`A1]?I>8>VB=G17&?VWJO_/P/^_:_X4?VWJO_`#\#_OVO^%'U^EYA
M[:)V=%<9_;>J_P#/P/\`OVO^%']MZK_S\#_OVO\`A1]?I>8>VB=G17&?VWJO
M_/P/^_:_X4?VWJO_`#\#_OVO^%'U^EYA[:)V=<SHW_(^^)/]RU_]`-4O[;U7
M_GX'_?M?\*J07-Y;:C=7T4N+BZ""5MH.=HP..U5',:*3W)=6+L=]17&?VWJO
M_/P/^_:_X5T&@W5Q=V+O=.'<2%00`.,#TJJ6+IU9<L2XU%)V1IT45QG]MZK_
M`,_`_P"_:_X55;$0HVYNHY34=SLZ*Q?#U]=WGVC[7('V;=N%`QG.>GTK:K2G
M452*E'8J+4E=!17)7NL:G%?7"1S@(LC*HV#@`\=JNZ#J-[=WSI=2AT$98`*!
MSD>E81QE.4^1;D*I%NQT%%%<QJ^J:A;:I-%;S!8UVX&P'^$5K6K1I1YI%2DH
MJ[.GKE/B&<:#!_U\K_Z"U5_[;U7_`)^!_P!^U_PJCJ\M]K%F(+F8%5;>OR`<
MX([?4UR3QM*46E<S=6+5C%TV^NK/$UC.T1_B4<J3[CI76:7XXC8K%J<?DMT\
MQ.4/U'4?K7&VJ/;3&*52IZ$&KDEN&[5S0Q$J;T>AFIN)Z?;W45S$LD,BNC#(
M93D&IJ\HM9[O3)?,LIFB.<E1RK?45T^E^.(V*Q:G'Y+=/,090_AU'ZUWTL5"
M>^AM&HF6-1_Y*1H__7I-745R5S<Q77Q"T:6&19$:TFPRG(-=;7;/9>A4>H44
M45!04444`%%%%`!1110`4444`%%%%`!1110`5Y=\8/\`CZTO_<D_FM>HUY=\
M8/\`CZTO_<D_FM;8?^(C*M\#/1],_P"07:?]<4_]!%6JJZ9_R"[3_KBG_H(J
MU63W-%L177_'K-_N-_*O+_A#_P`A34?^N*_^A5ZA=?\`'K-_N-_*O+_A#_R%
M-1_ZXK_Z%6U/^'+Y&<_CB>JT445@:A1110`4444`%%%%`!6'XD9%;3-^JS:?
MF\0`1HS>>?\`GF<=`??BMRN4\<_ZS0/^PI%_6KIJ\B9[&S?^(=+TNXD@OKQ(
M9(X?/8,#]S.,@XY.>PY]J;IWB72M5LY[JQO%EBMP3*0K`H`,Y*D9Q^':L6XM
M(+KXIPFXB20PZ:)(]PSM82'!^O-21HL/Q2E\L;?.TP/)C^(A\`G\`*KDC;Y7
M)YG<Q-/\06?B#Q?,9-?OX$$Z)8V]N62.51R=PV\Y/KC^6.HN?&F@6E^;*?4X
MEG#;2`&*J?0L!M'OD\=ZRM+>6.X\9/;Y\Y924QUW>6<5F^'K#Q%=^#X;>RB\
M/M87,1SYHE+MG@EL<;L_RK248O?R)3DCO+N_M;"R>[NIXXK=%W&1CQCMCU_#
MK61;>./#]W'/)!J*LL">9)F-P0OJ`1D_AFL&\TV6R'A#2M6>.:..=EDP249E
M'[L<@9ZXY%=NZ6_VJ-W6+[1M98V(&_'&0.^.!G\*R<8I=RTVSF?"_CJSUMQ:
MW$\:WTDKB**.)P&0<@Y.1G`]:T/#+(4U'9JLNH`7D@)D5E\D\?NQGJ![<53\
M`$'0[GVO9O\`T*N>CEEA\$^+6@)#_;Y@2/0E0?T)JW%-M(E2:2;.J/CKPZ+S
M[+_:L/F;MN0K;,_[^-N/?.*U+[5+/35@:\G$2SR"*-B"06/09'3IU/%9;V&G
M+X$:W$<?V'[%N^Z,8V[MWUSSGUKEKJ,WO@7PG%>J762]A1E;^)/F`_3%)0B]
MAN4D=AI_BW1-4OS966H1RW`S\N&&['7:2,-^!/K6Q7)^,K>*W?P[)#&L;0ZC
M%%'L`&U"#E1Z#@<>U=9422LFBHMZIA1114%!1110`4444`%%%%`!7,_#S_D3
M+3_?E_\`1C5TU<S\//\`D3+3_?E_]&-5KX'\OU)?Q+^NQTU%%%04%9^L3:G;
MVJ2Z3:PW4JN-\,C["Z=]K=`<XZ\=:T**:=@9R+V>M^)-4T^34].CTNTL)A<8
M^T+,\KCH`5&`/7/K5[QEIEWJVE6\-C%YLB7<<C#<%PHSD\D5T%%5SNZ:Z$\N
MC13UB"2ZT:]@A7=++`Z(N<9)4@=:S;30OM7@B#1]138YM5B<9!V,!UXXX(S^
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MHHHH`*KZA91:EI]Q9SY\N>,QMCK@BK%%`'(6$GBG0+1-._LB'5HH!MAN8[I8
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MW^8N16L<]X<FU.!8;"?PZ-.LH8\+)]L27D=L`9Y]:P/%>E3S^,;:SMF46^LJ
M@NT'7$39)_[YP*]`K/&C6_\`;QU=GE:X\GR%4D;$7.>!C.?QIQG:5P<+JQG>
M+=*NM2@TI+&'S/L]_%,X#!=J+G)Y(_(4_P`5:;=:D-*^R1>9]GU"*:3Y@-J#
M.3R>>O:MZBDIM6\AN*=S!\3Z;=:A/H[6L7F"VOXYI?F`VH,Y/)Y_"JVIZ?JN
MF>(WUG1K6*^6YB$5S:M((V)7[K*QX]!_GCIZ*%-K0'%,RM'NM8O'FDU33X;"
M(`".(3"5R>Y)'&.F!UX-:M%%2W<:5@HHHI#"BBB@`KQS0M&FOK&*8JRP#>-V
M/O'>W2O8ZY#P1!YW@FU'^W+_`.C&I5*?M*;5^J_4SG'F:1B_V:R\?:I![>8?
M\:/[//\`S]R?]_#_`(UT4NA;W)Q3/^$?]JXOJ7][\!>R\S`_L\_\_<G_`'\/
M^-']GG_G[D_[^'_&M_\`X1_VH_X1_P!J/J7G^`>R\S`_L\_\_<G_`'\/^-']
MGG_G[D_[^'_&M_\`X1_VH_X1_P!J/J7G^`>R\S`_L\_\_<G_`'\/^-']GG_G
M[D_[^'_&M_\`X1_VH_X1_P!J/J7G^`>R\S`_L\_\_<G_`'\/^-']GG_G[D_[
M^'_&M_\`X1_VH_X1_P!J/J7G^`>R\S`_L\_\_<G_`'\/^-']GG_G[D_[^'_&
MM_\`X1_VH_X1_P!J/J7G^`>R\S`_L\_\_<G_`'\/^-']GG_G[D_[^'_&M_\`
MX1_VH_X1_P!J/J7G^`>R\S`_L\_\_<G_`'\/^-']GG_G[D_[^'_&M_\`X1_V
MH_X1_P!J/J7G^`>R\S`_L\_\_<G_`'\/^-->R$:%Y+UE4=2TN`/UKH?^$?\`
M:L/QIHOD>$[Z3'W0G_H:U4<#=I<WX"=.RO<9_9Y_Y^Y/^_A_QH_L\_\`/W)_
MW\/^-;L>@9C7CL*=_P`(_P"U+ZE_>_`?LO,P/[//_/W)_P!_#_C1_9Y_Y^Y/
M^_A_QK?_`.$?]J/^$?\`:E]2\_P#V7F8']GG_G[D_P"_A_QH_L\_\_<G_?P_
MXUO_`/"/^U'_``C_`+4?4O/\`]EYF!_9Y_Y^Y/\`OX?\:/[//_/W)_W\/^-;
M_P#PC_M1_P`(_P"U'U+S_`/9>9@?V>?^?N3_`+^'_&C^SS_S]R?]_#_C6_\`
M\(_[4?\`"/\`M1]2\_P#V7F8']GG_G[D_P"_A_QH_L\_\_<G_?P_XUO_`/"/
M^U'_``C_`+4?4O/\`]EYF!_9Y_Y^Y/\`OX?\:/[//_/W)_W\/^-;_P#PC_M1
M_P`(_P"U'U+S_`/9>9@?V>?^?N3_`+^'_&C^SS_S]R?]_#_C6_\`\(_[4?\`
M"/\`M1]2\_P#V7F8']GG_G[D_P"_A_QH_L\_\_<G_?P_XUO_`/"/^U'_``C_
M`+4?4O/\`]EYF!_9Y_Y^Y/\`OX?\:/[//_/W)_W\/^-;_P#PC_M1_P`(_P"U
M'U+S_`/9>9SR60D!*7K,`<$B7//YT[^SS_S]R?\`?P_XTOA#1?.TZZ;'2\F7
M\C6]_P`(_P"U5+`V=N;\!*G=7N8']GG_`)^Y/^_A_P`:/[//_/W)_P!_#_C6
M_P#\(_[4?\(_[5/U+S_`?LO,P/[//_/W)_W\/^-']GG_`)^Y/^_A_P`:W_\`
MA'_:C_A'_:CZEY_@'LO,P/[//_/W)_W\/^-']GG_`)^Y/^_A_P`:W_\`A'_:
MC_A'_:CZEY_@'LO,P/[//_/W)_W\/^-']GG_`)^Y/^_A_P`:W_\`A'_:C_A'
M_:CZEY_@'LO,P/[//_/W)_W\/^-']GG_`)^Y/^_A_P`:W_\`A'_:C_A'_:CZ
MEY_@'LO,P/[//_/W)_W\/^-']GG_`)^Y/^_A_P`:W_\`A'_:C_A'_:CZEY_@
M'LO,P/[//_/W)_W\/^-']GG_`)^Y/^_A_P`:W_\`A'_:C_A'_:CZEY_@'LO,
MP/[//_/W)_W\/^--%D&=D%ZQ9?O*)>1]>:Z'_A'_`&K!TO1=_C'78\?<2W_5
M35+`WO[WX"=.W43^SS_S]R?]_#_C76^$X3!I<BF0R9F)R6S_``K5'_A'_:M/
M38I--MVB2+<&<MG=CL!Z>U72PWLY<URHPY7<UZ\V_L\_\_<G_?P_XUWWVN;_
M`)]Q_P!]_P#UJP/^$?\`:JK4?:VUV'*/,2^$+<P?;,RM)NV=6SC[U=+6)I=J
M^F>;LCW^9C/.,8S_`(UH?:YO^?<?]]__`%JTIPY(J)4596.*U*Q+ZI=M]I=<
MS.<"0\?,?>M+PG:F#5)&,[29A(P7S_$M6+C1#/<2RE<&1RV/J<U8TW3VTVX:
M5(]Q9"N,X[@_TK".&Y9\UR%3L[F]7$>(;,RZY</]H=,[?E#D8^45UGVN;_GW
M'_??_P!:LB^THWUY)<,FTOCC.>@`_I6M:E[2-KE2CS*QS']GG_G[D_[^'_&H
MKFW6UA:62[DVCL)#D^W6ND_X1_VK$\5Z7]BTR.3'68+_`..M_A7)/"<L6[_@
M9NG97.<DO2J--(6..%#'/T%9?VRZD8D3R\^CFK/V:2[90`=HZ5IVND*F"PR:
MRITV]D3%&9;Q7DQ'[Z8_\#-:]KII)'G.[>V<UJVNF,V`JX%;MEH?0L*ZH89;
MR-%3[G.V"):^.-*2"/8#;RDX[GUKTF-BRC-<?/9K!\0](4#_`)=9379`8%=K
M22278J/46BBBI*"BBB@`HHHH`****`"BBB@`HHHH`****`"O+OC!_P`?6E_[
MDG\UKU&O+OC!_P`?6E_[DG\UK;#_`,1&5;X&>CZ9_P`@NT_ZXI_Z"*M55TS_
M`)!=I_UQ3_T$5:K)[FBV(KK_`(]9O]QOY5Y?\(?^0IJ/_7%?_0J]0NO^/6;_
M`'&_E7E_PA_Y"FH_]<5_]"K:G_#E\C.?QQ/5:***P-0HHHH`****`"BBB@`K
M/U71K?6#9FX>5?LDZW">60,L.@.0>*T**:=M@:N4/['@_M[^U]\OVC[/]GVY
M&S;NW9QC.<^]']CP?V]_:^^7[1]G^S[<C9MW;LXQG.?>K]%',Q610L-'@TZ[
MOKB%I&>]D$D@<@@'&...GYUD-X%LDEE-CJ.JV$,K;VM[2YV19/7"X/6NFHIJ
M<EU$XIF5>^&].OM%CTN6%EMH@!%M8[HB!@%6/.1[U'I/ABVTJ\:[:ZOKVZ*>
M6LUY/YC(O4A>F*V:*.9VM<?*KW,2S\*VNGZQ)?VEW?1+)(TKVJS?N&8C!)7'
MX]:L:=H%GIUO>P+OFBO9GFE6;#`ENHZ#BM.BAR;!12.67X?Z<!Y)O=4:PW;O
ML)NCY&,YQMQG&>>M;&HZ):ZE'91R%XDLYTGB6+`&5Z#ITY[5HT4.<GU$HI%#
M5='@U?[)]H>5?LMPMPGED#++G`.0>.:OT44KE6"BBBD`4444`%%%%`!1110`
M5S/P\_Y$RT_WY?\`T8U=-7,_#S_D3+3_`'Y?_1C5:^!_+]27\2_KL=-1114%
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%<S:?\E)U#_L'Q_\`
MH5=-7,VG_)2=0_[!\?\`Z%5PZ^A,NATU%%%04%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7,_#S_D3+3_?E
M_P#1C5TU<S\//^1,M/\`?E_]&-5KX'\OU)?Q+^NQTNT4FT4ZBH*&[11M%.HH
M`;M%&T4ZB@!NT4;13J*`&[11M%.HH`;M%&T4ZB@!NT4;13J*`&[11M%.HH`;
MM%<Y\05`\#ZE_NI_Z,6NEKF_B#_R(^I?[J?^C%JZ?QKU)G\+.@B4>4G^Z*=M
M%)%_JD_W13Z@H;M%&T4ZB@!NT4;13J*`&[11M%.HH`;M%&T4ZB@!NT4;13J*
M`&[11M%.HH`;M%&T4ZB@!NT4;13J*`&[11M%.HH`YCP(H_LF]_["$_\`Z%72
M[17-^!/^03>_]A"?_P!"KIJNI\3)A\*&[11M%.HJ"ANT4;13J*`&[11M%.HH
M`;M%&T4ZB@!NT4;13J*`&[11M%.HH`;M%&T4ZB@!NT5S6C*/^$]\2?[EK_Z`
M:Z>N9T;_`)'WQ)_N6O\`Z`:N.S]/U1,MT=)M%&T4ZBH*&[11M%.HH`;M%&T4
MZB@!NT4;13J*`&[11M%.HH`;M%9FOZ,FLVD4,CE$CE$AP,DX!&/UK5I",C%)
MI-68/4XF;14A;R[>/"COW-7;+0^A85T?V9"V<"I%0+T%"22L@*EOIZ1`<5<5
M`O2G44P.7U'_`)*1H_\`UZ35U%<OJ/\`R4C1_P#KTFKJ*N>R]"8[L****@H*
M***`"BBB@`HHHH`****`"BBB@`HHHH`*\N^,'_'UI?\`N2?S6O4:\N^,'_'U
MI?\`N2?S6ML/_$1E6^!GH^F?\@NT_P"N*?\`H(JU573/^07:?]<4_P#015JL
MGN:+8BNO^/6;_<;^5>7_``A_Y"FH_P#7%?\`T*O3[L[;.<X)Q&QP/I7C_P`.
M-7_LB_O7^P7]YOB4;;.'S"O/4C(P*WI)NG)(RJ.TXGLU%<S_`,)K_P!2YXB_
M\`?_`+*C_A-?^I<\1?\`@#_]E67LY=C3GB=-17,_\)K_`-2YXB_\`?\`[*C_
M`(37_J7/$7_@#_\`94>SEV#GB=-17,_\)K_U+GB+_P``?_LJ/^$U_P"I<\1?
M^`/_`-E1[.78.>)TU%<S_P`)K_U+GB+_`,`?_LJ/^$U_ZESQ%_X`_P#V5'LY
M=@YXG345S/\`PFO_`%+GB+_P!_\`LJ/^$U_ZESQ%_P"`/_V5'LY=@YXG345S
M/_":_P#4N>(O_`'_`.RH_P"$U_ZESQ%_X`__`&5'LY=@YXG345S/_":_]2YX
MB_\``'_[*C_A-?\`J7/$7_@#_P#94>SEV#GB=-17,_\`":_]2YXB_P#`'_[*
MC_A-?^I<\1?^`/\`]E1[.78.>)TU%<S_`,)K_P!2YXB_\`?_`+*C_A-?^I<\
M1?\`@#_]E1[.78.>)TU%<S_PFO\`U+GB+_P!_P#LJ/\`A-?^I<\1?^`/_P!E
M1[.78.>)TU%<S_PFO_4N>(O_``!_^RH_X37_`*ESQ%_X`_\`V5'LY=@YXG34
M5S/_``FO_4N>(O\`P!_^RH_X37_J7/$7_@#_`/94>SEV#GB=-17,_P#":_\`
M4N>(O_`'_P"RH_X37_J7/$7_`(`__94>SEV#GB=-17,_\)K_`-2YXB_\`?\`
M[*C_`(37_J7/$7_@#_\`94>SEV#GB=-17,_\)K_U+GB+_P``?_LJ/^$U_P"I
M<\1?^`/_`-E1[.78.>)TU<S\//\`D3+3_?E_]&-1_P`)K_U+GB+_`,`?_LJP
M_!OBC^S_``S;V_\`8NM7.UI#YMO:;T.7)X.??%6H2Y7\OU)<US(]"HKF?^$U
M_P"I<\1?^`/_`-E1_P`)K_U+GB+_`,`?_LJCV<NQ7/$Z:BN9_P"$U_ZESQ%_
MX`__`&5'_":_]2YXB_\``'_[*CV<NP<\3IJ*YG_A-?\`J7/$7_@#_P#94?\`
M":_]2YXB_P#`'_[*CV<NP<\3IJ*YG_A-?^I<\1?^`/\`]E1_PFO_`%+GB+_P
M!_\`LJ/9R[!SQ.FHKF?^$U_ZESQ%_P"`/_V5'_":_P#4N>(O_`'_`.RH]G+L
M'/$Z:BN9_P"$U_ZESQ%_X`__`&5'_":_]2YXB_\``'_[*CV<NP<\3IJ*YG_A
M-?\`J7/$7_@#_P#94?\`":_]2YXB_P#`'_[*CV<NP<\3IJ*YG_A-?^I<\1?^
M`/\`]E1_PFO_`%+GB+_P!_\`LJ/9R[!SQ.FHKF?^$U_ZESQ%_P"`/_V5'_":
M_P#4N>(O_`'_`.RH]G+L'/$Z:N9M/^2DZA_V#X__`$*C_A-?^I<\1?\`@#_]
ME6';^*-GC>\O/[%UH[[-(_(%I^]7#?>*YX'O5QA+4F4UH>A45S/_``FO_4N>
M(O\`P!_^RH_X37_J7/$7_@#_`/95'LY=BN>)TU%<S_PFO_4N>(O_``!_^RH_
MX37_`*ESQ%_X`_\`V5'LY=@YXG345S/_``FO_4N>(O\`P!_^RH_X37_J7/$7
M_@#_`/94>SEV#GB=-17,_P#":_\`4N>(O_`'_P"RH_X37_J7/$7_`(`__94>
MSEV#GB=-17,_\)K_`-2YXB_\`?\`[*C_`(37_J7/$7_@#_\`94>SEV#GB=-1
M7,_\)K_U+GB+_P``?_LJ/^$U_P"I<\1?^`/_`-E1[.78.>)TU%<S_P`)K_U+
MGB+_`,`?_LJ/^$U_ZESQ%_X`_P#V5'LY=@YXG345S/\`PFO_`%+GB+_P!_\`
MLJ/^$U_ZESQ%_P"`/_V5'LY=@YXG345S/_":_P#4N>(O_`'_`.RH_P"$U_ZE
MSQ%_X`__`&5'LY=@YXG345S/_":_]2YXB_\``'_[*C_A-?\`J7/$7_@#_P#9
M4>SEV#GB=-17,_\`":_]2YXB_P#`'_[*C_A-?^I<\1?^`/\`]E1[.78.>)TU
M%<S_`,)K_P!2YXB_\`?_`+*C_A-?^I<\1?\`@#_]E1[.78.>)TU%<S_PFO\`
MU+GB+_P!_P#LJ/\`A-?^I<\1?^`/_P!E1[.78.>)TU%<S_PFO_4N>(O_``!_
M^RH_X37_`*ESQ%_X`_\`V5'LY=@YXG35S/P\_P"1,M/]^7_T8U'_``FO_4N>
M(O\`P!_^RK#\&^*/[/\`#-O;_P!BZU<[6D/FV]IO0Y<G@Y]\5:A+E?R_4ES7
M,CT*BN9_X37_`*ESQ%_X`_\`V5'_``FO_4N>(O\`P!_^RJ/9R[%<\3IJ*YG_
M`(37_J7/$7_@#_\`94?\)K_U+GB+_P``?_LJ/9R[!SQ.FHKF?^$U_P"I<\1?
M^`/_`-E1_P`)K_U+GB+_`,`?_LJ/9R[!SQ.FHKF?^$U_ZESQ%_X`_P#V5'_"
M:_\`4N>(O_`'_P"RH]G+L'/$Z:BN9_X37_J7/$7_`(`__94?\)K_`-2YXB_\
M`?\`[*CV<NP<\3IJ*YG_`(37_J7/$7_@#_\`94?\)K_U+GB+_P``?_LJ/9R[
M!SQ.FHKF?^$U_P"I<\1?^`/_`-E1_P`)K_U+GB+_`,`?_LJ/9R[!SQ.FHKF?
M^$U_ZESQ%_X`_P#V5'_":_\`4N>(O_`'_P"RH]G+L'/$Z:N;^(/_`"(^I?[J
M?^C%IO\`PFO_`%+GB+_P!_\`LJQ/&/BG^T/"M[;?V)K5MY@7][<6FR-<.IY.
M>.E5"$E)$SFN5G?1?ZI/]T4^N7C\:8C4?\([XB.`.18__94[_A-?^I<\1?\`
M@#_]E4^SEV*YXG345S/_``FO_4N>(O\`P!_^RH_X37_J7/$7_@#_`/94>SEV
M#GB=-17,_P#":_\`4N>(O_`'_P"RH_X37_J7/$7_`(`__94>SEV#GB=-17,_
M\)K_`-2YXB_\`?\`[*C_`(37_J7/$7_@#_\`94>SEV#GB=-17,_\)K_U+GB+
M_P``?_LJ/^$U_P"I<\1?^`/_`-E1[.78.>)TU%<S_P`)K_U+GB+_`,`?_LJ/
M^$U_ZESQ%_X`_P#V5'LY=@YXG345S/\`PFO_`%+GB+_P!_\`LJ/^$U_ZESQ%
M_P"`/_V5'LY=@YXG345S/_":_P#4N>(O_`'_`.RH_P"$U_ZESQ%_X`__`&5'
MLY=@YXG345S/_":_]2YXB_\``'_[*C_A-?\`J7/$7_@#_P#94>SEV#GB=-17
M,_\`":_]2YXB_P#`'_[*C_A-?^I<\1?^`/\`]E1[.78.>(>!/^03>_\`80G_
M`/0JZ:O/?"?BC[#I]U'_`&+K5QOO)9-T%IO`R?NDYZCN*W/^$U_ZESQ%_P"`
M/_V574A)R9,)KE1TU%<S_P`)K_U+GB+_`,`?_LJ/^$U_ZESQ%_X`_P#V51[.
M78KGB=-17,_\)K_U+GB+_P``?_LJ/^$U_P"I<\1?^`/_`-E1[.78.>)TU%<S
M_P`)K_U+GB+_`,`?_LJ/^$U_ZESQ%_X`_P#V5'LY=@YXG345S/\`PFO_`%+G
MB+_P!_\`LJ/^$U_ZESQ%_P"`/_V5'LY=@YXG345S/_":_P#4N>(O_`'_`.RH
M_P"$U_ZESQ%_X`__`&5'LY=@YXG345S/_":_]2YXB_\``'_[*C_A-?\`J7/$
M7_@#_P#94>SEV#GB=-17,_\`":_]2YXB_P#`'_[*C_A-?^I<\1?^`/\`]E1[
M.78.>)TU<SHW_(^^)/\`<M?_`$`T?\)K_P!2YXB_\`?_`+*L/3/%'D^+M;NO
M[%UI_/6`>4EIF2/:I'SKGC/;UJXPE9_UU1,IJZ/0J*YG_A-?^I<\1?\`@#_]
ME1_PFO\`U+GB+_P!_P#LJCV<NQ7/$Z:BN9_X37_J7/$7_@#_`/94?\)K_P!2
MYXB_\`?_`+*CV<NP<\3IJ*YG_A-?^I<\1?\`@#_]E1_PFO\`U+GB+_P!_P#L
MJ/9R[!SQ.FHKF?\`A-?^I<\1?^`/_P!E1_PFO_4N>(O_``!_^RH]G+L'/$Z:
MBN9_X37_`*ESQ%_X`_\`V5'_``FO_4N>(O\`P!_^RH]G+L'/$Z:BN9_X37_J
M7/$7_@#_`/94?\)K_P!2YXB_\`?_`+*CV<NP<\3IJ*YG_A-?^I<\1?\`@#_]
ME1_PFO\`U+GB+_P!_P#LJ/9R[!SQ.FHKF?\`A-?^I<\1?^`/_P!E1_PFO_4N
M>(O_``!_^RH]G+L'/$;J/_)2-'_Z])JZBO.[WQ/YGC;3;S^Q=97RK>1/):UQ
M*^>ZKGD#O6]_PFO_`%+GB+_P!_\`LJN<)67H3&:U.FHKF?\`A-?^I<\1?^`/
M_P!E1_PFO_4N>(O_``!_^RJ/9R[%<\3IJ*YG_A-?^I<\1?\`@#_]E1_PFO\`
MU+GB+_P!_P#LJ/9R[!SQ.FHKF?\`A-?^I<\1?^`/_P!E1_PFO_4N>(O_``!_
M^RH]G+L'/$Z:BN9_X37_`*ESQ%_X`_\`V5'_``FO_4N>(O\`P!_^RH]G+L'/
M$Z:BN9_X37_J7/$7_@#_`/94?\)K_P!2YXB_\`?_`+*CV<NP<\3IJ*YG_A-?
M^I<\1?\`@#_]E1_PFO\`U+GB+_P!_P#LJ/9R[!SQ.FHKF?\`A-?^I<\1?^`/
M_P!E1_PFO_4N>(O_``!_^RH]G+L'/$Z:O+OC!_Q]:7_N2?S6NK_X37_J7/$7
M_@#_`/95P?Q(UG^V+BP;^S]0LO+5QB\@\LMDCIR<]*VH0:FFS.K).#/6-,_Y
M!=I_UQ3_`-!%6JJ:4V[2+-L$9@0X/4?**MUSO<U6Q%=?\>LW^XW\J\O^$/\`
MR%-1_P"N*_\`H5>H77_'K-_N-_*O+_A#_P`A34?^N*_^A5M3_AR^1G/XXGJM
M%%%8&H4444`%%%9>IZS_`&=J>F6?D>9]OD:/?OQLP,YQCG]*:3>PF[&I1112
M&%%9VK3:I";/^RK:&</.JW'F-C9'W8<CG\_I3IM7@AUNWTMDD,]Q&TJL`-H"
M]<G.<_A3LQ7+]%%%(845C>'=8GU<ZE]H2)?LM[);IL!&57&"<D\U;UN]DTW1
M+V\A5&D@A:10XR"0,\U7*[V%=6N7J*I:/>2:AHUE=S!5DGA21@HX!(SQ5VI:
ML-:A116-INL3WGB75]/D2(0V7E>6R@[CN7)SSC^5-*XF[&S1112&%%%%`!11
M10`45C>+-8GT+P_-?6J1/+&R`"0$KRP'8CUK71MR*QZD9IVTN*^MAU%%%(84
M444`%<S\//\`D3+3_?E_]&-735S/P\_Y$RT_WY?_`$8U6O@?R_4E_$OZ['34
M445!04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7,VG_)2=0_[!
M\?\`Z%735S-I_P`E)U#_`+!\?_H57#KZ$RZ'34445!04444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%<S\//\`
MD3+3_?E_]&-735S/P\_Y$RT_WY?_`$8U6O@?R_4E_$OZ['34445!04444`%%
M%%`!1110`4444`%%%%`!1110`4444`%<W\0?^1'U+_=3_P!&+725S?Q!_P"1
M'U+_`'4_]&+5T_C7J3/X6=#%_JD_W13Z9%_JD_W13Z@H****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`YGP)_P`@F]_["$__`*%735S/@3_D
M$WO_`&$)_P#T*NFJZGQ,F'PH****@H****`"BBB@`HHHH`****`"BBB@`HHH
MH`*YG1O^1]\2?[EK_P"@&NFKF=&_Y'WQ)_N6O_H!JX[2]/U1,MT=-1114%!1
M110`4444`%%%%`!1110`4444`%%%%`!1110!R^H_\E(T?_KTFKJ*Y?4?^2D:
M/_UZ35U%7/9>A,=V%%%%04%%%%`!1110`4444`%%%%`!1110`4444`%>7?&#
M_CZTO_<D_FM>HUY=\8/^/K2_]R3^:UMA_P"(C*M\#/1],_Y!=I_UQ3_T$5:J
MKIG_`""[3_KBG_H(JU63W-%L177_`!ZS?[C?RKR_X0_\A34?^N*_^A5ZA=?\
M>LW^XW\J\O\`A#_R%-1_ZXK_`.A5M3_AR^1G/XXGJM%%%8&H4444`%<OXG_Y
M&?PS_P!?,G_H%=16-K&D3ZAK&CW<+QB.RF=Y`Q.2"N../\*N#LR9*Z,'4]*7
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MLEX"I5PP&X`D\$=\_P`A6OJFB:O/?:=JUA/8KJ=O"8IHY5;R7!ZX(^88.<?Y
MR:/H6K0>)9-7U:ZM9GEM?)*0J5$9W`A5SU'!Y)SSTH4ER6N%GS7L8OA_PU9Z
M]=ZVVIM+/;)J4P2V$A1`V>7.T@DXX]N?6EM7FM_"WBK29)7FATX21P.YR0A4
MD+GVK0M=`\1:1<7T^E7E@WVRZDE:"Y#E%!.58%0"&[$=*L6OA6>V\+ZE9O<)
M/J6HJ[3SMD*9&&/3H/I^':FYKOV$HOL8FK:C+;^%/#5@@O#%>Q()A9C,SHJ#
M*K]<_E4>EI'8>(M/?P_H6N:?!))Y=XES"XB=#T8DEL$&NAN_"]Q<>'=+MX;I
M;?4M-5&AG4;EWA<$'(^Z?\@]*GL(O%$E]$VJ7&E16J$LRVB.S2<8VDOT'.<C
MGBCG5M/,.5WU-ZN$BT.#7/'7B"*]DE-HGD%[='*K*=G&XCG`ZX]<>E=W7*S:
M!K=MXAU'5M)N[17N3&%@N`QC=0H!W8&00>1C-9TW:^MBYJ]BGI4C>&-7UW3+
M8O)86UK]LMXG8MY1QDJ">Q/^>M,T7P?8^(-$BU/67GN=1O$\W[1YS`Q9Z!0#
M@8]"#^7%;&B>'9X'O[S6IHKF_P!0&R;R@1&D?0(N><8_SW-&TT3Q1H]J=-TN
M_P!.>P4D0S7"/Y\2GL`/E)'.,]?8<#3FWL]2.7NM#(DFO=1\`"\G<SWNBWNX
M2D\N(VY)/T/Z5/XOOI+V_LKNQD)BTNW346V_Q!G4`?\`?(8UU.F>'K;3?#W]
MDY,L;HRRNPYD+?>/ZUE^&_"ESIVFW]OJLT,[W4:VX,9)`B5=JCD=>30IQO?M
M^H<KV%NF36/'6G(OSP:?:M=DCD;GX7]!FN3M[BQ\0&YOM:T77M2FDE=8GMHV
M:*!`<!4PP'UR.M=EX/\`#U[HD%R^ISQ3W4Q1=T1)`C10JC)`YZU6BT/Q!H=S
M<IX?N=.DL9Y#,L-Z'S"Q/(4IV^O^)(I):)@XMZLQ-2FOY?A9<+J4=TLL4ZQJ
M;I"LCH'&TL#WP<?A7HD7^J3_`'17/:SH6J:QX1?3[B[MY;^1U=I-I2,?,&VC
M`)P!P#U/>NB0;453U`Q6<Y)KYLN*:8ZBBBLRPHHHH`*YGX>?\B9:?[\O_HQJ
MZ:N9^'G_`")EI_OR_P#HQJM?`_E^I+^)?UV.FHHHJ"@HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"N9M/\`DI.H?]@^/_T*NFKF;3_DI.H?]@^/
M_P!"JX=?0F70Z:BBBH*"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`KF?AY_R)EI_OR_^C&KIJYGX>?\`(F6G
M^_+_`.C&JU\#^7ZDOXE_78Z:BBBH*"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`KF_B#_P`B/J7^ZG_HQ:Z2N;^(/_(CZE_NI_Z,6KI_&O4F?PLZ&+_5
M)_NBGTR+_5)_NBGU!04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110!S/@3_D$WO_`&$)_P#T*NFKF?`G_()O?^PA/_Z%735=3XF3#X4%%%%0
M4%%%%`!1110`4444`%%%%`!1110`4444`%<SHW_(^^)/]RU_]`-=-7,Z-_R/
MOB3_`'+7_P!`-7':7I^J)ENCIJ***@H****`"BBB@`HHHH`****`"BBLS7]6
M;1=-^UK$),2*I4G&0?>DVDKL-C3HK&TOQ3I^J;463R9S_P`LI>#GV/0UL!@>
ME$9*2NA)W%HHHIC.7U'_`)*1H_\`UZ35U%<OJ/\`R4C1_P#KTFKJ*N>R]"8[
ML****@H****`"BBB@`HHHH`****`"BBB@`HHHH`*\N^,'_'UI?\`N2?S6O4:
M\N^,'_'UI?\`N2?S6ML/_$1E6^!GH^F?\@NT_P"N*?\`H(JU573/^07:?]<4
M_P#015JLGN:+8BNO^/6;_<;^5>7_``A_Y"FH_P#7%?\`T*O4+K_CUF_W&_E7
ME_PA_P"0IJ/_`%Q7_P!"K:G_``Y?(SG\<3U6BBBL#4****`"BBN!O[D7/BF^
MM-<UW4=(VL!9+#+Y,4D>,[BV,$Y]3[>PJ,>8F4K'?45RNNS7NBW&A7TE[+-!
M'(+>\(.U)`PP'*C@<_SJ:_N;B^\;V&GVT\L<%I$UU=!'*A\\(IQUYYP:?(',
M=)17":/8:EXANM76XUN_M[.WOY4C2VE*R9SW8YPH'11ZU/IWB*]L?!FK37<G
MVB[TN:2V65Q_K""`I;\^?7%-T^S$I]SJ-6O_`.R])NKWR_,^SQ-)LW8W8&<9
M[4_3KO[?IMK=[-GGQ++LSG;N`.,]^M<5JF@:E#X1N=0DUV^FNI+5I+B&9]T#
M*PRRJN/EQV(].P-2:M<W]OX6\++IEP8+B9[>(')"G,?\0'49[57LTUHQ<[OJ
M=U17):M]K\)Z%(;74+R]OKV9(8WNW#B-VXRHQP.O'/:JNKZ/J?AW27U>TU[4
M;FZM0))8KF3?#*/X@$_AZYZG'ZU*A?J-SMT.WHKC/$6H:A<ZOX:72KQK0WZ2
M$DY90"JG)7HQ`)QGO5:\L]8T/Q%8:=INN7<D6IHZE[YO/,13DLO3G!Z=/7V%
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MJ^FV/',0P51PF3GY?:K'@/2/L^@6E_\`;[^3S;<C[/)-F%.?X5QQT_4U4H))
ML2DVT;OAW6?[?T6#4/(\CS2P\O?NQAB.N!Z5IUYQX4T&_P!4\'Q2C6KRT5!)
M]EBM'\L`[CDR'JV3VXP![UUWA'5)M9\,V=Y=$&=U*N0,;B"1G\<45()-V'"3
M=KFS1116184444`%<S\//^1,M/\`?E_]&-735S/P\_Y$RT_WY?\`T8U6O@?R
M_4E_$OZ['34445!16U"^ATS3Y[RY)$,"%VP,G`]*PK+Q-JUU);ROX;N(]/N&
M`6<7"LX5ONL8P,@=,^@K;U73HM6TNXL;C(CG0H2.H]"/H>:Y:'5-9\'"WMM<
MCCO=*#+"E_#P\8Y`WK^7^)-:02:\R)-I^1NV>O>?XBO-(N+?R)H$$D3;]PFC
M/\0X&,>G-+!KGVKQ'<Z7;V^^.UB#3W&_A'/1,8Y..>M97C>&2QBM?$5F`;G3
M7RX)QYD3<%3^?ZFKWA+36L-"66<A[N])NKA_5GYQ^`P*;4>7F!-WL5_"WC.+
MQ)<7%NUJUK-$-R*S[A(F<%@<#H1BM"'6_.\3W.C^1CR(%F\W?UR<8QC^M<-I
MUI+;>$-.\062YN=,GF:11UDA+G>/P'/YUO:3=17GQ#O;F!M\4NFQ.A'<$@BJ
ME"-VT1&;LKG85S,WBN\N;ZX@T'19=2CM7\N:8SK"F_N%)^]CO_\`JJ>R\4F^
MNTMAHFMVY?(\V>TV1KQGDYXJI\-^?!\+'[[2RE_7.X]:A1Y4W)%N5W9,U=#U
M^VUS36ND5X&B8I/%+PT3CJ#_`(UG67C>UU+Q+%I=C;R2P2*^+LG:C%1DA1CY
MAVSD5#X94-XI\4Q%083/'E2,@DJ=U%_&D/Q%T..)%2-+25551@*`.`!5<L;M
M>7Z"YG9,V==URWT&R6>9))9)'$<,,0R\KGH`*RXO%EY;7]K;Z[HDFFQW;>7#
M,+A9E+]E;:/ES_GOB/Q+SXS\+JWW/-F//3(48I?B/QX5+#[ZW$13USN[41BM
M$UN$F]7V.BO[Q-/T^XNY`62"-I&`ZD`9K.L+?5+JU@O+C4VCFE"R-;I"AA4'
MG;R-YX[[NO/3BM*ZMH[VRFMI@3'-&8WQZ$8-9NGP:U96T-F_V&6.(!!=&1PY
M0="8]N,XX^_[^U0MBGN;-%%%04%<S:?\E)U#_L'Q_P#H5=-7,VG_`"4G4/\`
ML'Q_^A5<.OH3+H=-1114%!1110`4444`%%%%`'/:AXID34Y-.T;39=3O(<&8
M+((XX@>Q<\;O;_"DL/%4K:I%INM:7-IEW/DP;I!+')CL''&?;_$56^'P#:3?
MRN!]HDOYC,>^[(ZT?$``6&F2+_KTU&'RO7/-;<L>;DL97=N:YU=%<1J>E+K/
MQ&>TGED6U.GJ\T:,5\X!SA21SC)S^%-UZP\-V5S;:=<6FI:@T<0\G3K5Y)!$
MN3\^`PZYQR3VXJ5!::E<[.VE8I$[#JJDC-97A35Y]=\/6]_=)&DLI;(C!"\,
M1W)]*Y_P1/AM=LH(KRWLK=E:"VNP0\(96)&"3@9&?_UUH_#K_D2;+ZR?^AM3
ME#E3^0E*[1T]8WB#6)])FTM8$B87=ZEO)O!.%.<D8(YK/\9R2W,^DZ.DSPQ:
MC.4G9#AFC49*Y]\UDZYX9LM!U+07TSS8()-2B#VYD9T+=G^8D@XX_+THA!:7
M"4GK8[^BN(U/2EUGXC/:3RR+:G3U>:-&*^<`YPI(YQDY_"I[NQM]-\9>&+2T
MC\N"**X"+N+8&WU/-+D7<?,^QV%%<OK/_(_^'/\`<N/_`$"N>U6?0)O$NJKX
MNEE<Q.%M`&D*(FT$A=G1NF<^U$:=P<['I-%<I\/-(73/#YD-L\$MQ(S?O,[V
M0$["P/`./3%=74R5G9%1=U<****D84444`%%%%`!7)>`K^TM_"%HDUU!&^^4
M[7D`/^L;L:ZVO%+"X>VMK)D&<JP*^O[UZFK4=.DY+NOU,YNS3/8/[5L/^?ZV
M_P"_J_XT?VMI_P#S_6W_`']7_&O/1>VQ`S'(#Z;*7[9;?W)/^^*\[Z]4_D(]
MJ^QZ#_:VG_\`/];?]_5_QH_M;3_^?ZV_[^K_`(UY]]LMO[DG_?%'VRV_NR?]
M\4?7JG\@>U?8]!_M;3_^?ZV_[^K_`(TG]K:?_P`_UM_W]7_&O/\`[7:_W7_[
MX-'VRU_NO_WP:/KU3^0/:OL>A#5+$\B\MR/^NJ_XT?VG8_\`/Y;_`/?U?\:\
M]^V6OH__`'P:/MEKZ/\`]\&CZ]/^0/:OL>A?VG8_\_EO_P!_5_QH_M.Q_P"?
MRW_[^K_C7GOVRU_NO_WP:/MEK_=?_O@T?7I_R![5]CT+^T['_G\M_P#OZO\`
MC1_:=C_S^6__`']7_&O/1=VOH_\`WP:/M=I_M?\`?!H^O3_D#VK['H7]IV/_
M`#^6_P#W]7_&E_M&S_Y^X/\`OX*\\^UVG^U_WP:/M=I_M?\`?!H^O3_D#VS[
M'H?]HV?_`#]P?]_!1_:-G_S]P?\`?P5YY]KM/]K_`+X-'VNT_P!K_O@T?7I_
MR![5]CT/^T;/_G[@_P"_@KG_`!W=07/@S4(H)HY9&"81&!)^=>PKG/M=I_M?
M]\&C[79^K?\`?!_PJHYA.+3Y!.JVK6/08]1LQ$G^EP=!_P`M!3O[1L_^?N#_
M`+^"O//M=GZM_P!\-_A1]KL_[S?]\'_"I^O3_D'[9]CT3[=:_P#/S#_WV*/M
MUK_S\P_]]BO._M5G_>;_`+X/^%'VNS]6_P"^#_A3^O3_`)`]L^QZ)]NM?^?F
M'_OL4?;K7_GYA_[[%>=_:[/U;_O@_P"%'VNS_O-_WP?\*/KT_P"0/;/L>B?;
MK7_GYA_[[%'VZU_Y^8?^^Q7G?VJR_OG_`+X;_"C[59?WS_W[;_"CZ_/^0/;/
ML>BB]M3TN(3_`,#%+]KM_P#GO%_WV*\Y^U67]\_]^V_PH^U67]\_]^V_PH^O
MS_D#VS['HWVNW_Y[Q?\`?8H^V6__`#WB_P"^Q7G/VJR_OG_OVW^%'VJR_OG_
M`+]M_A1]?G_('MGV/1OMEO\`\]XO^^Q1]LM_^>\7_?8KSG[59?WS_P!^V_PI
M?M%E_?\`_'&_PH^OR_D#VS['HOVRW_Y[Q?\`?8H%U`>D\9_X$*\Y^TV7]_\`
M\<;_``H^T67]_P#\</\`A1]?E_('MGV/1_M,'_/:/_OH4?:8/^>T?_?0KSC[
M19?W_P#QP_X4?:;+^_\`^.'_``H^OR_D#VS['H_VF#_GM'_WT*/M,'_/:/\`
M[Z%><?:;+^__`..'_"C[19?W_P#QP_X4?7Y?R![9]CI?`C+_`&7>KD;OM\[8
M[XW=:Z>N0\)2V[ZI*(6!;R3V(XW+77UW4JSK+G:L:4W>(PRQJ2"Z@CJ":!*C
M'"NI/H#7$^(Y;5==N1*X#C;D8/\`=%'AR6U;7;81."YW8&#_`'37-];?M.3E
MZV)]I[UK'<TUI$0X9E!]S3JX_P`6RVZ:K$)F`;R1V)XW-6]>JZ4.9*Y<Y<JN
M=:)8R0`ZDGWI]>>Z9-:-JMH$<;C,F.#UW"O0JG#UW63;5A0GS#6=4QN8+GU-
M'F)_>7\ZYOQB\*?8_.8#._&1_NUS/G67_/1?R-95L6Z<W'EN3*IRNUCTRD)`
MZD#ZTM87BUHETJ(S$!?.'7UVM754GR0<K7L:2=E<V]Z?WA^=+UKS3SK+_GHO
MY&O0M,*G2K0KRIA3'TVBL,/B76;7+8B$^;H620!DG`I-Z_WA^=9WB(H-"N3*
M0$^7)/\`O"N&\RR_YZ)2KXITI<O+<)U.5VL>F5SNDVT\?C77YY(9%AE2W\N1
MD(5\(<X/0XJ_X=*'0K8Q$%/FP1_O&CQ&4&A7)E("?+DG_>%="JVI.=NG_!&W
M=*1I9I:\S\RR_P">B5U_A)HFTN4PL&7SCT]=JUS4<6ZL^7EL3&IS.UC=I,TM
M>:;[+_GK'^=7B,1[&VE[E3GR]#TNBN9\'&$_;/(96^YG'_`JZ:M:-3VD%*UA
MQ?,KB45Y_J4ML-4NPTRAA,^1G_:-:7A.2!]4E$4BLWDG@'_:6N:&,YJG)RD*
MI=VL=?24M</XB>W&N7`DE56^7(+?[(K>O6]C'FM<N<N57.WS7.>/#_Q33_\`
M75:YGS+3_GNG_?5-D-E*A1YHRIZC=7%+'<R:Y3)U;K8Q[51<0[6^\O\`*MG3
MO$6I:40N_P"TP#^"0\@>S=?YUE+"MK<XBE61.H(/;WJQ)=6H)#3Q@CJ"W2N9
M5)0E>)FFT]#O-)\56.I[8]_DSG_EE)P3]#T-;88'I7CTLMF__+>(_P#`JU-*
M\57FFLJ><+N`?\LW;D?1J[Z6+OI-&T:G<Z;4?^2D:/\`]>DU=17#1:Q#JOCS
M2+B)74"VF4AQ@@UW`.:[Y-246NQ4.HM%%%26%%%%`!1110`4444`%%%%`!11
M10`4444`%>7?&#_CZTO_`')/YK7J->7?&#_CZTO_`')/YK6V'_B(RK?`ST?3
M/^07:?\`7%/_`$$5:JKIG_(+M/\`KBG_`*"*M5D]S1;$5U_QZS?[C?RKR_X0
M_P#(4U'_`*XK_P"A5ZA=?\>LW^XW\J\O^$/_`"%-1_ZXK_Z%6U/^'+Y&<_CB
M>JT445@:A1110`5RFMR:_=I>:<WAVTOK>0D13M<J$`/W24;G([XQTXKJZ*J,
MK.]A-7.=;PZW_"!G1;B57D2VV>83\H<<@_0$#\!5+X>17-SI]SK-_@W-\Z@-
M_L(-H_7-=-J%DNHZ?/:2221I.A1FC(#`'KC(-+8V46G6$%I;@B*!`BYZX`[U
M7/[K7<GEU3,GPMIMUIQU;[7%Y?VC4)9HOF!W(<8/!X_&J%GX9N+G1O$-A>IY
M'V^\EEA;(;Y3@JW!]1TZUT::E:R:E+8)+FZB02/'M/"GH<XQ4`U*X/B$Z?\`
MV?-]F$'F_;.=F[.-G3&?Q_"CFE=L.5',SP^+-0\/R:/+IUM;E83&]V9U?SP!
MC"IV+<<MP.>G%7+W1;^;2O#$,<&9+&>W>X&]?D"KAN_./;-=711[1]$'(C'\
M4:+)KNCFWMY5BN8Y%FA=N@=>F?:L6^7Q/XCT_P#LJ[TJ#3HIMHN+O[2L@*@C
M=L0<@GMD^WO7955N]2M;&>VAN9=DET_EPC:3N;KC@<?C2C-K2P2BF8NIZ+</
MXB\.36<.ZTL/,61MP&P%0%X)R>G:IM7TVZNO%6A7D,6ZWM?.\Y]P&W<H`XSD
M_A5W5M2N-.-F+?3YKSSYUB<QY_=*>KG@\#\/K6C1S-68^5:F#J>FW5QXOT6^
MBBW6ULDPE?<!MW+@<9R?PJB]GK7A[6[ZYTG3XM2LK]_-:+SUA>*3N<MP0?\`
M.._644*;V!Q,_2)]3N;=Y=5M(;1V?]W"DGF,BX_B;H3G)X[8JQ?V::AI]Q:2
M_<GC:,_0C%6*3I4WUN.VECC?#?AN_.E:C%KD*QRSVZ6<8W*W[M$(!R/4G/X5
M:\%Z3J5F+J[UJ$17<@CA50X;]W&H`.02.3DU=T?79+_2KW5)T46:22&W\L'<
M\2=SDXR2#Z5-)XCM(_#(UPQS_93&)=@4;\$XZ9QGGUK64I.ZMN0E%690\-Z-
M=VEEK,%Y'Y/VN\F>,[@V488!X/Z&F^$HM9TZQ32=1TU(X;:-E2[2X5A+\W&$
MZC@]3Z4W_A/;*/RVO=,U>QMY"`+BYM=L8STR03UK8U?7+/1+);F[=B'(6)(U
MW/*QZ*H[DTGS;-;@N7=/8I>#M-NM*\*V]G>Q>5<)OW)N#8RQ(Y!([TO@S3KK
M2?"]K:7T7E3QE]R;@V,L2.02.AJ32?$L.JWC6K6.HV4X3S%2\M_+WJ#@D<GI
MD?G6S4R;U3ZCBEI8**Q-5\5V6EWPL5AN[V]V[VM[.'S'1?4]`/Y\BEM=?75]
M-O&TM6CO[=#FVNXRC1OC*AE]_8TN1VN/F6QM45GZ%J@UG1;6^"A6E3+J/X6'
M##\P:T*35G8I.^H5S/P\_P"1,M/]^7_T8U=-7,_#S_D3+3_?E_\`1C52^!_+
M]27\2_KL=-1114%%34XKR?3Y4TVX2WNN#'(Z;ER#G!'H>F>V:YVYT/Q#KXCM
M=>N--BL%<22)8B3?+@Y"DMT'N*ZVBJC)QV)<;F7XETR;6/#UY86S1K+,@53(
M2%'(/.`?2KMG`UO800.06CB5"1TR!BIZ*5W:P[:W,7PQHLNC^'UT^\,4C;I"
MVPDJ0S$XY`[&LSPOX/N/#VOWER;F.6R>/R[=<G>B[MP!R,<=.M=;15<[U\Q<
MBT\@KDH]!U_0[BZ3P]<Z<]C<2&817H?,+'J%V]1]?_KGK:*49-#<;F-H6B2:
M)ILZ^>MS?W#M-+,Z[0\A]AT'2L*?1O%]QK=KJKOH(GMHVC109MI#=<C&?UKM
MJ*:FTVQ."M8P-9T*\UK2K-GN(K;5[1A-'-$"8Q)CD<\[3_G/2JG]AZYK%]:/
MXBN-/6TM)!,L%DK_`+UQTW%N@'MUKJJ*%-I`X)A1114%!1110`5S-I_R4G4/
M^P?'_P"A5TU<S:?\E)U#_L'Q_P#H57#KZ$RZ'34445!04444`%%%%`!1110!
MR\WA_5M+U2YO?#=W:+'>/OFM+Q6\L/W=2O(/M_\`6PZU\/ZG?ZK;ZCXDNK:1
MK0EK>UM%81*W'SDMR3[=OTKIJ*OVC)Y$8R:/.OC*35B\7V=K(6X7)W[M^<XQ
MC'XU2U'1-8@\12:OH,UCON(1%-%>*VWY>A!7G\/Y]NFHI*;0<J.<T#P_J&G7
MFK7.H7<-S+?A#O12N"`01C'`&0!UZ5;\*:1/H7AZWL+IXWEB+9,9)7EB>X'K
M6Q10YM[@HI&+XET.76+>WDLYQ;W]G*)K>1AE=WHWL:RKCP]X@U:\T^[U6]L@
MUG=)(+:V#"/:#DMD@DMV`X`_&NOHIJ;2L#@F8R:/.OC*35B\7V=K(6X7)W[M
M^<XQC'XU%XCT.[U&>QO]+GAAU"Q<M'YP)C=6X96QST]/_KC>HI<[O<.56L<K
M;Z!K<_B33M7U6\M':W$BO!`&"1@K@;,C))/))(]NE9NC6>IZG?ZS-HNMG3K;
M[<X,+VZ3,7XW,<XV@GH*[RL/4?!>@ZK=M=7FG(\S_>979-WN0I`)]ZM5._Y$
MN'8A\):M>:@-0MKZ:&Z:QG\E;J%=JS#&>0.,COCBNBJM8Z?:Z9:);6,$<$*=
M$08_$^I]SS5FHDTW=%Q32U"BBBI&%%%%`!1110`5YUX3T"*Z\.VU^[9D_>(%
M*YQB1O\`&O1:Y;X?H'\%V@/]^7_T8U.4(SIM2[K]2)).2O\`UL9DT0B<KY`;
M'O47_;L/S_\`K5V3Z;&YR13?[*B_NUS?5:7;\6'LXG'\?\^P_/\`^M1Q_P`^
MP_/_`.M78?V5%_=H_LJ+^[1]5I=OQ8>SB<?Q_P`^P_/_`.M1Q_S[?K_]:NP_
MLJ+^[1_947]VCZK2[?BP]G$X_C_GV_7_`.M1Q_S[?K_]:NP_LJ+^[1_947]V
MCZK2[?BP]G$X_C_GV_7_`.M1A?\`GW_6NP_LJ+^[1_947]VCZK2[?BP]G$X_
MY?\`GW_6CY?^??\`6NO_`+*B_NTG]DQ?W:/JM+M^+#V<3D?E_P"??]:,+_S[
M_K77?V3%_=H_LF+^[1]5I=OQ#V<3D<+_`,^_ZT83_GW_`%KKO[)B_NT?V3%_
M=H^JTNWXA[.)R.$_Y]_UJIJE]%IFG2W;VA=8\94'&<D#^M=S_9,7]VN?\=Z;
M'%X,U!P.0$_]#6G'"4G)*WXDRA%)LH#80#]G//O2X3_GW/YUUD>E1>4GR]A3
MO[)B_NTOJM+L5[.)R&(_^?<_G1^[_P"?<_G77_V3%_=I/[(B]*/JM/L'LXG(
M_N_^?<T8C_Y]S77?V1%Z4?V1%Z4OJM,/9Q.1Q'_S[FC$?_/N:Z[^R(O2C^R(
MO2CZK3#V<3D<1_\`/N:,1?\`/N:Z[^R(O2C^R(O2CZK3#V<3D<1?\^YHVQ?\
M\#77?V1%Z4?V1%Z4?5:8>SB<CB+_`)X&DQ%_S[FNO_LB+TI/['B]*/JM,/9Q
M.1Q#_P`^[48A_P"?=JZ[^QX_2C^QX_2CZK3#V<3D<0_\^[4;8?\`G@U==_8\
M?I1_8\?I1]5IA[.)R.V'_G@U&V'_`)X-77?V/'Z4?V/'Z4?5*8>SB8'@>^M]
M0O+B2WA>/8'C.[')#+FNTKC/`=H8].O)(CM;[;,N<#INKJ=EQ_SU/_?(_P`*
MZ%35+W8CA\)RVOK$=:N-T18_+S_P$4:`L0UJWVQ%6^;!_P"`FNAFTP3R&23Y
MG/4TD6F""421?*Z]#6/U>'-S=1<BO<TZY7Q0(CJ4?F1ECY(Y'U-;^VY_Y['_
M`+Y'^%03Z?\`:7#S'<P&,X'2M)P4U9E-7T.6TY8/[2M=L+`^<F#@>HKNZRDT
ME(W5UX93D'WJUMN?^>Q_[Y'^%*G2C35HBC%1V,CQ8(S]D\Q"WW\8_P"`USNR
MW_YXM^0KL[BQ:ZV^>V_;G'`XJ'^QH_2HGAX3ES,3@F[FO6+XH"'38_,4L/.'
M`^AJ_MN?^>Q_[Y'^%1SVDER@29]R@YQ@=:UE%25F4U=6.*V6_P#SQ?\`(5W>
MG8&FVNT8'DI@?@*H_P!C1^E6DBGC1424A5&`,#I^513HQIN\11BH[$>OA3HM
MP'4LORY`_P!X5QFRV_YXO^0KM9K>:XB,<LA9&ZC`_P`*K?V+'Z4JE"-1W8."
M>Y/H`4:+;A%*K\V`?]XT:^%.BW`<$K\N0/\`>%36\4EM"L487:N<9'XUD0:E
M=:GKVKZ3.D(@M5A*E5.X[AN.><=1Z5JJ=X<O2P.R5CG?+MO^>+_D*ZKPLJ+I
ML@C4J/./!^@IW]BQ^E6+>TDM4*0OL4G.,#K6-.A&#NA*"3N:%>=^5;?\\7_(
M5W.VY_Y['_OD?X52_L6/TJJE*-2W,.45+<J^$UB7[7Y2%<[,Y'^]715FV]BU
MIN\AMF[&>!S4VRZ_Y['_`+Y'^%7""A'E0TK*QQ^HQVQU.Z+1L6\Y\G'N:T?"
MR0KJ<AB0JWDGDCW%:;Z.LDC._+,22?4U+::?]CE,D0&XC;SZ?Y%91P\%+F)4
M$G<TZXO7X[=M:N#(C%OER0/]D5UF^?T3\C_C5*XTP7,[2R`;FQG'TQ5U*:J*
MS*E&YQ_E6O\`SS;\JKWKVUK;-(L)+=%!'&:[3^Q(_2L/Q=IBVVAM(HY\Q17/
M/#0C%M7,W321PTMV8HVD)S(W3ZUG)#)*W0\UK0Z5+<$.X(4=*U+73E3`5,GU
MK"G2E+X43&+>QCVND,V"XP*V;33D3&U,FMBTTAY",J:WK/150`L*ZX8>*UEJ
M:*"6YR$$<B>.=*&,?Z/+@5Z/!G8,URUW;K%\1='4#_ETFKK@,5UR5DO0<>HM
M%%%04%%%%`!1110`4444`%%%%`!1110`4444`%>7?&#_`(^M+_W)/YK7J->7
M?&#_`(^M+_W)/YK6V'_B(RK?`ST?3/\`D%VG_7%/_015JJNF?\@NT_ZXI_Z"
M*M5D]S1;$5U_QZS?[C?RKR_X0_\`(4U'_KBO_H5>H77_`!ZS?[C?RKR_X0_\
MA34?^N*_^A5M3_AR^1G/XXGJM07UT+*PN+EAN$,;2$>N!FIZBNK=+NTFMY,[
M)4*-CT(Q6"-3D-*T34]>TJ+5KKQ!J-O>72^;'';R;8(P?NC9WXQGGG]:GO6O
M]>\3R:-%J%Q9V=C"CW$MN=DLKMT`;^$?3W_"+3T\5Z1IZZ-!IUM.(OW<.HM<
M`(J=B8_O$@<?X][%_INKZ5XA.LZ3!'J'VB%8;JW:01,2HX=6/`^G^/&]]=UY
M&/3\QNFM>Z!XMCT>:^N+ZRO(&EA>Y;=+&Z]1N[C_`!'OFAH]AJ7B&ZU=;C6[
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M-8TR[U#%UITC1)?.H.%Q\K,#P2,9.3]:R]`NM;LKO6Y-,T^+4;=]2F4Q><(G
M1L_>R>"".W6M&U\+7\WA?5HKR:--4U4F63:?DC/9..W8]>O>G*VS\A1\CG-1
MUVQTHBYTCQ9J=[?Q2C=!.S/#*,X8`;0N/0Y/MV-;7C/2?M7B'1)/M]_%]IN/
M+VQ3;1%A?O(,<-[U7U&Q\3:KX932%T.VLXX50$BY1O-VD<(!PO(SR>GO6_XK
MTV_NAIMYID*3W%A<B7R&<)YB]"`3P#]:?,DU\^PK-IE'Q`EQHEKH-M;ZA?2;
MM1C1Y99B7D4DDAB,9'M3]0>]\0>*IM'M[ZXL+*RB62=[8[99';E0&[`?X_@[
M6K/5=;M-$F;3OL\\-^DT\/GJ_EH">=W`/&#QZT[4].U73/$KZUHUM'?+<Q"*
MYM6E$;9'W65CQZ?Y/$IKYZE/\"/36O=`\6QZ/-?7%]97D#2PO<MNEC=>HW=Q
M_B/?-#1[#4O$-UJZW&MW]O9V]_*D:6TI63.>['.%`Z*/6M72]-U/4/$(UO6;
M>.S,,)AMK1)!(5R?F9F'&3VQV/MS8\+:;=:<=6^UQ>7]HU"6:+Y@=R'&#P>/
MQH<K)]P2OZ$?@N_N[O3+FWOY3//8W3VIF/60+C!/O6AXCG>V\-ZE-&<.EM(5
M/H=IJGX6TVZTXZM]KB\O[1J$LT7S`[D.,'@\?C6CK5H;_1+ZU7[TT#H/J0<5
M$K<Y2ORF1IL`M_AO%&HP/[.+?B4)/\ZR;K_DC2_]>:?^A"M/P[(^I_#N&.$;
MI39O`%Z?,`5Q^E13Z)?O\-!I2P9OOLRQ^5O7[P()&<X_6K3L]>Y-KK3L9.N:
MAK=YX5-O>Z!):V!1//N8[A)W6,8)(0$>@[\#-;.LZ9)K.C:3?>'YHWELBL]L
M)ONRKCH??@>GX=:@DN_%-WIATY/#L-J9(O)^T37R.B#&"2JC)X_R:O"WU;PY
MI&G6FD6<.I1P1F.9&E\IR>S*3QC.<@\]*&[6M827<=HOBI=0OGTW4;*;3M3C
M4L89.5<`GE&_B''^&<4ZP\;:#J=]'9V=_P"9<2DA$\F09XSU*X[54L;#5M6\
M26VKZM9QZ='91ND-NLHE=RPP6+#C&.W7BNIJ)<J+CS,Y/P`BSV%_J+X:YN[R
M0R.>N`<!?H/ZUU(BC$K2A%$C`*7`Y(&<#/IR?SKDX].UOPOJ5V^C6<6I:=>2
MF;[.9A$\+GK@G@K_`/6Z=]K2)-7F\^YUB."U1@/*M8VWF,#.2S]"3[<8'UHF
MKOF3"&BL9?@=O+&M68^Y;ZE*$`[*><?SKJ:Y?P&OFZ;?:ASMO[Z6=,_W<X'\
MC744JGQ,</A05S/P\_Y$RT_WY?\`T8U=-7,_#S_D3+3_`'Y?_1C4+X'\OU!_
M$OZ['34445!04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7,VG_
M`"4G4/\`L'Q_^A5TU<S:?\E)U#_L'Q_^A5<.OH3+H=-1114%!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5S
M/P\_Y$RT_P!^7_T8U=-7,_#S_D3+3_?E_P#1C5:^!_+]27\2_KL=-1114%!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`5S?Q!_Y$?4O]U/\`T8M=)7-_
M$'_D1]2_W4_]&+5T_C7J3/X6=#%_JD_W13Z9%_JD_P!T4^H*"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`.9\"?\@F]_["$_\`Z%735S/@
M3_D$WO\`V$)__0JZ:KJ?$R8?"@HHHJ"@HHHH`****`"BBB@`HHHH`*2EHH`2
MBEHH`2N:T;_D??$G^Y:_^@&NFKF=&_Y'WQ)_N6O_`*`:N.TO3]43+='2T4M%
M04)12T4`)12T4`)12T4`)12T4`)5>]LH+Z$1W$8=`P;:>F15FBAJ^X'.7NE^
M8X5$"J.@`XJ6ST54P6'Z5M^6"<XIP`%`$$5JD8&`*G``I:*`.7U'_DI&C_\`
M7I-745R^H_\`)2-'_P"O2:NHJY[+T)CNPHHHJ"@HHHH`****`"BBB@`HHHH`
M****`"BBB@`KR[XP?\?6E_[DG\UKU&O+OC!_Q]:7_N2?S6ML/_$1E6^!GH^F
M?\@NT_ZXI_Z"*M55TS_D%VG_`%Q3_P!!%6JR>YHMB*Z_X]9O]QOY5Y?\(?\`
MD*:C_P!<5_\`0J]/NR19SD#)\ML#UXKQ_P"'%[J-G?WK:9I?]H.T2AU^T+%M
M&>N6ZUO25Z<OD95':<3V:BN9_MWQ/_T*/_E2B_PH_MWQ/_T*/_E2B_PK+V;\
MOO1ISK^DSIJ*YG^W?$__`$*/_E2B_P`*/[=\3_\`0H_^5*+_``H]F_+[T'.O
MZ3.FHKF?[=\3_P#0H_\`E2B_PH_MWQ/_`-"C_P"5*+_"CV;\OO0<Z_I,Z:BN
M9_MWQ/\`]"C_`.5*+_"C^W?$_P#T*/\`Y4HO\*/9OR^]!SK^DSIJ*YG^W?$_
M_0H_^5*+_"C^W?$__0H_^5*+_"CV;\OO0<Z_I,U]+T>#2/M?V=Y6^U7#7#[R
M#AFZ@8`XJ_7,_P!N^)_^A1_\J47^%']N^)_^A1_\J47^%-PD][?>A*27_#,Z
M:BN9_MWQ/_T*/_E2B_PH_MWQ/_T*/_E2B_PI>S?E]Z'SK^DSIJ*YG^W?$_\`
MT*/_`)4HO\*/[=\3_P#0H_\`E2B_PH]F_+[T'.OZ3.FHKF?[=\3_`/0H_P#E
M2B_PH_MWQ/\`]"C_`.5*+_"CV;\OO0<Z_I,Z:BN9_MWQ/_T*/_E2B_PH_MWQ
M/_T*/_E2B_PH]F_+[T'.OZ3-C3-)@TG[4+9Y=EQ,TY1B"J,>NWC@5>KF?[=\
M3_\`0H_^5*+_``H_MWQ/_P!"C_Y4HO\`"FX2?;[T)22_X9G345S/]N^)_P#H
M4?\`RI1?X4?V[XG_`.A1_P#*E%_A2]F_+[T/G7])G345S/\`;OB?_H4?_*E%
M_A1_;OB?_H4?_*E%_A1[-^7WH.=?TF=-4%[:B^LI[9I)(UF0H7C(#`$8X/K6
M!_;OB?\`Z%'_`,J47^%']N^)_P#H4?\`RI1?X4<C\OO0<R_I,W[&SBT^Q@M+
M<$10H$0'K@5/7,_V[XG_`.A1_P#*E%_A1_;OB?\`Z%'_`,J47^%'(_+[T',O
MZ3.FKF?AY_R)EI_OR_\`HQJ/[=\3_P#0H_\`E2B_PK#\&ZKKMMX9MX['P[]L
M@#2;9OMT<>[YSGY2,\'C\*M0?*_EU7F2Y+F1Z%17,_V[XG_Z%'_RI1?X4?V[
MXG_Z%'_RI1?X5'LWY?>BN=?TF=-17,_V[XG_`.A1_P#*E%_A1_;OB?\`Z%'_
M`,J47^%'LWY?>@YU_29TU%<S_;OB?_H4?_*E%_A1_;OB?_H4?_*E%_A1[-^7
MWH.=?TF=-17,_P!N^)_^A1_\J47^%']N^)_^A1_\J47^%'LWY?>@YU_29TU%
M<S_;OB?_`*%'_P`J47^%']N^)_\`H4?_`"I1?X4>S?E]Z#G7])G345S/]N^)
M_P#H4?\`RI1?X4?V[XG_`.A1_P#*E%_A1[-^7WH.=?TF=-17,_V[XG_Z%'_R
MI1?X4?V[XG_Z%'_RI1?X4>S?E]Z#G7])G345S/\`;OB?_H4?_*E%_A1_;OB?
M_H4?_*E%_A1[-^7WH.=?TF=-17,_V[XG_P"A1_\`*E%_A1_;OB?_`*%'_P`J
M47^%'LWY?>@YU_29TU<S:?\`)2=0_P"P?'_Z%1_;OB?_`*%'_P`J47^%8=OJ
MVNCQO>3+X=W736:*UM]NC&U=W#;L8.?2KC!Z_P":)E):'H5%<S_;OB?_`*%'
M_P`J47^%']N^)_\`H4?_`"I1?X5'LWY?>BN=?TF=-17,_P!N^)_^A1_\J47^
M%']N^)_^A1_\J47^%'LWY?>@YU_29TU%<S_;OB?_`*%'_P`J47^%']N^)_\`
MH4?_`"I1?X4>S?E]Z#G7])G345S/]N^)_P#H4?\`RI1?X4?V[XG_`.A1_P#*
ME%_A1[-^7WH.=?TF=-17,_V[XG_Z%'_RI1?X4?V[XG_Z%'_RI1?X4>S?E]Z#
MG7])G345S/\`;OB?_H4?_*E%_A1_;OB?_H4?_*E%_A1[-^7WH.=?TF=-17,_
MV[XG_P"A1_\`*E%_A1_;OB?_`*%'_P`J47^%'LWY?>@YU_29TU%<S_;OB?\`
MZ%'_`,J47^%']N^)_P#H4?\`RI1?X4>S?E]Z#G7])G345S/]N^)_^A1_\J47
M^%']N^)_^A1_\J47^%'LWY?>@YU_29TU%<S_`&[XG_Z%'_RI1?X4?V[XG_Z%
M'_RI1?X4>S?E]Z#G7])G345S/]N^)_\`H4?_`"I1?X4?V[XG_P"A1_\`*E%_
MA1[-^7WH.=?TF=-17,_V[XG_`.A1_P#*E%_A1_;OB?\`Z%'_`,J47^%'LWY?
M>@YU_29TU%<S_;OB?_H4?_*E%_A1_;OB?_H4?_*E%_A1[-^7WH.=?TF=-17,
M_P!N^)_^A1_\J47^%']N^)_^A1_\J47^%'LWY?>@YU_29TU<S\//^1,M/]^7
M_P!&-1_;OB?_`*%'_P`J47^%8?@W5==MO#-O'8^'?MD`:3;-]NCCW?.<_*1G
M@\?A5J#Y7\NJ\R7)<R/0J*YG^W?$_P#T*/\`Y4HO\*/[=\3_`/0H_P#E2B_P
MJ/9OR^]%<Z_I,Z:BN9_MWQ/_`-"C_P"5*+_"C^W?$_\`T*/_`)4HO\*/9OR^
M]!SK^DSIJ*YG^W?$_P#T*/\`Y4HO\*/[=\3_`/0H_P#E2B_PH]F_+[T'.OZ3
M.FHKF?[=\3_]"C_Y4HO\*/[=\3_]"C_Y4HO\*/9OR^]!SK^DSIJ*YG^W?$__
M`$*/_E2B_P`*/[=\3_\`0H_^5*+_``H]F_+[T'.OZ3.FHKF?[=\3_P#0H_\`
ME2B_PH_MWQ/_`-"C_P"5*+_"CV;\OO0<Z_I,Z:BN9_MWQ/\`]"C_`.5*+_"C
M^W?$_P#T*/\`Y4HO\*/9OR^]!SK^DSIJ*YG^W?$__0H_^5*+_"C^W?$__0H_
M^5*+_"CV;\OO0<Z_I,Z:N;^(/_(CZE_NI_Z,6F_V[XG_`.A1_P#*E%_A6)XQ
MU;7KGPK>Q7OAS[);L%WS_;HY-GSKCY0,GG`_&JA!\R_S1,Y+E?\`D=]%_JD_
MW13ZY>/7/$PC7'A+(P.?[2B_PIW]N^)_^A1_\J47^%3[-^7WHKG7])G345S/
M]N^)_P#H4?\`RI1?X4?V[XG_`.A1_P#*E%_A1[-^7WH.=?TF=-17,_V[XG_Z
M%'_RI1?X4?V[XG_Z%'_RI1?X4>S?E]Z#G7])G345S/\`;OB?_H4?_*E%_A1_
M;OB?_H4?_*E%_A1[-^7WH.=?TF=-17,_V[XG_P"A1_\`*E%_A1_;OB?_`*%'
M_P`J47^%'LWY?>@YU_29TU%<S_;OB?\`Z%'_`,J47^%']N^)_P#H4?\`RI1?
MX4>S?E]Z#G7])G345S/]N^)_^A1_\J47^%']N^)_^A1_\J47^%'LWY?>@YU_
M29TU%<S_`&[XG_Z%'_RI1?X4?V[XG_Z%'_RI1?X4>S?E]Z#G7])G345S/]N^
M)_\`H4?_`"I1?X4?V[XG_P"A1_\`*E%_A1[-^7WH.=?TF=-17,_V[XG_`.A1
M_P#*E%_A1_;OB?\`Z%'_`,J47^%'LWY?>@YU_28>!/\`D$WO_80G_P#0JZ:O
M/?">K:[;Z?=+9^'?M2&\E9G^W1IM8GE<$<X]:W/[=\3_`/0H_P#E2B_PJZD&
MY/\`S1,)+E1TU%<S_;OB?_H4?_*E%_A1_;OB?_H4?_*E%_A4>S?E]Z*YU_29
MTU%<S_;OB?\`Z%'_`,J47^%']N^)_P#H4?\`RI1?X4>S?E]Z#G7])G345S/]
MN^)_^A1_\J47^%']N^)_^A1_\J47^%'LWY?>@YU_29TU%<S_`&[XG_Z%'_RI
M1?X4?V[XG_Z%'_RI1?X4>S?E]Z#G7])G345S/]N^)_\`H4?_`"I1?X4?V[XG
M_P"A1_\`*E%_A1[-^7WH.=?TF=-17,_V[XG_`.A1_P#*E%_A1_;OB?\`Z%'_
M`,J47^%'LWY?>@YU_29TU%<S_;OB?_H4?_*E%_A1_;OB?_H4?_*E%_A1[-^7
MWH.=?TF=-7,Z-_R/OB3_`'+7_P!`-']N^)_^A1_\J47^%8>F:KKJ>+M;EB\.
M^9<R+!YT'VZ,>5A3M^;&&R.>.E7&#L_\UW1,I*Z/0J*YG^W?$_\`T*/_`)4H
MO\*/[=\3_P#0H_\`E2B_PJ/9OR^]%<Z_I,Z:BN9_MWQ/_P!"C_Y4HO\`"C^W
M?$__`$*/_E2B_P`*/9OR^]!SK^DSIJ*YG^W?$_\`T*/_`)4HO\*/[=\3_P#0
MH_\`E2B_PH]F_+[T'.OZ3.FHKF?[=\3_`/0H_P#E2B_PH_MWQ/\`]"C_`.5*
M+_"CV;\OO0<Z_I,Z:BN9_MWQ/_T*/_E2B_PH_MWQ/_T*/_E2B_PH]F_+[T'.
MOZ3.FHKF?[=\3_\`0H_^5*+_``H_MWQ/_P!"C_Y4HO\`"CV;\OO0<Z_I,Z:B
MN9_MWQ/_`-"C_P"5*+_"C^W?$_\`T*/_`)4HO\*/9OR^]!SK^DSIJ*YG^W?$
M_P#T*/\`Y4HO\*/[=\3_`/0H_P#E2B_PH]F_+[T'.OZ3&ZC_`,E(T?\`Z])J
MZBO.[W5==;QMILS^'=ETEO(([?[;&?,4]3NQ@8]*WO[=\3_]"C_Y4HO\*N<'
M9>G=$QDM3IJ*YG^W?$__`$*/_E2B_P`*/[=\3_\`0H_^5*+_``J/9OR^]%<Z
M_I,Z:BN9_MWQ/_T*/_E2B_PH_MWQ/_T*/_E2B_PH]F_+[T'.OZ3.FHKF?[=\
M3_\`0H_^5*+_``H_MWQ/_P!"C_Y4HO\`"CV;\OO0<Z_I,Z:BN9_MWQ/_`-"C
M_P"5*+_"C^W?$_\`T*/_`)4HO\*/9OR^]!SK^DSIJ*YG^W?$_P#T*/\`Y4HO
M\*/[=\3_`/0H_P#E2B_PH]F_+[T'.OZ3.FHKF?[=\3_]"C_Y4HO\*/[=\3_]
M"C_Y4HO\*/9OR^]!SK^DSIJ*YG^W?$__`$*/_E2B_P`*/[=\3_\`0H_^5*+_
M``H]F_+[T'.OZ3.FKR[XP?\`'UI?^Y)_-:ZO^W?$_P#T*/\`Y4HO\*X/XD7N
MI7MQ8'4]*_LYE5]@^TK-OY&?N],5M0@U-/\`5&=62<&>L:9_R"[3_KBG_H(J
MU532B3I%F6&TF!,C.<?**MUSO<U6Q%=?\>LW^XW\J\O^$/\`R%-1_P"N*_\`
MH5>H77_'K-_N-_*O+_A#_P`A34?^N*_^A5M3_AR^1G/XXGJM%%%8&H4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!7,_#S_D3+3_`'Y?_1C5TU<S\//^1,M/]^7_`-&-5KX'\OU)?Q+^
MNQTU%%%04%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5S-I_P`E
M)U#_`+!\?_H5=-7,VG_)2=0_[!\?_H57#KZ$RZ'34445!04444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%<S\/
M/^1,M/\`?E_]&-735S/P\_Y$RT_WY?\`T8U6O@?R_4E_$OZ['34445!04444
M`%%%%`!1110`4444`%%%%`!1110`4444`%<W\0?^1'U+_=3_`-&+725S?Q!_
MY$?4O]U/_1BU=/XUZDS^%G0Q?ZI/]T4^F1?ZI/\`=%/J"@HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@#F?`G_()O?^PA/_`.A5TU<SX$_Y
M!-[_`-A"?_T*NFJZGQ,F'PH****@H****`"BBB@`HHHH`****`"BBB@`HHHH
M`*YG1O\`D??$G^Y:_P#H!KIJYG1O^1]\2?[EK_Z`:N.TO3]43+='34445!04
M444`%%%%`!1110`4444`%%%%`!1110`4444`<OJ/_)2-'_Z])JZBN7U'_DI&
MC_\`7I-745<]EZ$QW84445!04444`%%%%`!1110`4444`%%%%`!1110`5Y=\
M8/\`CZTO_<D_FM>HUY=\8/\`CZTO_<D_FM;8?^(C*M\#/1],_P"07:?]<4_]
M!%6JJZ9_R"[3_KBG_H(JU63W-%L177_'K-_N-_*O+_A#_P`A34?^N*_^A5ZA
M=?\`'K-_N-_*O+_A#_R%-1_ZXK_Z%6U/^'+Y&<_CB>JT445@:A1110`4444`
M%%%%`!52\U;3]/=4O;ZUMG8959IE0D>N":MUQ>O_`-F_\+`L/[8^R?9OL+_\
M?6W9NW<?>XS50CS,F3LCK;2^M;^(RV5S#<1@[2\,@<`^F14]<)ISZ;'X]DGT
M`Q)I\-F6OGM_]1G^'&/ESCGCW]ZMIK_B6^LFU;3]/T\::,ND,SOY\J#J01\H
MSSC/Z]Z=/702F=A17+:OXP>VT72=2T^V$Z7TRH8B,L<@_*,'KD8[U0\3MXF?
MPC?M?)I,<97+K&9"RQ^GINSCVH5-NUP<UT.XHKEK*]US3?"=S>7ZZ:P@M!):
MB`.<X7/SY_#I[UH3:Q/'X-.K!(OM'V(7&T@[-VS.,9SC\:3@QJ2-FBN9O_$M
MW!H^C-;0V[7^JA%0RDK"C%023W[X`SFKVGW>LV]O=OKUO:8A3S$DLV8JXP<K
MM;G(Q]#FER-*X<R-BJ8U6S.K'3/.'VT1>=Y6T_<SC.<8_6L#1]8\2:K':ZC'
M::6VFW#C]TDK^>B9QDL?E)'4CVQUJV+_`/XK]K'[+:\6'F?:/+_>_?QMW?W?
M:GR6NF+FN=!17(6FO>(M8,]YI%IIC6,,S1>3-(XG?:>>1\JD]L]/>NN&2!D8
M/I2E%QW*4KBT445(PHHHH`****`"BBB@`KF?AY_R)EI_OR_^C&KIJYGX>?\`
M(F6G^_+_`.C&JU\#^7ZDOXE_78Z:BBBH*"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`*YFT_P"2DZA_V#X__0JZ:N9M/^2DZA_V#X__`$*KAU]"
M9=#IJ***@H****`"BBB@"M/J-G;7,=O<7=O%/+CRXWD56?G'`)R>:LUY[XST
MHZQXP6WC_P!>NF-+"0>0ZN2/\/QKJ-+\10W?A*/69B%18"\H'9E^\/S!K24+
M131"GJTS1&HV;7ILUN[<W:C)@$B[QQG[N<]*LUYKH%I+'XQT>^NQB[U&&>ZE
M]MV=H_!<5TEUKNK:AK-SI_AVVLR+/`N+F\9MFX_P*%YS[_7\7*G9V0E.ZU.F
MHK`T'7KJ]N;W3M4MXX-2LL%Q$28Y%/1ESSCV/_UAC:;XE\4ZWHHO[#3]/18U
M8N9RX\\@GB,`\8`QECR3[5/LV/G1W%%<\WC"W7PA%KGDN?-`5+<'EI,XV9QZ
M@\XZ=JH76N^)]&M5U+5[#3FT\$>=%;,_G1*>YS\IQD9Q^@YH5.3&YH["H;NZ
MAL;26YN7V0PJ7=L$X`Z\#FL76?$%Q%<V6GZ+!'<7UZGF(TI(BCC'\;8Y_`?_
M`%C3U*773X9UN/7(+$`6C-'-:,VUL@Y4AN<CUZ<T*#TN#EV.GM;F*]M8KFW?
M?#*@=&P1D'D'!J6N3BUUM%\':(MO;FZO;J&*&W@#8W-M')/8#_..M#Z]KVAW
M5J?$-MI[V5S((?.LB^87/3<&ZCZ?X`OV;Z"YT=917,:OXAU6W\4+H^F64-PT
MMJ)4:0D"-MQ!9SG[H`Z`9)J70];U&36KG1];@MDO(HQ/'):EO+D0\=&YR#_G
MCE<CM<?.KV.BJKJ6I6NDV3W=]+Y4"$!GVEL9.!P`36)>W7BXM/-96>DQ6\9;
M9'<2.TK@=\KA1GL#T[UF>*=677/AD=02,Q"8QDH3G:1(`1GOR*<:=VKB<[)G
M;@A@".AI:9%_JD_W13ZS+"BBB@`HHHH`*YGX>?\`(F6G^_+_`.C&KIJYGX>?
M\B9:?[\O_HQJM?`_E^I+^)?UV.FHHHJ"@HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`*YOX@_\B/J7^ZG_HQ:Z2N;^(/_`"(^I?[J?^C%JZ?QKU)G\+.A
MB_U2?[HI],B_U2?[HI]04%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`<SX$_Y!-[_V$)__`$*NFKF?`G_()O?^PA/_`.A5TU74^)DP^%!1
M114%!1110`4444`%%%%`!1110`45S7CJZFLM(MYK:5XI%N5PR'!^ZU9FF>.I
MHPJZG%YJ'_EM$,'\5Z?EBLI5HQERR)<DG9G<454L=2M-1A\RTG25>^T\CZCJ
M/QJW6J=R@KF=&_Y'WQ)_N6O_`*`:Z:N9T;_D??$G^Y:_^@&KCM+T_5$RW1TU
M%%%04%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'+ZC_R4C1_^O2:NHKE
M]1_Y*1H__7I-745<]EZ$QW84445!04444`%%%%`!1110`4444`%%%%`!1110
M`5Y=\8/^/K2_]R3^:UZC7EWQ@_X^M+_W)/YK6V'_`(B,JWP,]'TS_D%VG_7%
M/_015JJNF?\`(+M/^N*?^@BK59/<T6Q%=?\`'K-_N-_*O+_A#_R%-1_ZXK_Z
M%7J%U_QZS?[C?RKR_P"$/_(4U'_KBO\`Z%6U/^'+Y&<_CB>JT445@:A1159M
M0MEU)+`R_P"E/&91&%)^0'&<XP.:`+-%%%`!144EU!%/%!)-$DTV?+C9P&?'
M7`[XJ6@`KD=5L[:^^(UA#>6\-Q%]@<[)4#KG=UP:ZZBJC+E$U<H3Z5!_8USI
M]G#%;1RQ.@6)`J@L",X'UKS?3;;P9962VOB2QFM=5A^2:-S.2Y[,-IQ@_P">
M.:]7HJH5'%6)E"YQ.LP6]OI_A6.SMI;6W&HPE(9@0Z`Y.#DDYY]:WO%MM+=^
M%=2AMT:25H3M11DMCG`'K6Q4,EW;Q7$4$D\232Y\N-G`9\=<#J<4N=W7D/EW
M.9L]4M/%/@NZLM+E,ERED(WC*,NURA`&2,'D'I6/)XKM)O`DFE0PW#ZE%9&"
M>W$3`P[5VLS$C``QZYY`KT2BFII=!.+[G'W5WHL/@[1H/$,#/9S6T?[SRV98
MV"#'*\J3SC'O4/A*]*7&IG3I;^^T&"(-;F52S;P.4CW`$@`8QVX]<GMJ*.?1
MH.36YYHU]HYU*VD\%3746I33IYUI#&ZQ,O\`$9%(V@`$].F?Q'0+_P`E4?\`
M[!?_`+/75T4W4N)0/--9U+0999KK0GO['Q&SX$$$3J\C[N5=<;3TR?7WZ5Z-
M;&4VL1N`!-L'F`=-V.?UJ6BIE/F2148V84445!0445%!=07/F?9YHI?+<H^Q
MPVUAU!QT/M0!+14-W=16-I+<W#%(85+NP4G`'4X'-.@GCNK>.>!P\4BAT8="
M#R#18"2BBB@`KF?AY_R)EI_OR_\`HQJZ:N9^'G_(F6G^_+_Z,:K7P/Y?J2_B
M7]=CIJ***@HP-6\2S6NJC3-+TR34;X1^;(@E6)$3W8]^G%-G\27UKX>N-1N-
M$FBGM7Q-;M*/N\996`(8`']#Z5%K>A:G'K/]M^'YX5NS%Y<UM./DG4=.>QZ>
MGU'.;>@ZXOB&WN[>[LVMKJW;R;JVD.X#.>A[@C/^>:ULK)I&=W>UR?4=?M;#
MP\VK@^;!Y8>,`X\PG[H'UR*R]=\8RZ!9Z;-<Z6[2W8+21++S"``3_#\V`?;I
M6%I&E7+^)4\.W+!].TB9KQ,MDN#@QJ?H236WXGC2;Q7X;CD4,CR3JRGH08^1
M5*,4[/7J+FDU<U]3UJ.Q\/2ZM"@N(DB$J*&V[P>G.#CK5RRN?MEC;W.W9YT:
MR;<YQD9QFO/[EGT;P[X@\-W#$BWA,]FQ/WX6;I^!XKIEUO\`L?0]*_XENHWO
MFVR?\><'F;,*OWN1C.?T-3*GIH-3UU+VNZY;Z#9+/,DDLDCB.&&(9>5ST`%9
M<7BR\MK^UM]=T2338[MO+AF%PLRE^RMM'RY_SWQ0U.__`+4\2^%)VM;JV1I9
MSY5U'L<$*,9'\JN?$?CPJ6'WUN(BGKG=VIQBM(M;B<GJUT+VL^)&L-0BTW3[
M"34=1D3S/)1PBHGJS'@>W_ZLIHWB1]0U&;3-0L)-/U&)/,\EG$BNG]Y6'!Z_
MYYQ0T3+?$/Q"7^\L4`7/IMY_6EU;Y?B1H)3JUO.'QZ8./UHY5\-NE_U'=[^8
MX^*=7N+^^@TSP[]KCM)S`TOVU(\D>S#WK>TRXN[JR26_LOL5P2=T/FB3;SQ\
MPXYK`?POK-M>W]QI7B$6JW<S3F$V2.-Q_P!HDGL.WX5>\*ZU<ZQ97*WT<:7E
MG</;S>5G8Q7N,TI)6O']0BW?4L2WDZ^*;:S5\6[VDDC)@<L&4`YZ]":J>(_M
MMJD5Q:ZG=0B6YAA,:I$54,P4D;D)SSW-79[)QK\.I,\:V\-K)&^3SDLISZ8P
MI[U2\J]\0:!92RI%#*;F.XVG('EK)N'J<E0/Q]*2MHQN^J-FU@DMX=DMS+<M
MG/F2A`WT^50/TJ:BBLRPKF;3_DI.H?\`8/C_`/0JZ:N9M/\`DI.H?]@^/_T*
MKAU]"9=#IJ***@H****`"BBB@#E+G_DJ-G_V#F_]"-8-W872>)KCPLB-_9^H
M7*WI8=HN2Z^V6`'X>]>DT5JJENA#A<Y34@%^)&B`#`%K,`!]#5.TU:W\'Z_J
M\.M>9!;WLYN;:X$;,CYZK\H)R/\`/;/;T4N?2S0<O5')>'R^K^(]3UZ.*2.Q
MDA6WMFD3:9@.2X!YQZ'_``J7X??\B/:?]M/_`$-JZBF2S1P1/+-(D<:#<SN<
M!1ZDTG.ZL"C;4\YLK&ZO/A=ITEE"9YK2Z^TB)1DN%D;(`[]>E:&M^+;'Q)H<
MNEZ()KK4+Q1'Y'DL/*!(R7)&`!Z@GG\Z[%K^T2*&5KJ!8YR%B<R#$A/0*>^?
M:K%4ZFMVA<FEDSB]3!\+Z[I.J7*.]A%9?8IYD4GRCD88@=B>/\C,^I>(K?7O
M#6MG3XY7M(K1L73(41V(.54$9..]=;12YUHVM1\K[G!7<<]MH'A768H))XM.
MC5ITC&6",@!8#VQ4FMZW:>,H[72M!:2Z9[A))Y1$RI`BG))+`<GM^-=S5=;^
MT>&:9;J`Q0DK*XD&V,CJ&/;'O34^MA<G2YSY_P"2HC_L%?\`M2@_\E1'_8*_
M]J5TL4L<\22PNLD;@,KJ<AAZ@T^IY_RL/E/+`=%N;B_7Q3!>W>O><ZQ6X$N2
MO\`C"\;><\U/,"OP6A!&"'`(_P"VQKTRBK]MMH3[,9%_JD_W13Z**Q-0HHHH
M`****`"N'\$Z]9V'A>WMIB_F(TA.U<XRY(_0UW%>*Z,\Z.A@4L,?,O8BL<15
ME3I^[W_S,JC:::/4?^$JT_\`Z;?]\4?\)5I__3;_`+XKC?M4O_/F?^^__K4?
M:I?^?,_]]_\`UJ\_ZW7[+^OF1[29V7_"5:?_`--O^^*/^$JT_P#Z;?\`?%<;
M]JE_Y\S_`-]__6H^U2_\^9_[[_\`K4?6Z_9?U\P]I,[+_A*M/_Z;?]\4?\)5
MI_\`TV_[XKC?M4O_`#YG_OO_`.M1]JE_Y\S_`-]__6H^MU^R_KYA[29V7_"5
M:?\`]-O^^*/^$JT__IM_WQ7&_:I?^?,_]]__`%J/M4O_`#YG_OO_`.M1];K]
ME_7S#VDSLO\`A*M/_P"FW_?%'_"5:?\`]-O^^*XW[5+_`,^9_P"^_P#ZU'VJ
M7_GS/_??_P!:CZW7[+^OF'M)G9?\)5I__3;_`+XH_P"$JT__`*;?]\5QOVJ7
M_GS/_??_`-:C[5+_`,^9_P"^_P#ZU'UNOV7]?,/:3.R_X2K3_P#IM_WQ1_PE
M6G_]-O\`OBN-^U2_\^9_[[_^M1]JE_Y\S_WW_P#6H^MU^R_KYA[29V7_``E6
MG_\`3;_OBC_A*M/_`.FW_?%<;]JE_P"?,_\`??\`]:C[7+_SYG_OO_ZU'UNO
MV7]?,/:3.R_X2K3_`/IM_P!\5C>+=7M]8\,WEC:"0SRA0H9<#A@>OT%8WVN7
M_GS/_??_`-:C[7+_`,^9_P"^_P#ZU-8RNG>R_KYB=235CL$\46"QJ#YV0`/N
M4[_A*M/_`.FW_?%<;]KE_P"?,_\`??\`]:C[7+_SYG_OO_ZU+ZW7[+^OF/VD
MSLO^$JT__IM_WQ1_PE6G_P#3;_OBN-^UR_\`/F?^^_\`ZU'VN7_GS/\`WW_]
M:CZW7[+^OF'M)G9?\)5I_P#TV_[XH_X2K3_^FW_?%<;]KE_Y\S_WW_\`6H^U
MR_\`/F?^^_\`ZU'UNOV7]?,/:3.R_P"$JT__`*;?]\4?\)5I_P#TV_[XKC?M
M<O\`SYG_`+[_`/K4?:Y?^?,_]]__`%J/K=?LOZ^8>TF=E_PE6G_]-O\`OBC_
M`(2K3_\`IM_WQ7&_:Y?^?,_]]_\`UJ/M<O\`SYG_`+[_`/K4?6Z_9?U\P]I,
M[+_A*M/_`.FW_?%'_"5:?_TV_P"^*XW[7+_SYG_OO_ZU'VN7_GS/_??_`-:C
MZW7[+^OF'M)G9?\`"5:?_P!-O^^*/^$JT_\`Z;?]\5QOVN7_`)\S_P!]_P#U
MJ/M<O_/F?^^__K4?6Z_9?U\P]I,[+_A*M/\`^FW_`'Q1_P`)5I__`$V_[XKC
M?M<O_/F?^^__`*U'VN7_`)\S_P!]_P#UJ/K=?LOZ^8>TF=E_PE6G_P#3;_OB
MC_A*M/\`^FW_`'Q7&_:Y?^?,_P#??_UJ/M<O_/F?^^__`*U'UNOV7]?,/:3.
MR_X2K3_^FW_?%'_"5:?_`--O^^*XW[7+_P`^9_[[_P#K4?:Y?^?,_P#??_UJ
M/K=?LOZ^8>TF=)X&.RPO8F!#_:Y)?^`N<C^5=/7,^#Y7E^V;X?*QLQSG/WJZ
M:O2HU)5(*<]V:T_A1C?\)5I__3;_`+XJS8:U:ZC.T5OYFY5W'<N.,@?UKA/M
M<O\`SYG_`+[_`/K5N>$IWDU24/;F,>23G=G^)?:N&EB:TIJ,DK&<:DF[,Z^L
MF;Q)8P3R1/YNZ-BIPG<'%:U>>ZE<RKJEV!:%@)G&=_7YC[5TXFK.FDX%U)..
MQU]IK]G>W200^9O?.-R8'`S_`$K3KA_#MQ(^NVZM;%`=WS;LX^4^U=Q3PU2=
M2%YCA)R6IF7>OV=E=/!-YF],9VID<C/]:9#XDL9YXXD\W=(P493N3BN=\17$
MB:[<*ML7`V_-NQGY1[55TVYE;5+0&T*@S(,[^GS#VKEEB:RJ.*2M<S=25['H
M59]_K5KITZQ7'F;F7<-JYXR1_2M"N0\6SO'JD02W,@\D'.['\3>U=>(J2IPY
MH[FDVTKHJ^,M7M]4T>.*U$A9)@[97'&UA_45RU@0Z>6WX5K_`&J7_GS/_??_
M`-:LKS(OM#/$OEJ.2-V0/I7ESJ3J:R1@Y.6Y,J2VLPFMI'AD'1D.#72Z9XW>
M(K%JL.1T\Z(?S7_#\JXU_$*9(%N2/7?U_2H_[8$O2V/_`'W_`/6JZ4ZM/8<7
M*)[%9W]M?PB6UF25#W4]/KZ5A:-_R/OB3_<M?_0#7"V%Q=I<"6R$D$G]Y6Z_
M7U'UKI_"-[+)XIUEKMPUR\5OYA`P,A3C],9]Z]3#U_:)IKI^J-%+F:.YHI%.
M1FEK0U"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#E]1_Y*1H_P#UZ35U
M%<OJ/_)2-'_Z])JZBKGLO0F.["BBBH*"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"O+OC!_Q]:7_N2?S6O4:\N^,'_'UI?^Y)_-:VP_\`$1E6^!GH^F?\@NT_
MZXI_Z"*M55TS_D%VG_7%/_015JLGN:+8BNO^/6;_`'&_E7E_PA_Y"FH_]<5_
M]"KU"Z_X]9O]QOY5Y?\`"'_D*:C_`-<5_P#0JVI_PY?(SG\<3U6BBBL#4*Y;
MPU(U_K_B'4L!F6<6D0)Z+&.F?<G-=37*^!SL?78&`$D>IRD_0XQ_*KC\+)EN
MB[IWB>.]\,3ZO-!Y'V<2>;"7W;2F>,X[\=N]%CXGBO?";ZXT)C$<;L\);)#+
MGY<X]O3O7+:BK6FMZGX=4;8]5NX)H@/[C',I_P#'#1JH,6J7_AA<A=3OXID`
MSQ&WS2'\"GZUK[.+_/Y&?._Z[EO7-9*:OX4U.YM)5:2.9_L\7[Q\LBX4<#)Y
M%;6F>)KF;65TO5]*?3;F6,R09F659`.HR.A'I_+C-?75"^-O#"J,`?:`!_P`
M4NO#_BN?#)[_`.D?^@"EHTE;H_U'JFW?K_D3ZAXGG359--T;2Y-3NH%#3XE6
M)(L]!N/4^W_UZL:'XCCU;[5#<6[V-]9G%Q;RG.ST(;H1[_\`UB<70]2M-#\2
M:]9ZK/%:2S7/VF)YV"+(AZ88\<?X^AJ*U']O^(/$=YII#VSV?V-)E^[+)CG!
M[XZ9^E#@K;?,%)EP>,;^\26ZT?P]<7NGQDC[09UC+XZE4()8>F.OUJ[<^+;1
M/"G]O6J&:#Y<HQV$98*0>#R,_I6=X5\3Z19>$[:*\O(+6>SC,<T$K;9`R]?E
M/)S[?3K6)-!+#\)KZ:6)HA<W'VB.,CD(TJX_Q_&GR*]K=1<SM>_0W[CQK<6J
MI>SZ'=1Z,[!1>-(N[!X#&+J`3W)Z8]<5:U6XLAXMT))+(3W$JRF"Y$I'E`+D
M_*.&S[]*S/$WB72]1\'R6UG<I/=7BK#%;*?WN\D<%>HQCO\`U%.OH&MO%OA&
M"0Y>*"5&YSR(P*2BNUM_R&V^]]BY=>+YTUR]TBQTB6\O+?84"2A592NXEF(P
MF,X[Y-7=#\1IJL%W]IMGLKJR<K<P.V[9W!!'4$#K_P#KJCH7_(]^)?\`MW_]
M`JM9$IXH\7M'#YS"*$B(?QGRCQQZTG&.UNB_0$WN)<^.-1CTY]4M_#DTNECE
M+A[I49ESC<4P2!G].:ZC3;F:\TZ"XN;<6TLB[C$)!(%]/F'!XYKR_3[_`$V;
M2;;3;_Q=-%8LJB6Q%DP*]RGFX)P#^E>JVQA:VB-LR-!L'EE#E2N.,'THJQ4=
M+?F%.3?4H:]KL.A6B221R3SS.(H((_O2N>@'I]:KZ9K6ISWA@U70I=/0QEUF
M%PLR<=0Q'W>O'KSZ50\8RBPU30=4N`WV.UN669@,A-ZX#'VS5V\UJPU>*YTK
M3;J.ZNI[60@P,'5!C`W,#@<D4E'W5H.^NY1'C&_O$ENM'\/7%[I\9(^T&=8R
M^.I5""6'ICK]:MWGB^VC\*#7;.(W$1*CRV;802VT@\'!%4/"OB?2++PG;17E
MY!:SV<9CF@E;;(&7K\IY.?;Z=:Q7LKG_`(55>R^0RB:X-VD>.5C+@_R&?I5\
MBO9JVI/,[;]#MO$6M?V#HTE_Y'G[&4;-^W.2!UP?6HM:U]]-N+>SLK&2_O[@
M%D@5P@"CJ68\"N<\<>)-+U#PGY-G=QW$TYC<)$=Q0!E)+8^[V'/<T[QG>+9^
M)=/EDOWTG9;.8[Y8#,&8L`8RO0C'/XBIC3VNNXY3WL^QJ:-XGU'4==ETR[T/
M[&T"AI6-VKE01\N!@;@>F1TK%\/ZS>6=UKEKIFDS:C<_VE-(X$@B1%S@9=N,
MDCI]:TO!L^F75Y>746M_VKJ<P`ED>+R2$'0*A`P.><=ZF\$]=>_["LW]*;LK
MZ=NXE=VU-31-8@\1Z1YZQ-'DM%-#)U1APRFL[P+,W]C3V+MN;3KJ2USZA3D?
MH<?A3/!`P==`Z?VK-_2D\$@O+KTX^Y)J<NWG@XQS4R22DBD[V9U-%%%9&@5S
M/P\_Y$RT_P!^7_T8U=-7,_#S_D3+3_?E_P#1C5:^!_+]27\2_KL=-1114%&#
MJ$7BA-0E?2KC2Y+63!6.\1PT1Q@@%.H/7)]:D\/:'-I9N[J^N!<:A?.))W08
M08'"J/09/-;5%5S.UB>57N8EIHUQ!XOO]59XC!<P)&B@G<"N,Y&,?K3M6T>>
M^U[1[V)XQ%8O(T@8G<=RX&./\*V:*.9WN'*MCF/&GA27Q):Q-93)!>Q94,Y(
M5T;[RD@'Z]/YUOZ?;M::=;6[D%H8E0D="0`*L44.3:Y1J*3N8WB70GUJV@:U
MN/LU]:2>=;S8R`WH?8_YSTK._L/7-8OK1_$5QIZVEI()E@LE?]ZXZ;BW0#VZ
MUU5%-3:5A.*;.<U;0M177%UG0;BWCNVC\F>&Z!\J5>Q)7G(X_P`]7Z-H=^NK
MRZQKEQ;RWS1^3'';J1'"F<G!/))]_>N@HHYW:P<JO<YNX@\8)++%:W>CR0%C
MLFFC=95!]A\N1G`]<<UH>']#30=/:`3-<32R---,PP9'/4X[?2M2BDY-JP**
M3N%%%%24%%%%`!7,VG_)2=0_[!\?_H5=-7,VG_)2=0_[!\?_`*%5PZ^A,NAT
MU%%%04%%%%`!1110`5C:KJ^HVMT+?3-$GOW"AW<RK#&`<\!FZGCI6S7$Z[?&
M[\72:9J&MRZ/8PVZRQF*80M,QX)WGL.F/:K@KLF;LC>T+7_[86ZBGM)+.]LW
MV3V[L&VD\@AAU!'?_P#76):>.[[4M-^V:;X>GN4B5C<'SPJH1GA21ES@9.!Q
MD5#X#,!U;Q";2[N+R#=%LN)V+/)\K#).!GG-:/P_&?`UH#T_>?\`H;5I*,8W
MT[$)N5M>Y%XE\07%SX(.HZ+#*\5Q&2TRS"-[<>OJ3GC`-.CU.]N?"%[)KFBE
M+>.S#`-=AS<C;SRO*]OSK(TY&?X-3A02?)E.!Z!R36O=:G9:A\/;L6=U#,T>
MG_.J."R'9T8#IT/6G9+2W45V];]#.\17=M#X5\,74<!@MDN[>01*2Y1=I.`>
MIK53Q=<P7]K'JVBSZ?:7C^7!</*K?,?NAU'W"1V)X_,C&UB86_@WPG,RNRQ7
M%L[!%R<!"3@5:\6:Q8:]::=IVE745W<W5U&ZK"P8HHY+-_=P/7GKZ&GRIV37
M<5[:W[&UK/B1K#4(M-T^PDU'49$\SR4<(J)ZLQX'M_\`JRFC>)'O]1ETW4;"
M33M1C3S!"[AU=/56'!_SZ'&7]MM]$^(E])J<B6\-_;1^1/*=J$KPR[CP/Q]O
M44L=U!KGQ#MI],D2>"PM&6>>,[DW/]U<]#Z\>_I4<JMMTW*YG??J69/%MW/>
MW*:1HD^H6EH_ESW"S*GS#[P13R^/;K^1.3X>NK:3P9XCNIK<SVS7=Q(T+,4+
MKM!P3U%2^$-;T_0M(O;'5;J*TNK2YE,B2MM9@3D%1U;/MG]15729?/\``7BB
M8(Z"2XN7"N,,`5!Y'K5\MKJW8F]];]SH5UVTTCPIIMQ#:28GCC2ULXCO8L5X
M4$]<=S26/B:[.J0V&M:1)ILMR#]G;SUF20CD@E>AKFM:@'_"-^$[R>>YM[.!
M46>>V)#Q!D`#`CIT_6M"UTS0'U?3S_PE-]J-PDP>"%[Y9QN`)Y`!QP#SQ2Y(
MVOZCYG<T[KQ1?/J-U:Z+HDFHK:-LGE-PD0#XS@`]:WK6<W5I%.8I(C(@;RY5
MPRY'0CL:XW66TB&[O]2TKQ$NEZG&6$T7F`K*Z@CYHF^\>P(^HR:Z?0+Z?4]!
MLKRZB$4T\0=E`P.>X]CU_&HG%))I%Q>MF:-%%%9%A1110`4444`%>?\`A6QC
MD\)6]PJ8E=I`2.^'('Z"O0*Y7P!$)/!EIG^_+_Z,:FX1G!\RZK]2&DY*YFNE
MRK$!5Q_NTS%U_<7_`+YKLS81G^$?E1_9\7]T5C["G_*/DCV.,Q=?W%_[YHQ=
M?W%_[YKL_P"SXO[HH_L^+^Z*/84_Y0Y(]CC,77]Q?^^:,77]Q?\`OFNS_L^+
M^Z*/[/B_NBCV%/\`E#DCV.,Q=?W%_P"^:,77]Q?^^:[/^SXO[HH_L^+^Z*/8
M4_Y0Y(]CC,77]Q?^^:,77]Q?^^:[/^SXO[HH_L^+^Z*/84_Y0Y(]CC,77]Q?
M^^:,77]Q?^^:[/\`L^+^Z*/[/B_NBCV%/^4.2/8XS%U_<7_OFC%U_<7_`+YK
ML_[/B_NBC^SXO[HH]A3_`)0Y(]CC,77]Q?\`OFC%U_<7_OFNS_L^+^Z*/[/B
M_NBCV%/^4.2/8XS%U_<7_OFL_7KV]TW1KB[B6/?&!C<N1RP']:]#_L^+^Z*Y
MWQ[91Q^"M18*,@)_Z&M5##TG)+E)E%)-V,U?M14'8O(_NTN+K^XO_?-=A'I\
M7E)\H^Z*?_9\7]T5/L*?\I7)'L<9BZ_N+_WS1BZ_N+_WS79_V?%_=%']GQ?W
M11["G_*')'L<9BZ_N+_WS1BZ_N+_`-\UV?\`9\7]T4?V?%_=%'L*?\H<D>QQ
MF+K^XO\`WS1BZ_N+_P!\UV?]GQ?W11_9\7]T4>PI_P`H<D>QQF+K^XO_`'S1
MBZ_N+_WS79_V?%_=%']GQ?W11["G_*')'L<9BZ_N+_WS1BZ_N+_WS79_V?%_
M=%']GQ?W11["G_*')'L<9BZ_N+_WS1BZ_N+_`-\UV?\`9\7]T4?V?%_=%'L*
M?\H<D>QQF+K^XO\`WS1BZ_N+_P!\UV?]GQ?W11_9\7]T4>PI_P`H<D>QQF+K
M^XO_`'S1BZ_N+_WS79_V?%_=%']GQ?W11["G_*')'L<9BZ_N+_WS1BZ_N+_W
MS79_V?%_=%']GQ?W11["G_*')'L<U\/+^YU"UU"2Z"`I/Y:[5QP":[&N/\$6
M4;Z5>$J.+^<?^/5TG]GQ?W16S@H/ECL$/A1QF+K^XO\`WS6QX:$PU&3S5`'E
M'H/<5M_V?%_=%']GQ?W162HTXNZ0**1<KB+\7/\`:-SM5<>:V./<UU?]GQ?W
M11_9\7]T54H1G\2&TGN<YH0G_MB#S%`7YLX'^R:Z^J?]GQ?W11_9\7]T41A&
M"M%`DEL<YKHG_MB?RU!7Y<9'^R*KV`N?[1MMRKCS5SQ[BNK_`+/B_NBC^SXO
M[HJ?8TV[V%RHN5S'B43'48_*4$>4.H]S6W_9\7]T4?V?%_=%5**DK20VD]SS
MS6Y;F&PYPH=MI(&,C!_PKF)Y&,0A3J?O5Z3XRTIYM+MX[6)GD:X`PHSQM:N8
M30#:8,P&_P!.M<52C[]H(RE'70Y^VTQY2"1Q6Q:Z6D>.-QK6MM.>3`5<#Z5N
M66A]"PK:&&2UEJ4H=S$M=/D<@*N!4OAFR=?&6N*<Y5+?/_?)KL;?3HX@/E%8
MVB(%\>>(P.R6W_H!KK@DD[=OU13T:.EC7:HI]%%24%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`'+ZC_R4C1_^O2:NHKE]1_Y*1H__7I-745<]EZ$QW84
M445!04444`%%%%`!1110`4444`%%%%`!1110`5Y=\8/^/K2_]R3^:UZC7EWQ
M@_X^M+_W)/YK6V'_`(B,JWP,]'TS_D%VG_7%/_015JJNF?\`(+M/^N*?^@BK
M59/<T6Q%=?\`'K-_N-_*O+_A#_R%-1_ZXK_Z%7J%U_QZS?[C?RKR_P"$/_(4
MU'_KBO\`Z%6U/^'+Y&<_CB>JT445@:A6%9Z9<V'C"]NHH]UC?PJTC[Q\DJ\=
M.O(K=HIIV$U<@>RMI;J.ZDMH6N(QA)60%U'H#U'6AK&U>\2[>VA:Z1=JS&,%
MU'/`;J!R?SJ>BB['8BDM8)9XIY((GFASY<C("R9ZX/;-$EK!+/%/)!$\T.?+
MD9`63/7![9J6BE<"M>:;9:B$%]9V]R$SM\Z)7VYZXR*EAABMH4A@C2*)!A41
M0JJ/0`5)11<"E-H^FW%U]IGT^TEN,@^:\*L^1TY(SQ5#QEIUUJOA>ZM+&+S9
MY"FU-P7.'!/)('05N452DTT^PFDU8IQ:58QW*W8LK9;O',XB7S,XQ][&>G%3
M26EO+<13R01/-%GRY&0%DSUP>HS4U%*["Q%':P13RSQP1)-+CS)%0!GQP,GJ
M<53U/2ENM/U!+,1V]W=Q%#.JX8G&!N(Y.*T:*$V@L<7"?$L.B+HJ>'+14$7V
M?[0UVABQT+E,;B.^.M=)H6F'1M#M+`R>8T$85F]3U./;-:%%5*=]!*-ADL4<
M\3Q3(LD;@JR,,A@>H(J&STZST]66QM+>V5SEA#&$!/O@59HJ+E%*;1]-N+K[
M3/I]I+<9!\UX59\CIR1GBKG6EHIW"Q1CT/2XH9(H]-LDBEQYB+`@5\'(R,<X
M-8NL66K6GB>/6=.LH]23[/\`9_L[3")HCG)92>.>`>]=1134FF2XIG+Z;I^J
M:EXFCUK5;*'3Q;PM#'`LHDD?/=F'&.3@5T<%K!;>9]G@BB\QR[[$"[F/4G'4
M^]2T42DV-1L4KB#[#87;Z99QFX<-((T"IYDA'4G@9)[FJWAG26T70+:TD.9@
M"\ISGYV.6_4XK6HI<SM8+:W"BBBD,*YGX>?\B9:?[\O_`*,:NFKF?AY_R)EI
M_OR_^C&JU\#^7ZDOXE_78Z:BBBH*"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`*YFT_Y*3J'_8/C_\`0JZ:N9M/^2DZA_V#X_\`T*KAU]"9=#IJ
M***@H****`"BBB@`JM>:;9:B$%]9V]R$SM\Z)7VYZXR*LT47L!#%:6\#N\,$
M4;.`'9$`+`#`!]<#I2V]K!:0""V@BAA7.(XT"J,]>!4M%%P(K>U@M(!!;010
MPKG$<:!5&>O`J"'1].MH98H-/M(HIAB5$A51(/1@!SU/6KE%.["Q`;*U,<,9
MMH=D!#1+Y8Q&1P"H[8]J9;Z786EP\]M96T,TF=\D<2JS9.3D@9/-6J*+L5B"
M[LK6_B$5Y;0W$8.X)+&'&?7!I;6TM[*$0VD$4$0.0D2!5'X"IJ*5QE6;3+&X
MNTNI[*VDN(\;)7B4NN.1@D9%/^PVHBFB^S0^7.2TJ>6,2$]2P[Y]ZGHIW86(
MA;0"V^S"&,0;=GE!1MVXQC'3&.U06FD:=I\IDLK"TMY&&TM#"J$CTR!5RBB[
M"Q2GT;3+JY^T7&G6<L_!\UX%9N.G)&:NT447"P4444@"BBB@`HHHH`*YGX>?
M\B9:?[\O_HQJZ:N9^'G_`")EI_OR_P#HQJM?`_E^I+^)?UV.FHHHJ"@HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`*YOX@_\`(CZE_NI_Z,6NDKF_B#_R
M(^I?[J?^C%JZ?QKU)G\+.AB_U2?[HI],B_U2?[HI]04%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`<SX$_Y!-[_P!A"?\`]"KIJYGP)_R"
M;W_L(3_^A5TU74^)DP^%!1114%!1110`4444`%%%%`!1110`R1=RD5D3:4)I
M=Q%;5)@4`4;?3XX@/E%7%0+VI]%`!7,Z-_R/OB3_`'+7_P!`-=-7,Z-_R/OB
M3_<M?_0#5QVEZ?JB9;HZ:BBBH*"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@#E]1_Y*1H_P#UZ35U%<OJ/_)2-'_Z])JZBKGLO0F.["BBBH*"BBB@`HHH
MH`****`"BBB@`HHHH`****`"O+OC!_Q]:7_N2?S6O4:\N^,'_'UI?^Y)_-:V
MP_\`$1E6^!GH^F?\@NT_ZXI_Z"*M55TS_D%VG_7%/_015JLGN:+8BNO^/6;_
M`'&_E7E_PA_Y"FH_]<5_]"KT^\#M93B,$N8V"@>N.*\6TC2?%^D2R/IEC>V[
MNN'/E#D?\"%;T5>$E<RJ.TDSV^BO)?M'Q%]+W_OVG^%'VCXB^E[_`-^T_P`*
M7L/[R'[7R9ZU17DOVCXB^E[_`-^T_P`*/M'Q%]+W_OVG^%'L/[R#VODSUJBO
M)?M'Q%]+W_OVG^%'VCXB^E[_`-^T_P`*/8?WD'M?)GK5%>2_:/B+Z7O_`'[3
M_"C[1\1?2]_[]I_A1[#^\@]KY,]:HKR7[1\1?2]_[]I_A1]H^(OI>_\`?M/\
M*/8?WD'M?)GK5%>2_:/B+Z7O_?M/\*/M'Q%]+W_OVG^%'L/[R#VODSUJBO)?
MM'Q%]+W_`+]I_A1]H^(OI>_]^T_PH]A_>0>U\F>M45Y+]H^(OI>_]^T_PH^T
M?$7TO?\`OVG^%'L/[R#VODSUJBO)?M'Q%]+W_OVG^%'VCXB^E[_W[3_"CV']
MY![7R9ZU17DOVCXB^E[_`-^T_P`*/M'Q%]+W_OVG^%'L/[R#VODSUJBO)?M'
MQ%]+W_OVG^%'VCXB^E[_`-^T_P`*/8?WD'M?)GK5%>2_:/B+Z7O_`'[3_"C[
M1\1?2]_[]I_A1[#^\@]KY,]:HKR7[1\1?2]_[]I_A1]H^(OI>_\`?M/\*/8?
MWD'M?)GK5%>2_:/B+Z7O_?M/\*/M'Q%]+W_OVG^%'L/[R#VODSUJBO)?M'Q%
M]+W_`+]I_A1]H^(OI>_]^T_PH]A_>0>U\F>M5S/P\_Y$RT_WY?\`T8U<7]H^
M(OI>_P#?M/\`"JNG0^.].LDM[&"]A@4DJGE+QDY/49ZFJ5'W6N9$^TUO9GLE
M%>2_:/B+Z7O_`'[3_"C[1\1?2]_[]I_A4^P_O(KVODSUJBO)?M'Q%]+W_OVG
M^%'VCXB^E[_W[3_"CV']Y![7R9ZU17DOVCXB^E[_`-^T_P`*/M'Q%]+W_OVG
M^%'L/[R#VODSUJBO)?M'Q%]+W_OVG^%'VCXB^E[_`-^T_P`*/8?WD'M?)GK5
M%>2_:/B+Z7O_`'[3_"C[1\1?2]_[]I_A1[#^\@]KY,]:HKR7[1\1?2]_[]I_
MA1]H^(OI>_\`?M/\*/8?WD'M?)GK5%>2_:/B+Z7O_?M/\*/M'Q%]+W_OVG^%
M'L/[R#VODSUJBO)?M'Q%]+W_`+]I_A1]H^(OI>_]^T_PH]A_>0>U\F>M45Y+
M]H^(OI>_]^T_PH^T?$7TO?\`OVG^%'L/[R#VODSUJN9M/^2DZA_V#X__`$*N
M+^T?$7TO?^_:?X552'QVFI27BP7HNGC$;2>4O*@\#IBJC1M?WD2ZE[:,]DHK
MR7[1\1?2]_[]I_A1]H^(OI>_]^T_PJ?8?WD5[7R9ZU17DOVCXB^E[_W[3_"C
M[1\1?2]_[]I_A1[#^\@]KY,]:HKR7[1\1?2]_P"_:?X4?:/B+Z7O_?M/\*/8
M?WD'M?)GK5%>2_:/B+Z7O_?M/\*/M'Q%]+W_`+]I_A1[#^\@]KY,]:HKR7[1
M\1?2]_[]I_A1]H^(OI>_]^T_PH]A_>0>U\F>M45Y+]H^(OI>_P#?M/\`"C[1
M\1?2]_[]I_A1[#^\@]KY,]:HKR7[1\1?2]_[]I_A1]H^(OI>_P#?M/\`"CV'
M]Y![7R9ZU17DOVCXB^E[_P!^T_PH^T?$7TO?^_:?X4>P_O(/:^3/6J*\E^T?
M$7TO?^_:?X4?:/B+Z7O_`'[3_"CV']Y![7R9ZU17DOVCXB^E[_W[3_"C[1\1
M?2]_[]I_A1[#^\@]KY,]:HKR7[1\1?2]_P"_:?X4?:/B+Z7O_?M/\*/8?WD'
MM?)GK5%>2_:/B+Z7O_?M/\*/M'Q%]+W_`+]I_A1[#^\@]KY,]:HKR7[1\1?2
M]_[]I_A1]H^(OI>_]^T_PH]A_>0>U\F>M45Y+]H^(OI>_P#?M/\`"C[1\1?2
M]_[]I_A1[#^\@]KY,]:KF?AY_P`B9:?[\O\`Z,:N+^T?$7TO?^_:?X55TZ'Q
MWIUDEO8P7L,"DE4\I>,G)ZC/4U2H^ZUS(GVFM[,]DHKR7[1\1?2]_P"_:?X4
M?:/B+Z7O_?M/\*GV']Y%>U\F>M45Y+]H^(OI>_\`?M/\*/M'Q%]+W_OVG^%'
ML/[R#VODSUJBO)?M'Q%]+W_OVG^%'VCXB^E[_P!^T_PH]A_>0>U\F>M45Y+]
MH^(OI>_]^T_PH^T?$7TO?^_:?X4>P_O(/:^3/6J*\E^T?$7TO?\`OVG^%'VC
MXB^E[_W[3_"CV']Y![7R9ZU17DOVCXB^E[_W[3_"C[1\1?2]_P"_:?X4>P_O
M(/:^3/6J*\E^T?$7TO?^_:?X4?:/B+Z7O_?M/\*/8?WD'M?)GK5%>2_:/B+Z
M7O\`W[3_``H^T?$7TO?^_:?X4>P_O(/:^3/6JYOX@_\`(CZE_NI_Z,6N)^T?
M$7TO?^_:?X56U"+QYJ%C);7L%[+;R8WIY2\X.1T&>H%5&C:2?,B95;IJS/8(
MO]4G^Z*?7D@G^(@``6]P/^F:?X4OVCXB^E[_`-^T_P`*GV']Y#]KY,]:HKR7
M[1\1?2]_[]I_A1]H^(OI>_\`?M/\*/8?WD/VODSUJBO)?M'Q%]+W_OVG^%'V
MCXB^E[_W[3_"CV']Y![7R9ZU17DOVCXB^E[_`-^T_P`*/M'Q%]+W_OVG^%'L
M/[R#VODSUJBO)?M'Q%]+W_OVG^%'VCXB^E[_`-^T_P`*/8?WD'M?)GK5%>2_
M:/B+Z7O_`'[3_"C[1\1?2]_[]I_A1[#^\@]KY,]:HKR7[1\1?2]_[]I_A1]H
M^(OI>_\`?M/\*/8?WD'M?)GK5%>2_:/B+Z7O_?M/\*/M'Q%]+W_OVG^%'L/[
MR#VODSUJBO)?M'Q%]+W_`+]I_A1]H^(OI>_]^T_PH]A_>0>U\F>M45Y+]H^(
MOI>_]^T_PH^T?$7TO?\`OVG^%'L/[R#VODSM/`G_`"";W_L(3_\`H5=-7C=A
M#X[L(GCLX+V)'D:1AY2\L>IY%6OM'Q%]+W_OVG^%5.C=M\R)C4LK69ZU17DO
MVCXB^E[_`-^T_P`*/M'Q%]+W_OVG^%3[#^\BO:^3/6J*\E^T?$7TO?\`OVG^
M%'VCXB^E[_W[3_"CV']Y![7R9ZU17DOVCXB^E[_W[3_"C[1\1?2]_P"_:?X4
M>P_O(/:^3/6J*\E^T?$7TO?^_:?X4?:/B+Z7O_?M/\*/8?WD'M?)GK5%>2_:
M/B+Z7O\`W[3_``H^T?$7TO?^_:?X4>P_O(/:^3/6J*\E^T?$7TO?^_:?X4?:
M/B+Z7O\`W[3_``H]A_>0>U\F>M45Y+]H^(OI>_\`?M/\*/M'Q%]+W_OVG^%'
ML/[R#VODSUJN9T;_`)'WQ)_N6O\`Z`:XO[1\1?2]_P"_:?X55AA\=PW]S=10
M7JW,X43/Y2_/M&%[8X'I51HV3]Y$NI>VC/9**\E^T?$7TO?^_:?X4?:/B+Z7
MO_?M/\*GV']Y%>U\F>M45Y+]H^(OI>_]^T_PH^T?$7TO?^_:?X4>P_O(/:^3
M/6J*\E^T?$7TO?\`OVG^%'VCXB^E[_W[3_"CV']Y![7R9ZU17DOVCXB^E[_W
M[3_"C[1\1?2]_P"_:?X4>P_O(/:^3/6J*\E^T?$7TO?^_:?X4?:/B+Z7O_?M
M/\*/8?WD'M?)GK5%>2_:/B+Z7O\`W[3_``H^T?$7TO?^_:?X4>P_O(/:^3/6
MJ*\E^T?$7TO?^_:?X4?:/B+Z7O\`W[3_``H]A_>0>U\F>M45Y+]H^(OI>_\`
M?M/\*/M'Q%]+W_OVG^%'L/[R#VODSLM1_P"2D:/_`->DU=17C<D/CN34H;QX
M+TW42%(Y/*7Y5/4=,5:^T?$7TO?^_:?X54J-[>\B54M?1GK5%>2_:/B+Z7O_
M`'[3_"C[1\1?2]_[]I_A4^P_O(KVODSUJBO)?M'Q%]+W_OVG^%'VCXB^E[_W
M[3_"CV']Y![7R9ZU17DOVCXB^E[_`-^T_P`*/M'Q%]+W_OVG^%'L/[R#VODS
MUJBO)?M'Q%]+W_OVG^%'VCXB^E[_`-^T_P`*/8?WD'M?)GK5%>2_:/B+Z7O_
M`'[3_"C[1\1?2]_[]I_A1[#^\@]KY,]:HKR7[1\1?2]_[]I_A1]H^(OI>_\`
M?M/\*/8?WD'M?)GK5%>2_:/B+Z7O_?M/\*/M'Q%]+W_OVG^%'L/[R#VODSUJ
MO+OC!_Q]:7_N2?S6JWVCXB^E[_W[3_"LO6-*\8:P\3:G97MP8P0A\H<9Z_='
MM6E*GR24FT14GS1M9GLFF?\`(+M/^N*?^@BK55-*22/2+-)@5E6!`X/4':,U
M;KE>YNM@HHHI#"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MD8X4GT%`%6\U;3]/=4O;ZUMG8959IE0D>N":M`A@"""#T(KG_!2B?0%U"7#7
M5\[RSN>I.X@#Z`#`':MV..*U@5(T2*&-<!5`55`]NPJI))V$G=7)*CGN(;6!
MIKB6.&).6>1@JCZDU!9ZKI^H.R65]:W+*,L(9E<@>^#61<`7OCRWM[CYH;2R
M-S$AZ>87V[L>H`X],T*.NH-]C:L[^TU"-I+*Z@N44[2T,@<`^F15BLCQ%?KH
MFE7&HQ0QFYPD2L4R3EL#..2`6)Q]?6J&GZC>QZQ:P"?4;ZVFC83/<V#0"%@,
M@@^6HP>1@Y[<T^6ZNA<UG9G07=U#8VDMS<OLAA4N[8)P!UX'-21NLL:NARK`
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MBFF`>[;9"`"0YQGJ..GK5JN<;6(W.@'1W5+&[G:-D6,`;0C';C'RX([>E16L
M^JZG<ZVJZFUNEG<-'`(X8R?N@X8L#D<]L'KSTHY!<QU%07M[!IUG+=W<GEP1
M+N=L$X'T'-9$&J-?^&['4+G48M,2:-6ED&P?,>RE\J!G/4'\*S(_$-TWAO7Y
M(+Y+J73V807:*AWKM#`D`;21DC@8..E"@V#FCKDD1XED5OD9=P)XXJ.UO;:^
MB\VSN(;B/.-\3AQGTR*9,Q?2I&8Y)@))_P"`UQO@DC1VL(SA;;5;,2KV`F08
M;\UP?PH4;IL;E9I':O>VT5U':R7$*W$@RD3.`[#U`ZGI4]<';K]N\4:7K3CF
M\NY4@SVA2-@N/J<M^(JU+KUY>_VC-:W-]$]M*\5O;P:>TL<A0_QML/WCQPRX
M&*IT^PE,[*J$VMV$$5[)+/M2Q(%P=C'82`?3G@CIFLS^T;[5-5M+"*633LV2
MWEP513*"QP$`<$#!SGC/`Z5E17-]IEAXMN#.AO()`RRH@`)$:X.TY&<8SVS2
M4.X.?8[6-UEC5T.58`@^HIU8,UY>7VM0:9;W+6J+:"YFFC52[$G:JC<"H'!)
MX/;I5F[\VST]/MFM+;(K$/=,D:,W/RC+90'U^7GL!4\H[EZ\O(+"SENKI]D$
M2EG;!.`/8<U,K!U#*<@C(-<3<:J^H^#_`!)"]VEZMKOCCN4V_O$*AAG;QD9(
MR,=*Z74+F2R\-7-S#_K8;5G3ZA<BFX6!2N33:OIUO="UGO[2.X)`$3S*')/3
M@G/-7*Q_#UA;IX8M(BBRI<0"28N-WG,XRQ;/7.>]9MWK$MQK5]917=[9Q605
M%^R6)G+NRYRQV,`!P`.#UYHY;NR#FLKLZJDZ5R<FL:O/!X?7/V&XO99([A7@
M_NJ>0K<CID?49R*NVTU[_:NHZ1-?S2!((YXKG9&)5#$@J<+M/*\?+W-'(T',
M;D$\5S"LUO*DL3C*NC!E/T(J2N(T>]FT'X=P:@MQ+.QC5(H9$4I&S/M&`JAC
MUS@DUI:?J%ZNLVMN)]1OK:9&$SW-@T`A8#((/EJ,'D8.>W--TVKB4]CI:*Y_
MPO-J.I6OVZ^OF91+)&D*1H%(#L`6.W.?H0.!UYJUX@U"XLK>UBLRJW%Y<);I
M(PR(\Y);'<@`X'K4\NO*/FTN:U%8>IW%YX?T>[NC>-?,`BPK<(JE79MO)0*"
MO(XQG@\\\0WDU_H4VGS3ZC)>0W%PMM-'+$B@%^C(54$8(Z$G@^M"A<.:QJ2:
MS8Q0WLSSXCL3MN#L;Y#@'TYX(Z9JZK!U#*<@C(-<1??\@7QI_P!=F_\`125T
M%_,D%K;-<:TFF0E`%/[M6=L>L@(QCL!GWJG#L)2+][?V^GQI)=2>6DDBQ*=I
M.68X`X]ZLUP5_J=SJW@NRF,L4MTFI1Q";;\DA63"M@=CP3C\*WS<WNEZ_8VM
MQ>/>07R2#YXT4Q.@W?+M`^4C(P<G@<T.G9>8*9O45RL%YJNH>'9-<BOS`VUY
MH;41HT6Q2<*Q*[R2!R0PZ\"G?VI?:MJVF0V5T;2VN[#[3)A%9UY7[NX$9YQS
MD8SQG%+D8^='45'+<10&,32I&9&V(&8#<WH/4\'BL36[@V43"7Q&EA*(B858
M0@R$#JP<'=S_`'=M9.H3SZUI_A>^-S+;O<7,6Y(E3:K%&RPW*3GZY&.U"A?4
M3G8ZQ]0MH]1CL&DQ=2QF1$VGE1P3G&*LUB-=W-MXEL;!KEY8&LY9)"ZKN=E9
M0"<`>IZ8%4(+S5=0\.R:Y%?F!MKS0VHC1HMBDX5B5WDD#DAAUX%'(/F.JHKE
M_P"UK[5-9TN&SNC:VUY8&Y<"-68'*_=)!`/..01UXK0T&]N9I]1L[N7SWLKC
MRUF*A6=2H8;@`!D9QP!TH<&D"DF;%%%%04%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!16;XAGDMM`O)879)$CRK*<$'-<58ZU=7L6?MUPKK
M]Y3*?TYKGKXA4=T1.?*>CT5P7VN\_P"?^X_[_'_&C[7>?\_]Q_W^/^-<_P#:
M,.S(]LCO:*X+[7>?\_\`<?\`?X_XT?:[S_G_`+C_`+_'_&C^T8=F'MD=[17!
M?:[S_G_N/^_Q_P`:/M=Y_P`_]Q_W^/\`C1_:,.S#VR.]HK@OM=Y_S_W'_?X_
MXT?:[S_G_N/^_P`?\:/[1AV8>V1WM%<%]KO/^?\`N/\`O\?\:R?$'BJ?0[,O
M]NN)+AQ^[C\X_F>>E../C)V46"K)]#U.BN3\%Z]+?^&;"6\E:6XD0EW8\D[C
M3;NV'BOQ1<Z=>22?V781(9((W*B:1^1N(YP`.GK7H17,:MV.NHK!M]+TKP99
M7M[;F:"T"!WA\QG0$=U!.=QR!U["JB^+[VW>";5=!GLM/G<(ER9U<KN^[O0<
MK[YZ57(W\(N:VYU-%<]J/B:YMM:ETJQTF6^NEB25`LH12"3G<Q&%QCWR35%/
M'-U<VDDMEX?NIGM<B]4RJHA(SE0<?.>,X`]*%3DPYT=?16#J'BJ&SLM,NX;6
M:YBU!@$6/[XRI887N>W4?6DTOQ%=SZL-.U;27TVXDC,D&9UE60#[PR.A'I_D
MKDE:X<RO8VX+B&Y0O;RQRJ&*ED8,`1P1QW%25R&A:K'H_AFXGDC>5VU":.**
M/[TCM(0%%7['Q%?27OV+4]&DL;J2-I+9?M"RK-MZKN'W3]:;@];`IHZ"BN-\
M*:QK=UJ=_%=Z9)Y!O'$DKWBO]F.T?NPO<=.G'-6I?%]UB6[M-#GN=)A9@]XL
MR`D*<,RQ]6`QZ\TW3=["4U:YU%1K<0O.\"RQM-&`SQAAN4'H2.HS6-JGB1K:
M6SM]+L7U*[NXS-'$L@C`C'\18].O%9_AN]EO_%^L2W%G-9S"W@5X9<$@C=G!
M'!'H>])0=FV/F5['6T445!0445R7CJ^FL%L'AD=06?<%8C(XJ*D^2+D)NRN=
M;17G45\9HE=;Z4`]C,01^M=9X8D,FFR$S&7]Z?F+;NPXKGHXM59\MK$1J<SL
M;-%%>>_:7_Y_Y/\`O\?\:O$8A4;75[CG/E/0J*QO#$ADTV0F8R_O3\Q;=V'%
M;-:TY\\5+N5%W5PHKSW[2_\`S_R?]_C_`(UT/A24R?:\SM+C9U?=C[U<U+&*
MI-02,XU5)VL=#117GOVE_P#G_D_[_'_&M,1B%1M=7N5.?*>A45XQJOC">#7;
M&QL;N8C[3&)I/,.,;AE1_6O1]<OEN/"^J8_Y])?_`$$UI1G[5)VL-2NKG05&
M+B%KAH%EC,R*&:,,-P!Z$CKBO,Y;30=/TG3;KP[<HFO.T(5+>Y,C.QQN5UR<
M#KGITQ[5UMLVSQWJC;2VVQA.%&2>6Z5TNG8E3N='17,KXJU"&YMSJ.@3V=C<
MRK%'</<(S`M]W=&.5SWYXJ74O$]Q:ZU+I5CI,M]=+$DJ!)0BD'.=S$84#'XD
MXJ?9R*YT=#17/0^*_-\.7^HO9/%<V!=)[5I/NNO;=CITYQ5>+QC<&XM)+G1;
MBWTR[E6*&[>49+'[N8\9`)Z$]L&CV<@YT=316%J?B"ZAU%['2-*?4KB)5><"
M=8EC#=!N/4G'3TIK>+;=/#S:D]M.)5D^SFTQ^\\[.-GOSW]/RI<D@YD;<EQ#
M#)''++&CRDK&K,`7.,X`[\5)7$W.J7][XFT"'4M'FT^5;B1E)E66-AY9'WAW
M]JZZ[O[33XUDO;J"V1CM#32!`3Z9-.4&K`I7N6**S/\`A)=$_P"@SIW_`(%)
M_C6@<31':YVNO#(?7N#4M-;CNF/HK@_$'AFQT..RO-+:Y767NHTCF,SO).2?
MFW9..1DG@?E6CK-JOB'Q;#HUXSG3X+7[3+$K%1*Y;:H)'.!UJ^1;WT)YGV.K
MHKD]$M%\/^,+C1[-G&GS6@N8H6<L(F#;3C/8]:9#ITECX\L'N+R:\N)K28O)
M)P!@K@*HX4>WN:.1=PYO(Z^BN,\<V45SJND27FE7VHV4:S>;':1LS`D+M^Z1
MCGW[5>\&G0A;W4>AVLUG(K@7-O/N$B-R!D,3C\#2</=Y@YO>L=+1114%A111
M0!BP:->::TJ:3?0PVLC%Q!/;&41L22=I#K@'/0YK6@C>*!$DE:9U&#(P`+'U
MP`!^0J2BFVWN)*P5FZCI)NKN"^M+C[-?0`HLA3>K(3DHRY&1QV((/>M*BA.P
M-7,FXT>?4[&XMM6O1*DP`46\7E",@Y##)8[LX[XX''7,]E;:E&Z?;M0AG1%Q
MB*V\LN?5B6;],?TJ_11S/8+(YN7PK<-I-SI,.IF+3Y=^Q1#F1-W.TONP5R3Q
M@''&:M2Z%.FI0WUC>113I:BU;SK?S`5!R",,I4]>Y'3TK:HI\\A<J.?A\*^5
MI45E]M9_+OA>>8T8RWS[MI`('X_I6K>PWTC(UC>108!#++!YBMTP>&4@CZXY
MZ5;HH<FQ\J11T?3$T?3(K.-VD"9+.P`W,223@=.2>*9<VNJM-*;74H(XG^ZL
MUKO:/C'RD.O'?D'^E:-%*[O<+:6,2+PS#;1Z5';3.L>G2M+\XW-*6#`Y/&.6
MSTJQI^C_`&&74W\_?]NG,V-F-F5`QUYZ>U:=%/F;#E1ST?AB2VMM(%M>(+G3
M$9$>6#>CAA@Y7<"#TP0?7UH_X1=VT_6+>6_WR:H=S2>2!L.T`X&>1QQ[=SUK
MH:*?/(7(B%H-UF8-W6/9NQ[8S6#=^#TN_"UII!O'CDM0NRY1,'C@\9[@D=:Z
M2BDI-;#<4]S+ET2-KC2GA<11Z<3MC"YW`IM`SGBHH]&N[&YN6TR_CAM[F0S/
M%+;F0HY^\4.X8SUP0>?RK9HHYF'*C*N](F?48-0LKL0W<<1@=IHO,65.O*@K
MSGG(/KQ5/_A%F.GZQ;/?O(^IG+2O&,H=H!X!`(XZ<8Z5T-%"FT+E1D76BRF_
MM[^QNE@NXH?(<R1>8DD?7!4,IR#R"#Z]:9=:)=7,]A=_;XS?6;2$/);[HV#C
M!&P,",<8.[/KG-:L5S#.\B0S1R-$VV148$H?0^AJ6CF:#E1SW_"+NVGZQ;RW
M^^35#N:3R0-AV@'`SR../;N>M;GD(UMY$@#H4V,".&&,&I:*3DWN-)(Q;;1]
M1L+?[)9:I&EFORQ"6VWRQ+_=#[@#CME3VSFGOH]S!J4U[IMZD+W"J+A)X/-5
MV48#`!EP<<'L>..*UZ*?,PY495SHSW5UI=Q+=EI+&1I&)C'[TE2.V,=??^M2
MII>S7;C4?-SYUND/E[>FTDYSGW]*N33Q6Z!IY4C4L%!=@`23@#GN30L\33O`
MLJ&9`&:,,-R@]"1[X-%V%D8MOX9V:%)HUS="6R`Q`4CV2Q_-N&6W$$CCG`Z5
M?LK;4HW0WVH0SHBXQ%;>67/JQ+-^F/Z5?J.*XAG:1898Y&B;9(%8$HWH?0T.
M38<J14T73/[(TX6OF^;B1WW;=OWF+8QD^M)K&E+JUHD?FM#-#(LT$JC)CD7H
M<=QZCN*T**7,[W"RM8R;C1Y]3L+FTU>[2:.90H%O#Y00@Y##+,=V<=\<#BFC
M1KJYFM&U6^CN8[1Q)&D4'E;G`P&<EFSCK@8&:V**?,PY48<_AOS[+6K?[5C^
MU'+;O+_U65"],\]/:GW&B3_VK%J%C=Q13K;?9F$T'F`KG((PRD'KW(/'I6NS
M*B%G8*JC)).`!389XKF%)H)$EB<95T8,K#U!%'-(7*C`_P"$1!T1=.-_)@7G
MVKS@@#_?W8],^^,>W:KEOH]PVJ17VI7JW,EO&8X%CA\M5W?>9OF.6(`'8=>*
MUZ*.=ARHP$\-W$%A+IEMJ(BTR0L/+\C,J(WWE5]V`.3C*D@'\:N1Z+'#J]M>
M0N$BM[4VJ0A>V00<Y[8Q6G11SMARHQ)M!N/[3OKJTODA2_5%G5H-[C:-OR-N
M`''J&&>:9_PC3)H>F6,5V%GTYTDBF:+*LRY'*YZ$$]_QK>HHYV'*C-_LJ236
M+749[A&DAMWA94BVJY8J<C)./N].>O6J2>&[B"PETRVU$1:9(6'E^1F5$;[R
MJ^[`')QE20#^-;]%',Q\J,M-#CBUFTO89`D5K:FU2$+V)!!SGMCTJ6PTS[#?
M:A<^;O\`MDJR;=N-F%"XSGGI5^BES,+(****0PHHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`S]=M9;W1+JW@7=)(FU1G'>N)'AQ+*(+<`[NY-
M>BGI6=?:>+GK6-6@JCNV3*',</\`V?9>H_*C[!9>H_*NG.@+Z4?V`OI67U2/
M=D^S7<YC[!9>H_*C[!9>H_*NG_L!?2C^P%]*/JD>[#V:[G,?8++U'Y4?8++U
M'Y5T_P#8"^E']@+Z4?5(]V'LUW.8^P67J/RH^P67J/RKI_[`7TH_L!?2CZI'
MNP]FNYS'V"R]1^54=7\.:?JEFT7F>7(!\D@'W3_45VO]@+Z4?V`OI36$2=U)
MA[-=SE_"-K/I^GVMK-C?$"IVG(/)Z5MS_;M`\02ZK!8W%_97L2I<);+NEC=>
M%(7N"/\`/KJ6VC+"X.*V8TV*!77%\I;5SEM2FO?%_A_4;6WTJ[LL*AA-ZHC:
M5PV[;M[#@<YQS[55U+4+_P`5:>FCIH>H6DDSI]IFN(PL4:JP+%6_B/'''O7;
M45:G;H2X7ZF%:6\R>-M0G:*00M9Q*LA4[20S9`/3-5M'M+B+3O$*R02HTUY<
M-&&0@N"HP1Z@UTU%+G'RGGMT+K3_``_X0`LY)+J&=?\`1V/EL3M/'/0_6M:U
MFN_$7BFQO_[-O+&ST^.3F\C\MY'<8P!SP!SFM[4-*AU&XLIIFD5K.;SHPA`!
M.,<\=.:O53J:;:DJ&IY_<Z!=7OA!D>QDF>WU.2Y-J^8VFCWMD`]>0<C%6O#.
MF:0-9CGT[PQJ5@\*L3<7A=`N1C`4L=V<GZ5VU%#JMIH/9J]SEM%EN-/\0ZII
M]QIU[MN[MYX[I(\PA2HZMV/&/K7+VWAW3].5['4_">I7MZCE4N+8N89@3\I+
M!@%Z\\<5ZC10JK0.G<Y&^BN/#^N6&I6VF7-S9"Q^QO#:CS9(<'<N!GD<8S_]
M;,_A]KVZ\3ZG?W6GSV<4]O#Y0EZD`MUQP&Q@E<G&>:Z>BIY]+6'RZA1114%A
M7.>+=&EUC[&(_P#5Q%BYSSSC_"NCIDB;UQ4SBIQY6)JZL>>R:9:V_P`KKC'M
MFNI\*1Q1Z7((?N^<3TQSM6BYT99G)Q5K3X&T^!HDCW`MNSG'8?X5E3P\:;YD
MV3&"3N:5>;?9;+_*FO0?/D_YXC_OK_ZU8G]@+Z556BJEKL<HJ1/X4CBCTN00
M_=\XGICG:M;E9NGP-I\#1)'N!;=G..P_PJUY\G_/$?\`?7_UJN$>6*BAI65C
MS[[+9?Y4UTGA"*"+[9Y'?9GC']ZG?V`OI5[3;,Z;YFQ-WF8SSCIG_&L88>,)
M<R;)4$G<U:\V^RV7^5->@^?)_P`\1_WU_P#6K$_L!?2KJT54M=CE%2//]:\,
MVUW<V][8OLN8959E(($@!'ZUUC)+/X>U&*-'DD>VD5549+$J<`"M3^P%]*T;
M+3Q;]*JE#V>B=P4;*Q%X?T>RL-.M)8M/M[>Z-NBR.L*H^<#()QGK5&:UOCXF
MUF6TC='DT]$@E9?E,GS8&3QP2*Z0<"EK7G=VPY3RJ/2%E.G/%X<U==4CN86O
M+VXWD$[AN8<G=D]\<#FNUMK:=?'M]<-#((&LHU60J=I(8Y`/3-=!15RJN1*A
M8XRXL;MM&\7(+6<O<3N85$9S(-BC*CO^%7=;M+B7PWI,4<$KR1W%J714)*@$
M9)';'>NFHI>T8^0X#Q!H5K%XHN[W5="O=5M;M$,3V>YGB90%*E58<'`.?\B>
M;1FB\+6T^BZ--:M;7RWRV4LA,D@7CG)."1_#[>M=Q13]J[(7LUJ<=+?WNN:]
MHL\>C:A:VEO</ODN8]C9,;?PC.%Z?,3U.*ZF[L+34(UCO;6"Y13N"S1AP#ZX
M-6**ARO:Q2C;<S/^$:T3_H#:=_X"I_A5^1A;V[LD;,(T)$<8Y.!T`J2BDVWN
M.R1Y_IVN7!U235=8T#7I;SE+>..R)CMH_1<D98]VP/3I6MJWVO2_$EMKUO87
M=W;36OV>XA@3=*G.Y3M[^A]*ZJBK=17O8E0TW.9T1+O5?$5QKES9SV<`MQ;6
M\,Z[9"-VYF8=N>!67=>()I/%-IJ"^']>\FW@DB8?8CDEB,$<XQQ7=44*:O>P
M<NFYCZIKTVEM`W]D:A=P2IG=:Q[W1O[K+GCCO5/P]!=W>N:AK=U9R64=RB10
M0R\2%5S\SCL3Z=?Z])14\UE9(=M;A1114E!1110!@^#?^0))_P!?=Q_Z-:MZ
MLS0--ETK3FMYV1G,\LF4)(PSEAU`[&K\T,5Q"\4\:2Q.,,CJ"K#T(-5)WDR8
MZ(DKFQ,UOXLUN9`"T=A"P!Z9'F&MNSTZST]66QM+>V5SEA#&$!/O@5GR:/.V
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M%*J,'CKP:K:5I^JZ/:)IT`LI;2)B(IY)&$BH3G!C"X)&2,[AG@TKQ"TB#5?$
MT^C:A/;75N)#.BG3O+4CSG/!C8Y.#D@YXXJR^HZB]_;:7#]E6]^S"XN9V1FC
M3G&%3<"<G/5N`.]5M5\,S:U=W=Q=3(DD:!=.,9)\@@[MYX^\6`SCL,9J8Z;J
M::A;:K&;1[W[,+>ZA:1EC?G.Y6VDC!SQMZ&CW;>8>]<K77B2\L=,UH31V[7^
MF*K94'RY5;E6VYR.,@C)Y'6K(U34K2]TT7RVC07[&,)"K!H6VEAEB<..".BU
M7O/#=W>Z9K)DD@&H:FJK@$^7$JC"KG&3WR<#.>@K0U#2YKN72&C:,"RG$DFX
MGD;"O''7)H]W^O3_`##WA/%6H3:7X<N[FU(6<!4C8_PEF"@_AG-.MO#6F6ZQ
M-]E1KE"&-T?]<S=2QD^\<]^>1QTXJSJVFQ:OI=Q8W!81S+M++U4]01]#BJMO
M_;J+'#,NG':<-<B1R64'KY6T8)'^WP3GGI4I^[H4UKJ01ZCJFJR7S:6;.&&U
ME:!/M$;.9G7J<JPVC/'?U]JJMXGN[RUT>33;>$2:B[QNLQ)$3*#GD8S@@_4#
MMFK4&FZGI4UZFF_9)K>ZF:=3/(R-"[?>&`IWC//5?3WJ.W\--9?V)';RJ\>G
MO(\K/PTA=3D@#_:;IZ57N_UZ$^\.N=3U2'7+32H_LDDD]L\KSF-E5"&`SMW$
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M5=3M1!)');BWE260H5`;<&4A3GJ>#CMS5:+86KW*0UQ-.BU^Z-G#FUNA&JPK
ML:9BJ8W'N<MC/I5B;4=3TJ>Q;4FLY;>ZE6!O(C9&A=ON\ECN&00>!V/M44OA
MF2[MM:@FG6,7]PLT+IDE"H7!(X[KTJ673M2U66R75%M(H;659V\B1G,SK]WJ
MJ[1GGOZ4O=#4@AU;6+^XU9+06,26$S1H9$=S)A00"`PQU^]SUZ<<[&DZ@NJZ
M3:WRH8Q<1J^PG.W(Z9JIIFDSV4VKO(T9%[<&6/:3P"H'/'7CWJ?0;"72]"L[
M*=D:6"((Q0DJ3[9J96MH.-^I3@U'4]4N+UM.-I%;VLQ@43HS-,Z_>Y##8,\=
M&]<=J>VHWU]J]U8Z<;>!;-4\V:>-I=SL,A54,N,#N3WZ5';:;J>DW%ZFGBTF
MMKJ9IU,\C*T+-]X8"G>,\CE>X]Z<=-O[#6+N^T\6TZWBIYT4\C1;748#*0K<
M$=L=NM/0-3)U35)-3T!!<1I'=6VJ0V\ZH<KO61>5]B"#^-:-J6'C75C&`S_8
MX-H8X!.7ZG!Q4<GAF<Z481-$UW-?I>SN054D.&(4<G@#`S5J71KF35=4N8[@
M0K=VB01NA.^-AN^;_P`>&.:J\;67];"L[C)M1U+3M6T^&^:TEM[YVB`AC9&B
M;;N')8AAP1T7L?:LS1_[3;5?$2Z>;6-5O2V^=&?>VQ?EP",=N<GKTI;7PI<I
M=Z3.UGI5L]E(&FD@+-)<?*026*@]><'.<]>.;D&EZQIMWJDUD;&5;Z=I465V
M7RSM`#9"G/3E>.@YYHT6W]:BU>XL7B:74+32A8PHEUJ._P#UN66$)]\D#!;!
MX`R,YZBI5UB\M+Z\L+[[/)/':FZ@EB1D5U'!!4DD$'WY![5"GAF:PMM):PG2
M2ZT[>/WV56</]\$C.WGD'!J<:/=W5Y=W]\8$N9+4VL,43%DC4Y))8@$DG'88
M`[TO=Z;#]X71;W5]1TF*_F6R4SQ*\<`##!..2^3QU.-OH,]Z2+4=1M]=73+R
M2TD-Q;-+!-%"R;64@$,I<Y'(/!'0TDFBW;>#8]*BN%BNDMTC\Q68*2N,C(P<
M'&,]<&JVG^&Y;;Q#;ZBMEIEC%'"\30VF26)QABVU<]#QCCU.>#W=0UT(/"ZW
MB6.K/--:RPK=W.Z/[.P+-N.3G>1M/IC\:GLM:F;2="M[*VMHKK4(MX"H1#`H
M4%B%!R>H`&1UZU:T[2KVP_M&V(MWM;F66:.7S&#@OSM*[<<'/.[TXJO#X>O+
M6PT1X)(#?:9%Y95F(CE4J`PW8R.@(.#TZ4VTV[@DTB==8O+2^O+"^^SR3QVI
MNH)8D9%=1P05))!!]^0>U4X/$&JC1M.U>Z2R^S7+1+)!&K;U#D+N#DXZD';M
MZ<9[U=&CW=U>7=_?&!+F2U-K#%$Q9(U.226(!))QV&`.]0OX?NF\(V.E"2'S
M[?R-[9.T[&4G!QGMQQ2]T/>.BHHHK(T"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*2EHH`3`HP*6B@!,"C`I:*
M`$P*,"EHH`3`HP*6B@!,"C`I:*`$P*6BB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`$Q1@4M%`"8%&!2T4`)@48%+10`F!1@4M%`"8%&!2T4`
M)@48I:*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHIDL8FB>-BP5P5)5BI_`CD?44`/HKEAIL?_"7M9?:=1^S"Q$NS^T)_O[\
M9SOSTKIHXQ%$L:EBJ@*"S%C^)/)^IJI)(2=Q]%%<QXCL5MY]/>&YOXS<WZ1R
MA;Z8`JV20!NP/PQ1%7=@;LCIZ*Y/78!INK>'Q:I<3G[7(0LD[2,28R/O.20/
M_K\5JV^NE9K^#4X$M9;*(3N4E\Q&C(/S`D*>-I!&/SIN&ET+FULS7HK"C\07
M*M92WFGK!:7SB.&03[W4MRF]=H`R/1C@U-XJFEM_"VI2P2/%*D#%71B&4^H(
MI<KND',K7->BL3Q'/+!X-O9X97CF6U++(C$,#CJ#1<:W/;ZE9Z;;V?VB:XMC
M,':;8JX(!W<$XYZC)]N]"BV@YDC;HKF[_6(;SPWK`U&PW-9;H[FV$QVO@!AM
M<`'!!'.`?:M"SU0'5CI9M_*"VR3POOR'7H1TZ@X[GK1R.P<R-2BN?B\3O<[8
M[:R#SSW,L-LK3;5D2,X:0M@[1UZ`]OP6;Q,UKI^J2W-F%N]-`,L"R[E8-RI5
MMHX(]1VHY)!S(WZ*P[C7KFTLX9KBP2-[J=(;:-I^26S@R';A.!T&[TIFMS@Z
M3`VK:<K-]LB01I<';N+@*X8`$@9Z$#I^-"@PYD;9MX6N%N#%&9U4H)"HW!3U
M&>N*DKFA>:K_`,)S/;QQPM`+1&$;73A0N]AOQL(W>WL.:LQ^)4&BZC?7$'E2
MV#R1RP;\_,O0`X_BR,<=Z;@P4D;E%0VLLDUI#+-%Y,CH&>/=G82.1GCI6-_P
MD=S+82ZE:::)M.B+?.9]LKHIPS*FW!'!(!8$X[5*BV-M(WZ*X_6&EU;Q)I*+
M:6=[926\D\4<\Q"2<+\S+L(R`>.O4]*Z>YL8;N!89#,B*00()GB([8RA!Q[4
MW&UKB3O<LT5S'ANQ2=[Z6>YOY&MK^2./??3$!5(P"-V"/KFIF\3RBR_M/["O
M]D^8%\_S_P!YMSMW[-N-N?\`:SCG':FX:V0*6EV=#16%?>*8=+O+RWOH3&T4
M:R6VUMQN@>,*,?>W8&.>N:NM=:D8(3#IT7G-&'D66YVHA[J&"DDC_=`]Z7*Q
M\R-"BL!?%*/HUK=K;$7%S<?9!`\@"I+D@AG`/`P>0#GCCFMBTDN)(<W<"PR@
MX*I)O4^X.`<?4#^M)Q:W!-,GHK.U&]U"V65[/3XYTB0L3+<^67XSA0%;_P`>
MV_UK%UC6+NZA\/W>EJH@N[F-L/.T9;*L=C`*>/4\\CIWIJ#8G)(ZNBHX3*T*
M&=$24CYE1RR@^Q(&?R%<CKNIWBZI=WUK+*+71FA$L:.0LNXYDR.API7Z41CS
M.P2E9'945GW>K"VOM-MUC$BWSLH<-C:`I;.,<YQ44NNI;W^HP2PL([&V6Y9U
M.2P.[("_\!]>]'*QW1JT5DV>HZA>Z?\`:!8VZB6$2P$7>Y3GLQV?*<'L&'7G
MUP;&]N)OAQ)<:Q;)=VPM2QS=.9)\$\,=HV_4$TU!B<D=I16'/K4MKJ5GI=G8
M><\]L94+3;50`@88X)QSU&3TX[U<TG5#J(N8YH/(N;64Q31A]ZYP""K8&001
MV%)Q:5Q\RV-"BLF;5[B35)K#3;2.XDMT5IWFF,2*6^ZH(5B3CGI@>M$^L3B[
MM[&VLM]]+#Y[QRR[$A7I\S@-SG@8![]*.5AS(UJ*Y77-5:_\*Z];7$'V>\M(
M2LL0?>N",JRM@9!'L._%3G_D<=*_[!TO_H24^307,='16+>ZW=Z<\$MWIR1V
M4LRPEQ<`R1[C@%DVXQG'1CUK.CN+J+Q[JJ6=JL\CVT!S))Y<:@;NK`$Y.>``
M>_2A0;!R1U=%8:^*(CI0N3;R?:OM'V,VH8$^?G&W=TQWSZ<X[5-#J]Q'JL-A
MJ5I';R7",T#PSF5'*_>4DJI!`P>G///%+E8^9&M16)H^N7>KQ/<1Z<$MD9T+
M&?YW921\B[<$<#DD<D^F:<=9N[;4[.VU"QCABO&9(I([C>0P&0K+M&,@'H2,
MC\:.5WL+F1LT5S6BWFJR^)-8BFCA,,<T8(-T[>4#&#\@*8.>IZ<^M)INKV>G
M:!YUK8O'YMY)!%;I(7,DID(^\>@)!)]!ZTW!AS(Z:BLF'5[B/58;#4K2.WDN
M$9H'AG,J.5^\I)52"!@].>>>*SXO%EU+I,VIKI0%G;NZS$W'SD*Q!9%V_-@#
M/)7N/>ER,.9'344U'61%=3E6&0?44ZI*"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#)%
ME<?\)>U[Y?\`HQL1%OR/O[\XQUZ5I31+/"\3EPKC!*.4;\"""/PJ2BFW<216
ML[&*Q5EA>X8,<GSKB24_@7)Q^%4M>LKB];3#;Q[_`"+Z.63D#:@!R>?K6M10
MFT[@UI8QM8L+BZUG19X(]T5M.[RMN`V@H0.O7D]JKWVB3ZAJ^J[QLMKO3UMU
MER#ALOGC.>,BNAHIJ;0G%,YC1])BM_LD<WABUAN8<![L+#LRO\:D9?)QD94=
M>2*VM8L/[5T>[L=^PW$31AB.A(X-7:*')MW!125CFKV+5=5T,Z3)IS022J(9
MKEI4,04?>9<$L<@<`J.O.*MR:=<#Q=9WB1YM8K)X2^X<,64@8Z]!6U13YV'*
M<K?:-?36/BB..#+WQ!MQO7Y_W:CUXY!ZXJSKUAJ'DV-YI4(EOK97CV;E7*NF
M#R2!PP4_A70T4<[#E1RM]X8$4>C/'91:A'I\9AEMI`I,@8`%AN^7<",\XSSS
M4E]I!N/#.IV^G:)%82W"!4B7RD>0C^]M.T=\?,?PKIJ*/:,.1&=JD/FZ<L$N
MFC4(7PLL.Y,XQU`8@'G'<>HK!30M1'A];98I`HU".:"WDF#M!`KK\I8G'`!.
M`3Z<UU]%"FT#BF8DUM=VWBT7\=J]Q;S6JV[&-T!B8.3DAB,C#=LGCI6-J^G2
M/XV@LX2#::CY=S=+GIY)]/1OD'X5VE5AI]L-1:_$?^E-'Y1<L3\F<X`S@<TX
MSL)QN6",@CUKEK6RU6P\.R:$EB97"/#%=^:@BV-G#,,[P0#R`IY'6NJHJ5*Q
M35S`AT6:SUC1O)4O;65G)`\A('/R`<9SSM-;]%%)MO<$K&/H6GSVD6I)=1[!
M/>RRI\P.4;&#Q6/I7AV/3K5+&Y\-6EW+$Q5;TI#LD7.0S$_.#@X(VGD5V%%5
MSL7*CE=<T*_UR_ENL>0VG@'306!#R@AB[8['`4`^YQ4M['JMU=VLUQ9WK6K6
MWSVMI=K$T4^>=S!UW+C@8)Z=*Z6BCG8<B.5TO2;BQ\-O8ZAI(O5DN96D@$RN
M=A8E6!<@-VZD'OUXK1\,V%SIVGRQ7"R11&9C;P22^8T$7`52V3Z=,G&>M;-%
M#FW<%%(YG4['4KG5+U9(;RXMI$5;0P7GD1Q'!#>8`RL>><X;CH.U0IHVH0>&
MM`C%L7N=.FCEE@5UW$`$$`D[<_-GKVKK**/:/8.1$0ED:U\WR)%DV;O)8KNS
MC[N0<9_''O7-:7X4N6T6:*_U"ZAEOR\EW#$(67<_49*$],#KVXKJJ*2DUL-Q
M3W.1MM,U>WTS17GMS/=:7.R-&LBYEBP4#*2<9P0<$CH:N65OJ8US5=1FL$5)
MK:-;>)IERVW=\K$9`//;(YZFNBHIN;8N2QS>BZ3+:ZU<3VMA)IEA)#A[9Y%(
M>4G[P1&95P!CC&?2JL6EZB/`=UHC6+BYCMVBC?S$V3')P5.[(XQ]X#K7744>
MT8<B,/\`LZZ_X2JQO/*_T>*Q>%WW#ARRD#&<]C4ND6-Q:ZMK$TT>V.YN%>(Y
M!W`(H)]N0>M:]%+F8<I@BWO=)U^_NH;.6]MKX(^(70/$ZKMP0[*"",<@]C23
M6U_;Z[#JZ69G$MJ+>>WBD7>A#%@5+;01R0>1VK?HHYPY3E+S1+Z]T[Q!<F#9
M=ZE$L<-MO4E55<#<<[=Q)/0X''-:#:?<GQ)I]T(_W,-E)$[[APY*8&.O8UMT
M4^=ARHX:ZT76+VQACN;6\EOH[E))IWO1Y#J),Y2,/CI@X*KC![]=<V^HV/BJ
M_P!0BL6N;6>&*,".1`Y*[N0&(&!GG)'48S7144W4;%R(Y(>']1_LQ+K;$-0&
MHG43;[_EYX\O=TSMXSTS[<UH&UNM6UVQO9[.2S@L0[*LSH7D=AMZ(S`*!GJ<
MY[5NT4G-L?*C"T;3[^R\+RVRA8+XF<Q%B&"EG8J3C([@UDPZ/J,]]HMQ)97R
M/;2A[I[J^$@)*$$HH<KC/H%/(P,9QV=%"F]0Y$8EE;7=CXEU*1K5Y+:^:-TG
M1TQ'M3:0P)#=AT!ZUFQZ#J":);[8U%W::C)>)$SC$B[W.,C(!*MQ[]<5UM%'
M.PY481M;K5M=L;V>SDLX+$.RK,Z%Y'8;>B,P"@9ZG.>U4K;1KZ/P+J&G-!B[
MF^T;(]Z\[F8KSG'.1WKJJ*.=ARHAM$:*SA1QAEC4$>AQ4U%%04%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>pbl_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbl_logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!K`&L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#X7HHHKZP^
M3"BBB@`HHHH`****`"BBB@`HHHH`****`"@\45^@GP7_`."??[-VA?\`!.'X
M>_'/XR>*?BMH\GC/5+K1W30)+22".>.ZODCVQM:NZJ8K-BQ+GYL^H`SJ5%!*
M_4TITW.]NA^??2C&*^[/VM/^"1_AWPS/\%=>^"_B_5?%O@GXV:M!H^FR:M;B
M.]LYIBI1V*I'N78)"P,<93R3G.<A/^"QO_!*CPS_`,$]]*\$Z[X%U3Q-K7AW
MQ%-<Z??2:Q<03R6MW'M:-5:&*)<,@EX()!A;G'`SCB:<FDMW^AI+#3BFWT_4
M^%**_1N7_@GE^RI\%?V3?@[X_P#BYXT^+^CWWQ0TF*\`T>2TGM89O*B>;"_8
MV=4'F@@$L:H?%3_@B-I-E^V)\%_"/@WQW<:I\.?C39W.JZ=J]U!']LM;6UMT
MN9L*`JR,\4D11MB\O@KA&)2Q4.M^O3L'U6?ETZ]S\\\8_P`]*#Q7W9^TC^S;
M^Q[X:T[XE>%_#_C/XJ^!?B-\.Y9;:W/BNR2YL_$,\;,ACB6WB,@#LJ_O&$>!
M('VLH(#?V7?^"=_PD\&_L66_QZ_:*\4>)-(\-^([HV?AO1/#X3[;?D,ZAB65
MMQ;RY65?E"HFXN0P`?UB-KV?W;A]7E?ENOO/A6@<FOM+]N[_`()V_#[P3^RY
MX=^/7P)\4:SXF^&>L78T^_M=751?:1.2RC<51,J'4QL",J2A#.K!AW'_``5W
M_P""+^F_L,?#/1_'7P\U#Q-KWA59_L6O#6)89Y].E<@02AHHHU\ER2ARN0Y3
MD[P%%BH-I=_S70'AIJ_E^O4_/4<_C1V_6OT$^,/_``1W\+V7[5G[/?PU\(>(
M_$$*_%[0FUC5;W6)8;@V0B@:XF\E8XH_^64<@56)RQ&3C)K/_:'_`&9/V.?"
M5M\2?".E^-/BUX%^(WP\,T%M)XJL4GL_$-S$63;''!%YFUW`^=A$0LF\*R@@
M"Q,':U_N!X:2U=OO/@NBC/';';'2BN@P89Q7ZU>#OVD=(_9>_P""`_P-U_6O
MAOX+^*%K>>*K[3DTKQ/9I=6EN[7FLR"X1'1@)%$3*#C(61AGM7Y*YKM'\8?$
M3Q;\+=-\*MJGC34_!.FW#7>GZ.;JYGTJUFS(6EB@R8E?=)+EE&29'YRS9PQ%
M)5$D]KFV'JN#;6[7^1^H7_!.K]LO7OV_/VJY/B+XXTSP[X.^%G[-OA:[U/3]
M+TFU9++2I983"KODG<5MH[DK@!4$("H"2U;OQ(U/X:_M[?\`!-GX[^%?A_\`
M$#6/B-K_`(5U6Y^(T3:GI4MA-I\DLTET\,*.H\Q"JW:`+G:9U!`RN?R1\/?%
MCQA\._#NN>'=)\2^)M"T?75,.KZ9::C-:V^HJ-R[+B)6"R``D8<'J1W.=/X:
M^)/B5\);BZN_!]_XX\,RZI;_`&:ZFT::ZLVNX3AO+=HB-Z$X.TY&>W6L)85<
MW-%VVL;QQ3Y>5J^]S]8_B'^U5X)_9B_82_8W;QW\-?!?Q`\/^(-+MK>\FU[3
MHKR30K=(K7S9[99$8>9M?..,^6!D5P__``4F\/?'3XE?\%@/AWX?\%^,]!T*
M2VT]-6^&UY-*EI8V<3QXN5+;'$LCO"ZE`K^9&$&W!P?S,\3^.O'WQ`TK2?"N
MLZQXPURP\,0[-,T>]O+FZATF(JHVP0N2(EVA!\H`P$]J=K/Q:^(7Q1N=#M]0
M\3>,O$DWA.,)H\=QJ-S>-HZ+L`%N"Q,*C8F`@7&Q1V&"&%Y7S75]?Q"6*YO=
ML[:?@?L]X93XC?M<^`?BEX-_:Y^"OAG1])\%^'[JYMO'D,0@B66('$EN[LQS
ML+R^;$RHHC970;]M?/WQ*^"FO_\`!0[_`((I?!-/A;91^(O$'PROCI^LZ+:2
M(MQ&562)CM8@&3_4R8ZE)B?45\#>.OVM?C1\<?!TWA_Q!\0?B'XHT*W53<6-
MWJUU<VY"<JTJ[B&P5R"X.",]1SR_PA_:`\<?L_ZO-?\`@?QAXB\)W5TOES2:
M3J$EIYZ@'`D"$!@,\!@<'D4HX62U35[W\ARQ,7HT[6MTO_2/T/\`CS\+]2_8
M:_X(+K\//B((M)\<_$+Q6FH6.C&5'N+9%FAE;<%)`"QP`L1PIF13ACBOJ/\`
M;@_:ST7X:_\`!3G2_@_\0Q'=_"?XS?#RST;4X9GVQV-W)?ZE'!<`_P#+,-N$
M;,,$9C?(\NOQ;^*?B;XF?''Q)_:_C*\\:>*M55?*6ZU5[F[EC0?PJSY*KUX&
M`/SK*^+/Q3\9?%GQ0M_XZ\2>)_$VM6<"V:W&O:A/>74$2LSB(-,S,JAI';;D
M`%V]<T_JO-K)]_QMMZ"^M<ND5V^Y=S]9?^"KWP:\:ZG^WK^S-X1^%OB2Q\/^
M--*\/R0:+JNHW@M(U>W8<L0K;MR(V8PK;PS+M8$@^E?#Q?B7^USIWQ$^'?[7
MGP9\+Z7X=\+Z'<R)\08;80PQ/&0!-;NY;+%#),)(2@7R]K(-V*_'>#7/BU^U
M3K$6H77B#Q=XPNO"<2-'J&KZY)*NC(7&P">XD"PY<#:`P)*G&36I\>/VE/CI
M>V5UX!^(GCSXAW5O9[$N=(U76)Y8GP`R%U9R)!C#`G<",$'O4_59<JC=:=>N
M_0:Q<>9O77ITVZGCO7G=].>OX]Z*.ISZ\_\`ZO\`/045Z".!A7[<?L0P_&*;
M_@B9\&O^%(^(O"OAKQ7_`&SJ/VFY\0%/LLEE_:.JAXUWQR#S#)Y)'&<(W(YK
M\1Z_27X4_'+]FGX[?\$E_A;\%?BA\7-2\":[X2UN\UJZCLO#U]?2(YNM2\M"
MR6[1$-%=ALJQ(X'!!QR8R+<8Z=>U^CZ'9@Y6E+T[VZKJ='_P<!W-Q9?`3X&V
M/CVPT[4OC!);O/JWB;1].>'3;J$1[7A2=E"R$R%'"C[F&8+&)5!^KOVI?BG\
M?/AA\,/`%]\*?%WPDT#P]9^!K6]U"T\3W*1WT\R1%F,"%264HJJ!D9;-?GQ_
MP4E_;'^#>N_L6_#'X`_![4O$'C+2?`NH?VG-XEU6VD@D<[+E3"BRJDA#-<NQ
M&U518XU&[^'V7]J#XB_L5_MQ6'P_U3QK\=/%7AW6O"?A6TT*2UTOP]?M&#&"
MS9+V+Y(=V&5..!UKD]F^2*DG;7I?\.AU>T7-)Q:OIUM^/4PO^")W[0_B3]J[
M_@KGXF\?>,)+6;Q%K_A&X^UO;0"")O)^PP)M0<#Y(DZ=^>YKWO\`X)5_\$EO
MBE^QK^VOKGC_`,77/A.;0]0TN^LHET^_DFFWS3Q2)E6B48"H<\\9''-?)?\`
MP3M^/?P$_83_`."GGB?6-/\`B!J%[\)(O#DEAI7B"^TJZ>XO9I4LY'5H8[<2
MKB59U!,8&(QS@@GD?^"/?[67P_\`V6/V]=>\:>//$']@^&;W2-0M8;PV-S=>
M9))<0O&/+AC>0956.2H`QS@D9TJ4YOF<-K+I^1G2G!<JGJ[OKZ'KG_!'`;_`
M7[:'?_BD;G&?^N>H_P"`K\TP<GKZ'DY_S_\`6K[X_P""2/[6/PA^">H?M`:7
M\4/&$WA71OB7I@TRRNH=-N[N26.0W:R,HAADVLJ3*1O`&3WP:\E_;5^#W[+O
MP^^%EA>_!+XM>*_'GBJ358X;O3]4TJ>TABLC%,7F#26D(+"185`W$XD)QC)&
MU.7+4::>MNGD8U(\U.+36E^NNY^MW_!3_P"./Q^^!>NWFO?#'Q9\*='\'Z!X
M5DU?4-.\03)_:UU/"UR\AMXBN75HDC5`",NK"OP?^.7QEUO]H?XLZ]XV\226
M\FN>([DW=Z]O%Y,9D(`.%&0HXZ5^H/[?7Q-_8<_X*"_&/3?&GB;X]>+-%U#2
M]'BT1(-,\-WXB:..>>8,WF6#'=FX8'G&`.,YS^87Q]T#P?X7^,GB#3_A_K=Y
MXD\&6EV8])U.[@:&>\A`&'9&1&5NO!13Q6>!CRK56?I;\33&RYGH[KUO^!].
M_L=?L^CXA_LQ^*/!?BB1]'NO&GV?Q-X>MK>2-M4U:&T+"0QP.R@(_P!R-G90
MQ8M@JI->=?&#P%-^TAHNK?$MO%'@OPOH/AZ.WT./2+^XO?[1L%BC,<%NX%L?
M,F=868E&(^]DJ%8+V6L?&+P+\5M-^%_C?3/B!'\._B!\.]+M-(O;6_T^ZN([
MF.W!"R1&%6#!LR`H?O+)M8C&6UOCY\6_@5\?=.C\21Z_=:&EC>W6IZGX371I
M8I/$U^T819Q+&Y6,2"-.2Y*JSGY6=BW>>3K>Y\7YVC'3/;/^??\`.BC/^3_G
MZ"BF;!7T%\9/V"KOX0_L+?#CXW2>);:^M?B)?/8QZ2MDR266S[0-QF+D/_Q[
MGC:/O5\^CFOT>_;`T6\US_@@I^S3'96MS=R)KMPS+!$9&49U#G`'3D<UC5FX
MRBEU9O1@I1DWT7ZH_.$\'Z5]>?M1?\$AO%W[+O[%'A/XR:AKMOJ$>O"Q:^T9
M+%HIM%6ZA+H7D+$-M;9&V%4[Y!UYKR;]B']F>\_:2_;(\`_#V[LKJ&+7-6B;
M4(GC,;I91YFN&P<$8@CDQ[X]J_<+XU>";O\`:_G_`&@OAC>>-OAKK7A_Q-H%
MO8^$M#TS75GU;1[VT1VD>[M]H5`+SRC\K':(E!P>F&(Q#A.*6W7T-\/AE.,K
M[]/4_-#]DO\`X(K>&_VN?`?AV]T+]HKX>_\`"2ZSI,6JW7AFVABO-2TL,J[T
MEB2YWJ49PI)48)`->5_M)_\`!/'PS\%?BY\-/"/A?XW>!OB;<_$#6#I%U+H+
M13_\(^XFMHD:=(YY"=QN&(#%<^2P'2O8/^#<FPFTS_@HMJEO<Q20W%OX4U"*
M2.1<-&PN+4,ISSD$'(KY9_9^&?V\O!/_`&/UAU_[",?^?\*<93YVG+1*^RZB
M<8.FFHZMVW?2QZ/\1/\`@F7??#__`(*.:3^SP_BZUN;W5)[2`:V-/98HS/;K
M/DP[R3C./O"NA_:L_P""//BC]F7]J7X6_#2W\36?B3_A:=PEI9:K#8-;QVLH
MN%AF#(9&+>4C1NQR.&QCBOI;]I)L_P#!R_X2_P"O_2/_`$W)7U5X!\:^%_B'
M?_$#Q]XJ83:I^R?X^\7WMNK_`#,]G/;SR\Y[?O2%]#;+C&%QA+$U%RR\OQ>W
MXFL</3;E'S_#K^!^4O\`P4R_X)>7G_!-Z/P.UUXTL?&">,C?JAMM/:T%I]D^
MS@@YD?=G[1CC&-E>[?$S_@@AX1^">O0Z7XR_:G^%_A'4Y[<745GK4<-A<20E
MG02*DMVK%"R.NX#!*-W!`S?^"ROBF^\<_L1_L<ZYJ4WVC4=8\.:I?7<I'^MF
MECTMW8_5F)_&O?/^"]WQ4\!^'?C%_P`(YK7P';Q]XNUCP'LTKQ@FM75NV@M)
M/?1P@6T<3)*8909OF<;M^TX'):JU&HJ^KO?;H_,'3IIR=M%;OU1\7?LN_P#!
M+&V_:H_:R^(7PUT+XI>'WTOP)9M?IXFM;47ECJL2R1(639-M"_O,[@Y'R5UG
MQ8_X(E7VE_!+Q1XZ^%_Q@^'/QDTWP;;-=ZM;Z!<J]Q#&BEWV^7)*A94#/L9E
M9@IV@G`/=?\`!N#:+IG[2?Q4CU"WN(XX?!$ZW$.#'(%^TP%AS]TX_F*]9\!_
M$CX6_L\_\$F/BA\6/V9_`VL+=>([G_A&/$A\0:DTU[HD95HEG**SHP3[5&ZJ
MNW_CX#.2(]M.I6J1J<J?;HK:BITJ<J?,UWZN^A^0]%!./_K]?\_XT5Z)YP=:
M^M/V??\`@M5\<OV9O@[H?@7PK?>&X=!\/QO%9I<Z2LTJJ\CR-N<GGYG/8<5\
MET5$Z<9JTE<N%24'>+L?2UK_`,%8/BU:_M77'QG\[PY)XXN-(&BB>32U:WA@
M^7E(\X5R%VENI#,.]>8_`7]J_P`;?LX?'Z#XF>&M21/%D,MS*\]U$)H[EKA7
M6;S(SPP;S&..,,%(Y%>;T4O9PM:WD/VD[WOYGM7P5_;Z\?\`[/\`^TQXB^+'
MAAM#LO%GB@WAO=U@KVH^U3+-*$BSA!O48QT'`XKS+PO\1-2\(?$W3_%UF\*Z
MQI>J1ZO`S1AD$Z2B925Z8W@?+Z<5A457)'L3[21[9XM_;_\`B)XU_:]L?CA?
M7.DMX\T^6":&5+(+:AH8A$F8LX/R`5'>?M]?$B\M?B]#_:5G#%\;IDN/%"16
MP59G65Y/W7_//)D=6QU4XKQ>BI]G#L5[2?<]/^./[7?C+]H;X6?#OP=XDFTZ
M;1?A?8RZ=H2P6HA=(I%A5O,8'YSB"/GZU]+C_@X?_:0'_,2\(_\`@C3_`.*_
MS_/X9HI2HTWI)#C6J1=TSZ"\`_\`!3/XI?#7]H#QU\3-+NM$7Q1\1+62SUB2
M73UDA:-RC-L0G"<QKT]*Y7X#_MH>./V=?A7X\\%^'[C39/#?Q(LOL6M65]9K
M<(Z[)(]\>3^[DVRM\PYRJ'^$8\GHI^RAV%[6?</7MGL****T,PHHHH`****`
7"BBB@`HHHH`****`"BBB@`HHHH`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
